
<html lang="en"     class="pb-page"  data-request-id="9cf30690-9e6f-4a93-b2b4-18ea2be459e5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2017.60.issue-24;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.7b01290"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma" /></meta><meta name="dc.Creator" content="James S.  Scott" /></meta><meta name="dc.Creator" content="Sébastien L.  Degorce" /></meta><meta name="dc.Creator" content="Rana  Anjum" /></meta><meta name="dc.Creator" content="Janet  Culshaw" /></meta><meta name="dc.Creator" content="Robert D. M.  Davies" /></meta><meta name="dc.Creator" content="Nichola L.  Davies" /></meta><meta name="dc.Creator" content="Keith S.  Dillman" /></meta><meta name="dc.Creator" content="James E.  Dowling" /></meta><meta name="dc.Creator" content="Lisa  Drew" /></meta><meta name="dc.Creator" content="Andrew D.  Ferguson" /></meta><meta name="dc.Creator" content="Sam D.  Groombridge" /></meta><meta name="dc.Creator" content="Christopher T.  Halsall" /></meta><meta name="dc.Creator" content="Julian A.  Hudson" /></meta><meta name="dc.Creator" content="Scott  Lamont" /></meta><meta name="dc.Creator" content="Nicola A.  Lindsay" /></meta><meta name="dc.Creator" content="Stacey K.  Marden" /></meta><meta name="dc.Creator" content="Michele F.  Mayo" /></meta><meta name="dc.Creator" content="J. Elizabeth  Pease" /></meta><meta name="dc.Creator" content="David R.  Perkins" /></meta><meta name="dc.Creator" content="Jennifer H.  Pink" /></meta><meta name="dc.Creator" content="Graeme R.  Robb" /></meta><meta name="dc.Creator" content="Alan  Rosen" /></meta><meta name="dc.Creator" content="Minhui  Shen" /></meta><meta name="dc.Creator" content="Claire  McWhirter" /></meta><meta name="dc.Creator" content="Dedong  Wu" /></meta><meta name="dc.Description" content="Herein we report the optimization of a series of pyrrolopyrimidine inhibitors of interleukin-1 receptor associated kinase 4 (IRAK4) using X-ray crystal structures and structure based design to iden..." /></meta><meta name="Description" content="Herein we report the optimization of a series of pyrrolopyrimidine inhibitors of interleukin-1 receptor associated kinase 4 (IRAK4) using X-ray crystal structures and structure based design to iden..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 11, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01290" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01290" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01290" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01290" /></link>
        
    
    

<title>Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01290" /></meta><meta property="og:title" content="Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0024.jpeg" /></meta><meta property="og:description" content="Herein we report the optimization of a series of pyrrolopyrimidine inhibitors of interleukin-1 receptor associated kinase 4 (IRAK4) using X-ray crystal structures and structure based design to identify and optimize our scaffold. Compound 28 demonstrated a favorable physicochemical and kinase selectivity profile and was identified as a promising in vivo tool with which to explore the role of IRAK4 inhibition in the treatment of mutant MYD88L265P diffuse large B-cell lymphoma (DLBCL). Compound 28 was shown to be capable of demonstrating inhibition of NF-κB activation and growth of the ABC subtype of DLBCL cell lines in vitro at high concentrations but showed greater effects in combination with a BTK inhibitor at lower concentrations. In vivo, the combination of compound 28 and ibrutinib led to tumor regression in an ABC-DLBCL mouse model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01290"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01290">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01290&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01290&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01290&amp;href=/doi/10.1021/acs.jmedchem.7b01290" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 10071-10091</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01293" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01250" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell Lymphoma</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+S.++Scott">James S. Scott</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-2263-7024" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=S%C3%A9bastien+L.++Degorce">Sébastien L. Degorce</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rana++Anjum">Rana Anjum</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Janet++Culshaw">Janet Culshaw</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+D.+M.++Davies">Robert D. M. Davies</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nichola+L.++Davies">Nichola L. Davies</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Keith+S.++Dillman">Keith S. Dillman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+E.++Dowling">James E. Dowling</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lisa++Drew">Lisa Drew</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+D.++Ferguson">Andrew D. Ferguson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-1018-9631" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sam+D.++Groombridge">Sam D. Groombridge</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+T.++Halsall">Christopher T. Halsall</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julian+A.++Hudson">Julian A. Hudson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Lamont">Scott Lamont</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicola+A.++Lindsay">Nicola A. Lindsay</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stacey+K.++Marden">Stacey K. Marden</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michele+F.++Mayo">Michele F. Mayo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J.+Elizabeth++Pease">J. Elizabeth Pease</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+R.++Perkins">David R. Perkins</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer+H.++Pink">Jennifer H. Pink</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Graeme+R.++Robb">Graeme R. Robb</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alan++Rosen">Alan Rosen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Minhui++Shen">Minhui Shen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Claire++McWhirter">Claire McWhirter</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dedong++Wu">Dedong Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Oncology, IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Oncology, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Oncology, IMED Biotech Unit, AstraZeneca, Macclesfield SK10 4TG, United Kingdom</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#b4ded5d9ddd19ac7d7dbc0c0f4d5c7c0c6d5ced1dad1d7d59ad7dbd9"><span class="__cf_email__" data-cfemail="0369626e6a662d70606c777743627077716279666d6660622d606c6e">[email protected]</span></a>. Phone: +44(0)1223223578.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01290&amp;href=/doi/10.1021%2Facs.jmedchem.7b01290" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 10071–10091</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 27, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 August 2017</li><li><span class="item_label"><b>Published</b> online</span>11 December 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 December 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01290" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01290</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10071%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJames%2BS.%2BScott%252C%2BS%25C3%25A9bastien%2BL.%2BDegorce%252C%2BRana%2BAnjum%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D24%26contentID%3Dacs.jmedchem.7b01290%26title%3DDiscovery%2Band%2BOptimization%2Bof%2BPyrrolopyrimidine%2BInhibitors%2Bof%2BInterleukin-1%2BReceptor%2BAssociated%2BKinase%2B4%2B%2528IRAK4%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BMutant%2BMYD88L265P%2BDiffuse%2BLarge%2BB-Cell%2BLymphoma%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10091%26publicationDate%3DDecember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01290"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4328</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">28</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01290" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;S. Scott&quot;},{&quot;first_name&quot;:&quot;Sébastien&quot;,&quot;last_name&quot;:&quot;L. Degorce&quot;},{&quot;first_name&quot;:&quot;Rana&quot;,&quot;last_name&quot;:&quot;Anjum&quot;},{&quot;first_name&quot;:&quot;Janet&quot;,&quot;last_name&quot;:&quot;Culshaw&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;D. M. Davies&quot;},{&quot;first_name&quot;:&quot;Nichola&quot;,&quot;last_name&quot;:&quot;L. Davies&quot;},{&quot;first_name&quot;:&quot;Keith&quot;,&quot;last_name&quot;:&quot;S. Dillman&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;E. Dowling&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;Drew&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;D. Ferguson&quot;},{&quot;first_name&quot;:&quot;Sam&quot;,&quot;last_name&quot;:&quot;D. Groombridge&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;T. Halsall&quot;},{&quot;first_name&quot;:&quot;Julian&quot;,&quot;last_name&quot;:&quot;A. Hudson&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Lamont&quot;},{&quot;first_name&quot;:&quot;Nicola&quot;,&quot;last_name&quot;:&quot;A. Lindsay&quot;},{&quot;first_name&quot;:&quot;Stacey&quot;,&quot;last_name&quot;:&quot;K. Marden&quot;},{&quot;first_name&quot;:&quot;Michele&quot;,&quot;last_name&quot;:&quot;F. Mayo&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Elizabeth Pease&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;R. Perkins&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;H. Pink&quot;},{&quot;first_name&quot;:&quot;Graeme&quot;,&quot;last_name&quot;:&quot;R. Robb&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;Rosen&quot;},{&quot;first_name&quot;:&quot;Minhui&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Claire&quot;,&quot;last_name&quot;:&quot;McWhirter&quot;},{&quot;first_name&quot;:&quot;Dedong&quot;,&quot;last_name&quot;:&quot;Wu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;10071-10091&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01290&quot;},&quot;abstract&quot;:&quot;Herein we report the optimization of a series of pyrrolopyrimidine inhibitors of interleukin-1 receptor associated kinase 4 (IRAK4) using X-ray crystal structures and structure based design to identify and optimize our scaffold. Compound 28 demonstrated a favorable physicochemical and kinase selectivity profile and was identified as a promising in vivo tool with which to explore the role of IRAK4 inhibition in the treatment of mutant MYD88L265P diffuse large B-cell lymphoma (DLBCL). Compound 28 was shown to be capable of demonstrating inhibition of NF-κB activation and growth of the ABC subtype of DLBCL cell lines in vitro at high concentrations but showed greater effects in combination with a BTK inhibitor at lower concentrations. In vivo, the combination of compound 28 and ibrutinib led to tumor regression in an ABC-DLBCL mouse model.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01290&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01290" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01290&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01290" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01290&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01290" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01290&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01290&amp;href=/doi/10.1021/acs.jmedchem.7b01290" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01290" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01290" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01290%26sid%3Dliteratum%253Aachs%26pmid%3D29172502%26genre%3Darticle%26aulast%3DScott%26date%3D2017%26atitle%3DDiscovery%2Band%2BOptimization%2Bof%2BPyrrolopyrimidine%2BInhibitors%2Bof%2BInterleukin-1%2BReceptor%2BAssociated%2BKinase%2B4%2B%2528IRAK4%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BMutant%2BMYD88L265P%2BDiffuse%2BLarge%2BB-Cell%2BLymphoma%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D24%26spage%3D10071%26epage%3D10091%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291297" title="Cell signaling">Cell signaling</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/jmcmar.2017.60.issue-24/20171228/jmcmar.2017.60.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0024.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Herein we report the optimization of a series of pyrrolopyrimidine inhibitors of interleukin-1 receptor associated kinase 4 (IRAK4) using X-ray crystal structures and structure based design to identify and optimize our scaffold. Compound <b>28</b> demonstrated a favorable physicochemical and kinase selectivity profile and was identified as a promising in vivo tool with which to explore the role of IRAK4 inhibition in the treatment of mutant MYD88<sup>L265P</sup> diffuse large B-cell lymphoma (DLBCL). Compound <b>28</b> was shown to be capable of demonstrating inhibition of NF-κB activation and growth of the ABC subtype of DLBCL cell lines in vitro at high concentrations but showed greater effects in combination with a BTK inhibitor at lower concentrations. In vivo, the combination of compound <b>28</b> and ibrutinib led to tumor regression in an ABC-DLBCL mouse model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86378" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86378" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non-Hodgkin lymphoma (NHL) comprising 30–35% of all NHLs.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> More than half of DLBCL patients can be cured with immunochemotherapy, however, approximately 30–40% of patients will develop relapsed/refractory disease that remains a major cause of morbidity and mortality due to the limited therapeutic options.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The molecularly distinct subtype “activated B-cell like” (ABC) DLBCL has particularly poor clinical outcomes with this standard treatment regimen when compared to the “germinal center B cell-like” (GCB) DLBCL, which has a favorable prognosis.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In ABC-DLBCL patients, recurrent gain of function mutations in the essential adaptor protein MYD88 is seen in 39% of patients, with one dominant mutation of MYD88, L265P, occurring in 29% of cases.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Occurrence of L265P mutation in DLBCL patients has been linked to poor prognosis on standard immunochemotherapy regimen.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">MYD88 is an adaptor protein of the Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs) that participates in the innate immune response and plays a crucial role in the homeostasis of human B-cells.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> After activation of TLRs, MYD88 is phosphorylated and subsequently recruits IRAKs and other downstream proteins such as TRAF6, resulting in NF-κB, JAK kinase/STAT3 activation, and secretion of IL6, IL10, and interferon-β.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> In ABC-DLBCL cells, an L265P mutation of MYD88 leads to a spontaneous assembly of a stable signaling complex involving IRAK4, IRAK1, and TRAF6 that leads to an increase in kinase activity of IRAK4, resulting in constitutive NF-κB activation, promoting cell proliferation and survival.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> MYD88 has also been found to be mutated at different frequencies in several lymphoid neoplasms including Waldenström’s macroglobulinemia (90%), primary cutaneous leg type DLBCL (69%), central nervous system lymphomas (38–50%), and primary testicular lymphomas (68%).<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13">(9-13)</a> IRAK4-mediated signaling is also important for inflammation and bridges innate and adaptive immunity. IRAK4 or MYD88 deficiency has been linked to susceptibility to bacterial infections in children, particularly recurrent pyogenic bacterial infections.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a></div><div class="NLM_p">Given the critical role of IRAK4 in inflammatory processes and MYD88 driven cell proliferation, the inhibition of IRAK4 activity presents an attractive therapeutic approach for the treatment of inflammatory diseases and cancer. A number of groups have reported chemical equity capable of inhibiting this target. This area has recently been reviewed,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> with notable contributions published in the literature from groups including Amgen,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> UCB,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Astellas,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Merck,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Pfizer,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and Nimbus.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In the context of oncology, the contribution made by Nimbus was particularly significant in that it showed IRAK4 inhibition, together with inhibition of B-cell receptor (BCR) signaling, could have synergistic effects on ABC DLBCL killing.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> This was also demonstrated in vivo, where a modest tumor growth inhibition effect in OCI-LY10 xenografts with an IRAK4 inhibitor was significantly enhanced by cotreatment with ibrutinib, an inhibitor of Bruton’s tyrosine kinase (BTK).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> As a starting point for our program, we were intrigued by the tricyclic scaffold reported by Nimbus and profiled a representative example (<b>1</b>) in terms of biological activity, selectivity, and physicochemical properties.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This compound showed potency against IRAK4 (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) and a good level of selectivity against a panel of kinases.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> A crystal structure (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) showed that this compound binds at the ATP site, forming interactions with the kinase “hinge” (Val263 and Met265) and a salt bridge with Asp272. The hinge-binding is unusual in that it involves an interaction between the sulfur atom and the carbonyl of Val263, which can be understood as the donation of electron density from the carbonyl to a charge-depleted region in the valence shell of the aromatic sulfur.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0001.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. X-ray crystal structure of tricylic inhibitor <b>1</b> in complex with IRAK4 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K75">5K75</a>). Green dotted lines indicate intermolecular interactions involved in binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We therefore embarked on a medicinal chemistry program to investigate and understand the structure–activity relationship (SAR) surrounding this scaffold and to develop and optimize novel chemical equity in order to validate IRAK4 as an oncology target.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04334" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04334" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of compounds is described below (<a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch6" aria-label="6">6</a>). Bicyclic compounds <b>2</b>–<b>5</b> and <b>8</b>–<b>10</b> were prepared through an S<sub>N</sub>Ar reaction with <i>trans</i>-<i>N</i>,<i>N</i>-dimethylcyclohexane-1,4-diamine and the corresponding chloroheterocycle under microwave conditions (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0012.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Core Variation with S<sub>N</sub>Ar Displacement<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>trans</i>-H<sub>2</sub>NCyNMe<sub>2</sub>, DIPEA, iPrOH, MW, 85–150 °C, 4–14 h, 17–61%.</p></p></figure><div class="NLM_p">In cases where the requisite chloroheterocycle was not available, these were constructed as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Tricyclic compound <b>6</b> was constructed through formation of cyclopentyl hydrazone <b>6a</b> followed by a Fischer indole synthesis to <b>6b</b>, which proceeded in good yield (79% over 2 steps). Chlorination to <b>6c</b> and an S<sub>N</sub>Ar reaction with <i>trans</i>-<i>N</i>,<i>N</i>-dimethylcyclohexane-1,4-diamine gave <b>6</b>. In the case of dimethyl substituted <b>7</b>, the required chloroheterocycle was prepared through assembly of benzyl protected pyrrole <b>7a</b>, followed by construction of the pyrimidine ring <b>7b</b> using formic acid. Chlorination gave <b>7c</b>, which was displaced with <i>trans</i>-dimethylcyclohexane-1,4-diamine to give <b>7d</b>. Removal of the benzyl protecting group using aluminum trichloride gave <b>7</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Core Variation through Heterocycle Construction<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) cyclopentanone, EtOH, 80 °C, 4 h, 89%; (b) Ph<sub>2</sub>O, 250 °C, 6 h, 89%; (c) POCl<sub>3,</sub> 100 °C, 45 min, 85%; (d) <i>trans</i>-H<sub>2</sub>NCyNMe<sub>2</sub>, DIPEA, iPrOH, MW, 160 °C, 9 h, 39%; (e) HCl, PhMe, Δ, 24 h, 36%; (f) HCOOH, Δ, 7 h, 90%; (g) POCl<sub>3,</sub> PhNMe<sub>2</sub>, Δ, 3.5 h, 100%; (h) <i>trans</i>-H<sub>2</sub>NCyNMe<sub>2</sub>, DIPEA, iPrOH, MW, 150 °C, 10 h, 52%; (i) AlCl<sub>3</sub>, PhMe, Δ, 135 min, 32%.</p></p></figure><div class="NLM_p">Variation of the 5-position was achieved via the 5-bromo substituted key intermediate <b>11a</b>, prepared by S<sub>N</sub>Ar reaction on the 4-chloro group of SEM protected 4-chloro-5-bromo-pyrrolopyrimidine with <i>trans</i>-dimethylcyclohexane-1,4-diamine (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The alkyl group of compounds <b>11</b> and <b>15</b>–<b>17</b> could then be installed by Negishi reaction with organozincates followed by deprotection of the SEM group (steps b,c) or alternatively, in the case of compounds <b>12</b> and <b>18</b>–<b>21</b>, through Suzuki reaction with alkenyl organoboronates followed by hydrogenation and removal of the SEM protection<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (steps d,e,c). The 5-trifluoromethyl group was introduced using a trifluoromethylsulfonium salt<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> from the protected iodo intermediate to give <b>14a</b>, followed by S<sub>N</sub>Ar reaction and removal of the SEM group to give <b>14</b>. Attempts to introduce the analogous 5-<i>tert</i>-butyl substituent directly from the 5-bromo precursor <b>11a</b> were unsuccessful, therefore this analogue was synthesized by condensation of 6-aminopyrimidine-2,4-diol with 2-bromo-3,3-dimethylbutanal to construct the pyrrole ring of <b>13a</b>. Bis-chlorination with phosphorus oxychloride gave <b>13b</b>, which underwent a regioselective S<sub>N</sub>Ar reaction in which the 4-chloro group was preferentially displaced to give <b>13c</b>. Hydrogenation to remove the 2-chloro substituent gave <b>13</b>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0014.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Variation of the 5-Position of the Pyrrolopyrimidine<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>trans</i>-H<sub>2</sub>NCyNMe<sub>2</sub>, DIPEA, iPrOH, MW, 130 °C, 5 h, 70%; (b) R<sub>2</sub>Zn or RZnBr, Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, THF, 80 °C, 3–16 h, 55–100%; (c) TBAF, THF, 80 °C, 16–72 h, 9–35% or TFA, CH<sub>2</sub>Cl<sub>2,</sub> 20 °C, 3–24 h then NH<sub>3</sub>/MeOH, 1–24 h, 44–81%; (d) RBpin, Pd(PPh<sub>3</sub>)<sub>4</sub> or Pd(dtbpf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub> or K<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 85–90 °C, 5–16 h, 41–67%; (e) Pd/C, H<sub>2</sub>, EtOH/THF or MeOH, rt, 3–16 h, 28–100% (alkenes) or Pd/C, NH<sub>4</sub>HCO<sub>2</sub>, MeOH, Δ, 4–8 h, 57–82% (furyls); (f) Cu, Ph<sub>2</sub>SCF<sub>3</sub>·CF<sub>3</sub>SO<sub>2</sub>, DMF, 80 °C, 16 h, 44%; (g) <i>trans</i>-H<sub>2</sub>NCyNMe<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, MeCN, 80 °C, 4 h, 51%; (h) NaOAc, H<sub>2</sub>O, 20 °C, 3 d, 72%; (i) POCl<sub>3</sub>, DIPEA, Δ, 16 h, 100%; (j) <i>trans</i>-H<sub>2</sub>NCyNMe<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, MeCN, MW, 140 °C, 16 h, 84%; (k) Pd/C, H<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, MeOH, 20 °C, 16 h, 16%.</p></p></figure><div class="NLM_p">Variation of the linker atom was carried out using a similar approach to that described above by S<sub>N</sub>Ar displacement of the 4-chloro group of SEM protected 4-chloro-5-bromo-pyrrolopyrimidine (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). In the case of the NMe linked compound <b>22</b>, the conditions were similar to those used for the NH linker. For the oxygen linked analogue <b>23</b>, the <i>trans</i>-4-(dimethylamino)cyclohexanol was treated with sodium hydride before reaction with the chloroheterocycle, using DMF as solvent. The 5-THP substituent was introduced in each case by Suzuki coupling with cyclohexenyl boronate and hydrogenation, followed by removal of the SEM protection.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0015.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Variation of the 4-Linkage of the Pyrrolopyrimidine (NMe<sub>2</sub>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>trans</i>-HXCyNMe<sub>2</sub>, (DIPEA, iPrOH, 90 °C, 12 h, 75% for <b>22</b> or NaH, DMF, 20 °C, 24 h, 63% for <b>23</b>); (b) dihydropyranylBpin, Pd(PPh<sub>3</sub>)<sub>4</sub> or Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane or DME, H<sub>2</sub>O, 85–100 °C, 1–6 h, 60–85%; (c) Pd/C, H<sub>2</sub>, MeOH or EtOH/THF, rt, 3–16 h, 86–93%; (d) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1–3 h then NH<sub>3</sub>/MeOH, 1–24 h, 32–67%.</p></p></figure><div class="NLM_p">For variation of the amine capping group, two complementary strategies were employed (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). The first was to install the entire aminocyclohexanamine fragment with defined stereochemistry through S<sub>N</sub>Ar reaction, followed by Suzuki coupling with cyclohexenyl boronate, hydrogenation, and removal of the SEM group (route I; <b>25</b>–<b>29</b>, <b>32</b>). The alternative approach was to use the S<sub>N</sub>Ar to introduce an aminocyclohexanone fragment at C4, followed by a Suzuki reaction to install a cyclohexenyl group at C5. Reductive amination could then be employed to install the desired amine capping group, although the cis/trans stereochemistry was poorly controlled and so separation of the isomers was required. Hydrogenation and SEM deprotection gave the desired products (route II; <b>24</b>, <b>30</b>, <b>31</b>).</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0016.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Variation of the 4-Substituent of the Pyrrolopyrimidine<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) H<sub>2</sub>NCyY or H<sub>2</sub>NCyX, where X = N[(CH<sub>2</sub>)<sub>2</sub>]<sub>2</sub>NBz for <b>25</b>/<b>26</b> and N[(CH<sub>2</sub>)<sub>2</sub>]<sub>2</sub>CHCO<sub>2</sub>Me for <b>29</b>, DIPEA, <sup>i</sup>PrOH or <sup>n</sup>BuOH, MW, 80–150 °C, 3–18 h, 53–100%; (b) dihydropyranylBpin, Pd(PPh<sub>3</sub>)<sub>4</sub> or Pd(dtbpf)Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub> or K<sub>2</sub>CO<sub>3</sub>, THF or 1,4-dioxane or DME, H<sub>2</sub>O, 80–100 °C, 3–16 h, 52–100%; (c) Pd/C, H<sub>2</sub>, MeOH or EtOAc or EtOH/THF, rt, 11–18 h, 29–100%; (d) for <b>29</b> (i) LiOH, H<sub>2</sub>O, THF, rt, 2 h, 86%, (ii) Me<sub>2</sub>NH, HATU, DIPEA, DMF, rt, 2 h, 24%; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1–3 h then NH<sub>3</sub>/MeOH, 1–24 h, or Me<sub>2</sub>NCOCl for <b>25</b>/MeSO<sub>2</sub>Cl for <b>26</b>, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1 h then TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1 h, NH<sub>3</sub>/MeOH, 1–24 h, 39–74%; (f) 4-H<sub>2</sub>N-cyclohexanone, DIPEA, <sup>i</sup>PrOH, MW, 120 °C, 36 h, 34%; (g) HY, NaBH(OAc)<sub>3</sub>, AcOH, CH<sub>2</sub>Cl<sub>2</sub> or MeCN, 15–25 °C, 16–18 h, 52–100%.</p></p></figure><div class="NLM_p">For the oxygen linked ether <b>33</b>, an analogous approach to that described above was used (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>). For the thioether <b>34</b>, the 4-chloro group was first converted to the thiol <b>34a</b>, which wa then used in an S<sub>N</sub>2 reaction with the mesylate of <i>cis</i>-4-morpholinocyclohexanol, proceeding with inversion of stereochemistry to set up the desired <i>trans</i>-stereochemistry of <b>34d</b>. The 5-THP group was introduced under standard conditions in the presence of the sulfur, however the reduction of the alkene required Wilkinson’s catalyst at elevated temperature. Removal of the SEM group under acidic conditions gave <b>34</b>.</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0017.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Variation of the 4-Linkage of the Pyrrolopyrimidine (Morpholine)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>trans</i>-4-morpholinocyclohexanol, NaH, DMF, 20 °C, 24 h, 61%; (b) dihydropyranylBpin, Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DME or 1,4-dioxane, H<sub>2</sub>O, 80–85 °C, 2–6 h, 73–100%; (c) Pd/C, H<sub>2</sub>, EtOH/THF, rt, 3 h, 97%; (d) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1–3 h then NH<sub>3</sub>/MeOH, 1–24 h, 25–56%; (e) Na<sub>2</sub>S, DMSO, rt, 2 h, 78%; (f) <i>cis</i>-4-morpholinocyclohexanol mesylate, K<sub>2</sub>CO<sub>3</sub>, MeCN, 80 °C, 16 h, 92%; (g) Rh(PPh<sub>3</sub>)<sub>3</sub>Cl, H<sub>2</sub>, THF, 50 °C, 7 d, 30%.</p></p></figure><div class="NLM_p">For variations of the six-membered ring of the core (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>), the corresponding pyridine was made by a Suzuki reaction on the unprotected azaindole core followed by SEM protection of the NH to give <b>35b</b>. A Buchwald–Hartwig amination of the 4-chloro group with <i>trans</i>-4-morpholinocyclohexanamine using a third-generation Brettphos precatalyst<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> proceeded in moderate yield (56%), then hydrogenation and removal of the SEM protection gave <b>35</b>. The 3-cyano derivative <b>36</b> was synthesized by bromination of the available 3-cyano pyrrolopyridine, SEM protection, and an S<sub>N</sub>Ar reaction to install the C4 amine of <b>36c</b>. A subsequent Suzuki reaction, hydrogenation, and deprotection gave <b>36</b>.</div><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0018.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Variation of the Six-Membered Ring<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) dihydropyranylBpin, Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 80 °C, 1–2 h, 76% for <b>35a</b>, 100% for <b>36a</b>; (b) SEMCl, NaH, THF, rt, 4–16 h, 48% for <b>35b</b>, 63% for <b>36b</b>; (c) LHMDS, <i>trans</i>-H<sub>2</sub>NCyMorph, BrettPhos Pd G3, THF, 80 °C, 16 h, 56%; (d) Pd/C, H<sub>2</sub> (2 atm), MeOH, rt, 2–3 h, 84% for <b>35</b>, 100% for <b>36</b>; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 3–4 h then NH<sub>3</sub>/MeOH, 3–4 h, 61% for <b>35</b>, 70% for <b>36</b>; (f) NBS, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 100% (g) <i>trans</i>-H<sub>2</sub>NCyMorph, DIPEA, iBuOH, MW, 180 °C, 5 h, 81%.</p></p></figure><div class="NLM_p">Examination of the SAR, through deconstruction of the cyclopentyl ring of <b>1</b> revealed that opening the ring to 5,6-dimethyl substituted <b>2</b> reduced potency ∼10× (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Further truncation of the 5-substituent <b>3</b>, 6-substituent <b>4</b> or both groups <b>5</b> reduced potencies in line with lipophilicity with ligand lipophilic efficiency (LLE) scores remaining around 5. We hypothesized that replacement of the thiophene sulfur with a pyrrole NH could make a more traditional, and potentially stronger, hydrogen bond with the carbonyl and introduce polarity to the hinge binding motif. The fully analogous tricycle <b>6</b> had reduced potency, albeit with lower lipophilicity and similar LLE. Opening of the ring to 5,6-dimethyl <b>7</b> reduced potency and LLE further, and the 6-methyl analogue <b>8</b> had even lower activity. By contrast, however, the 5-methyl bicycle <b>9</b> had improved enzyme potency relative to the original tricycle start point <b>1</b> and at significantly lower lipophilicity (log <i>D</i><sub>7.4</sub> 0.1) with consequently higher cellular LLE (6.6), suggesting the 5-substituted pyrrolopyrimidine core as a potentially interesting template for further optimization. Removal of all substitution <b>10</b> reduced potency, but the unsubstituted core remained at higher LLE than the original tricyclic core. The divergent SAR between the S and N cores is shown graphically in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Effect of Substitution on Thienopyrimidine and Pyrrolopyrimidine Cores</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0019.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">A</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">IRAK4 Enz IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">IRAK4 Cell IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">log <i>D</i><sub>7.4</sub><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">IRAK4 Cell LLE<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">–(CH<sub>2</sub>)<sub>3</sub>–</td><td class="colsep0 rowsep0" align="left">–(CH<sub>2</sub>)<sub>3</sub>–</td><td class="colsep0 rowsep0" align="center">0.14</td><td class="colsep0 rowsep0" align="center">0.49</td><td class="colsep0 rowsep0" align="center">1.2</td><td class="colsep0 rowsep0" align="center">5.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="center">1.5</td><td class="colsep0 rowsep0" align="center">2.5</td><td class="colsep0 rowsep0" align="center">0.7</td><td class="colsep0 rowsep0" align="center">4.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="center">1.6</td><td class="colsep0 rowsep0" align="center">3.6</td><td class="colsep0 rowsep0" align="center">0.6</td><td class="colsep0 rowsep0" align="center">4.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="center">2.4</td><td class="colsep0 rowsep0" align="center">4.3</td><td class="colsep0 rowsep0" align="center">0.3</td><td class="colsep0 rowsep0" align="center">5.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="center">4.3</td><td class="colsep0 rowsep0" align="center">8.4<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center">0.1</td><td class="colsep0 rowsep0" align="center">5.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">–(CH<sub>2</sub>)<sub>3</sub>–</td><td class="colsep0 rowsep0" align="left">–(CH<sub>2</sub>)<sub>3</sub>–</td><td class="colsep0 rowsep0" align="center">0.41</td><td class="colsep0 rowsep0" align="center">1.7<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center">0.5</td><td class="colsep0 rowsep0" align="center">5.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="center">9.0</td><td class="colsep0 rowsep0" align="center">23<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center">0.6</td><td class="colsep0 rowsep0" align="center">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>30<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center">–0.2</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="center">0.005<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">0.14</td><td class="colsep0 rowsep0" align="center">0.1</td><td class="colsep0 rowsep0" align="center">6.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="center">0.64</td><td class="colsep0 rowsep0" align="center">1.4<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center">–0.6</td><td class="colsep0 rowsep0" align="center">6.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Enzyme inhibition based on <i>n</i> ≥ 3 with SEM within 0.3 units unless otherwise stated.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Cell inhibition based on <i>n</i> ≥ 2 with SEM within 0.3 units unless otherwise stated.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">log <i>D</i><sub>7.4</sub> determined by shake flask method.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Cell LLE calculated from pIC<sub>50</sub>-log <i>D</i>.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">SEM = 0.28.</p></div><div class="footnote" id="t1fn6"><sup>f</sup><p class="last"><i>n</i> = 1.</p></div></div></div><figure id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0002.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Plot of IRAK4 enzyme pIC<sub>50</sub> (A), cell pIC<sub>50</sub> (B), cell LLE (C) against scaffolds with A = S or N showing divergent SAR between the cores. X = out of range value.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Exploration of the 5-substitution<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> with larger alkyl groups (<b>11</b>, <b>12</b>) showed cell potency increasing in line with lipophilicity; unfortunately, metabolism in rat hepatocytes was also seen to increase (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Tertiary butyl (<b>13</b>) and trifluoromethyl (<b>14</b>) substituents had reduced potency and LLE values. Cyclic secondary alkyl substituents (<b>15</b>–<b>17</b>) showed a similar trend of potency increasing in line with lipophilicity as the ring size increased from 3 to 5, but LLE remained constant and rat hepatocyte metabolism increased. In an attempt to increase polarity, cyclic ethers were investigated. In the tetrahydrofurans, both 2-substituted stereoisomers (<b>18a</b>/<b>b</b>) showed similar potency, but with the 3-substituted isomers (<b>19a</b>/<b>b</b>), a clear preference for one isomer was observed.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Unfortunately, despite having low log <i>D</i><sub>7.4</sub> values, the compounds were rapidly turned over by rat hepatocytes. Expansion to the tetrahydropyrans showed an increase in LLE for both 3- and 4-substituted isomers (<b>20</b> and <b>21</b>), with the 4-isomer (<b>21</b>) having an advantage of increased stability in rat hepatocytes. The 4-THP substituent was considered to offer an attractive balance of cellular potency/low lipophilicity/low turnover in rat hepatocytes, and a crystal structure of <b>21</b> in IRAK4 was obtained (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Comparison of the crystal structures of <b>21</b> and <b>1</b> showed a clear difference in positioning of the two scaffolds with the pyrrolopyrimidine core being held closer into the hinge by virtue of the tighter hydrogen bond between the pyrrolo NH and the carbonyl of Val262 (O--N distance is 2.9 Å, cf. O--S distance for the tricyclic compound at 3.7 Å). Closer inspection of the structures suggested that 6-substituents on the pyrrolopyrimidine ring may clash with the protein surface, potentially explaining the reduced potency observed with <b>7</b> and <b>8</b> and that the enhancement in potency seen with 5-subsitution may be rationalized by the placement of lipophilicity in a similar region occupied by the cyclopentyl ring of the tricyclic core. The 4-THP of <b>21</b> shows a lipophilic stacking interaction with Tyr262 as well as a hydrogen bond to Lys213.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Exploration of 5-Substituent</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0020.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">IRAK4 Enz IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">IRAK4 cell IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">log <i>D</i><sub>7.4</sub></th><th class="colsep0 rowsep0" align="center" char=".">IRAK4 cell LLE</th><th class="colsep0 rowsep0" align="center" char=".">rat heps Cl<sub>int</sub><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">0.005<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">0.14</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">6.6</td><td class="colsep0 rowsep0" align="char" char=".">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char=".">0.013</td><td class="colsep0 rowsep0" align="char" char=".">0.063</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">6.6</td><td class="colsep0 rowsep0" align="char" char=".">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">iPr</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="char" char=".">0.029</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">6.5</td><td class="colsep0 rowsep0" align="char" char=".">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">tBu</td><td class="colsep0 rowsep0" align="char" char=".">0.14</td><td class="colsep0 rowsep0" align="char" char=".">0.81</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td><td class="colsep0 rowsep0" align="char" char=".">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.099</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="char" char=".">66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">cPr</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">0.075</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">cBu</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.042</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="char" char=".">52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">cPn</td><td class="colsep0 rowsep0" align="char" char=".">0.006<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char=".">0.023</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="char" char=".">71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18a</b></td><td class="colsep0 rowsep0" align="left">2-THF<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">0.27</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="char" char=".">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18b</b></td><td class="colsep0 rowsep0" align="left">2-THF<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">0.28</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b></td><td class="colsep0 rowsep0" align="left">3-THF<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">0.54</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="char" char=".">120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19b</b></td><td class="colsep0 rowsep0" align="left">3-THF<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">0.008</td><td class="colsep0 rowsep0" align="char" char=".">0.034</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char=".">73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">3-THP<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">0.016</td><td class="colsep0 rowsep0" align="char" char=".">0.066</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">6.9</td><td class="colsep0 rowsep0" align="char" char=".">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">4-THP</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.059</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Separated enantiomers of unknown stereochemistry.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Racemic mixture.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Rate of metabolism (μL/min/10<sup>6</sup> cells) determined from DMSO stock solution in isolated rat hepatocytes diluted to 1 × 10<sup>6</sup> cells/mL.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">SEM = 0.28.</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">SEM = 0.33.</p></div></div></div><figure id="fig3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0003.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of pyrrolopyrimidine inhibitor <b>21</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K72">5K72</a>) in complex with IRAK4 and overlaid with tricyclic inhibitor <b>1</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K75">5K75</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The effect of changes to the atom linking the 4-position of the pyrrolopyrimidine to the cyclohexyl motif was examined (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Methylation of the nitrogen (<b>22</b>) resulted in a reduction in enzyme and cell potency relative to the unsubstituted amine (<b>21</b>) and an increase in log <i>D</i><sub>7.4</sub> (+0.4). Switching to an ether linkage (<b>23</b>) also reduced potency, despite a sizable increase in log <i>D</i><sub>7.4</sub> (+1.0), and showed increased turnover in rat hepatocytes. On balance, the 4-NH linker was viewed as optimal and variations in the amine group were subsequently investigated.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Variation of 4-Linker</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0021.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center" char=".">IRAK4 Enz IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">IRAK4 cell IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">log <i>D</i><sub>7.4</sub></th><th class="colsep0 rowsep0" align="center" char=".">IRAK4 cell LLE</th><th class="colsep0 rowsep0" align="center" char=".">rat heps Cl<sub>int</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.059</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">NMe</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="char" char=".">0.40</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="char" char=".">0.044</td><td class="colsep0 rowsep0" align="char" char=".">0.28</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr></tbody></table></div></div><div class="NLM_p">More detailed profiling of compound <b>21</b> highlighted poor permeability (<i>P</i><sub>app</sub> <1 × 10<sup>–6</sup> cm/s as measured in a Caco-2 assay) and a high degree of efflux (ER = 32) as potential concerns. We attributed this to the strength of the basic nitrogen (cpK<sub>A(BH+)</sub> = 10.6) and overall polarity (log <i>D</i><sub>7.4</sub> = 0.2). To address this, we designed analogues with increased lipophilicity and attenuated basicity (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Capping the basic nitrogen with various groups such as amide (<b>24</b>), urea (<b>25</b>), and sulphonamide (<b>26</b>) increased the log <i>D</i><sub>7.4</sub> and gave modest gains in permeability, although efflux remained an issue. In contrast, capping with a methyl carbamate (<b>27</b>) gave significantly enhanced permeability and removed the efflux liability observed with previous compounds, although the potency was slightly reduced compared to <b>21</b>. Introduction of a morpholine was also observed to enhance permeability and reduce efflux, with <b>28</b> exhibiting high potency in both enzyme and cellular assays and good stability in rat hepatocytes. Piperidines with amides in the 4-position (<b>29</b>) were also found to have activity, and attempts were made to conformationally rigidify and increase lipophilicity with lactams such as <b>30</b> and <b>31</b>. Intriguingly, both enantiomers of the lactam were very potent in both enzyme and cell although low permeability and high efflux ratios precluded further progression of these compounds. Our interpretation was that these groups project toward bulk solvent, and hence, in the absence of a preference from the protein, both enantiomers are accommodated equally well.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Variation of Amine Capping Group</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0022.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">IRAK4 Enz IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">IRAK4 cell IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">log <i>D</i><sub>7.4</sub></th><th class="colsep0 rowsep0" align="center" char=".">IRAK4 cell LLE</th><th class="colsep0 rowsep0" align="center" char=".">rat heps Cl<sub>int</sub></th><th class="colsep0 rowsep0" align="center">Caco2 <i>P</i><sub>app</sub> (ER)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.059</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="center"><1 (32)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char=".">0.002<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">0.058</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td><td class="colsep0 rowsep0" align="center">3 (38)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.034</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="center">2 (16)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="char" char=".">0.14</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="center">5 (9)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.082</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="center">20 (2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="char" char=".">0.052</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="center">14 (3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="char" char=".">0.009<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">0.27<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char=".">–0.1</td><td class="colsep0 rowsep0" align="char" char=".">6.7</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="center"><1 (8)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="char" char=".">0.002<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">0.042</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">6.4</td><td class="colsep0 rowsep0" align="char" char=".">7.3</td><td class="colsep0 rowsep0" align="center"><1 (>50)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.038</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="char" char=".">6.6</td><td class="colsep0 rowsep0" align="char" char=".">7.3</td><td class="colsep0 rowsep0" align="center"><1 (>50)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Compounds were incubated at 10 μM in cultured Caco-2 cells. Permeability (× 10<sup>–6</sup> cm/s) was measured in both the apical to basolateral (A to B) and basolateral to apical (B to A) directions with efflux ratio (ER) calculated from (BtoA)/(AtoB);</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">SEM = 0.40;</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">SEM = 0.37;</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">SEM = 0.31;</p></div><div class="footnote" id="t4fn5"><sup>e</sup><p class="last"><i>n</i> = 1.</p></div></div></div><div class="NLM_p">The crystal structure of <b>28</b> revealed a near identical binding mode to compound <b>21</b> and a highly complementary shape to the pocket (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). The basic morpholine moiety is larger than the dimethylamine of <b>21</b> and the ring is sandwiched between Asp272 (making a salt-bridge) and the backbone of Met192 (a strong polar interaction).</div><figure id="fig4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0004.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of inhibitor <b>28</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K76">5K76</a>) in complex with IRAK4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Morpholine <b>28</b> offered an attractive balance of potency and permeability and prompted us to explore close analogues by varying the linker and hinge binding group (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Synthesis of the <i>cis</i>-stereoisomer (<b>32</b>) confirmed the stereochemical preference for the <i>trans</i>-stereochemistry across the cyclohexyl ring. In line with previously observed SAR, the ether linkage (<b>33</b>) reduced potency, raised lipophilicity, and increased instability in rat hepatocytes. The thioether (<b>34</b>) offered similar potency and rat hepatocyte metabolism but at higher lipophilicity (Δlog <i>D</i> +1.5) and with a consequent reduction in aqueous solubility (5 μM compared with 130 μM for <b>28</b> at pH 7.4). Replacement of the pyrrolopyrimidine with a pyrrolopyridine (<b>35</b>) and incorporation of a 3-cyano group (<b>36</b>) did not offer any advantage. On the overall balance of properties, compound <b>28</b> was selected for further profiling.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Linker and Hinge Binder Analogues of <b>28</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0023.gif" alt="" id="fx6" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">stereo</th><th class="colsep0 rowsep0" align="center" char=".">IRAK4 Enz IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">IRAK4 cell IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">log <i>D</i><sub>7.4</sub></th><th class="colsep0 rowsep0" align="center" char=".">IRAK4 cell LLE</th><th class="colsep0 rowsep0" align="center" char=".">rat heps Cl<sub>int</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">trans</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="char" char=".">0.052</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">cis</td><td class="colsep0 rowsep0" align="char" char=".">0.57</td><td class="colsep0 rowsep0" align="char" char=".">3.1<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">trans</td><td class="colsep0 rowsep0" align="char" char=".">0.033</td><td class="colsep0 rowsep0" align="char" char=".">0.16</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char=".">110</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">trans</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">0.035</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">trans</td><td class="colsep0 rowsep0" align="char" char=".">0.022</td><td class="colsep0 rowsep0" align="char" char=".">0.34<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">CCN</td><td class="colsep0 rowsep0" align="left">trans</td><td class="colsep0 rowsep0" align="char" char=".">0.056</td><td class="colsep0 rowsep0" align="char" char=".">0.300</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">22</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last"><i>n</i> = 1.</p></div></div></div><div class="NLM_p">In terms of solid-state profile, compound <b>28</b> presents as a stable crystalline anhydrate with a melting point >300 °C. The compound converts to a dihydrate during aqueous solubility measurements, but with drying and heating the crystalline anhydrate can be reformed. The compound is a weak base with a calculated p<i>K</i><sub>a</sub> of 7.84 for the morpholine-N. Solubility of the free form is pH dependent with increasing solubility at lower pH. Solubility in water at 25 °C is 84 μM, and aqueous solubility in buffered pH 7.4 at 25 °C is 130 μM. Compound <b>28</b> shows good hydrolytic stability across the pH range 1–10.</div><div class="NLM_p">To better understand the potential to further optimize this scaffold, we were keen to understand the energy penalty required for the molecules to adopt the bioactive conformation. The structure of the anhydrous form of <b>28</b> was determined by single-crystal X-ray diffraction. In the molecule, all three saturated six-membered rings adopt “chair” conformations, and the two groups attached to the cyclohexane ring sit in the equatorial positions of the “chair”. A centrosymmetric dimeric structure forms via intermolecular hydrogen bonding between the pyrrolopyrimidine units. Additional but weaker CH-X hydrogen bonds form between the adjacent polarized CH bond and the THP group of neighboring molecules (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).</div><figure id="fig5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0005.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Single crystal X-ray structure of <b>28</b>. (B) Crystal packing in the unit cell showing a centrosymmetric dimeric structure linked by intermolecular hydrogen bonding between the pyrrolopyrimidine units and flanked by two additional units bound through the THP moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition, 2D-NMR was used to look at the conformation populations of <b>28</b> in solution. Fitted results indicate that 90% of the population exists as a single conformer (including indistinguishable, symmetrical conformations). Evolution of the proton coupling constants indicate all saturated rings exist in chair conformations with equatorial substitution. The overall conformation of <b>28</b> bound to IRAK4 is very similar to those observed in the ligand single-crystal structure and to the NMR-derived solution conformation (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). There is essentially a perfect overlap of all atoms, with the exception of the terminal morpholine group. Differences in the orientation of this group between the three structures suggests several near-degenerate rotational conformations are possible here. This implies that the molecule is largely preorganized for binding and is in an unstrained conformation upon formation of the protein ligand complex.</div><figure id="fig6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0006.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Overlay between small molecule X-ray structure (gray carbons), major solution conformation as determined by NMR (orange carbons), and observed conformation of <b>28</b> bound to IRAK4 protein (purple carbons). Overlay based on pyrrolopyrimidine unit only.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Plasma protein binding showed high amounts of free drug across species (mouse 77% free; rat 59% free; dog 86% free; human 76% free). No inhibition was observed (IC<sub>50</sub> values >30 μM) of five cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) in a high throughput human liver microsome assay. The compound showed no discernible activity (IC<sub>50</sub> > 100 μM) against the hERG ion channel and was inactive (IC<sub>50</sub> > 30 μM) against a wider selection (NaV1.5, Ito Kv4.3, Iks) of ion channels. Selectivity against other kinase targets was investigated by profiling <b>28</b> in a panel (Millipore kinase selectivity panel) of 275 kinases at a concentration of 0.1 μM (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). The profile was generally clean (IRAK4 + 4/275 > 75%inh; 8/275 > 50%inh) but showed inhibition of the CLK family (×3) and haspin kinase. These hits were followed up with concentration response data (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>) and confirmed inhibition of CLK1, 2, and 4 and haspin together with other members of the IRAK family. We also generated <i>K</i><sub>d</sub> data (DiscoverX <i>K<sub>d</sub></i>ELECT)<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> for the IRAK isoforms, which showed >30× selectivity for IRAK4 over IRAK1 and >100× selectivity over IRAK2 and 3.</div><figure id="fig7" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0007.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Millipore kinome selectivity for <b>28</b> (%inhibition @ 0.1 μM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Inhibitory Concentrations and Selected <i>K</i><sub>d</sub> Values for <b>28</b> in Kinases Identified in the Kinome Selectivity Profile As Having %Inhibition >75%</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">selectivity</th><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>d</sub> (μM)</th><th class="colsep0 rowsep0" align="center">selectivity</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IRAK4</td><td class="colsep0 rowsep0" align="center">0.005</td><td class="colsep0 rowsep0" align="center">1.0×</td><td class="colsep0 rowsep0" align="char" char=".">0.0007</td><td class="colsep0 rowsep0" align="center">1.0×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IRAK3</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.093</td><td class="colsep0 rowsep0" align="center">>130×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IRAK2</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.170</td><td class="colsep0 rowsep0" align="center">>200×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IRAK1</td><td class="colsep0 rowsep0" align="center">0.023</td><td class="colsep0 rowsep0" align="center">4.6×</td><td class="colsep0 rowsep0" align="char" char=".">0.026</td><td class="colsep0 rowsep0" align="center">37×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLK1</td><td class="colsep0 rowsep0" align="center">0.050</td><td class="colsep0 rowsep0" align="center">10.0×</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLK2</td><td class="colsep0 rowsep0" align="center">0.005</td><td class="colsep0 rowsep0" align="center">1.0×</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLK3</td><td class="colsep0 rowsep0" align="center">>1</td><td class="colsep0 rowsep0" align="center">>200×</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLK4</td><td class="colsep0 rowsep0" align="center">0.008</td><td class="colsep0 rowsep0" align="center">1.6×</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">haspin</td><td class="colsep0 rowsep0" align="center">0.004</td><td class="colsep0 rowsep0" align="center">0.8×</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="center"> </td></tr></tbody></table></div></div><div class="NLM_p">Plasma pharmacokinetic parameters for compound <b>28</b> were determined in Han Wistar rats (male; intravenous and oral) and beagle dogs (male; intravenous only). The compound was administered orally (PO) in rats as a suspension in 0.5% hydroxypropylmethylcellulose, 0.1% Tween in water at a dose of 5 mg/kg and intravenously (IV) as a solution in 5% DMSO:95% hydroxylpropyl β-cyclodextrin (30% w/v) in water at doses of 1 and 2 mg/kg in dog and rat, respectively, as shown in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. The compound was characterized by high clearance (Cl) in rat (75 mL/min/kg) despite moderate predictions based on hepatocyte data (Cl<sub>int</sub> 15 μL/min/10<sup>6</sup> cells, predicted clearance 42 mL/min/kg) with low bioavailability consistent with a high first pass effect. In dog, the clearance was lower (29 mL/min/kg) and in better accordance with the in vitro predictions based on hepatocyte data (Cl<sub>int</sub> 5 μL/min/10<sup>6</sup> cells, predicted clearance 24 mL/min/kg). No discernible turnover was observed in human hepatocytes (Cl<sub>int</sub> < 1.1 μL/min/10<sup>6</sup> cells; <i>n</i> = 8), translating through to a low to moderate predicted clearance in vivo (<6 mL/min/kg). A rat bile duct cannulated study (2 mg/kg IV, using the same formulation as the rat IV study) was carried out to investigate the under prediction observed when scaling clearance from rat hepatocytes. A significant proportion of compound was excreted as a parent in the urine (∼27%) with low levels of parent eliminated in the bile (∼2%). The amount eliminated in the urine was in excess of what would be expected from passive diffusion alone, suggesting active secretion was occurring. By considering the active renal secretion component, clearance due to metabolism was calculated as 50 mL/min/kg and in much closer agreement with the prediction from hepatocytes (42 mL/min/kg). This data suggested that the amount of active renal secretion occurring in the dog was low, given the good prediction of clearance when scaling from dog hepatocytes.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetic Parameters for Compound <b>28</b><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Cl (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">PO half-life (h)</th><th class="colsep0 rowsep0" align="center" char=".">IV half-life (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i><sub>abs</sub> (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="center">2, 5</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="char" char=".">29</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Compounds were dosed intravenously at either 1 (dog) or 2 mg/kg (rat) in 5% DMSO:95% hydroxylpropyl β-cyclodextrin (30% w/v) in water and orally at 5 mg/kg (rat) using a 0.5% hydroxypropylmethylcellulose, 0.1% Tween suspension in water, at a volume of 2 and 4 mL/kg (rat, intravenous and orally respectively) and 1 mL/kg (dog).</p></div></div></div><div class="NLM_p">Oncogenic activation of NF-κB pathway via MYD88 involves IκB kinase β (IKKβ)-mediated phosphorylation and degradation of IκB proteins.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Treatment of OCI-LY10 cells, an ABC-DLBCL cell line harboring a MYD88 mutation, with compound <b>28</b> suppressed IKK activation, as indicated by decreased phosphorylation of IκBα (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A). The inhibition of NF-kB signaling by compound <b>28</b> also inhibited growth of OCI-LY10 cells in a dose-dependent manner, whereas SUDHL2, a GCB-cell line, was not sensitive to IRAK4 inhibition (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>B). Similar data was obtained in other ABC and GCB-DLBCL cell lines (data not shown).</div><figure id="fig8" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0008.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>28</b> inhibits NF-κB signaling and growth of ABC-DLBCL cell line. (A) Dose-dependent inhibition of IκBα phosphorylation in OCI-LY10 cells upon treatment of cells with compound <b>28</b> for 14 h. (B) OCI-LY10 and SUDHL2 were monitored for growth in the presence of various concentrations of compound <b>28</b> in a 3-day growth assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While compound <b>28</b> inhibits phosphorylation of IκBα and shows a concentration dose response, we did not observe complete inhibition of IκBα phosphorylation at concentrations up to 3.3 μM. In addition to MYD88, the OCI-LY10 cell line has a mutation in CD79A. ABC-DLBCL cell lines, like OCI-LY10, are characterized by genetic aberrations in both the BCR signaling (CD79A or B, CARD11) and the MYD88 pathways, suggesting that dual inhibition of these two pathways could be required for complete inhibition of NF-κB signaling.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Bruton’s tyrosine kinase (BTK) is a crucial kinase in the BCR signaling pathway that maintains NF-κB signaling, and it has been shown to be a promising therapeutic target in ABC-DLBCL.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Addition of 3 nM of the BTK inhibitor ibrutinib<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> to compound <b>28</b> inhibits NF-κB signaling (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>A) at much lower concentrations than either compound <b>28</b> or ibrutinib alone and leads to complete inhibition of IκBα phosphorylation at concentrations above 0.37 μM (compare <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A with <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>A). Inhibition of NF-κB activity translates to synergistic effects on the loss of cell viability in cells treated with a combination of compound <b>28</b> and ibrutinib (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>B). There is an increase in cell death in OCI-LY10 cells upon increasing concentrations of compound <b>28</b> and BTK inhibitor ibrutinib (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>B,C). In contrast, no increased cell killing was observed for SUDHL2, a GCB-DLBCL cell line that is not dependent on MYD88 or BCR signaling (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>B). Induction of cell death upon combination of compound <b>28</b> and ibrutinib in OCI-LY10 cells was also confirmed by detection of cleaved caspase 3 in cellular lysates which is a known marker of apoptosis (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>D).</div><figure id="fig9" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0009.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>28</b> combines synergistically with ibrutinib to inhibit growth and NF-κB signaling in vitro in OCI-LY10 cells. (A) Effects of compound <b>28</b> upon combination with ibrutinib (3 nM) on IκBα phosphorylation in OCI-LY10 cells. (B) Percent growth inhibition of compound <b>28</b> on proliferation of OCI-LY10 or SUDHL2 cells upon combination with ibrutinib in a 5 × 5 dose matrix in a 3-day growth assay. (C) Schematic to show the typical scale in a combination growth assay where % growth inhibition is measured from 0 to 200, and 100 is regarded as zero growth or stasis. Increasing numbers from 100 to 200 exemplifies increase in cell death. (D) Western blots showing induction of apoptosis, as measured by cleavage of caspase 3 upon treatment of OCI-LY10 cells with a combination of 10 nM ibrutinib and either 0.3 or 3 μM of compound <b>28</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We subsequently investigated the antitumor efficacy of compound <b>28</b> in combination with ibrutinib in OCI-LY10 xenograft studies in mouse. As shown in <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a> and <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>, both compound <b>28</b> (12.5 mg/kg) and ibrutinib (12 mg/kg) dosed orally (qd) had modest antitumor activity as single agents, but a combination of both agents led to tumor regression. All three regimens were well tolerated throughout treatment (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>B). The in vivo efficacy data is consistent with the in vitro data where either of the compounds alone (compound <b>28</b> or ibrutinib) leads to cellular stasis but a combination of both leads to cell death and synergistic inhibition of NF-κB signaling. We considered whether any of the off-targets identified (CLK1, 2, 4 or haspin; <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>) could be making a contribution to the observed efficacy.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> While it is not possible to rule this out, we were reassured by the subsequent in vivo profiling of additional in-house derived IRAK4 chemical equity with improved selectivity against these targets. These compounds produced similar findings to <b>28</b> both as single agent and in combination with ibrutinib, and we aim to publish these findings in due course.</div><figure id="fig10" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0010.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Antitumor activity of compound <b>28</b> in combination with ibrutinib in OCI-LY10, an ABC-subtype DLBCL xenograft. (A) Daily oral dosing of Vehicle (×), ibrutinib 12 mg/kg (■), compound <b>28</b> 12.5 mg/kg (●), and combination (▲) in female SCID mice (<i>n</i> = 10 per data point) with blue coloring representing duration of dosing. (B) Body weight data for the four dose groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Antitumor Activity of Compound <b>28</b>, Ibrutinib, and Combination in the OCI-LY10 Xenograft Model</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">treatment</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">schedule</th><th class="colsep0 rowsep0" align="center" char=".">tumor growth inhibition (day 51) (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>p</i>-value (day 51)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vehicle</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">qd (po)</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ibrutinib</td><td class="colsep0 rowsep0" align="center">12</td><td class="colsep0 rowsep0" align="center">qd (po)</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">0.0079</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>28</b></td><td class="colsep0 rowsep0" align="center">12.5</td><td class="colsep0 rowsep0" align="center">qd (po)</td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="char" char=".">0.0009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ibrutinib</td><td class="colsep0 rowsep0" align="center">12</td><td class="colsep0 rowsep0" align="center">qd (po)</td><td class="colsep0 rowsep0" align="char" char=".">>100</td><td class="colsep0 rowsep0" align="char" char="."><0.0001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>28</b></td><td class="colsep0 rowsep0" align="center">12.5</td><td class="colsep0 rowsep0" align="center">qd (po)</td><td class="colsep0 rowsep0" align="char" char=".">>100</td><td class="colsep0 rowsep0" align="char" char="."><0.0001</td></tr></tbody></table></div></div><div class="NLM_p">Pharmacokinetic analysis (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>) of compound <b>28</b> indicated sufficient exposure to give coverage over the cellular IRAK4 IC<sub>50</sub> for up to 6 h daily with or without ibrutinib. No apparent drug–drug interactions were observed in terms of the concentrations of compound <b>28</b> when co-dosed with ibrutinib. Compound <b>28</b> as a single agent leads to modest tumor growth inhibition, and this may be due to the partial coverage over IRAK4 IC<sub>50</sub> for 6 h and presence of lower levels of the compound in circulation at later time points. But in combination with ibrutinib, these levels of IRAK4 inhibition appear sufficient to inhibit NF-kB signaling resulting in inhibition of cell growth and survival.</div><figure id="fig11" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0011.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Steady-state plasma concentration with time in mice bearing OCI-LY10 xenografts. Female SCID mice were administered seven daily oral doses and plasma taken post-seventh dose of compound <b>28</b> 12.5 mpk alone (●) and in combination with ibrutinib (▲) (<i>n</i> = 3 per data point).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28041" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28041" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, we have identified and optimized a series of pyrrolopyrimidine inhibitors of IRAK4 using X-ray crystal structures to identify key interactions and optimize our scaffold. This led to the identification of compound <b>28</b> as a potent inhibitor of IRAK4. Comparison of small molecule X-ray structure and solution phase NMR data of <b>28</b> with the X-ray structure of the protein–ligand complex confirmed the ligand was conformationally preorganized for binding. Compound <b>28</b> showed a favorable physicochemical and kinase selectivity profile and was identified as a promising in vivo tool with which to explore the potential role of IRAK4 inhibition in the treatment of mutant MYD88<sup>L265P</sup> DLBCL. Compound <b>28</b> inhibited NF-κB activation and growth of ABC-DLBCL cell lines in a dose-dependent manner. In combination with a BTK inhibitor, compound <b>28</b> completely inhibited NF-κB signaling and induced cell death at lower concentration in vitro in OCI-LY10 cells. In vivo, the combination of compound <b>28</b> and ibrutinib led to tumor regression in an ABC-DLBCL mouse model (OCI-LY10). This is consistent with OCI-LY10 being driven by both CD79 and MYD88 mutations wherein inhibition of both the BCR signaling and MYD88 signaling would be synergistic in inhibiting the NF-κB pathway. This data suggests that pyrrolopyrimidine inhibitors of IRAK4 in combination with a BTK inhibitor has therapeutic potential for the treatment of DLBCL.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52014" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52014" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedures</h3><div class="NLM_p">All solvents and chemicals used were reagent grade. Anhydrous solvents THF, DCM, and DMF were purchased from Aldrich. Solutions were dried over anhydrous magnesium sulfate or sodium sulfate, and solvent was removed by rotary evaporation under reduced pressure. Microwave reactions were run in a Biotage “Initiator Robot 60” (100–120/220–240 V, 50–60 Hz, 100 VA). Flash column chromatography was carried out using prepacked silica cartridges (from 4 g up to 330 g) from Grace, Redisep, or Silicycle and eluted using an Isco Companion system. The purity of compounds submitted for screening was >95% as determined by UV analysis of liquid chromatography–mass spectroscopy (LCMS) chromatograms at 254 nM and substantiated using the total absorption chromatogram (TAC). Further support for the purity statement was provided by using the MS total ion current (TIC) trace in ESI +ve and –ve ion modes, HRMS, and NMR analysis. NMR spectra were recorded on a Varian INOVA (600 MHz), Varian Gemini 2000 (300 MHz), Bruker Avance 700 (700 MHz), Bruker Avance 500 (500 MHz), or Bruker Avance DPX400 (400 MHz) and were determined in CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, or MeOH-<i>d</i><sub>4</sub>. Chemical shifts are reported in ppm relative to TMS (0.00 ppm) or solvent peaks as the internal reference. Splitting patterns are indicated as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad peak. Analytical LCMS was carried out using a suitable system, such as a Waters 2790/95 LC system with a 2996 PDA and a 2000 amu ZQ single quadrupole mass spectrometer, or a UPLC system utilizing a Waters Aquity Binary pump with sample manager, Aquity PDA and SQD mass spectrometer. Accurate mass and MSMS fragmentation data were obtained using a Thermo Scientific hybrid LTQ-FT mass spectrometer with an Agilent 1100 quaternary pump with PDA and autosampler; 5 μL of sample dissolved in 50:50 acetonitrile:water 0.1% formic acid was injected onto a Thermo Scientific Hypersil Gold 50 mm × 2.1 mm 5 μm particle LC column and eluted with a gradient of 5–100% B over 17 min with 3 min re-equilibration time at 5% B. The flow rate was 0.5 mL/min with A being 0.1% formic acid in water and B 0.1% formic acid in acetonitrile. The MS and MSMS spectra were obtained in ESI +ve mode in both the ion trap and ion cyclotron resonance (ICR) cell using helium as the collision gas at a normalized collision energy of 35 eV. The ICR cell was run at resolution settings of 25000 in MS mode and 12500 in MSMS mode.</div><div class="NLM_p">All IC<sub>50</sub> data are quoted as geometric mean values, and statistical analysis is available in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01290/suppl_file/jm7b01290_si_001.pdf" class="ext-link">Supporting Information</a>.</div><div class="NLM_p">All experimental activities involving animals were carried out in accordance with AstraZeneca animal welfare protocols which are consistent with The American Chemical Society Publications rules and ethical guidelines.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5,6-Dimethylthieno[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (<b>2</b>)</h4><div class="NLM_p last">4-Chloro-5,6-dimethylthieno[2,3-<i>d</i>]pyrimidine (0.15 g, 0.76 mmol), (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethylcyclohexane-1,4-diamine (0.107 g, 0.76 mmol), and DIPEA (0.396 mL, 2.27 mmol) were dissolved in <sup>i</sup>PrOH (1.5 mL) and sealed into a microwave tube. The reaction was heated to 85 °C for 12 h in a microwave reactor and then cooled to room temperature. The reaction mixture was evaporated to dryness and redissolved in EtOAc (50 mL) and washed sequentially with water (50 mL) and saturated brine (50 mL). The organic layer was dried over magnesium sulfate, filtered, and evaporated to afford crude product that was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5,6-dimethylthieno[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (69 mg, 30%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO, 30 °C) 1.24–1.35 (2H, m), 1.37–1.50 (2H, m), 1.79–1.87 (2H, m), 1.99–2.07 (2H, m), 2.11–2.20 (1H, m), 2.18 (6H, s), 2.38 (3H, s), 2.44 (3H, s), 3.96–4.07 (1H, m), 6.01 (1H, d), 8.24 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 13.01, 13.92, 26.81, 30.69, 41.38, 49.31, 62.38, 116.36, 124.41, 128.07, 152.58, 156.36, 163.84. <i>m</i>/<i>z</i>: ES– [M – H]<sup>−</sup> 303. HRMS (ESI) for C<sub>16</sub>H<sub>24</sub>N<sub>4</sub>S (MH<sup>+</sup>): calcd 305.1800, found 305.1791.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-Dimethyl-<i>N</i>4-(6-methylthieno[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (<b>3</b>)</h4><div class="NLM_p last">4-Chloro-6-methylthieno[2,3-<i>d</i>]pyrimidine (0.15 g, 0.81 mmol), (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethylcyclohexane-1,4-diamine (0.121 g, 0.85 mmol), and DIPEA (0.426 mL, 2.44 mmol) were dissolved in <sup>i</sup>PrOH (1.5 mL) and sealed into a microwave tube. The reaction was heated to 85 °C for 4 h in the microwave reactor and then cooled to room temperature. The reaction mixture was evaporated to dryness and redissolved in EtOAc (50 mL) and washed sequentially with water (50 mL) and saturated brine (50 mL). The organic layer was dried over magnesium sulfate, filtered, and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0–100% 1 M NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(6-methylthieno[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (0.116 g, 49%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO, 30 °C) 1.25–1.42 (4H, m), 1.78–1.92 (2H, m), 1.94–2.06 (2H, m), 2.14–2.26 (1H, m), 2.20 (6H, s), 2.50 (3H, s) <i>obscured by DMSO peak</i>, 3.93–4.10 (1H, m), 7.32 (1H, d), 7.42 (1H, d), 8.24 (1H, s). <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 291. HRMS (ESI) for C<sub>15</sub>H<sub>22</sub>N<sub>4</sub>S (MH<sup>+</sup>): calcd 291.1643, found 291.1643.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-Dimethyl-<i>N</i>4-(5-methylthieno[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (<b>4</b>)</h4><div class="NLM_p last">4-Chloro-5-methylthieno[2,3-<i>d</i>]pyrimidine (0.15 g, 0.81 mmol), (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-cyclohexane-1,4-diamine (0.121 g, 0.85 mmol), and DIPEA (0.426 mL, 2.44 mmol) were dissolved in <sup>i</sup>PrOH (1.5 mL) and sealed into a microwave tube. The reaction was heated to 100 °C for 6 h in the microwave reactor and then cooled to room temperature. The reaction mixture was evaporated to dryness and redissolved in EtOAc (50 mL) and washed sequentially with water (50 mL) and saturated brine (50 mL). The organic layer was dried over magnesium sulfate, filtered, and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0–100% 1 M NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(5-methylthieno[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (0.133 g, 56%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 27 °C) 1.18–1.33 (4H, m), 1.41–1.60 (2H, m), 1.92–2.01 (2H, m), 2.21–2.34 (1H, m), 2.31 (6H, s), 2.58 (3H, s), 4.07–4.19 (1H, m), 5.25 (1H, d), 6.82 (1H, s), 8.41 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 17.23, 26.79, 30.63, 41.38, 49.33, 62.37, 115.40, 117.67, 129.63, 153.41, 157.21, 166.85. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 291. HRMS (ESI) for C<sub>15</sub>H<sub>22</sub>N<sub>4</sub>S (MH<sup>+</sup>): calcd 291.1643, found 291.1643.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-Dimethyl-<i>N</i>4-(thieno[2,3-<i>d</i>]pyrimidin-4-yl)-cyclohexane-1,4-diamine (<b>5</b>)</h4><div class="NLM_p last">4-Chlorothieno[2,3-<i>d</i>]pyrimidine (0.16 g, 0.94 mmol), (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethylcyclohexane-1,4-diamine (0.140 g, 0.98 mmol), and DIPEA (0.491 mL, 2.81 mmol) were dissolved in <sup>i</sup>PrOH (1.5 mL) and sealed into a microwave tube. The reaction was heated to 85 °C for 4 h in the microwave reactor and cooled to room temperature. The reaction mixture was evaporated to dryness and redissolved in EtOAc (50 mL), then washed sequentially with water (50 mL) and saturated brine (50 mL). The organic layer was dried over magnesium sulfate, filtered, and evaporated to afford crude product that was purified by flash silica chromatography, elution gradient 0–100% 1 M NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(thieno[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (0.159 g, 61%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO, 27 °C) 1.23–1.44 (4H, m), 1.81–1.92 (2H, m), 1.95–2.07 (2H, m), 2.13–2.25 (1H, m), 2.19 (6H, s), 3.97–4.10 (1H, m), 7.53 (1H, d), 7.62–7.68 (2H, m), 8.32 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 26.84, 31.14, 41.34, 48.94, 62.35, 115.98, 119.55, 122.20, 153.75, 156.21, 165.51. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 277. HRMS (ESI) for C<sub>14</sub>H<sub>20</sub>N<sub>4</sub>S (MH<sup>+</sup>): calcd 277.1487, found 277.1481.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-Dimethyl-<i>N</i>4-(5,6,7,8-tetrahydrocyclopenta[4,5]pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (<b>6</b>)</h4><div class="NLM_p last">DIPEA (0.270 mL, 1.55 mmol) was added to a solution of 4-chloro-5,6,7,8-tetrahydrocyclopenta[4,5]pyrrolo[2,3-<i>d</i>]pyrimidine (100 mg, 0.52 mmol) and (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethylcyclohexane-1,4-diamine (95 mg, 0.67 mmol) in <sup>i</sup>PrOH (2 mL). The mixture was heated under microwave irradiation at 150 °C for 7 h and then heated at 160 °C for 2 h. The mixture was concentrated under vacuum, and the residue was diluted with EtOAc (15 mL) and water (10 mL). The layers were separated, and the aqueous phase was extracted with further portions of EtOAc (2 × 15 mL). The combined extracts were dried over magnesium sulfate, filtered, and evaporated. The crude product was purified by flash silica chromatography, elution gradient 0–10% 7N NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(5,6,7,8-tetrahydrocyclo-penta[4,5]pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (60.0 mg, 39%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO, 27 °C) 1.19–1.48 (4H, m), 1.77–1.88 (2H, m), 1.89–2.00 (2H, m), 2.07–2.17 (1H, m), 2.18 (6H, s), 2.30–2.43 (2H, m), 2.73 (2H, t), 2.85 (2H, t), 3.90–4.04 (1H, m), 5.94 (1H, d), 7.97 (1H, s), 11.25 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 25.25, 25.78, 27.05, 27.77, 31.39, 41.40, 48.73, 62.51, 99.77, 114.49, 138.59, 150.02, 154.41, 154.64. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 300. HRMS (ESI) for C<sub>17</sub>H<sub>25</sub>N<sub>5</sub> (MH<sup>+</sup>): calcd 300.2188, found 300.2178.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5,6-Dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (<b>7</b>)</h4><div class="NLM_p last">Aluminum trichloride (247 mg, 1.85 mmol) was added to (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(7-benzyl-5,6-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (100 mg, 0.26 mmol) in toluene (2 mL) under nitrogen, and the mixture was heated at reflux for 135 min. The mixture was then cooled to room temperature, and ice–water was added. The mixture was stirred and allowed to warm to room temperature over 20 min, then washed with DCM (3 × 15 mL). The aqueous phase was then basified with 2 M aqueous potassium carbonate, resulting in a precipitate of white solid, which remained as a fine suspension in the aqueous phase, and extracted with DCM (4 × 15 mL). The combined extracts were dried over magnesium sulfate, filtered, and evaporated to afford crude product that was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 19 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5,6-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (33.9 mg, 32%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO, 30 °C) 1.22–1.34 (2H, m), 1.34–1.46 (2H, m), 1.77–1.87 (2H, m), 1.97–2.05 (2H, m), 2.10–2.18 (1H, m), 2.18 (6H, s), 2.18 (3H, s), 2.26 (3H, s), 3.93–4.04 (1H, m), 5.52 (1H, d), 7.97 (1H, s), 11.07 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 10.50, 10.54, 26.96, 31.26, 41.39, 48.73, 62.49, 102.75, 103.37, 126.76, 149.53, 150.26, 155.40. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 288. HRMS (ESI) for C<sub>16</sub>H<sub>25</sub>N<sub>5</sub> (MH<sup>+</sup>): calcd 288.2188, found 288.2201.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-Dimethyl-<i>N</i>4-(6-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (<b>8</b>)</h4><div class="NLM_p last">4-Chloro-6-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (102 mg, 0.61 mmol), (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethylcyclohexane-1,4-diamine (82 mg, 0.58 mmol), and DIPEA (0.318 mL, 1.82 mmol) were dissolved in <sup>i</sup>PrOH (3 mL) and sealed into a microwave tube. The reaction was heated in the microwave to 100 °C for 4 h, 140 °C for 4 h, and 150 °C for a further 6 h. The crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7 M NH<sub>3</sub>/MeOH, and fractions containing the desired product were evaporated to dryness to afford a brown solid. The crude product was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(6-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclo-hexane-1,4-diamine (51.0 mg, 31%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO, 30 °C) 1.23–1.41 (4H, m), 1.78–1.91 (2H, m), 1.93–2.06 (2H, m), 2.11–2.21 (1H, m), 2.18 (6H, s), 2.28 (3H, s), 3.89–4.02 (1H, m), 6.21 (1H, s), 6.83 (1H, d), 7.99 (1H, s), 11.22 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 13.29, 26.95, 31.67, 41.39, 48.58, 62.52, 96.11, 102.90, 130.55, 150.32, 150.54, 154.51. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 274. HRMS (ESI) for C<sub>15</sub>H<sub>23</sub>N<sub>5</sub> (MH<sup>+</sup>): calcd 274.2032, found 274.2047.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-Dimethyl-<i>N</i>4-(5-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (<b>9</b>)</h4><div class="NLM_p last">4-Chloro-5-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (102 mg, 0.61 mmol), (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethylcyclohexane-1,4-diamine (82 mg, 0.58 mmol), and DIPEA (0.318 mL, 1.82 mmol) were dissolved in <sup>i</sup>PrOH (3 mL) and sealed into a microwave tube. The reaction was heated in the microwave to 100 °C for 4 h, 140 °C for 4 h, and 150 °C for a further 6 h. The crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7 M NH<sub>3</sub>/MeOH, and fractions containing the desired product were evaporated to dryness to afford a brown solid. The crude product was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(5-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclo-hexane-1,4-diamine (98 mg, 59%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO, 30 °C) 1.21–1.49 (4H, m), 1.79–1.87 (2H, m), 1.97–2.06 (2H, m), 2.11–2.20 (1H, m), 2.18 (6H, s) 2.36 (3H, s), 3.95–4.09 (1H, m), 5.64 (1H, d), 6.79 (1H, s), 8.03 (1H, s), 11.13 (1H, s). <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 274. HRMS (ESI) for C<sub>15</sub>H<sub>23</sub>N<sub>5</sub> (MH<sup>+</sup>): calcd 274.2032, found 274.2047.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-Dimethyl-<i>N</i>4-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (<b>10</b>)</h4><div class="NLM_p last">4-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.16 g, 1.04 mmol), (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethylcyclo-hexane-1,4-diamine (0.156 g, 1.09 mmol), and DIPEA (0.546 mL, 3.13 mmol) were dissolved in iPrOH (1.5 mL) and sealed into a microwave tube. The reaction was heated to 120 °C for 4 h in the microwave reactor and cooled to room temperature. The reaction mixture was evaporated to dryness and redissolved in EtOAc (50 mL) and washed sequentially with water (50 mL) and saturated brine (50 mL). The organic layer was dried over magnesium sulfate, filtered, and evaporated to afford crude product that was purified by flash silica chromatography, elution gradient 0–100% 1 M NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (47 mg, 17%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO, 27 °C) 1.24–1.41 (4H, m), 1.79–1.92 (2H, m), 1.95–2.08 (2H, m), 2.22 (6H, s), 2.51–2.60 (1H, m), 3.91–4.05 (1H, m), 6.55 (1H, dd), 7.00–7.05 (1H, m), 7.09 (1H, d), 8.06 (1H, s), 11.40 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 26.84, 31.55, 41.27, 48.53, 62.54, 98.73, 102.39, 120.50, 150.13, 151.45, 155.43. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 260. HRMS (ESI) for C<sub>14</sub>H<sub>21</sub>N<sub>5</sub> (MH<sup>+</sup>): calcd 260.1875, found 260.1884.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-Ethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (<b>11</b>)</h4><div class="NLM_p last">Tetra-<i>n</i>-butylammonium fluoride (1.25 g, 4,79 mmol) was added to (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-ethyl-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclo-hexane-1,4-diamine (400 mg, 0.96 mmol) in THF (1.5 mL). The resulting mixture was stirred at 80 °C for 3 days. The reaction mixture was purified by flash C18-flash chromatography, elution gradient 0–30% MeOH in water. Fractions containing the desired product were evaporated to dryness and then purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 0.1% NH<sub>4</sub>HCO<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-ethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (40 mg, 15%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO, 25 °C) 1.19 (3H, t), 1.23–1.37 (2H, m), 1.36–1.49 (2H, m), 1.78–1.86 (2H, m), 1.97–2.05 (2H, m), 2.10–2.20 (1H, m), 2.16 (6H, s), 2.79 (2H, q), 3.97–4.13 (1H, m), 5.55 (1H, d), 6.80 (1H, s), 8.05 (1H, s), 11.21 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 14.78, 19.45, 26.92, 31.24, 41.39, 48.75, 62.45, 101.53, 115.65, 117.23, 150.81, 151.19, 156.00. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 288. HRMS (ESI) for C<sub>16</sub>H<sub>25</sub>N<sub>5</sub> (MH<sup>+</sup>): calcd 288.2188, found 288.2201.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-Isopropyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (<b>12</b>)</h4><div class="NLM_p last">TFA (25 mL) was added to a stirred solution of (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-isopropyl-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclo-hexane-1,4-diamine (9.95 g, 23.0 mmol) in DCM (200 mL) at room temperature and stirred for 24 h. The crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 1 M NH<sub>3</sub>/MeOH, and pure fractions were allowed to stand for 24 h. The mixture was evaporated to dryness to afford crude material that was purified by flash silica chromatography, elution gradient 0–10% 1 M NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness to afford a white solid that was triturated with Et<sub>2</sub>O, filtered, and dried to afford a white solid. The solid was sonicated in water (35 mL) for 10 min, collected by filtration, washed with water, and dried under high vacuum overnight to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-isopropyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (3.075 g, 44%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 30 °C) 1.17–1.34 (2H, m), 1.35 (6H, d), 1.42–1.57 (2H, m), 1.89–2.01 (2H, m), 2.22–2.35 (3H, m), 2.31 (6H, s), 2.99–3.13 (1H, m), 4.09–4.23 (1H, m), 4.88 (1H, d), 6.74–6.78 (1H, m), 8.29 (1H, s), 9.28 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 23.8, 25.3, 27.0, 31.4, 41.4, 48.8, 62.5, 101.1, 115.8, 121.4, 150.9, 151.2, 155.8. HRMS (ESI) for C<sub>17</sub>H<sub>28</sub>N (MH<sup>+</sup>): calcd 302.2339, found 302.2339.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Formic Acid Salt of (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-(<i>tert</i>-butyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (<b>13</b>)</h4><div class="NLM_p last">(1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-(<i>tert</i>-Butyl)-2-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (580 mg, 1.66 mmol), potassium carbonate (229 mg, 1.66 mmol), and 10% Pd/C (200 mg, 0.19 mmol) in MeOH (40 mL) were stirred under an atmosphere of hydrogen at 2 atm pressure and 20 °C for 16 h. The reaction mixture was filtered through Celite, and the solvent was removed under reduced pressure. The crude product was purified by flash C18-flash chromatography, elution gradient 0–50% MeOH, in water and then by preparative HPLC (XSelect CSH Prep C18 OBD column, 5 μ silica, 19 mm diameter, 150 mm length), using decreasingly polar mixtures of water (containing formic acid) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford the formic acid salt of (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-(<i>tert</i>-butyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (98 mg, 16%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO, 22 °C) 1.25–1.45 (4H, m), 1.38 (9H, s), 1.86–1.90 (2H, m), 2.15–2.20 (2H, m), 2.25 (6H, s), 2.32–2.38 (1H, m), 4.02–4.10 (1H, m), 5.12 (1H, d), 6.87 (1H, d), 8.10 (1H, s), 8.29 (1H, s), 11.35 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 25.87, 30.23, 31.31, 31.88, 40.44, 48.70, 62.28, 100.95, 117.06, 124.04, 150.92, 151.80, 154.68, 164.49. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 316. HRMS (ESI) for C<sub>18</sub>H<sub>29</sub>N<sub>5</sub> (MH<sup>+</sup>): calcd 316.2501, found 316.2495.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Formic Acid Salt of (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-Dimethyl-<i>N</i>4-(5-(trifluoromethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (<b>14</b>)</h4><div class="NLM_p last">Tetra-<i>n</i>-butylammonium fluoride (714 mg, 2.73 mmol) was added to (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(5-(trifluoromethyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (250 mg, 0.55 mmol) in THF (2 mL). The resulting solution was stirred at 80 °C for 16 h. The solvent was removed under reduced pressure, and the crude product was purified by flash C18-flash chromatography, elution gradient 5–100% MeOH, in water and subsequently by preparative HPLC (XSelect CSH Prep C18 OBD column, 5 μ silica, 19 mm diameter, 150 mm length), using decreasingly polar mixtures of water (containing 1% formic acid) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford the formic acid salt of (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(5-(trifluoromethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (37 mg, 18%) as a white solid. <sup>1</sup>H NMR (300 MHz, MeOD-<i>d</i><sub>4</sub>, 22 °C) 1.38–1.56 (2H, m), 1.64–1.84 (2H, m), 2.14–2.23 (2H, m), 2.30–2.41 (2H, m), 2.84 (6H, s), 3.15–3.36 (1H, m), 4.14–4.26 (1H, m), 7.80 (1H, s), 8.30 (1H, s), 8.56 (1H, s) (2 × NH not observed). <sup>13</sup>C NMR (126 MHz, DMSO) 25.62 (s), 30.80 (s), 40.20 (s), 48.56 (s), 62.19 (s), 98.06 (s), 101.95 (q, <i>J</i> = 36.6 Hz), 124.04 (q, <i>J</i> = 265.2 Hz), 124.17 (q, <i>J</i> = 6.1 Hz), 151.60 (s), 152.93 (s), 154.25 (s). <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 328. HRMS (ESI) for C<sub>15</sub>H<sub>20</sub>F<sub>3</sub>N<sub>5</sub> (MH<sup>+</sup>): calcd 328.1749, found 328.1731.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-Cyclopropyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (<b>15</b>)</h4><div class="NLM_p last">Tetra-<i>n</i>-butylammonium fluoride (730 mg, 2.79 mmol) was added to (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-cyclopropyl-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (240 mg, 0.56 mmol) in THF (0.5 mL). The resulting mixture was stirred at 80 °C for 16 h. The crude product was purified by flash C18-flash chromatography, elution gradient 0–100% MeOH in water, and subsequently by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-cyclopropyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (15 mg, 9%) as a white solid. <sup>1</sup>H NMR (300 MHz, MeOD-<i>d</i><sub>4</sub>, 25 °C) 0.50–0.56 (2H, m), 0.80–0.87 (2H, m), 1.22–1.47 (4H, m), 1.81–1.96 (3H, m), 2.10–2.19 (2H, m), 2.25 (6H, s), 2.26–2.37 (1H, m), 3.85–3.96 (1H, m), 6.69 (1H, s), 7.95 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 6.24, 6.93, 26.72, 31.49, 41.35, 48.57, 62.37, 102.56, 115.55, 118.20, 150.27, 151.49, 156.13. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 300. HRMS (ESI) for C<sub>17</sub>H<sub>25</sub>N<sub>5</sub> (MH<sup>+</sup>): calcd 300.2188, found 300.2178.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-Cyclobutyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (<b>16</b>)</h4><div class="NLM_p last">Tetra-<i>n</i>-butylammonium fluoride (613 mg, 2.34 mmol) was added to (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-cyclobutyl-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethyl-cyclohexane-1,4-diamine (260 mg, 0.59 mmol) in THF (0.25 mL). The resulting mixture was stirred at 80 °C for 24 h. The reaction mixture was purified by flash C18-flash chromatography, elution gradient 0–100% MeOH in water, and then by preparative HPLC (XBridge Prep C18 OBD column, 5 μ silica, 50 mm diameter, 100 mm length), eluting with decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN. Fractions containing the desired compound were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-cyclobutyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (28 mg, 15%) as a white solid. <sup>1</sup>H NMR (300 MHz, MeOD-<i>d</i><sub>4</sub>, 25 °C) 1.33–1.57 (4H, m), 1.89–1.98 (1H, m), 2.03–2.09 (2H, m), 2.11–2.25 (5H, m), 2.35 (6H, s), 2.42–2.49 (3H, m), 3.75–3.88 (1H, m), 3.95–4.09 (1H, m), 6.88 (1H, s), 8.07 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 17.74, 26.79, 28.88, 31.31, 31.87, 41.34, 48.65, 62.42, 100.99, 116.73, 118.54, 150.93, 151.36, 155.81. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 314. HRMS (ESI) for C<sub>18</sub>H<sub>27</sub>N<sub>5</sub> (MH<sup>+</sup>): calcd 314.2345, found, 314.2323.</div></div><div id="sec4_1_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-Cyclopentyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (<b>17</b>)</h4><div class="NLM_p last">Tetra-<i>n</i>-butylammonium fluoride (1.085 g, 4.15 mmol) was added to (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-cyclopentyl-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (380 mg, 0,83 mmol) in THF (1.5 mL). The resulting mixture was stirred at 80 °C for 16 h. The reaction mixture was purified by flash C18-flash chromatography, elution gradient 0–100% MeOH in water, and then by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 50 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 0.1% NH<sub>4</sub>HCO<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1-(5-cyclopentyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-<i>N</i>4,<i>N</i>4-dimethylcyclohexane-1,4-diamine (94 mg, 35%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO, 25 °C) 1.22–1.49 (4H, m), 1.50–1.60 (2H, m), 1.60–1.76 (4H, m), 1.79–1.88 (2H, m), 1.92–2.05 (4H, m), 2.10–2.21 (1H, m), 2.19 (6H, s), 3.40 (1H, p), 3.97–4.12 (1H, m), 5.50 (1H, d), 6.82–6.85 (1H, m), 8.06 (1H, s), 11.23 (1H, d). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 24.58, 26.85, 31.31, 33.30, 36.55, 41.38, 48.73, 62.42, 101.48, 116.06, 118.21, 150.89, 151.12, 155.77. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 328. HRMS (ESI) for C<sub>19</sub>H<sub>29</sub>N<sub>5</sub> (MH<sup>+</sup>): calcd 328.2501, found 328.2510.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-Dimethyl-<i>N</i>4-(5-(tetrahydrofuran-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (<b>18</b>)</h4><div class="NLM_p last">TFA (1.25 mL) was added to (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(5-(tetrahydrofuran-2-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (80 mg, 0.17 mmol) in DCM (5 mL). The resulting solution was stirred at 20 °C for 3 h. The crude material was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 1 M NH<sub>3</sub>/MeOH and allowed to stand in the ammonia solution for 2 h. Product containing fractions were evaporated to dryness, and then the crude product was purified by flash silica chromatography, elution gradient 0–100% of 20% 1 M NH<sub>3</sub>/MeOH in DCM in 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(5-(tetrahydrofuran-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (40 mg, 70%) as a white solid. Separation of isomers by chiral chromatography was carried out by dissolving the sample in EtOH (5 mL) then using an Agilent 1100, IC column (20 μm silica, 4.6 mm diameter, 250 mm length), eluting with heptane/EtOH–MeOH/TEA, 80/20/0.2 to give first eluting isomer <b>18a</b> (16 mg, 28%, 100% chiral purity) and second eluting isomer <b>18b</b> (18 mg, 32%, 99.4% chiral purity). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 30 °C) 1.18–1.38 (2H, m), 1.40–1.55 (2H, m), 1.91–2.03 (3H, m), 2.04–2.21 (2H, m), 2.21–2.35 (4H, m), 2.33 (6H, s), 3.95 (1H, td), 3.99–4.13 (2H, m), 4.92–5.01 (1H, m), 6.88 (1H, s), 7.24 (1H, d), 8.31 (1H, s), 11.05 (1H, s), <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 24.89, 26.63, 26.66, 31.75, 31.79, 32.29, 41.38, 48.38, 62.25, 66.89, 75.38, 101.14, 113.96, 118.54, 151.11, 151.75, 155.69. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 330. HRMS (ESI) for C<sub>18</sub>H<sub>27</sub>N<sub>5</sub>O (MH<sup>+</sup>): calcd 330.2294, found 330.2308.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-Dimethyl-<i>N</i>4-(5-(tetrahydrofuran-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (<b>19</b>)</h4><div class="NLM_p last">TFA (2.5 mL) was added to (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(5-(tetrahydrofuran-3-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (0.19 g, 0.41 mmol) in DCM (10 mL). The resulting solution was stirred at 20 °C for 3 h. The crude material was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 1 M NH<sub>3</sub>/MeOH and allowed to stand in the ammonia solution for 2 h. Product containing fractions were evaporated to dryness and then purified by flash silica chromatography, elution gradient 0–100% of 20% 1 M NH<sub>3</sub>/MeOH in DCM in 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(5-(tetrahydrofuran-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (0.110 g, 81%) as a beige gum. Separation of isomers by chiral chromatography was carried out by dissolving the sample in EtOH (5 mL) then using an Agilent 1100, ID column, (20 μm silica, 4.6 mm diameter, 250 mm length), eluting with heptane/EtOH–MeOH/TEA, 75/25/0.2 to give first eluting isomer <b>19a</b> (46 mg, 34%, 100% chiral purity) and second eluting isomer <b>19b</b> (57 mg, 42%, 99.1% chiral purity). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 30 °C) 1.20–1.39 (2H, m), 1.39–1.54 (2H, m), 1.89–2.06 (3H, m), 2.18–2.33 (3H, m), 2.30 (6H, s), 2.37–2.48 (1H, m), 3.58–3.75 (2H, m), 3.93–4.06 (2H, m), 4.07–4.20 (1H, m), 4.20–4.28 (1H, m), 6.46 (1H, d), 6.76 (1H, s), 8.27 (1H, s), 9.27 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 26.82, 26.86, 31.26, 31.35, 34.35, 35.87, 41.34, 48.79, 62.47, 67.89, 73.37, 100.65, 115.86, 117.75, 151.25, 151.37, 155.52. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 330. HRMS (ESI) for C<sub>18</sub>H<sub>27</sub>N<sub>5</sub>O (MH<sup>+</sup>): calcd 330.2294, found 330.2308.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-Dimethyl-<i>N</i>4-(5-(tetrahydro-2<i>H</i>-pyran-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (<b>20</b>)</h4><div class="NLM_p last">TFA (1.0 mL) was added to (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(5-(tetrahydro-2<i>H</i>-pyran-3-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (25 mg, 0.05 mmol) in DCM (4 mL). The resulting solution was stirred at 20 °C for 3 h. The crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 1 M NH<sub>3</sub>/MeOH and allowed to stand in the ammonia solution for 2 h. Product containing fractions were evaporated to dryness and then purified by flash silica chromatography, elution gradient 0–100% of 20% 1 M NH<sub>3</sub>/MeOH in DCM in 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(5-(tetrahydro-2<i>H</i>-pyran-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (10.0 mg, 55%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 30 °C) 1.26–1.41 (2H, m), 1.50–1.66 (2H, m), 1.67–1.84 (3H, m), 2.03–2.17 (2H, m), 2.17–2.25 (1H, m), 2.27–2.39 (2H, m), 2.47 (6H, s), 2.52–2.67 (1H, m), 2.90–3.00 (1H, m), 3.34 (1H, dd), 3.45–3.54 (1H, m), 3.95–4.04 (1H, m), 4.10–4.27 (2H, m), 4.88 (1H, d), 6.85 (1H, s), 8.29 (1H, s), 10.22 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 25.31, 26.05, 30.48, 30.61, 30.79, 33.62, 40.39, 40.51, 48.46, 62.73, 67.31, 73.07, 101.20, 115.15, 117.32, 150.59, 151.08, 155.71. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 344. HRMS (ESI) for C<sub>19</sub>H<sub>29</sub>N<sub>5</sub>O (MH<sup>+</sup>): calcd 344.2450, found 344.2449.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-Dimethyl-<i>N</i>4-(5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (<b>21</b>)</h4><div class="NLM_p last">Tetra-<i>n</i>-butylammonium fluoride (911 mg, 3.48 mmol) was added to (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (330 mg, 0.70 mmol) in THF (1.5 mL). The resulting mixture was stirred at 80 °C for 16 h. The reaction mixture was purified by flash C18-flash chromatography, elution gradient 0–100% MeOH in water, and then by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 0.1% NH<sub>4</sub>HCO<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1-dimethyl-<i>N</i>4-(5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (40 mg, 17%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO, 25 °C) 1.20–1.48 (4H, m), 1.50–1.65 (2H, m), 1.76–1.89 (4H, m), 1.90–2.05 (2H, m), 2.05–2.20 (1H, m), 2.17 (6H, s), 3.15–3.35 (1H, m), 3.54 (2H, t), 3.84–3.96 (2H, m), 3.96–4.15 (1H, m) 5.52 (1H, d), 6.83 (1H, s), 8.06 (1H, s), 11.30 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 26.87, 31.21, 31.92, 34.07, 41.40, 48.88, 62.48, 66.86, 101.01, 116.40, 119.12, 150.78, 151.15, 155.70. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 344. HRMS (ESI) for C<sub>19</sub>H<sub>29</sub>N<sub>5</sub>O (MH<sup>+</sup>): calcd 344.2450, found 344.2449.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1,<i>N</i>4-Trimethyl-<i>N</i>4-(5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (<b>22</b>)</h4><div class="NLM_p last">TFA (2 mL) was added to (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1,<i>N</i>4-trimethyl-<i>N</i>4-(5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (520 mg, 1.07 mmol) in DCM (2 mL) at 25 °C. The resulting mixture was stirred at 25 °C for 1 h and evaporated. Then 2.5 M NH<sub>3</sub>/MeOH (4 mL) was added and the mixture was stirred a further 3 h. The reaction mixture was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 50 mm diameter, 150 mm length), using decreasingly polar mixtures of water (containing 0.1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>1,<i>N</i>1,<i>N</i>4-trimethyl-<i>N</i>4-(5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)cyclohexane-1,4-diamine (120 mg, 32%) as a white solid. <sup>1</sup>H NMR (300 MHz, MeOD-<i>d</i><sub>4</sub>, 25 °C) 1.26–1.46 (2H, m), 1.55–1.94 (6H, m), 2.00–2.12 (4H, m), 2.22–2.38 (1H, m), 2.31 (6H, d), 3.01 (3H, s), 3.04–3.17 (1H, m), 3.60 (2H, t), 3.89–3.99 (1H, m), 3.98–4.10 (2H, m), 7.04 (1H, s), 8.19 (1H, s). (NH not seen). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 27.15, 27.56, 32.37, 33.38, 34.51, 41.35, 59.62, 62.28, 67.46, 104.63, 118.84, 119.14, 149.46, 152.73, 161.18. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 358. HRMS (ESI) for C<sub>20</sub>H<sub>31</sub>N<sub>5</sub>O (MH<sup>+</sup>): calcd 358.2607, found 358.2595.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (1<i>r</i>,4<i>r</i>)-<i>N</i>,<i>N</i>-Dimethyl-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)cyclohexanamine (<b>23</b>)</h4><div class="NLM_p last">TFA (5 mL) was added to (1<i>r</i>,4<i>r</i>)-<i>N</i>,<i>N</i>-dimethyl-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)cyclohexanamine (0.23 g, 0.48 mmol) in DCM (10 mL). The resulting solution was stirred at 20 °C for 3 h. The crude material was purified by ion exchange chromatography using an SCX column. The desired product was eluted from the column using 1 M NH<sub>3</sub>/MeOH and allowed to stand in the ammonia solution for 2 h. Product containing fractions were evaporated to dryness and then purified by flash silica chromatography, elution gradient 0–100% of 20% 1 M NH<sub>3</sub>/MeOH in DCM in 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford (1<i>r</i>,4<i>r</i>)-<i>N</i>,<i>N</i>-dimethyl-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)cyclohexanamine (0.112 g, 67%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 30 °C) 1.45–1.67 (4H, m), 1.79 (2H, qd), 1.92–2.06 (4H, m), 2.24–2.42 (3H, m), 2.34 (6H, s), 3.13 (1H, tt), 3.43–3.64 (2H, m), 4.08 (2H, dd), 5.26 (1H, td), 6.85 (1H, d), 8.38 (1H, s), 9.08 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 25.43, 29.83, 33.23, 33.41, 41.52, 61.78, 67.43, 73.02, 103.30, 118.86, 119.38, 150.31, 152.75, 161.72. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 345. HRMS (ESI) for C<sub>19</sub>H<sub>28</sub>N<sub>4</sub>O<sub>2</sub> (MH<sup>+</sup>): calcd 345.2291, found 345.2293.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 1-(4-((1<i>r</i>,4<i>r</i>)-4-((5-(Tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazin-1-yl)ethanone (<b>24</b>)</h4><div class="NLM_p last">TFA (2 mL) was added to 1-(4-((1<i>r</i>,4<i>r</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazin-1-yl)ethanone (400 mg, 0.72 mmol) in DCM (10 mL) at 25 °C. The reaction was stirred at room temperature for 2 h, and then the solvent was removed under reduced pressure. The residue was dissolved in MeOH (10 mL), and 7N NH<sub>3</sub>/MeOH (5 mL, 35 mmol) was added at room temperature and stirred for 2 h. The solvent was removed under reduced pressure, and the crude product was purified by preparative HPLC (XSelect CSH Prep C18 OBD column, 5 μ silica, 19 mm diameter, 150 mm length), using decreasingly polar mixtures of water (containing 0.1% NH<sub>4</sub>HCO<sub>3</sub>) and MeCN as eluents. The later fractions containing the desired compound were evaporated to dryness to afford 1-(4-((1<i>r</i>,4<i>r</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazin-1-yl)ethanone (42.0 mg, 14%) as a white solid. <sup>1</sup>H NMR (300 MHz, MeOD-<i>d</i><sub>4</sub>, 27 °C) 1.35–1.60 (4H, m), 1.62–1.82 (2H, m), 1.90–2.05 (4H, m), 2.10 (3H, s), 2.19–2.23 (2H, m), 2.36–2.51 (1H, m), 2.57–2.70 (4H, m), 3.10–3.19 (1H, m), 3.50–3.73 (6H, m), 3.98–4.13 (3H, m), 6.88 (1H, s), 8.09 (1H, s) (2 × NH not observed). <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 427. HRMS (ESI) for C<sub>23</sub>H<sub>34</sub>N<sub>6</sub>O<sub>2</sub> (MH<sup>+</sup>): calcd 427.2821, found 427.2803.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i>,<i>N</i>-Dimethyl-4-((1<i>r</i>,4<i>r</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxamide (<b>25</b>)</h4><div class="NLM_p last">Dimethylcarbamic chloride (8.9 μL, 0.10 mmol) was added in one portion to <i>N</i>-((1<i>r</i>,4<i>r</i>)-4-(piperazin-1-yl)cyclohexyl)-5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-((2-(trimethylsilyl)ethoxy)-methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (50 mg, 0.10 mmol) and DIPEA (34 μL, 0.19 mmol) in DCM (4 mL) at 21 °C under nitrogen. The resulting mixture was stirred at room temperature for 1 h. TFA (0.8 mL) was added, and the reaction left to stir at ambient temperature for 1 h. The crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 1 M NH<sub>3</sub>/MeOH and product containing fractions were left to stand at room temperature overnight. Solvent was removed under reduced pressure then the residue was dissolved in DCM, and the crude product was purified by flash silica chromatography, elution gradient 0–16% MeOH in DCM. Pure fractions were evaporated to dryness, triturated with Et<sub>2</sub>O, and filtered to afford <i>N</i>,<i>N</i>-dimethyl-4-((1<i>r</i>,4<i>r</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxamide (13.0 mg, 29%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 30 °C) 1.17–1.33 (2H, m), 1.46–1.63 (2H, m), 1.72–1.86 (2H, m), 1.90–2.03 (4H, m), 2.27–2.37 (2H, m), 2.37–2.49 (1H, m), 2.52–2.65 (4H, m), 2.82–2.93 (1H, m), 2.83 (6H, s), 3.22–3.34 (4H, m), 3.56 (2H, t), 4.06–4.21 (3H, m), 4.74 (1H, d), 6.77 (1H, s), 8.30 (1H, s), 9.15 (1H, s). <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 456. HRMS (ESI) for C<sub>24</sub>H<sub>37</sub>N<sub>7</sub>O<sub>2</sub> (MH+): calcd 456.3087, found 456.3075.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-((1<i>r</i>,4<i>r</i>)-4-(4-(Methylsulfonyl)piperazin-1-yl)cyclohexyl)-5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7H-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>26</b>)</h4><div class="NLM_p last">Methanesulfonyl chloride (8.3 μL, 0.11 mmol) was added in one portion to <i>N</i>-((1<i>r</i>,4<i>r</i>)-4-(piperazin-1-yl)cyclohexyl)-5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-((2-(trimethylsilyl)ethoxy)-methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (50 mg, 0.10 mmol) and DIPEA (34 μL, 0.19 mmol) in DCM (4 mL) at 21 °C under nitrogen. The resulting mixture was stirred at room temperature for 1 h. TFA (0.8 mL) was added and the reaction left to stir for 1 h. The crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 1 M NH<sub>3</sub>/MeOH, and pure fractions were left to stand at room temperature for 2 h. The mixture was evaporated to dryness, and the crude product was purified by flash silica chromatography, elution gradient 0–10% MeOH in DCM. Pure fractions were evaporated to dryness, triturated with Et<sub>2</sub>O, and filtered to afford <i>N</i>-((1<i>r</i>,4<i>r</i>)-4-(4-(methylsulfonyl)piperazin-1-yl)cyclohexyl)-5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (4.0 mg, 9%) as a cream solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 30 °C) 1.19–1.33 (2H, m), 1.46–1.62 (2H, m), 1.72–1.87 (2H, m), 1.88–2.03 (4H, m), 2.27–2.39 (2H, m), 2.39–2.51 (1H, m), 2.65–2.75 (4H, m), 2.78 (3H, s), 2.82–2.93 (1H, m), 3.18–3.31 (4H, m), 3.56 (2H, t), 4.06–4.23 (3H, m), 4.74 (1H, d), 6.77 (1H, s), 8.30 (1H, s), 8.99 (1H, s). <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 463.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Methyl 4-((1<i>r</i>,4<i>r</i>)-4-((5-(Tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (<b>27</b>)</h4><div class="NLM_p last">TFA (4 mL) was added in one portion to a solution of methyl 4-((1<i>r</i>,4<i>r</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (370 mg, 0.65 mmol) in DCM (2 mL) under nitrogen. The resulting solution was stirred at room temperature for 1 h. The reaction mixture was purified by ion exchange chromatography, using an SCX column. The column was eluted with 1 M NH<sub>3</sub>/MeOH, and fractions containing the desired product were left to stand until complete deprotection was achieved, then evaporated to dryness. The crude product was purified by flash silica chromatography, elution gradient 0–10% MeOH in DCM. Pure fractions were evaporated to dryness and triturated with Et<sub>2</sub>O to give a solid which was collected by filtration and dried under vacuum to give methyl 4-((1<i>r</i>,4<i>r</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-cyclohexyl)piperazine-1-carboxylate (213 mg, 74%) as a white powder. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 30 °C) 1.18–1.30 (2H, m), 1.45–1.58 (2H, m), 1.72–1.86 (2H, m), 1.89–2.00 (4H, m), 2.27–2.36 (2H, m), 2.36–2.45 (1H, m), 2.51–2.58 (4H, m), 2.81–2.92 (1H, m), 3.44–3.52 (4H, m), 3.52–3.60 (2H, m), 3.70 (3H, s), 4.07–4.20 (3H, m), 4.74 (1H, d), 6.77 (1H, d), 8.30 (1H, s), 9.43 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 26.73, 31.31, 31.90, 34.06, 43.62, 48.44, 48.85, 52.24, 62.36, 66.86, 101.00, 116.41, 119.12, 150.78, 151.14, 154.98, 155.66. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 443. HRMS (ESI) for C<sub>23</sub>H<sub>34</sub>N<sub>6</sub>O<sub>3</sub> (MH<sup>+</sup>): calcd 443.2771, found 443.2787.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>N</i>-((1<i>r</i>,4<i>r</i>)-4-Morpholinocyclohexyl)-5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>28</b>)</h4><div class="NLM_p last">TFA (50 mL) was added in one portion to <i>N</i>-((1<i>r</i>,4<i>r</i>)-4-morpholinocyclohexyl)-5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (4.95 g, 9.60 mmol) in DCM (25 mL) under nitrogen. The resulting solution was stirred at room temperature for 1 h. The crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 1 M NH<sub>3</sub>/MeOH, and fractions were evaporated to dryness. The crude material was purified by flash silica chromatography, elution gradient 0–10% 1 M NH<sub>3</sub>/ MeOH in DCM. Pure fractions were evaporated to dryness and triturated with Et<sub>2</sub>O (50 mL) to give a solid which was collected by filtration and dried under vacuum to give <i>N</i>-((1<i>r</i>,4<i>r</i>)-4-morpholinocyclohexyl)-5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (2.15 g, 58%) as a white powder. <sup>1</sup>H NMR (400 MHz, DMSO, 30 °C) 1.22–1.50 (4H, m), 1.49–1.63 (2H, m), 1.78–1.92 (4H, m), 1.99–2.10 (2H, m), 2.17–2.29 (1H, m), 3.15–3.29 (1H, m), 3.48–3.62 (6H, m), 3.85–3.95 (2H, m), 3.96–4.10 (1H, m), 5.48 (1H, d), 6.83 (1H, d), 8.07 (1H, s), 11.26 (1H, s), (4H obscured by overlapping DMSO peak). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 30 °C) 1.17–1.31 (2H, m), 1.44–1.58 (2H, m), 1.75–1.87 (2H, m), 1.93–2.03 (4H, m), 2.27–2.37 (3H, m), 2.55–2.62 (4H, m), 2.82–2.93 (1H, m), 3.51–3.61 (2H, m), 3.70–3.76 (4H, m), 4.07–4.22 (3H, m), 4.76 (1H, d), 6.80 (1H, s), 8.31 (1H, s), 10.19 (1H, s). <sup>13</sup>C NMR (176 MHz, CDCl<sub>3</sub>, 30 °C) 27.1, 32.8, 34.4, 34.8, 49.3, 49.9, 63.2, 67.5, 68.2, 101.7, 116.4, 119.3, 151.2, 151.9, 156.4. HRMS (ESI) for C<sub>21</sub>H<sub>32</sub>N<sub>5</sub>O<sub>2</sub> (MH<sup>+</sup>): calcd 386.2556, found 386.2556.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>N</i>,<i>N</i>-Dimethyl-1-((1<i>r</i>,4<i>r</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperidine-4-carboxamide (<b>29</b>)</h4><div class="NLM_p last">TFA (2 mL) was added to a solution of <i>N</i>,<i>N</i>-dimethyl-1-((1<i>r</i>,4<i>r</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-cyclohexyl)piperidine-4-carboxamide (50 mg, 0.09 mmol) in DCM (2 mL), and the solution was stirred at room temperature for 3 h. The crude reaction solution was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 1 M NH<sub>3</sub>/MeOH in DCM. Pure fractions were allowed to stand for 2 h, then evaporated to dryness to afford crude product as a gum. The crude product was purified by flash silica chromatography, elution gradient 0–10% 1 M NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness to afford <i>N</i>,<i>N</i>-dimethyl-1-((1<i>r</i>,4<i>r</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperidine-4-carboxamide (15 mg, 39%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 30 °C) 1.17–1.32 (2H, m), 1.49–1.63 (2H, m), 1.65–2.04 (10H, m), 2.23–2.40 (4H, m), 2.40–2.57 (2H, m), 2.81–2.92 (1H, m), 2.92–3.03 (2H, m), 2.96 (3H, s), 3.05 (3H, s), 3.57 (2H, td), 4.07–4.21 (3H, m), 4.76 (1H, d), 6.80 (1H, s), 8.31 (1H, s), 10.18 (1H, s). <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 455. HRMS (ESI) for C<sub>25</sub>H<sub>38</sub>N<sub>6</sub>O<sub>2</sub> (MH<sup>+</sup>): calcd 455.3134, found 455.3110.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (3<i>aS</i>,7<i>aR</i>)-1-Methyl-5-((1<i>r</i>,4<i>S</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)hexahydro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-2(3<i>H</i>)-one (<b>30</b>)</h4><div class="NLM_p last">TFA (3 mL) was added to (3<i>aS</i>,7<i>aR</i>)-1-methyl-5-(4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-cyclohexyl)hexahydro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-2(3<i>H</i>)-one (300 mg, 0.51 mmol) in DCM (5 mL) at 25 °C. The resulting mixture was stirred at 25 °C for 1 h. The solvent was removed under reduced pressure, and then MeOH (5 mL) and 7 M NH<sub>3</sub>/MeOH (5 mL) were added and the mixture stirred a further 3 h. The crude product was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 50 mm diameter, 150 mm length), using decreasingly polar mixtures of water (containing 0.1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness and purified by preparative chiral-HPLC (Column: Chiralpak IA 2 cm × 25 cm, 5um; mobile phase A, Hex-HPLC; mobile phase B, EtOH-HPLC; flow rate, 18 mL/min; gradient, 50 to 50 B in 15 min; 254/220 nm). The fractions containing the second eluted isomer were combined and evaporated to afford the desired compound (3<i>aS</i>,7<i>aR</i>)-1-methyl-5-((1<i>s</i>,4<i>R</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)hexahydro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-2(3<i>H</i>)-one (26.0 mg, 26%) as a white solid. <sup>1</sup>H NMR (300 MHz, MeOD-<i>d</i><sub>4</sub>, 25 °C) 1.38–1.66 (4H, m), 1.66–1.81 (2H, m), 1.92–2.03 (6H, m), 2.06–2.34 (4H, m), 2.34–2.60 (4H, m), 2.60–2.85 (1H, m), 2.80 (3H, s), 2.78–2.89 (1H, m), 3.08–3.22 (1H, m), 3.59–3.73 (3H, m), 3.99–4.12 (3H, m), 6.88 (1H, d), 8.08 (1H, s) (2 × NH not visible). <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 453; <i>m</i>/<i>z</i>: ES+ [M + H]+ 453. HRMS (ESI) for C<sub>25</sub>H<sub>36</sub>N<sub>6</sub>O<sub>2</sub> (MH<sup>+</sup>): calcd 453.2978, found 453.2995.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (3<i>aR</i>,7<i>aS</i>)-1-Methyl-5-((1<i>r</i>,4<i>R</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)hexahydro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-2(3H)-one (<b>31</b>)</h4><div class="NLM_p last">TFA (54 μL, 0.70 mmol) was added to (3<i>aR</i>,7<i>aS</i>)-1-methyl-5-(4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-cyclohexyl)hexahydro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-2(3<i>H</i>)-one (410 mg, 0.70 mmol) in DCM (5 mL) at 25 °C. The resulting mixture was stirred at 25 °C for 1 h. The solvent was removed under reduced pressure, and then MeOH (5 mL) and 7 M NH<sub>3</sub>/MeOH (5 mL) were added and the mixture stirred a further 3 h. The reaction mixture was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 50 mm diameter, 150 mm length), eluting with decreasingly polar mixtures of water (containing 0.1% NH<sub>3</sub>) and MeCN. Fractions containing isomers of the desired product were evaporated to dryness and then purified by preparative chiral-HPLC (Column: Chiralpak IA 2 cm × 25 cm, 5 μm; mobile phase A, Hex-HPLC; mobile phase B, EtOH-HPLC; flow rate, 18 mL/min; gradient, 50 to 50 B in 30 min; 254/220 nm). The fractions containing the second eluted isomer were combined and evaporated to afford the desired compound (3<i>aR</i>,7<i>aS</i>)-1-methyl-5-((1<i>r</i>,4<i>R</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)hexahydro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-2(3<i>H</i>)-one (95 mg, 53%) as a white solid. <sup>1</sup>H NMR (300 MHz, MeOD-<i>d</i><sub>4</sub>, 25 °C) 1.30–1.60 (4H, m), 1.63–1.82 (2H, m), 1.90–2.03 (6H, m), 2.05–2.72 (9H, m), 2.77–2.88 (1H, m), 2.80 (3H, s), 3.15 (1H, tt), 3.59–3.73 (3H, m), 3.96–4.11 (3H, m), 6.88 (1H, d), 8.09 (1H, s) (2 × NH not visible). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 26.32, 26.56, 26.73, 26.84, 31.44, 31.89, 32.24, 34.07, 35.21, 44.43, 48.89, 50.39, 55.87, 62.51, 66.85, 100.98, 116.38, 119.12, 150.78, 151.13, 155.65, 174.24. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 453. HRMS (ESI) for C<sub>25</sub>H<sub>36</sub>N<sub>6</sub>O<sub>2</sub> (MH<sup>+</sup>): calcd 453.2978, found 453.2995.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-((1<i>s</i>,4<i>s</i>)-4-Morpholinocyclohexyl)-5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>32</b>)</h4><div class="NLM_p last">TFA (4.0 mL) was added in one portion to <i>N</i>-((1<i>s</i>,4<i>s</i>)-4-morpholinocyclohexyl)-5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (400 mg, 0.78 mmol) in DCM (15 mL) under nitrogen. The resulting solution was stirred at room temperature for 2.5 h. The crude product was purified by ion exchange chromatography using an SCX column. The desired product was eluted from the column using 1 M NH<sub>3</sub>/MeOH, and fractions were combined and left at room temperature for 2 h. The material was adsorbed onto silica and then purified by flash silica chromatography, elution gradient 0–10% 1 M NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness, and the residual solid was triturated with Et<sub>2</sub>O, stirred for 30 min, and filtered. The solid was dried under vacuum to give <i>N</i>-((1<i>s</i>,4<i>s</i>)-4-morpholinocyclohexyl)-5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (138 mg, 46%) as a white powder. <sup>1</sup>H NMR (400 MHz, DMSO, 30 °C) 1.46–1.72 (8H, m), 1.84–2.03 (4H, m), 2.20–2.31 (1H, m), 2.39–2.51 (4H, m), 3.14–3.25 (1H, m), 3.46–3.63 (6H, m), 3.88–4.00 (2H, m), 4.22–4.33 (1H, m), 5.43 (1H, d), 6.87 (1H, d), 8.09 (1H, s), 11.31 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 23.90, 28.25, 32.70, 34.01, 45.77, 49.42, 61.03, 66.65, 67.13, 101.28, 116.70, 118.90, 150.73, 151.14, 155.64. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 386. HRMS (ESI) for C<sub>21</sub>H<sub>31</sub>N<sub>5</sub>O<sub>2</sub> (MH<sup>+</sup>): calcd 386.2556, found 386.2539.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 4-((1<i>r</i>,4<i>r</i>)-4-((5-(Tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)cyclohexyl)morpholine (<b>33</b>)</h4><div class="NLM_p last">TFA (5 mL) was added to 4-((1<i>r</i>,4<i>r</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)cyclohexyl)morpholine (0.40 g, 0.77 mmol) in DCM (10 mL). The resulting solution was stirred at 20 °C for 3 h. The crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 1 M NH<sub>3</sub>/MeOH and allowed to stand in the ammonia solution for 2 h. Product containing fractions were evaporated to dryness and then purified by flash silica chromatography, elution gradient 0–10% MeOH in DCM. Pure fractions were evaporated to dryness to afford 4-((1<i>r</i>,4<i>r</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)cyclohexyl)morpholine (0.169 g, 56%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 30 °C) 1.45–1.63 (4H, m), 1.72–1.86 (2H, m), 1.92–2.06 (4H, m), 2.27–2.40 (3H, m), 2.54–2.63 (4H, m), 3.07–3.18 (1H, m), 3.56 (2H, td), 3.70–3.78 (4H, m), 4.04–4.13 (2H, m), 5.21–5.31 (1H, m), 6.84 (1H, dd), 8.38 (1H, s), 8.78 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 25.41, 29.95, 33.22, 33.41, 49.54, 61.54, 66.62, 67.43, 73.08, 103.28, 118.86, 119.38, 150.31, 152.74, 161.70. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 387. HRMS (ESI) for C<sub>21</sub>H<sub>30</sub>N<sub>4</sub>O<sub>3</sub> (MH<sup>+</sup>): calcd 387.2396, found 387.2402.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 4-((1<i>r</i>,4<i>r</i>)-4-((5-(Tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)thio)cyclohexyl)morpholine (<b>34</b>)</h4><div class="NLM_p last">TFA (4 mL) was added to 4-((1<i>r</i>,4<i>r</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)thio)cyclohexyl)morpholine (70 mg, 0.13 mmol) in DCM (4 mL) at 25 °C. The resulting mixture was stirred at 25 °C for 2 h, and then the solvent was removed under reduced pressure. The solid was diluted with MeOH (4 mL), and then 7N NH<sub>3</sub>/MeOH (4 mL) was added to the mixture which was stirred at 25 °C for 1 h. The solvent was removed under reduced pressure, and the crude product was purified by flash C18-flash chromatography, elution gradient 0–50% MeCN in water with 0.1% HCOOH. Pure fractions were evaporated to dryness to afford 4-((1<i>r</i>,4<i>r</i>)-4-((5-(tetrahydro-2<i>H</i>-pyran-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)thio)cyclohexyl)morpholine (13.0 mg, 25%) as a pale-yellow solid. <sup>1</sup>H NMR (300 MHz, MeOD-<i>d</i><sub>4</sub>, 30 °C) 1.44–1.65 (4H, m), 1.65–1.81 (2H, m), 1.97–2.17 (4H, m), 2.29–2.46 (3H, m), 2.61–2.73 (4H, m), 3.26–3.45 (1H, m), 3.61 (2H, dt), 3.70–3.79 (4H, m), 4.01–4.18 (3H, td), 7.13 (1H, s), 8.46 (1H, s) (NH not observed). <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 403. HRMS (ESI) for C<sub>21</sub>H<sub>30</sub>N<sub>4</sub>O<sub>2</sub>S (MH<sup>+</sup>): calcd 403.2168, found 403.2172.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-((1<i>r</i>,4<i>r</i>)-4-Morpholinocyclohexyl)-3-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-amine (<b>35</b>)</h4><div class="NLM_p last">TFA (1.0 mL, 13.0 mmol) was added to <i>N</i>-((1<i>r</i>,4<i>r</i>)-4-morpholinocyclohexyl)-3-(tetrahydro-2<i>H</i>-pyran-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-amine (300 mg, 0.58 mmol) in DCM (10 mL) at room temperature. The resulting mixture was stirred at room temperature for 16 h then evaporated to dryness. The residue was dissolved in MeOH (10 mL), and then 7N NH<sub>3</sub>/MeOH (1.0 mL) was added to the solution. The resulting solution was stirred for 3 h at room temperature, and then the solvent was removed under reduced pressure. The crude product was purified by flash C18-flash chromatography, elution gradient 0–60% MeCN in water (containing 0.1% NH<sub>4</sub>OH). Pure fractions were evaporated to dryness to afford <i>N</i>-((1<i>r</i>,4<i>r</i>)-4-morpholinocyclohexyl)-3-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-amine (136 mg, 61%) as a beige solid. <sup>1</sup>H NMR (400 MHz, DMSO, 30 °C) 1.20–1.67 (6H, m), 1.82–1.94 (4H, m), 2.05–2.15 (2H, m), 2.19–2.30 (1H, m), 2.43–2.60 (4H, m), 3.09–3.24 (1H, m), 3.30–3.43 (1H, m), 3.45–3.65 (6H, m), 3.85–3.97 (2H, m), 4.85 (1H, d), 6.16 (1H, d), 6.82 (1H, d), 7.78 (1H, d), 10.93 (1H, s). <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 385. <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 26.55, 31.19, 32.97, 34.46, 49.43, 50.55, 62.37, 66.67, 67.04, 96.68, 105.60, 116.57, 118.64, 144.11, 147.39, 149.66. <i>m</i>/<i>z</i>: ES+ [M + H]+ 385. HRMS (ESI) for C<sub>22</sub>H<sub>32</sub>N<sub>4</sub>O<sub>2</sub> (MH<sup>+</sup>): calcd 385.2604, found 385.2608.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 4-(((1<i>r</i>,4<i>r</i>)-4-Morpholinocyclohexyl)amino)-3-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carbonitrile (<b>36</b>)</h4><div class="NLM_p last">TFA (1 mL) was added to 4-(((1<i>r</i>,4<i>r</i>)-4-morpholinocyclohexyl)amino)-3-(tetrahydro-2<i>H</i>-pyran-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carbonitrile (260 mg, 0.39 mmol) in DCM (10 mL) at room temperature. The resulting mixture was stirred at room temperature for 4 h. The resulting mixture was evaporated to dryness,  then the residue was dissolved in MeOH (10 mL), and then 7N NH<sub>3</sub>/MeOH (1 mL) was added to the solution. The resulting solution was stirred for 4 h at room temperature, then the solvent was removed under reduced pressure, and the crude product was purified by flash C18-flash chromatography, elution gradient 0–40% MeCN in water (containing 0.1% ammonia). Pure fractions were evaporated to dryness to afford 4-(((1<i>r</i>,4<i>r</i>)-4-morpholinocyclohexyl)amino)-3-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carbonitrile (110 mg, 70%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO, 30 °C) 1.22–1.68 (6H, m), 1.80–1.96 (4H, m), 2.09–2.33 (3H, m), 2.44–2.60 (4H, m), 3.17–3.30 (1H, m), 3.44–3.59 (6H, m), 3.92 (2H, dd), 3.98–4.10 (1H, m), 5.54 (1H, d), 7.01 (1H, s), 8.05 (1H, s), 11.65 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO, 30 °C) 26.26, 32.21, 32.72, 34.18, 49.38, 52.09, 61.84, 66.65, 66.91, 81.41, 104.64, 118.69, 120.08, 120.81, 149.09, 149.31, 149.39. <i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 410. HRMS (ESI) for C<sub>23</sub>H<sub>31</sub>N<sub>5</sub>O<sub>2</sub> (MH<sup>+</sup>): calcd 410.2556, found 410.2564.</div></div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> IRAK4 Enzyme Potency Assay</h3><div class="NLM_p last">The inhibitory activity of compounds against IRAK4 were determined by calliper off-chip incubation mobility shift assays, using a microfluidic chip to measure the conversion of fluorescent labeled peptide to a phosphorylated product. Fluorescently tagged peptide substrates were purchased from PerkinElmer (Waltham, MA). Twelve point half-log compound concentration–response curves, with a top concentration of 100 μM, were generated from 10 mM stocks of compound solubilized in DMSO using an Echo 555 (Labcyte Inc., Sunnyvale, CA). All assays were preformed in white Greiner 384-well low volume plates (Greiner Bio-One, UK) in a total reaction volume of 12 μL and 1% (v/v) final DMSO concentration. Enzymes and substrates were added separately to the compound plates and incubated at room temperature. The kinase reaction was then quenched by the addition of 10 μL of stop buffer (100 mM HEPES pH 7.5, 5% v/v DMSO, 44 mM EDTA, 0.22% v/v CR-3 0.033% Brij35). Stopped assay plates were read using a Calliper LabChip EZ reader (PerkinElmer Waltham, MA). IC<sub>50</sub> values were calculated using a Genedata Screener (Genedata AG, Basel, Switzerland). This assay has an MDR of 2.05 (MDR calculated from all compounds screened within a one-year period).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Full length human IRAK4 was purchased from Invitrogen (Thermo Fisher Scientific, Waltham, MA). The kinase reaction (500 μM ATP, 0.3 nM IRAK4, 1.5 μM peptide 8 (5-FAM-IPTSPITTTYFFFKKK-COOH) in phosphorylation buffer (50 mM HEPES pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM DTT 0.01% Tween 20, 0.05 mg mL<sup>–1</sup> BSA) was quenched after a 240 min incubation. Truncated human IRAK1 aa194-712 was purchased from Carna Biosciences (Kobe, Japan). The kinase reaction (25 μM ATP, 0.5 nM IRAK1, 1.5 μM peptide 10 (5-FAM-KKKVSRSGLYRSPSMPENLNRPR-COOH)) in phosphorylation buffer (50 mM HEPES pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM DTT 0.01% Tween 20, 0.05 mg mL<sup>–1</sup> BSA) was quenched after a 240 min incubation.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> IRAK4 Cell Potency Assay</h3><div class="NLM_p last">Karpas-299 cells were cultured in RPMI 1640 containing 10% FBS supplemented with 1% <span class="smallcaps smallerCapital">l</span>-glutamine and 50 μM β-mercaptoethanol. Cells were plated in 96-well plate predosed with compounds at various concentrations at 2.5 × 10<sup>5</sup> cells per well and incubated at 37 °C for 1 h. Cells were then stimulated with 25 ng/mL recombinant IL-1 (R&D Systems, no. 201-LB-025) at 37 °C for 10 min, followed by fixation in 4% paraformaldehyde for 10 min and permeabilization in ice-cold 90% MeOH. Cells were washed twice with PBS containing 0.5% BSA, blocked with PBS supplemented with 10% FBS at room temperature for 20 min, and stained with anti-pIRAK4 (Thr345/Ser346) (CST, no. 11927) for 1 h, followed by antirabbit IgG conjugated to Alexa Fluor 647 (CST, no. 4414) for 30 min. Flow cytometry was performed on a FACSCanto II (BD Biosciences), and data were analyzed in FlowJo to generate IC<sub>50</sub> values. This assay has an MDR of 3.68 (MDR calculated from all compounds screened within a one-year period).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Signaling Assays</h3><div class="NLM_p">OCI-LY10 cells (in IMDM medium) were treated with increasing concentrations of compound <b>28</b> and DMSO as a control for 14 h at 37 °C. In a combination signaling assay, 3 nM ibrutinib alone and a combination of increasing concentrations of compound <b>28</b> and 3 nM ibrutinib was incubated with cells for 14 h at 37 °C. Cells were then lysed, and 30 μg of lysate was loaded onto 4–12% polyacrylamide gel. The gel was transferred to nitrocellulose membranes, and the membranes were Western blotted following typical procedures with antibodies for p-IκBα, IκBα, p-BTK, and vinculin (Cell Signaling Technology) following typical procedures.</div><div class="NLM_p last">For caspase 3 processing assay, OCI-LY10 cells were treated with either ibrutinib (10 nM) or compound <b>28</b> (0.3 or 3 μM) alone or a combination of ibrutinib and compound <b>28</b> for 6 and 24 h. Cells were then lysed and lysates run on the gel and transferred membranes blotted with antibodies for cleaved caspase 3 and pIκBα (Cell Signaling Technology).</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Growth Inhibition Assays</h3><div class="NLM_p last">A “5 × 5 dose matrix” was used to evaluate the combination effects between compound <b>28</b> and ibrutinib, where all possible mixtures of serially diluted single agents at the indicated concentrations were evaluated including zero in a growth assay. At the end of day 3, the viable cells were measued using Alamar blue reagent (a resazurin-based solution that functions as a cell health indicator by using the reducing power of living cells to quantitatively measure viability). Fluorescence with excitation wavelength at 530–560 nm and emission wavelength at 590 nm was measured. Cell growth was determined at day zero (<i>V</i><sub>0</sub>) before compound dosing and after 72 h of treatment (<i>V</i>), after treatment with the compound <i>T</i>. A GI reading of 0% represents no growth inhibition, GI 100% represents complete growth inhibition (cytostatic effect), and GI 200% represents complete death of cells. Compounds reaching an activity plateau of GI 200% are considered cytotoxic (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>C). Genedata screener calculates GI by applying the following test and equation.<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/jm-2017-01290b_m001.gif" alt="" /></img></span><span class="NLM_disp-formula" id="ueq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/jm-2017-01290b_m002.gif" alt="" /></img></span>where <i>T</i> is the signal measure for a test article, <i>V</i> is the vehicle-tretaed control measure after 72 h, and <i>V</i><sub>0</sub> is the vehicle control measure at time zero.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> In Vivo Efficacy Study</h3><div class="NLM_p last">The antitumor activity of compound <b>28</b>, Ibrutinib, and combination was evaluated in mice bearing OCI-LY10 tumors. Briefly, female CB.17 SCID mice, 5–6 weeks old, were obtained from Charles River Laboratories (Wilmington, MA). The mice were maintained in accordance with the <i>Guide for the Care and Use of Laboratory Animals</i> (National Research Council). OCI-LY10 cells (5 × 10<sup>6</sup>) were injected subcutaneously into the area under the right flank of each mouse. Then 34 days after tumor cell inoculation, mice were randomized into treatment groups: vehicle control, <b>28</b> (12.5 mg/kg), ibrutinib (12 mg/kg), and combination of <b>28</b> (12.5 mg/kg) and ibrutinib (12 mg/kg). Treatments were administered daily orally. A mouse was considered to have a partial regression (PR) when tumor volume was reduced by 50% or greater and complete tumor regression (CR) when no palpable tumor could be detected. Measures of antitumor activity, tumor growth inhibition (TGI), and partial and complete regression are shown in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>. Tumor volumes following administration of the test articles, with time after tumor inoculation, are plotted in <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>. All treatments were well tolerated with no body weight loss as with vehicle control animals. Plasma was collected via tail-microsampling 7 days post daily dose of compound <b>28</b> and concentration determined via liquid chromatography mass spectrometry.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Formulation of Compounds</h3><div class="NLM_p last"><b>28</b> was prepared at 10% captisol, pH = 4. Ibrutinib was prepared in 0.5% methyl cellulose.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01290">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07075" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07075" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01290" class="ext-link">10.1021/acs.jmedchem.7b01290</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental procedures for the synthesis of intermediates together with biological data and associated errors, kinase selectivity data, NMR conformation, crystallography, and molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01290/suppl_file/jm7b01290_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01290/suppl_file/jm7b01290_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01290/suppl_file/jm7b01290_si_001.pdf">jm7b01290_si_001.pdf (1.34 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01290/suppl_file/jm7b01290_si_002.csv">jm7b01290_si_002.csv (2.13 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Crystal structures of IRAK4 in complex with compounds <b>1</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K75">5K75</a>), <b>21</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K72">5K72</a>), <b>28</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K76">5K76</a>), and crystal structure of <b>28</b> (1572736). Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b01290" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01056" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01056" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James S. Scott</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2263-7024" title="Orcid link">http://orcid.org/0000-0002-2263-7024</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#650f04080c004b16060a11112504161117041f000b0006044b060a08"><span class="__cf_email__" data-cfemail="1d777c707478336e7e7269695d7c6e696f7c677873787e7c337e7270">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sébastien L. Degorce</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rana Anjum</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Janet Culshaw</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Macclesfield SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert D. M. Davies</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Macclesfield SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nichola L. Davies</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keith S. Dillman</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James E. Dowling</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa Drew</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew D. Ferguson</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1018-9631" title="Orcid link">http://orcid.org/0000-0002-1018-9631</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sam D. Groombridge</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Macclesfield SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher T. Halsall</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Macclesfield SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julian A. Hudson</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Macclesfield SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Lamont</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicola A. Lindsay</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stacey K. Marden</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Sciences, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michele F. Mayo</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Elizabeth Pease</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David R. Perkins</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Macclesfield SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer H. Pink</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Macclesfield SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Graeme R. Robb</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan Rosen</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minhui Shen</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claire McWhirter</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dedong Wu</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Sciences, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d78e8095-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i66">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73784" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73784" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Kurt Pike, Tom Moss and Chuck Omer are thanked for their valuable contributions regarding the manuscript, India L. Neveras is thanked for in vivo support. All experimental activities involving animals were carried out in accordance with AstraZeneca animal welfare protocols which are consistent with The American Chemical Society Publications rules and ethical guidelines.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i67" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i67"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i68" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i68"> Abbreviations Used</h2><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">B-cell receptor</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">Cl<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">Cy</td><td class="NLM_def"><p class="first last">cyclohexyl</p></td></tr><tr><td class="NLM_term">DLBCL</td><td class="NLM_def"><p class="first last">diffuse large B-cell lymphoma</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">efflux ratio</p></td></tr><tr><td class="NLM_term">IKKβ</td><td class="NLM_def"><p class="first last">inhibitor of nuclear factor kappa-B kinase</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">IRAK4</td><td class="NLM_def"><p class="first last">interleukin-1 receptor associated kinase 4</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus tyrosine kinase</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">ligand lipophilic efficiency</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">microwave</p></td></tr><tr><td class="NLM_term">MYD88</td><td class="NLM_def"><p class="first last">myeloid differentiation primary response gene 88</p></td></tr><tr><td class="NLM_term">NF</td><td class="NLM_def"><p class="first last">nuclear factor</p></td></tr><tr><td class="NLM_term">NHL</td><td class="NLM_def"><p class="first last">non-Hodgkin lymphoma</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub></td><td class="NLM_def"><p class="first last">apparent permeability</p></td></tr><tr><td class="NLM_term">R-CHOP</td><td class="NLM_def"><p class="first last">chemotherapeutic combination of cyclophosphamide, doxorubicin, vincristine, and prednisone together with the monoclonal antibody rituximab</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">trimethylsilylethoxymethyl</p></td></tr><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 3</p></td></tr><tr><td class="NLM_term">TLR</td><td class="NLM_def"><p class="first last">Toll-like receptor</p></td></tr><tr><td class="NLM_term">TRAF6</td><td class="NLM_def"><p class="first last">TNF receptor-associated factor 6</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">steady-state volume of distribution</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i69">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72725" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72725" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 35 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naishadham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Cancer statistics</span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.3322/caac.21166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.3322%2Fcaac.21166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=23335087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A280%3ADC%252BC3szgvFSqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2013&pages=11-30&author=R.+Siegelauthor=D.+Naishadhamauthor=A.+Jemal&title=Cancer+statistics&doi=10.3322%2Fcaac.21166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2013</span></div><div class="casAuthors">Siegel Rebecca; Naishadham Deepa; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics.  A total of 1,660,290 new cancer cases and 580,350 cancer deaths are projected to occur in the United States in 2013.  During the most recent 5 years for which there are data (2005-2009), delay-adjusted cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.5% per year in women.  Overall, cancer death rates have declined 20% from their peak in 1991 (215.1 per 100,000 population) to 2009 (173.1 per 100,000 population).  Death rates continue to decline for all 4 major cancer sites (lung, colorectum, breast, and prostate).  Over the past 10 years of data (2000-2009), the largest annual declines in death rates were for chronic myeloid leukemia (8.4%), cancers of the stomach (3.1%) and colorectum (3.0%), and non-Hodgkin lymphoma (3.0%).  The reduction in overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of approximately 1.18 million deaths from cancer, with 152,900 of these deaths averted in 2009 alone.  Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket and other underserved populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQA4Ff_lauq0IkFb3mqPUYDfW6udTcc2eY2M_vQET6rmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szgvFSqsw%253D%253D&md5=1b89010b6bcfc5472f32879085ab4ccc</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21166%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DNaishadham%26aufirst%3DD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2013%26volume%3D63%26spage%3D11%26epage%3D30%26doi%3D10.3322%2Fcaac.21166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sehn, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donaldson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chhanabhai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgerald, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klasa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacPherson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinelli, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, J. M.</span><span> </span><span class="NLM_article-title">Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5027</span><span class="NLM_x">–</span> <span class="NLM_lpage">5033</span><span class="refDoi"> DOI: 10.1200/JCO.2005.09.137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1200%2FJCO.2005.09.137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=15955905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFWmtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5027-5033&author=L.+H.+Sehnauthor=J.+Donaldsonauthor=M.+Chhanabhaiauthor=C.+Fitzgeraldauthor=K.+Gillauthor=R.+Klasaauthor=N.+MacPhersonauthor=S.+O%E2%80%99Reillyauthor=J.+J.+Spinelliauthor=J.+Sutherlandauthor=K.+S.+Wilsonauthor=R.+D.+Gascoyneauthor=J.+M.+Connors&title=Introduction+of+combined+CHOP+plus+rituximab+therapy+dramatically+improved+outcome+of+diffuse+large+B-cell+lymphoma+in+British+Columbia&doi=10.1200%2FJCO.2005.09.137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia</span></div><div class="casAuthors">Sehn, Laurie H.; Donaldson, Jane; Chhanabhai, Mukesh; Fitzgerald, Catherine; Gill, Karamjit; Klasa, Richard; MacPherson, Nicol; O'Reilly, Susan; Spinelli, John J.; Sutherland, Judy; Wilson, Kenneth S.; Gascoyne, Randy D.; Connors, Joseph M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5027-5033</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">For more than two decades, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been the std. therapy for diffuse large B-cell lymphoma (DLBCL).  The addn. of rituximab to CHOP has been shown to improve outcome in elderly patients with DLBCL.  We conducted a population-based anal. to assess the impact of this combination therapy on adult patients with DLBCL in the province of British Columbia (BC).  We compared outcomes during a 3-yr period; 18 mo before (prerituximab) and 18 mo after (postrituximab) institution of a policy recommending the combination of CHOP and rituximab for all patients with newly diagnosed advanced-stage (stage III or IV or stage I or II with "B" symptoms or bulky [> 10 cm] disease) DLBCL.  A total of 292 patients were evaluated; 140 in the prerituximab group (median follow-up, 42 mo) and 152 in the postrituximab group (median follow-up, 24 mo).  Both progression-free survival (risk ratio, 0.56; 95% CI, 0.39 to 0.81; P = .002) and overall survival (risk ratio, 0.40; 95% CI, 0.27 to 0.61, P < .0001) were significantly improved in the postrituximab group.  After controlling for age and International Prognostic Index score, era of treatment remained a strong independent predictor of progression-free survival (risk ratio, 0.59; 95% CI, 0.41 to 0.85; P = .005) and overall survival (risk ratio, 0.43; 95% CI, 0.29 to 0.66; P < .001).  The benefit of treatment in the postrituximab era was present regardless of age.  The addn. of rituximab to CHOP chemotherapy has resulted in a dramatic improvement in outcome for DLBCL patients of all ages in the province of BC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJyQAmyoPMTLVg90H21EOLACvtfcHk0lgjqdZhxDDrBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFWmtLs%253D&md5=b9d4a2e52564591eda23216437d6df52</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.09.137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.09.137%26sid%3Dliteratum%253Aachs%26aulast%3DSehn%26aufirst%3DL.%2BH.%26aulast%3DDonaldson%26aufirst%3DJ.%26aulast%3DChhanabhai%26aufirst%3DM.%26aulast%3DFitzgerald%26aufirst%3DC.%26aulast%3DGill%26aufirst%3DK.%26aulast%3DKlasa%26aufirst%3DR.%26aulast%3DMacPherson%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DS.%26aulast%3DSpinelli%26aufirst%3DJ.%2BJ.%26aulast%3DSutherland%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26atitle%3DIntroduction%2520of%2520combined%2520CHOP%2520plus%2520rituximab%2520therapy%2520dramatically%2520improved%2520outcome%2520of%2520diffuse%2520large%2520B-cell%2520lymphoma%2520in%2520British%2520Columbia%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5027%26epage%3D5033%26doi%3D10.1200%2FJCO.2005.09.137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Camicia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassa, P. O.</span><span> </span><span class="NLM_article-title">Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="refDoi"> DOI: 10.1186/s12943-015-0474-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1186%2Fs12943-015-0474-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=26654227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpt1Olurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=207&author=R.+Camiciaauthor=H.+C.+Winklerauthor=P.+O.+Hassa&title=Novel+drug+targets+for+personalized+precision+medicine+in+relapsed%2Frefractory+diffuse+large+B-cell+lymphoma%3A+a+comprehensive+review&doi=10.1186%2Fs12943-015-0474-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review</span></div><div class="casAuthors">Camicia, Rosalba; Winkler, Hans C.; Hassa, Paul O.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207/1-207/62</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Diffuse large B-cell lymphoma (DLBCL) is a clin. heterogeneous lymphoid malignancy and the most common subtype of non-Hodgkin's lymphoma in adults, with one of the highest mortality rates in most developed areas of the world.  More than half of DLBLC patients can be cured with std. R-CHOP regimens, however approx. 30 to 40 % of patients will develop relapsed/refractory disease that remains a major cause of morbidity and mortality due to the limited therapeutic options.  Recent advances in gene expression profiling have led to the identification of at least three distinct mol. subtypes of DLBCL: a germinal center B cell-like subtype, an activated B cell-like subtype, and a primary mediastinal B-cell lymphoma subtype.  Moreover, recent findings have not only increased our understanding of the mol. basis of chemotherapy resistance but have also helped identify mol. subsets of DLBCL and rational targets for drug interventions that may allow for subtype/subset-specific molecularly targeted precision medicine and personalized combinations to both prevent and treat relapsed/refractory DLBCL.  Novel agents such as lenalidomide, ibrutinib, bortezomib, CC-122, epratuzumab or pidilizumab used as single-agent or in combination with (rituximab-based) chemotherapy have already demonstrated promising activity in patients with relapsed/ refractory DLBCL.  Several novel potential drug targets have been recently identified such as the BET bromodomain protein (BRD)-4, phosphoribosyl-pyrophosphate synthetase (PRPS)-2, macrodomain-contg. mono-ADP-ribosyltransferase (ARTD)-9 (also known as PARP9), deltex-3-like E3 ubiquitin ligase (DTX3L) (also known as BBAP), NF-kappaB inducing kinase (NIK) and transforming growth factor beta receptor (TGFssR).  This review highlights the new insights into the mol. basis of relapsed/refractory DLBCL and summarizes the most promising drug targets and exptl. treatments for relapsed/refractory DLBCL, including the use of novel agents such as lenalidomide, ibrutinib, bortezomib, pidilizumab, epratuzumab, brentuximab-vedotin or CAR T cells, dual inhibitors, as well as mechanism-based combinatorial exptl. therapies.  We also provide a comprehensive and updated list of current drugs, drug targets and preclin. and clin. exptl. studies in DLBCL.  A special focus is given on STAT1, ARTD9, DTX3L and ARTD8 (also known as PARP14) as novel potential drug targets in distinct mol. subsets of DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJp4JiT_yM07Vg90H21EOLACvtfcHk0lgjqdZhxDDrBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpt1Olurk%253D&md5=c4365573bf9b7d942ecdefadf08c7741</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1186%2Fs12943-015-0474-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-015-0474-2%26sid%3Dliteratum%253Aachs%26aulast%3DCamicia%26aufirst%3DR.%26aulast%3DWinkler%26aufirst%3DH.%2BC.%26aulast%3DHassa%26aufirst%3DP.%2BO.%26atitle%3DNovel%2520drug%2520targets%2520for%2520personalized%2520precision%2520medicine%2520in%2520relapsed%252Frefractory%2520diffuse%2520large%2520B-cell%2520lymphoma%253A%2520a%2520comprehensive%2520review%26jtitle%3DMol.%2520Cancer%26date%3D2015%26volume%3D14%26spage%3D207%26doi%3D10.1186%2Fs12943-015-0474-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sidorova, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvonkov, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarikov, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severina, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovrigina, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troitskaya, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savchenko, V. G.</span><span> </span><span class="NLM_article-title">MYD88 L265P Mutation is a possible unfavorable prognostic factor in patients with diffuse B-Cell lymphoma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">5051</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=5051&author=A.+A.+Sidorovaauthor=E.+E.+Zvonkovauthor=A.+B.+Sudarikovauthor=N.+A.+Severinaauthor=A.+M.+Kovriginaauthor=V.+V.+Troitskayaauthor=V.+G.+Savchenko&title=MYD88+L265P+Mutation+is+a+possible+unfavorable+prognostic+factor+in+patients+with+diffuse+B-Cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSidorova%26aufirst%3DA.%2BA.%26aulast%3DZvonkov%26aufirst%3DE.%2BE.%26aulast%3DSudarikov%26aufirst%3DA.%2BB.%26aulast%3DSeverina%26aufirst%3DN.%2BA.%26aulast%3DKovrigina%26aufirst%3DA.%2BM.%26aulast%3DTroitskaya%26aufirst%3DV.%2BV.%26aulast%3DSavchenko%26aufirst%3DV.%2BG.%26atitle%3DMYD88%2520L265P%2520Mutation%2520is%2520a%2520possible%2520unfavorable%2520prognostic%2520factor%2520in%2520patients%2520with%2520diffuse%2520B-Cell%2520lymphoma%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D5051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Alizadeh, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisen, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lossos, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenwald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldrick, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabet, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marti, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibshirani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherlock, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greiner, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisenburger, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armitage, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">403</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">511</span><span class="refDoi"> DOI: 10.1038/35000501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1038%2F35000501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10676951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1Shtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=403&publication_year=2000&pages=503-511&author=A.+A.+Alizadehauthor=M.+B.+Eisenauthor=R.+E.+Davisauthor=C.+Maauthor=I.+S.+Lossosauthor=A.+Rosenwaldauthor=J.+C.+Boldrickauthor=H.+Sabetauthor=T.+Tranauthor=X.+Yuauthor=J.+I.+Powellauthor=L.+Yangauthor=G.+E.+Martiauthor=T.+Mooreauthor=J.+Hudsonauthor=L.+Luauthor=D.+B.+Lewisauthor=R.+Tibshiraniauthor=G.+Sherlockauthor=W.+C.+Chanauthor=T.+C.+Greinerauthor=D.+D.+Weisenburgerauthor=J.+O.+Armitageauthor=R.+Warnkeauthor=R.+Levyauthor=W.+Wilsonauthor=M.+R.+Greverauthor=J.+C.+Byrdauthor=D.+Botsteinauthor=P.+O.+Brownauthor=L.+M.+Staudt&title=Distinct+types+of+diffuse+large+B-cell+lymphoma+identified+by+gene+expression+profiling&doi=10.1038%2F35000501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling</span></div><div class="casAuthors">Alizadeh, Ash A.; Eisen, Michael B.; Davis, R. Eric; Ma, Chi; Lossos, Izidore S.; Rosenwald, Andreas; Boldrick, Jennifer C.; Sabet, Hajeer; Tran, Truc; Yu, Xin; Powell, John I.; Yang, Liming; Marti, Gerald E.; Moore, Troy; Hudson, James, Jr.; Luo, Lisheng; Lewis, David B.; Tibshirani, T, Robert; Sherlock, Gavin; Chan, Wing C.; Greiner, Timothy C.; Weisenburger, Dennis D.; Armitage, James O.; Wamke, Roger; Levy, Ronald; Wilson, Wyndham; Grever, Michael R.; Byrd, John C.; Botstein, David; Brown, Patrick O.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">403</span>
        (<span class="NLM_cas:issue">6769</span>),
    <span class="NLM_cas:pages">503-511</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clin. heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease.  We proposed that this variability in natural history reflects unrecognized mol. heterogeneity in the tumors.  Using DNA microarrays, we have conducted a systematic characterization of gene expression in B-cell malignancies.  Here we show that there is diversity in gene expression among the tumors of DLBCL patients, apparently reflecting the variation in tumor proliferation rate, host response and differentiation state of the tumor.  We identified two molecularly distinct forms of DLBCL which had gene expression patterns indicative of different stages of B-cell differentiation.  One type expressed genes characteristic of germinal center B cells ('germinal center B-like DLBCL'); the second type expressed genes normally induced during in vitro activation of peripheral blood B cells ('activated B-like DLBCL').  Patients with germinal center B-like DLBCL had a significantly better overall survival than those with activated B-like DLBCL.  The mol. classification of tumors on the basis of gene expression can thus identify previously undetected and clin. significant subtypes of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof-ooPQqcS3rVg90H21EOLACvtfcHk0lg3yIy0Yj9ufg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1Shtrg%253D&md5=d56170148faf43b53abfd129a38b6c9e</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1038%2F35000501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35000501%26sid%3Dliteratum%253Aachs%26aulast%3DAlizadeh%26aufirst%3DA.%2BA.%26aulast%3DEisen%26aufirst%3DM.%2BB.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DLossos%26aufirst%3DI.%2BS.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DBoldrick%26aufirst%3DJ.%2BC.%26aulast%3DSabet%26aufirst%3DH.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DPowell%26aufirst%3DJ.%2BI.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DMarti%26aufirst%3DG.%2BE.%26aulast%3DMoore%26aufirst%3DT.%26aulast%3DHudson%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DD.%2BB.%26aulast%3DTibshirani%26aufirst%3DR.%26aulast%3DSherlock%26aufirst%3DG.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DGreiner%26aufirst%3DT.%2BC.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DArmitage%26aufirst%3DJ.%2BO.%26aulast%3DWarnke%26aufirst%3DR.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DWilson%26aufirst%3DW.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DBotstein%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DP.%2BO.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DDistinct%2520types%2520of%2520diffuse%2520large%2520B-cell%2520lymphoma%2520identified%2520by%2520gene%2520expression%2520profiling%26jtitle%3DNature%26date%3D2000%26volume%3D403%26spage%3D503%26epage%3D511%26doi%3D10.1038%2F35000501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Ngo, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jhavar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlhammer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesser, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenwald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Hermelink, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimsza, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffe, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delabie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeland, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braziel, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubbs, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisenburger, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Oncogenically active MYD88 mutations in human lymphoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">470</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span><span class="refDoi"> DOI: 10.1038/nature09671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1038%2Fnature09671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=21179087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVCksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=470&publication_year=2011&pages=115-119&author=V.+N.+Ngoauthor=R.+M.+Youngauthor=R.+Schmitzauthor=S.+Jhavarauthor=W.+Xiaoauthor=K.+H.+Limauthor=H.+Kohlhammerauthor=W.+Xuauthor=Y.+Yangauthor=H.+Zhaoauthor=A.+L.+Shafferauthor=P.+Romesserauthor=G.+Wrightauthor=J.+Powellauthor=A.+Rosenwaldauthor=H.+K.+Muller-Hermelinkauthor=G.+Ottauthor=R.+D.+Gascoyneauthor=J.+M.+Connorsauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+I.+Fisherauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=L.+M.+Staudt&title=Oncogenically+active+MYD88+mutations+in+human+lymphoma&doi=10.1038%2Fnature09671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenically active MYD88 mutations in human lymphoma</span></div><div class="casAuthors">Ngo, Vu N.; Young, Ryan M.; Schmitz, Roland; Jhavar, Sameer; Xiao, Wenming; Lim, Kian-Huat; Kohlhammer, Holger; Xu, Weihong; Yang, Yandan; Zhao, Hong; Shaffer, Arthur L.; Romesser, Paul; Wright, George; Powell, John; Rosenwald, Andreas; Muller-Hermelink, Hans Konrad; Ott, German; Gascoyne, Randy D.; Connors, Joseph M.; Rimsza, Lisa M.; Campo, Elias; Jaffe, Elaine S.; Delabie, Jan; Smeland, Erlend B.; Fisher, Richard I.; Braziel, Rita M.; Tubbs, Raymond R.; Cook, J. R.; Weisenburger, Denny D.; Chan, Wing C.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">470</span>
        (<span class="NLM_cas:issue">7332</span>),
    <span class="NLM_cas:pages">115-119</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) remains the least curable form of this malignancy despite recent advances in therapy.  Constitutive nuclear factor (NF)-κB and JAK kinase signaling promotes malignant cell survival in these lymphomas, but the genetic basis for this signaling is incompletely understood.  Here we describe the dependence of ABC DLBCLs on MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signaling, and the discovery of highly recurrent oncogenic mutations affecting MYD88 in ABC DLBCL tumors.  RNA interference screening revealed that MYD88 and the assocd. kinases IRAK1 and IRAK4 are essential for ABC DLBCL survival.  High-throughput RNA resequencing uncovered MYD88 mutations in ABC DLBCL lines.  Notably, 29% of ABC DLBCL tumors harbored the same amino acid substitution, L265P, in the MYD88 Toll/IL-1 receptor (TIR) domain at an evolutionarily invariant residue in its hydrophobic core.  This mutation was rare or absent in other DLBCL subtypes and Burkitt's lymphoma, but was obsd. in 9% of mucosa-assocd. lymphoid tissue lymphomas.  At a lower frequency, addnl. mutations were obsd. in the MYD88 TIR domain, occurring in both the ABC and germinal center B-cell-like (GCB) DLBCL subtypes.  Survival of ABC DLBCL cells bearing the L265P mutation was sustained by the mutant but not the wild-type MYD88 isoform, demonstrating that L265P is a gain-of-function driver mutation.  The L265P mutant promoted cell survival by spontaneously assembling a protein complex contg. IRAK1 and IRAK4, leading to IRAK4 kinase activity, IRAK1 phosphorylation, NF-κB signaling, JAK kinase activation of STAT3, and secretion of IL-6, IL-10 and interferon-β.  Hence, the MYD88 signaling pathway is integral to the pathogenesis of ABC DLBCL, supporting the development of inhibitors of IRAK4 kinase and other components of this pathway for the treatment of tumors bearing oncogenic MYD88 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5pEPxh1G6J7Vg90H21EOLACvtfcHk0lg3yIy0Yj9ufg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVCksQ%253D%253D&md5=3dff4d54af8f64bb9e57f04cf274fee8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature09671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09671%26sid%3Dliteratum%253Aachs%26aulast%3DNgo%26aufirst%3DV.%2BN.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DSchmitz%26aufirst%3DR.%26aulast%3DJhavar%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DLim%26aufirst%3DK.%2BH.%26aulast%3DKohlhammer%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DRomesser%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DR.%2BI.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DOncogenically%2520active%2520MYD88%2520mutations%2520in%2520human%2520lymphoma%26jtitle%3DNature%26date%3D2011%26volume%3D470%26spage%3D115%26epage%3D119%26doi%3D10.1038%2Fnature09671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Fernández-Rodríguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellosillo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-García, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez-González, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimeno, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vela, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besses, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salar, A.</span><span> </span><span class="NLM_article-title">MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">2104</span><span class="NLM_x">–</span> <span class="NLM_lpage">2106</span><span class="refDoi"> DOI: 10.1038/leu.2014.184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1038%2Fleu.2014.184" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=2104-2106&author=C.+Fern%C3%A1ndez-Rodr%C3%ADguezauthor=B.+Bellosilloauthor=M.+Garc%C3%ADa-Garc%C3%ADaauthor=B.+S%C3%A1nchez-Gonz%C3%A1lezauthor=E.+Gimenoauthor=M.+C.+Velaauthor=S.+Serranoauthor=C.+Bessesauthor=A.+Salar&title=MYD88+%28L265P%29+mutation+is+an+independent+prognostic+factor+for+outcome+in+patients+with+diffuse+large+B-cell+lymphoma&doi=10.1038%2Fleu.2014.184"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fleu.2014.184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2014.184%26sid%3Dliteratum%253Aachs%26aulast%3DFern%25C3%25A1ndez-Rodr%25C3%25ADguez%26aufirst%3DC.%26aulast%3DBellosillo%26aufirst%3DB.%26aulast%3DGarc%25C3%25ADa-Garc%25C3%25ADa%26aufirst%3DM.%26aulast%3DS%25C3%25A1nchez-Gonz%25C3%25A1lez%26aufirst%3DB.%26aulast%3DGimeno%26aufirst%3DE.%26aulast%3DVela%26aufirst%3DM.%2BC.%26aulast%3DSerrano%26aufirst%3DS.%26aulast%3DBesses%26aufirst%3DC.%26aulast%3DSalar%26aufirst%3DA.%26atitle%3DMYD88%2520%2528L265P%2529%2520mutation%2520is%2520an%2520independent%2520prognostic%2520factor%2520for%2520outcome%2520in%2520patients%2520with%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DLeukemia%26date%3D2014%26volume%3D28%26spage%3D2104%26epage%3D2106%26doi%3D10.1038%2Fleu.2014.184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Iwasaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medzhitov, R.</span><span> </span><span class="NLM_article-title">Regulation of adaptive immunity by the innate immune system</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">327</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.1126/science.1183021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1126%2Fscience.1183021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=20075244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktlWkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2010&pages=291-295&author=A.+Iwasakiauthor=R.+Medzhitov&title=Regulation+of+adaptive+immunity+by+the+innate+immune+system&doi=10.1126%2Fscience.1183021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of Adaptive Immunity by the Innate Immune System</span></div><div class="casAuthors">Iwasaki, Akiko; Medzhitov, Ruslan</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">5963</span>),
    <span class="NLM_cas:pages">291-295</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Twenty years after the proposal that pattern recognition receptors detect invasion by microbial pathogens, the field of immunol. has witnessed several discoveries that have elucidated receptors and signaling pathways of microbial recognition systems and how they control the generation of T and B lymphocyte-mediated immune responses.  However, there are still many fundamental questions that remain poorly understood, even though sometimes the answers are assumed to be known.  Here, the authors discuss some of these questions, including the mechanisms by which pathogen-specific innate immune recognition activates antigen-specific adaptive immune responses and the roles of different types of innate immune recognition in host defense from infection and injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9JwoyOJ_s1bVg90H21EOLACvtfcHk0lhE7wZaItsa0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktlWkuw%253D%253D&md5=8af81826f9cee93a51dff10ffb8140de</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.1183021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1183021%26sid%3Dliteratum%253Aachs%26aulast%3DIwasaki%26aufirst%3DA.%26aulast%3DMedzhitov%26aufirst%3DR.%26atitle%3DRegulation%2520of%2520adaptive%2520immunity%2520by%2520the%2520innate%2520immune%2520system%26jtitle%3DScience%26date%3D2010%26volume%3D327%26spage%3D291%26epage%3D295%26doi%3D10.1126%2Fscience.1183021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">O’Neill, L. A.</span><span> </span><span class="NLM_article-title">The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">226</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00701.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1111%2Fj.1600-065X.2008.00701.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=19161412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGlsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=2008&pages=10-18&author=L.+A.+O%E2%80%99Neill&title=The+interleukin-1+receptor%2FToll-like+receptor+superfamily%3A+10+years+of+progress&doi=10.1111%2Fj.1600-065X.2008.00701.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The interleukin-1 receptor/toll-like receptor superfamily: 10 years of progress</span></div><div class="casAuthors">O'Neill, Luke A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-18</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The interleukin-1 receptor (IL-1R)/Toll-like receptor (TLR) superfamily was first defined in 1998 as a family of proteins that contain the Toll-IL-1 receptor domain.  At that time, there were a no. of orphan receptors in the IL-1R branch, and the TLRs had yet to be shown to be key innate immune receptors that sense microbial products.  We now know a great deal more about this superfamily, with the description of novel IL-1 family members such as IL-1F6 signaling via IL-1Rrp2 and IL33 signaling via ST2.  Remarkable progress has been made in our understanding of the functions of the TLRs, leading to a renaissance of interest in innate immunity.  The importance of IL-1 is also being rediscovered, with the observation that Nalp3 is a key regulator of caspase-1, the enzyme that processes pro-IL-1β into the mature cytokine.  This area has therefore proved very fruitful in terms of improving our knowledge of the mol. basis for innate immunity and inflammation, and we can anticipate further discoveries in the coming years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGGZYo1rHKc7Vg90H21EOLACvtfcHk0li2oEfZkOGscw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGlsrfF&md5=5765db66cbf1fcff210c715dea71cdb2</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00701.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00701.x%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%2BA.%26atitle%3DThe%2520interleukin-1%2520receptor%252FToll-like%2520receptor%2520superfamily%253A%252010%2520years%2520of%2520progress%26jtitle%3DImmunol.%2520Rev.%26date%3D2008%26volume%3D226%26spage%3D10%26epage%3D18%26doi%3D10.1111%2Fj.1600-065X.2008.00701.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Wang, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeelall, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horikawa, K.</span><span> </span><span class="NLM_article-title">Toll-like receptors and cancer: MYD88 Mutation and Inflammation</span> <span class="citation_source-journal">Front. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="refDoi"> DOI: 10.3389/fimmu.2014.00367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.3389%2Ffimmu.2014.00367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=25132836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FivValtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=367&author=J.+Q.+Wangauthor=Y.+S.+Jeelallauthor=L.+L.+Fergusonauthor=K.+Horikawa&title=Toll-like+receptors+and+cancer%3A+MYD88+Mutation+and+Inflammation&doi=10.3389%2Ffimmu.2014.00367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation</span></div><div class="casAuthors">Wang James Q; Jeelall Yogesh S; Ferguson Laura L; Horikawa Keisuke</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">367</span>
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    </div><div class="casAbstract">Pattern recognition receptors (PRRs) expressed on immune cells are crucial for the early detection of invading pathogens, in initiating early innate immune response and in orchestrating the adaptive immune response.  PRRs are activated by specific pathogen-associated molecular patterns that are present in pathogenic microbes or nucleic acids of viruses or bacteria.  However, inappropriate activation of these PRRs, such as the Toll-like receptors (TLRs), due to genetic lesions or chronic inflammation has been demonstrated to be a major cause of many hematological malignancies.  Gain-of-function mutations in the TLR adaptor protein MYD88 found in 39% of the activated B cell type of diffuse large B cell lymphomas and almost 100% of Waldenstrom's macroglobulinemia further highlight the involvement of TLRs in these malignancies.  MYD88 mutations result in the chronic activation of TLR signaling pathways, thus the constitutive activation of the transcription factor NFκB to promote cell survival and proliferation.  These recent insights into TLR pathway driven malignancies warrant the need for a better understanding of TLRs in cancers and the development of novel anti-cancer therapies targeting TLRs.  This review focuses on TLR function and signaling in normal or inflammatory conditions, and how mutations can hijack the TLR signaling pathways to give rise to cancer.  Finally, we discuss how potential therapeutic agents could be used to restore normal responses to TLRs and have long lasting anti-tumor effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLaqWjAreWhjdblLE_E9PWfW6udTcc2eYJ1dVE8Wi-Erntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FivValtw%253D%253D&md5=22747c832ecae697e2aa767fddbeb43a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2014.00367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2014.00367%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BQ.%26aulast%3DJeelall%26aufirst%3DY.%2BS.%26aulast%3DFerguson%26aufirst%3DL.%2BL.%26aulast%3DHorikawa%26aufirst%3DK.%26atitle%3DToll-like%2520receptors%2520and%2520cancer%253A%2520MYD88%2520Mutation%2520and%2520Inflammation%26jtitle%3DFront.%2520Immunol.%26date%3D2014%26volume%3D5%26spage%3D367%26doi%3D10.3389%2Ffimmu.2014.00367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Varettoni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcaini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zibellini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boveri, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rattotti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riboni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlandi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonfichi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascutto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangiacavalli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croci, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiaccadori, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morello, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrera, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paulli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cazzola, M.</span><span> </span><span class="NLM_article-title">Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">2522</span><span class="NLM_x">–</span> <span class="NLM_lpage">2528</span><span class="refDoi"> DOI: 10.1182/blood-2012-09-457101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1182%2Fblood-2012-09-457101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2013&pages=2522-2528&author=M.+Varettoniauthor=L.+Arcainiauthor=S.+Zibelliniauthor=E.+Boveriauthor=S.+Rattottiauthor=R.+Riboniauthor=A.+Corsoauthor=E.+Orlandiauthor=M.+Bonfichiauthor=M.+Gottiauthor=C.+Pascuttoauthor=S.+Mangiacavalliauthor=G.+Crociauthor=V.+Fiaccadoriauthor=L.+Morelloauthor=M.+L.+Guerreraauthor=M.+Paulliauthor=M.+Cazzola&title=Prevalence+and+clinical+significance+of+the+MYD88+%28L265P%29+somatic+mutation+in+Waldenstrom%E2%80%99s+macroglobulinemia+and+related+lymphoid+neoplasms&doi=10.1182%2Fblood-2012-09-457101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-09-457101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-09-457101%26sid%3Dliteratum%253Aachs%26aulast%3DVarettoni%26aufirst%3DM.%26aulast%3DArcaini%26aufirst%3DL.%26aulast%3DZibellini%26aufirst%3DS.%26aulast%3DBoveri%26aufirst%3DE.%26aulast%3DRattotti%26aufirst%3DS.%26aulast%3DRiboni%26aufirst%3DR.%26aulast%3DCorso%26aufirst%3DA.%26aulast%3DOrlandi%26aufirst%3DE.%26aulast%3DBonfichi%26aufirst%3DM.%26aulast%3DGotti%26aufirst%3DM.%26aulast%3DPascutto%26aufirst%3DC.%26aulast%3DMangiacavalli%26aufirst%3DS.%26aulast%3DCroci%26aufirst%3DG.%26aulast%3DFiaccadori%26aufirst%3DV.%26aulast%3DMorello%26aufirst%3DL.%26aulast%3DGuerrera%26aufirst%3DM.%2BL.%26aulast%3DPaulli%26aufirst%3DM.%26aulast%3DCazzola%26aufirst%3DM.%26atitle%3DPrevalence%2520and%2520clinical%2520significance%2520of%2520the%2520MYD88%2520%2528L265P%2529%2520somatic%2520mutation%2520in%2520Waldenstrom%25E2%2580%2599s%2520macroglobulinemia%2520and%2520related%2520lymphoid%2520neoplasms%26jtitle%3DBlood%26date%3D2013%26volume%3D121%26spage%3D2522%26epage%3D2528%26doi%3D10.1182%2Fblood-2012-09-457101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Treon, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripsas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcaini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkus, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohani, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laramie, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skifter, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lincoln, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, Z. R.</span><span> </span><span class="NLM_article-title">MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">826</span><span class="NLM_x">–</span> <span class="NLM_lpage">833</span><span class="refDoi"> DOI: 10.1056/NEJMoa1200710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1056%2FNEJMoa1200710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=22931316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGktLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=826-833&author=S.+P.+Treonauthor=L.+Xuauthor=G.+Yangauthor=Y.+Zhouauthor=X.+Liuauthor=Y.+Caoauthor=P.+Sheehyauthor=R.+J.+Manningauthor=C.+J.+Pattersonauthor=C.+Tripsasauthor=L.+Arcainiauthor=G.+S.+Pinkusauthor=S.+J.+Rodigauthor=A.+R.+Sohaniauthor=N.+L.+Harrisauthor=J.+M.+Laramieauthor=D.+A.+Skifterauthor=S.+E.+Lincolnauthor=Z.+R.+Hunter&title=MYD88+L265P+somatic+mutation+in+Waldenstr%C3%B6m%E2%80%99s+macroglobulinemia&doi=10.1056%2FNEJMoa1200710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia</span></div><div class="casAuthors">Treon, Steven P.; Xu, Lian; Yang, Guang; Zhou, Yangsheng; Liu, Xia; Cao, Yang; Sheehy, Patricia; Manning, Robert J.; Patterson, Christopher J.; Tripsas, Christina; Arcaini, Luca; Pinkus, Geraldine S.; Rodig, Scott J.; Sohani, Aliyah R.; Harris, Nancy Lee; Laramie, Jason M.; Skifter, Donald A.; Lincoln, Stephen E.; Hunter, Zackary R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">826-833</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Waldenstrom's macroglobulinemia is an incurable, IgM-secreting lymphoplasmacytic lymphoma (LPL).  The underlying mutation in this disorder has not been delineated.  METHODS We performed whole-genome sequencing of bone marrow LPL cells in 30 patients with Waldenstrom's macroglobulinemia, with paired normal-tissue and tumor-tissue sequencing in 10 patients.  Sanger sequencing was used to validate the findings in samples from an expanded cohort of patients with LPL, those with other B-cell disorders that have some of the same features as LPL, and healthy donors.  RESULTS Among the patients with Waldenstrom's macroglobulinemia, a somatic variant (T→C) in LPL cells was identified at position 38182641 at 3p22.2 in the samples from all 10 patients with paired tissue samples and in 17 of 20 samples from patients with unpaired samples.  This variant predicted an amino acid change (L265P) in MYD88, a mutation that triggers IRAK-mediated NF-κB signaling.  Sanger sequencing identified MYD88 L265P in tumor samples from 49 of 54 patients with Waldenstrom's macroglobulinemia and in 3 of 3 patients with non-IgM-secreting LPL (91%0 of all patients with LPL).  MYD88 L265P was absent in paired normal tissue samples from patients with Waldenstrom's macroglobulinemia or non-IgM LPL and in B cells from healthy donors and was absent or rarely expressed in samples from patients with multiple myeloma, marginal-zone lymphoma, or IgM monoclonal gammopathy of unknown significance.  Inhibition of MYD88 signaling reduced IκBα and NF-κB p65 phosphorylation, as well as NF-κB nuclear staining, in Waldenstrom's macroglobulinemia cells expressing MYD88 L265P.  Somatic variants in ARID1A in 5 of 30 patients (17%), leading to a premature stop or frameshift, were also identified and were assocd. with an increased disease burden.  In addn., 2 of 3 patients with Waldenstrom's macroglobulinemia who had wild-type MYD88 had somatic variants in MLL2.  CONCLUSIONS MYD88 L265P is a commonly recurring mutation in patients with Waldenstrom's macroglobulinemia that can be useful in differentiating Waldenstrom's macroglobulinemia and non-IgM LPL from B-cell disorders that have some of the same features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8DO7wCi3bbrVg90H21EOLACvtfcHk0li2oEfZkOGscw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGktLrN&md5=fc9ac9b80297d49c8d5f2fa0965415de</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1200710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1200710%26sid%3Dliteratum%253Aachs%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DSheehy%26aufirst%3DP.%26aulast%3DManning%26aufirst%3DR.%2BJ.%26aulast%3DPatterson%26aufirst%3DC.%2BJ.%26aulast%3DTripsas%26aufirst%3DC.%26aulast%3DArcaini%26aufirst%3DL.%26aulast%3DPinkus%26aufirst%3DG.%2BS.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DSohani%26aufirst%3DA.%2BR.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DLaramie%26aufirst%3DJ.%2BM.%26aulast%3DSkifter%26aufirst%3DD.%2BA.%26aulast%3DLincoln%26aufirst%3DS.%2BE.%26aulast%3DHunter%26aufirst%3DZ.%2BR.%26atitle%3DMYD88%2520L265P%2520somatic%2520mutation%2520in%2520Waldenstr%25C3%25B6m%25E2%2580%2599s%2520macroglobulinemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D826%26epage%3D833%26doi%3D10.1056%2FNEJMoa1200710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Pham-Ledard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappellen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beylot-Barry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlio, J. P.</span><span> </span><span class="NLM_article-title">MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">2118</span><span class="NLM_x">–</span> <span class="NLM_lpage">2120</span><span class="refDoi"> DOI: 10.1038/jid.2012.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1038%2Fjid.2012.102" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2012&pages=2118-2120&author=A.+Pham-Ledardauthor=D.+Cappellenauthor=F.+Martinezauthor=B.+Vergierauthor=M.+Beylot-Barryauthor=J.+P.+Merlio&title=MYD88+somatic+mutation+is+a+genetic+feature+of+primary+cutaneous+diffuse+large+B-cell+lymphoma%2C+leg+type&doi=10.1038%2Fjid.2012.102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fjid.2012.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2012.102%26sid%3Dliteratum%253Aachs%26aulast%3DPham-Ledard%26aufirst%3DA.%26aulast%3DCappellen%26aufirst%3DD.%26aulast%3DMartinez%26aufirst%3DF.%26aulast%3DVergier%26aufirst%3DB.%26aulast%3DBeylot-Barry%26aufirst%3DM.%26aulast%3DMerlio%26aufirst%3DJ.%2BP.%26atitle%3DMYD88%2520somatic%2520mutation%2520is%2520a%2520genetic%2520feature%2520of%2520primary%2520cutaneous%2520diffuse%2520large%2520B-cell%2520lymphoma%252C%2520leg%2520type%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2012%26volume%3D132%26spage%3D2118%26epage%3D2120%26doi%3D10.1038%2Fjid.2012.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Montesinos-Rongen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godlewska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiestler, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siebert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deckert, M.</span><span> </span><span class="NLM_article-title">Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma</span> <span class="citation_source-journal">Acta Neuropathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">791</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1007/s00401-011-0891-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1007%2Fs00401-011-0891-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2011&pages=791-792&author=M.+Montesinos-Rongenauthor=E.+Godlewskaauthor=A.+Brunnauthor=O.+D.+Wiestlerauthor=R.+Siebertauthor=M.+Deckert&title=Activating+L265P+mutations+of+the+MYD88+gene+are+common+in+primary+central+nervous+system+lymphoma&doi=10.1007%2Fs00401-011-0891-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs00401-011-0891-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-011-0891-2%26sid%3Dliteratum%253Aachs%26aulast%3DMontesinos-Rongen%26aufirst%3DM.%26aulast%3DGodlewska%26aufirst%3DE.%26aulast%3DBrunn%26aufirst%3DA.%26aulast%3DWiestler%26aufirst%3DO.%2BD.%26aulast%3DSiebert%26aufirst%3DR.%26aulast%3DDeckert%26aufirst%3DM.%26atitle%3DActivating%2520L265P%2520mutations%2520of%2520the%2520MYD88%2520gene%2520are%2520common%2520in%2520primary%2520central%2520nervous%2520system%2520lymphoma%26jtitle%3DActa%2520Neuropathol.%26date%3D2011%26volume%3D122%26spage%3D791%26epage%3D792%26doi%3D10.1007%2Fs00401-011-0891-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Kraan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Keimpema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horlings, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schilder-Tol, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oud, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noorduyn, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluin, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersten, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spaargaren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pals, S. T.</span><span> </span><span class="NLM_article-title">High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">719</span><span class="NLM_x">–</span> <span class="NLM_lpage">720</span><span class="refDoi"> DOI: 10.1038/leu.2013.348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1038%2Fleu.2013.348" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=719-720&author=W.+Kraanauthor=M.+van+Keimpemaauthor=H.+M.+Horlingsauthor=E.+J.+Schilder-Tolauthor=M.+E.+Oudauthor=L.+A.+Noorduynauthor=P.+M.+Kluinauthor=M.+J.+Kerstenauthor=M.+Spaargarenauthor=S.+T.+Pals&title=High+prevalence+of+oncogenic+MYD88+and+CD79B+mutations+in+primary+testicular+diffuse+large+B-cell+lymphoma&doi=10.1038%2Fleu.2013.348"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.348%26sid%3Dliteratum%253Aachs%26aulast%3DKraan%26aufirst%3DW.%26aulast%3Dvan%2BKeimpema%26aufirst%3DM.%26aulast%3DHorlings%26aufirst%3DH.%2BM.%26aulast%3DSchilder-Tol%26aufirst%3DE.%2BJ.%26aulast%3DOud%26aufirst%3DM.%2BE.%26aulast%3DNoorduyn%26aufirst%3DL.%2BA.%26aulast%3DKluin%26aufirst%3DP.%2BM.%26aulast%3DKersten%26aufirst%3DM.%2BJ.%26aulast%3DSpaargaren%26aufirst%3DM.%26aulast%3DPals%26aufirst%3DS.%2BT.%26atitle%3DHigh%2520prevalence%2520of%2520oncogenic%2520MYD88%2520and%2520CD79B%2520mutations%2520in%2520primary%2520testicular%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DLeukemia%26date%3D2014%26volume%3D28%26spage%3D719%26epage%3D720%26doi%3D10.1038%2Fleu.2013.348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Picard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bustamante, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soudais, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupuis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fieschi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elbim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Ghonaium, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Rayes, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Jumaah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Hajjar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Mohsen, I. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frayha, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rucker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawn, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aderem, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tufenkeji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haraguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gougerot-Pocidalo, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozinsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casanova, J. L.</span><span> </span><span class="NLM_article-title">Pyogenic bacterial infections in humans with IRAK-4 deficiency</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">2076</span><span class="NLM_x">–</span> <span class="NLM_lpage">2079</span><span class="refDoi"> DOI: 10.1126/science.1081902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1126%2Fscience.1081902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=12637671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlCisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=2076-2079&author=C.+Picardauthor=A.+Puelauthor=M.+Bonnetauthor=C.+L.+Kuauthor=J.+Bustamanteauthor=K.+Yangauthor=C.+Soudaisauthor=S.+Dupuisauthor=J.+Feinbergauthor=C.+Fieschiauthor=C.+Elbimauthor=R.+Hitchcockauthor=D.+Lammasauthor=G.+Daviesauthor=A.+Al-Ghonaiumauthor=H.+Al-Rayesauthor=S.+Al-Jumaahauthor=S.+Al-Hajjarauthor=I.+Z.+Al-Mohsenauthor=H.+H.+Frayhaauthor=R.+Ruckerauthor=T.+R.+Hawnauthor=A.+Aderemauthor=H.+Tufenkejiauthor=S.+Haraguchiauthor=N.+K.+Dayauthor=R.+A.+Goodauthor=M.+A.+Gougerot-Pocidaloauthor=A.+Ozinskyauthor=J.+L.+Casanova&title=Pyogenic+bacterial+infections+in+humans+with+IRAK-4+deficiency&doi=10.1126%2Fscience.1081902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Pyogenic Bacterial Infections in Humans with IRAK-4 Deficiency</span></div><div class="casAuthors">Picard, Capucine; Puel, Anne; Bonnet, Marion; Ku, Cheng-Lung; Bustamante, Jacinta; Yang, Kun; Soudais, Claire; Dupuis, Stephanie; Feinberg, Jacqueline; Fieschi, Claire; Elbim, Carole; Hitchcock, Remi; Lammas, David; Davies, Graham; Al-Ghonaium, Abdulaziz; Al-Rayes, Hassan; Al-Jumaah, Sulaiman; Al-Hajjar, Sami; Al-Mohsen, Ibrahim Zaid; Frayha, Husn H.; Rucker, Rajivi; Hawn, Thomas R.; Aderem, Alan; Tufenkeji, Haysam; Haraguchi, Soichi; Day, Noorbibi K.; Good, Robert A.; Gougerot-Pocidalo, Marie-Anne; Ozinsky, Adrian; Casanova, Jean-Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">5615</span>),
    <span class="NLM_cas:pages">2076-2079</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Members of the Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) superfamily share an intracytoplasmic Toll-IL-1 receptor (TIR) domain, which mediates recruitment of the interleukin-1 receptor-assocd. kinase (IRAK) complex via TIR-contg. adapter mols.  The authors describe three unrelated children with inherited IRAK-4 deficiency.  Their blood and fibroblast cells did not activate nuclear factor κB and mitogen-activated protein kinase (MAPK) and failed to induce downstream cytokines in response to any of the known ligands of TIR-bearing receptors.  The otherwise healthy children developed infections caused by pyogenic bacteria.  These findings suggest that, in humans, the TIR-IRAK signaling pathway is crucial for protective immunity against specific bacteria but is redundant against most other microorganisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGone924bm7Fl7Vg90H21EOLACvtfcHk0lhqRds4Mqa0tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlCisLo%253D&md5=4c70a72ac33d3e3ce8b194befd8a3211</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.1081902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1081902%26sid%3Dliteratum%253Aachs%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DPuel%26aufirst%3DA.%26aulast%3DBonnet%26aufirst%3DM.%26aulast%3DKu%26aufirst%3DC.%2BL.%26aulast%3DBustamante%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DSoudais%26aufirst%3DC.%26aulast%3DDupuis%26aufirst%3DS.%26aulast%3DFeinberg%26aufirst%3DJ.%26aulast%3DFieschi%26aufirst%3DC.%26aulast%3DElbim%26aufirst%3DC.%26aulast%3DHitchcock%26aufirst%3DR.%26aulast%3DLammas%26aufirst%3DD.%26aulast%3DDavies%26aufirst%3DG.%26aulast%3DAl-Ghonaium%26aufirst%3DA.%26aulast%3DAl-Rayes%26aufirst%3DH.%26aulast%3DAl-Jumaah%26aufirst%3DS.%26aulast%3DAl-Hajjar%26aufirst%3DS.%26aulast%3DAl-Mohsen%26aufirst%3DI.%2BZ.%26aulast%3DFrayha%26aufirst%3DH.%2BH.%26aulast%3DRucker%26aufirst%3DR.%26aulast%3DHawn%26aufirst%3DT.%2BR.%26aulast%3DAderem%26aufirst%3DA.%26aulast%3DTufenkeji%26aufirst%3DH.%26aulast%3DHaraguchi%26aufirst%3DS.%26aulast%3DDay%26aufirst%3DN.%2BK.%26aulast%3DGood%26aufirst%3DR.%2BA.%26aulast%3DGougerot-Pocidalo%26aufirst%3DM.%2BA.%26aulast%3DOzinsky%26aufirst%3DA.%26aulast%3DCasanova%26aufirst%3DJ.%2BL.%26atitle%3DPyogenic%2520bacterial%2520infections%2520in%2520humans%2520with%2520IRAK-4%2520deficiency%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D2076%26epage%3D2079%26doi%3D10.1126%2Fscience.1081902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">von Bernuth, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pankla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrabieh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustapha, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghandil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camcioglu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasconcelos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirvent, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitor, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrero-Mata, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aróstegui, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsina, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz-Ortiz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortuny, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yagüe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antón, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janniere, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garty, B. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issekutz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maródi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Gallego, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banchereau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaussabel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casanova, J. L.</span><span> </span><span class="NLM_article-title">Pyogenic bacterial infections in humans with MYD88 deficiency</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">321</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">696</span><span class="refDoi"> DOI: 10.1126/science.1158298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1126%2Fscience.1158298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=18669862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVKnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2008&pages=691-696&author=H.+von+Bernuthauthor=C.+Picardauthor=Z.+Jinauthor=R.+Panklaauthor=H.+Xiaoauthor=C.+L.+Kuauthor=M.+Chrabiehauthor=I.+B.+Mustaphaauthor=P.+Ghandilauthor=Y.+Camciogluauthor=J.+Vasconcelosauthor=N.+Sirventauthor=M.+Guedesauthor=A.+B.+Vitorauthor=M.+J.+Herrero-Mataauthor=J.+I.+Ar%C3%B3steguiauthor=C.+Rodrigoauthor=L.+Alsinaauthor=E.+Ruiz-Ortizauthor=M.+Juanauthor=C.+Fortunyauthor=J.+Yag%C3%BCeauthor=J.+Ant%C3%B3nauthor=M.+Pascalauthor=H.+H.+Changauthor=L.+Janniereauthor=Y.+Roseauthor=B.+Z.+Gartyauthor=H.+Chapelauthor=A.+Issekutzauthor=L.+Mar%C3%B3diauthor=C.+Rodriguez-Gallegoauthor=J.+Banchereauauthor=L.+Abelauthor=X.+Liauthor=D.+Chaussabelauthor=A.+Puelauthor=J.+L.+Casanova&title=Pyogenic+bacterial+infections+in+humans+with+MYD88+deficiency&doi=10.1126%2Fscience.1158298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Pyogenic Bacterial Infections in Humans with MyD88 Deficiency</span></div><div class="casAuthors">von Bernuth, Horst; Picard, Capucine; Jin, Zhongbo; Pankla, Rungnapa; Hui, Xiao; Ku, Cheng-Lung; Chrabieh, Maya; Ben Mustapha, Imen; Ghandil, Pegah; Camcioglu, Yildiz; Vasconcelos, Julia; Sirvent, Nicolas; Guedes, Margarida; Vitor, Artur Bonito; Herrero-Mata, Maria Jose; Arostegui, Juan Ignacio; Rodrigo, Carlos; Alsina, Laia; Ruiz-Ortiz, Estibaliz; Juan, Manel; Fortuny, Claudia; Yaguee, Jordi; Anton, Jordi; Pascal, Mariona; Chang, Huey-Hsuan; Janniere, Lucile; Rose, Yoann; Garty, Ben-Zion; Chapel, Helen; Issekutz, Andrew; Marodi, Laszlo; Rodriguez-Gallego, Carlos; Banchereau, Jacques; Abel, Laurent; Li, Xiaoxia; Chaussabel, Damien; Puel, Anne; Casanova, Jean-Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">5889</span>),
    <span class="NLM_cas:pages">691-696</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">MyD88 is a key downstream adapter for most Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs).  MyD88 deficiency in mice leads to susceptibility to a broad range of pathogens in exptl. settings of infection.  We describe a distinct situation in a natural setting of human infection.  Nine children with autosomal recessive MyD88 deficiency suffered from life-threatening, often recurrent pyogenic bacterial infections, including invasive pneumococcal disease.  However, these patients were otherwise healthy, with normal resistance to other microbes.  Their clin. status improved with age, but not due to any cellular leakiness in MyD88 deficiency.  The MyD88-dependent TLRs and IL-1Rs are therefore essential for protective immunity to a small no. of pyogenic bacteria, but redundant for host defense to most natural infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo9Ly_7pHPp7Vg90H21EOLACvtfcHk0ljt4CP_qpC_-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVKnurc%253D&md5=c81dbb50564824a9a49bebf826d1c2c2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscience.1158298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1158298%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BBernuth%26aufirst%3DH.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DPankla%26aufirst%3DR.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DKu%26aufirst%3DC.%2BL.%26aulast%3DChrabieh%26aufirst%3DM.%26aulast%3DMustapha%26aufirst%3DI.%2BB.%26aulast%3DGhandil%26aufirst%3DP.%26aulast%3DCamcioglu%26aufirst%3DY.%26aulast%3DVasconcelos%26aufirst%3DJ.%26aulast%3DSirvent%26aufirst%3DN.%26aulast%3DGuedes%26aufirst%3DM.%26aulast%3DVitor%26aufirst%3DA.%2BB.%26aulast%3DHerrero-Mata%26aufirst%3DM.%2BJ.%26aulast%3DAr%25C3%25B3stegui%26aufirst%3DJ.%2BI.%26aulast%3DRodrigo%26aufirst%3DC.%26aulast%3DAlsina%26aufirst%3DL.%26aulast%3DRuiz-Ortiz%26aufirst%3DE.%26aulast%3DJuan%26aufirst%3DM.%26aulast%3DFortuny%26aufirst%3DC.%26aulast%3DYag%25C3%25BCe%26aufirst%3DJ.%26aulast%3DAnt%25C3%25B3n%26aufirst%3DJ.%26aulast%3DPascal%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DH.%2BH.%26aulast%3DJanniere%26aufirst%3DL.%26aulast%3DRose%26aufirst%3DY.%26aulast%3DGarty%26aufirst%3DB.%2BZ.%26aulast%3DChapel%26aufirst%3DH.%26aulast%3DIssekutz%26aufirst%3DA.%26aulast%3DMar%25C3%25B3di%26aufirst%3DL.%26aulast%3DRodriguez-Gallego%26aufirst%3DC.%26aulast%3DBanchereau%26aufirst%3DJ.%26aulast%3DAbel%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChaussabel%26aufirst%3DD.%26aulast%3DPuel%26aufirst%3DA.%26aulast%3DCasanova%26aufirst%3DJ.%2BL.%26atitle%3DPyogenic%2520bacterial%2520infections%2520in%2520humans%2520with%2520MYD88%2520deficiency%26jtitle%3DScience%26date%3D2008%26volume%3D321%26spage%3D691%26epage%3D696%26doi%3D10.1126%2Fscience.1158298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Genung, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guckian, K. M.</span><span> </span><span class="NLM_article-title">Small molecule inhibition of interleukin-1 receptor-associated kinase 4 (IRAK4)</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">163</span><span class="refDoi"> DOI: 10.1016/bs.pmch.2016.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fbs.pmch.2016.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=28314411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A280%3ADC%252BC1czot12hsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=117-163&author=N.+E.+Genungauthor=K.+M.+Guckian&title=Small+molecule+inhibition+of+interleukin-1+receptor-associated+kinase+4+%28IRAK4%29&doi=10.1016%2Fbs.pmch.2016.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4)</span></div><div class="casAuthors">Genung N E; Guckian K M</div><div class="citationInfo"><span class="NLM_cas:title">Progress in medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">117-163</span>
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    </div><div class="casAbstract">In recent years, interleukin-1 receptor-associated kinase 4, IRAK4, has become an attractive target for many medicinal chemistry programmes.  Target inhibition is of potential therapeutic value in areas including autoimmune disorders, cancer, inflammatory diseases, and possibly neurodegenerative diseases.  Results from high-throughput screening efforts have led, in conjunction with structure-based drug design, to the identification of highly potent and selective small molecule IRAK4 inhibitors from many diverse chemical series.  In vitro and in vivo studies with entities from distinct structural classes have helped elucidate the downstream pharmacological responses associated with IRAK4 inhibition as a proof of concept in disease models, leading to the recent initiation of human clinical trials.  Within this review, we will highlight the considerable effort by numerous groups dedicated to the development of small molecule IRAK4 inhibitors for the treatment of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZNiMykZj_Wv6xYuD7tu2XfW6udTcc2eaaTGNz7uPLc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czot12hsg%253D%253D&md5=30805b2fb55ac3e6be120a7557c0f24c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmch.2016.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmch.2016.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DGenung%26aufirst%3DN.%2BE.%26aulast%3DGuckian%26aufirst%3DK.%2BM.%26atitle%3DSmall%2520molecule%2520inhibition%2520of%2520interleukin-1%2520receptor-associated%2520kinase%25204%2520%2528IRAK4%2529%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D56%26spage%3D117%26epage%3D163%26doi%3D10.1016%2Fbs.pmch.2016.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Powers, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesche, H.</span><span> </span><span class="NLM_article-title">Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2842</span><span class="NLM_x">–</span> <span class="NLM_lpage">2845</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.03.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2006.03.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=16563752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFygsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=2842-2845&author=J.+P.+Powersauthor=S.+Liauthor=J.+C.+Jaenauthor=J.+Liuauthor=N.+P.+C.+Walkerauthor=Z.+Wangauthor=H.+Wesche&title=Discovery+and+initial+SAR+of+inhibitors+of+interleukin-1+receptor-associated+kinase-4&doi=10.1016%2Fj.bmcl.2006.03.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4</span></div><div class="casAuthors">Powers, Jay P.; Li, Shyun; Jaen, Juan C.; Liu, Jinqian; Walker, Nigel P. C.; Wang, Zhulun; Wesche, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2842-2845</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">High-throughput screening of a small-mol. compd. library resulted in the identification of a novel series of N-acyl 2-aminobenzimidazoles that are potent inhibitors of interleukin-1 receptor-assocd. kinase-4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgZ37zw75f-7Vg90H21EOLACvtfcHk0lgBx90gCj_HBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFygsb8%253D&md5=7a8a2ebe4c155ac8999ff4a63e3ed139</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.03.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.03.020%26sid%3Dliteratum%253Aachs%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DN.%2BP.%2BC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWesche%26aufirst%3DH.%26atitle%3DDiscovery%2520and%2520initial%2520SAR%2520of%2520inhibitors%2520of%2520interleukin-1%2520receptor-associated%2520kinase-4%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D2842%26epage%3D2845%26doi%3D10.1016%2Fj.bmcl.2006.03.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lively, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomooka, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, J. P.</span><span> </span><span class="NLM_article-title">Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">5546</span><span class="NLM_x">–</span> <span class="NLM_lpage">5550</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.10.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2015.10.060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5546-5550&author=Z.+Wangauthor=D.+Sunauthor=S.+Johnstoneauthor=Z.+Caoauthor=X.+Gaoauthor=J.+C.+Jaenauthor=J.+Liuauthor=S.+Livelyauthor=S.+Miaoauthor=A.+Sudomauthor=C.+Tomookaauthor=N.+P.+C.+Walkerauthor=M.+Wrightauthor=X.+Yanauthor=Q.+Yeauthor=J.+P.+Powers&title=Discovery+of+potent%2C+selective%2C+and+orally+bioavailable+inhibitors+of+interleukin-1+receptor-associate+kinase-4&doi=10.1016%2Fj.bmcl.2015.10.060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.10.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.10.060%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DJohnstone%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLively%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DTomooka%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DN.%2BP.%2BC.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitors%2520of%2520interleukin-1%2520receptor-associate%2520kinase-4%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5546%26epage%3D5550%26doi%3D10.1016%2Fj.bmcl.2015.10.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Buckley, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gowers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higueruelo, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rausch, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, J. L.</span><span> </span><span class="NLM_article-title">IRAK-4 inhibitors. Part 1: A series of amides</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3211</span><span class="NLM_x">–</span> <span class="NLM_lpage">3214</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2008.04.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=18474425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD1cXms1yiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3211-3214&author=G.+M.+Buckleyauthor=L.+Gowersauthor=A.+P.+Higuerueloauthor=K.+Jenkinsauthor=S.+R.+Mackauthor=T.+Morganauthor=D.+M.+Parryauthor=W.+R.+Pittauthor=O.+Rauschauthor=M.+D.+Richardauthor=V.+Sabinauthor=J.+L.+Fraser&title=IRAK-4+inhibitors.+Part+1%3A+A+series+of+amides&doi=10.1016%2Fj.bmcl.2008.04.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">IRAK-4 inhibitors. Part 1: A series of amides</span></div><div class="casAuthors">Buckley, George M.; Gowers, Lewis; Higueruelo, Alicia Perez; Jenkins, Kerry; Mack, Stephen R.; Morgan, Trevor; Parry, David M.; Pitt, William R.; Rausch, Oliver; Richard, Marianna D.; Sabin, Verity; Fraser, Joanne L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3211-3214</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The synthesis and profile of a series of amides, e.g., I, are described.  Some of these compds. were potent IRAK-4 inhibitors and two examples were evaluated in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2WnghW2pEwbVg90H21EOLACvtfcHk0lgBx90gCj_HBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXms1yiu78%253D&md5=75fb794d58ae52827a58b8ff59394111</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.058%26sid%3Dliteratum%253Aachs%26aulast%3DBuckley%26aufirst%3DG.%2BM.%26aulast%3DGowers%26aufirst%3DL.%26aulast%3DHigueruelo%26aufirst%3DA.%2BP.%26aulast%3DJenkins%26aufirst%3DK.%26aulast%3DMack%26aufirst%3DS.%2BR.%26aulast%3DMorgan%26aufirst%3DT.%26aulast%3DParry%26aufirst%3DD.%2BM.%26aulast%3DPitt%26aufirst%3DW.%2BR.%26aulast%3DRausch%26aufirst%3DO.%26aulast%3DRichard%26aufirst%3DM.%2BD.%26aulast%3DSabin%26aufirst%3DV.%26aulast%3DFraser%26aufirst%3DJ.%2BL.%26atitle%3DIRAK-4%2520inhibitors.%2520Part%25201%253A%2520A%2520series%2520of%2520amides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3211%26epage%3D3214%26doi%3D10.1016%2Fj.bmcl.2008.04.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Buckley, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceska, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gowers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groom, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higueruelo, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rausch, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabin, V.</span><span> </span><span class="NLM_article-title">IRAK-4 inhibitors. Part II: A structure-based assessment of imidazo1,2-a]pyridine binding</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3291</span><span class="NLM_x">–</span> <span class="NLM_lpage">3295</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2008.04.039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3291-3295&author=G.+M.+Buckleyauthor=T.+A.+Ceskaauthor=J.+L.+Fraserauthor=L.+Gowersauthor=C.+R.+Groomauthor=A.+P.+Higuerueloauthor=K.+Jenkinsauthor=S.+R.+Mackauthor=T.+Morganauthor=D.+M.+Parryauthor=W.+R.+Pittauthor=O.+Rauschauthor=M.+D.+Richardauthor=V.+Sabin&title=IRAK-4+inhibitors.+Part+II%3A+A+structure-based+assessment+of+imidazo1%2C2-a%5Dpyridine+binding&doi=10.1016%2Fj.bmcl.2008.04.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.039%26sid%3Dliteratum%253Aachs%26aulast%3DBuckley%26aufirst%3DG.%2BM.%26aulast%3DCeska%26aufirst%3DT.%2BA.%26aulast%3DFraser%26aufirst%3DJ.%2BL.%26aulast%3DGowers%26aufirst%3DL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DHigueruelo%26aufirst%3DA.%2BP.%26aulast%3DJenkins%26aufirst%3DK.%26aulast%3DMack%26aufirst%3DS.%2BR.%26aulast%3DMorgan%26aufirst%3DT.%26aulast%3DParry%26aufirst%3DD.%2BM.%26aulast%3DPitt%26aufirst%3DW.%2BR.%26aulast%3DRausch%26aufirst%3DO.%26aulast%3DRichard%26aufirst%3DM.%2BD.%26aulast%3DSabin%26aufirst%3DV.%26atitle%3DIRAK-4%2520inhibitors.%2520Part%2520II%253A%2520A%2520structure-based%2520assessment%2520of%2520imidazo1%252C2-a%255Dpyridine%2520binding%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3291%26epage%3D3295%26doi%3D10.1016%2Fj.bmcl.2008.04.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Buckley, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fosbeary, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gowers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higueruelo, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rausch, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabin, V.</span><span> </span><span class="NLM_article-title">IRAK-4 inhibitors. Part III: A series of imidazo1,2-a]pyridines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3656</span><span class="NLM_x">–</span> <span class="NLM_lpage">3660</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2008.04.042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3656-3660&author=G.+M.+Buckleyauthor=R.+Fosbearyauthor=J.+L.+Fraserauthor=L.+Gowersauthor=A.+P.+Higuerueloauthor=L.+A.+Jamesauthor=K.+Jenkinsauthor=S.+R.+Mackauthor=T.+Morganauthor=D.+M.+Parryauthor=W.+R.+Pittauthor=O.+Rauschauthor=M.+D.+Richardauthor=V.+Sabin&title=IRAK-4+inhibitors.+Part+III%3A+A+series+of+imidazo1%2C2-a%5Dpyridines&doi=10.1016%2Fj.bmcl.2008.04.042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.042%26sid%3Dliteratum%253Aachs%26aulast%3DBuckley%26aufirst%3DG.%2BM.%26aulast%3DFosbeary%26aufirst%3DR.%26aulast%3DFraser%26aufirst%3DJ.%2BL.%26aulast%3DGowers%26aufirst%3DL.%26aulast%3DHigueruelo%26aufirst%3DA.%2BP.%26aulast%3DJames%26aufirst%3DL.%2BA.%26aulast%3DJenkins%26aufirst%3DK.%26aulast%3DMack%26aufirst%3DS.%2BR.%26aulast%3DMorgan%26aufirst%3DT.%26aulast%3DParry%26aufirst%3DD.%2BM.%26aulast%3DPitt%26aufirst%3DW.%2BR.%26aulast%3DRausch%26aufirst%3DO.%26aulast%3DRichard%26aufirst%3DM.%2BD.%26aulast%3DSabin%26aufirst%3DV.%26atitle%3DIRAK-4%2520inhibitors.%2520Part%2520III%253A%2520A%2520series%2520of%2520imidazo1%252C2-a%255Dpyridines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3656%26epage%3D3660%26doi%3D10.1016%2Fj.bmcl.2008.04.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Kondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomura, Y.</span><span> </span><span class="NLM_article-title">Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats</span> <span class="citation_source-journal">Naunyn-Schmiedeberg's Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span><span class="refDoi"> DOI: 10.1007/s00210-014-1023-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1007%2Fs00210-014-1023-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=25052043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Sjsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2014&pages=909-919&author=M.+Kondoauthor=A.+Taharaauthor=K.+Hayashiauthor=M.+Abeauthor=H.+Inamiauthor=T.+Ishikawaauthor=H.+Itoauthor=Y.+Tomura&title=Renoprotective+effects+of+novel+interleukin-1+receptor-associated+kinase+4+inhibitor+AS2444697+through+anti-inflammatory+action+in+5%2F6+nephrectomized+rats&doi=10.1007%2Fs00210-014-1023-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats</span></div><div class="casAuthors">Kondo, Mitsuhiro; Tahara, Atsuo; Hayashi, Kazumi; Abe, Masaki; Inami, Hiroshi; Ishikawa, Takeshi; Ito, Hiroyuki; Tomura, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">909-919</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Renal inflammation is a final common pathway of chronic kidney disease (CKD), and its progression can be used to effectively gauge the degree of renal dysfunction.  Interleukin-1 (IL-1) receptor-assocd. kinase 4 (IRAK-4) has been reported to be a pivotal mol. for IL-1 receptor- and Toll-like receptor-induced signaling and activation of proinflammatory mediators.  In this study, we hypothesized that if inflammation plays a key role in renal failure, then the anti-inflammatory effect of IRAK-4 inhibitor should be effective in improving CKD.  To det. its pharmacol. potency, we investigated the renoprotective properties of the novel IRAK-4 inhibitor AS2444697 (N-[3-carbamoyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide hydrochloride (1:1)) in 5/6 nephrectomized (Nx) rats, a model of CKD.  Six weeks' repeated administration of AS2444697 (0.3-3 mg/kg, twice daily) dose-dependently and significantly reduced urinary protein excretion and prevented the development of glomerulosclerosis and interstitial fibrosis without affecting the blood pressure.  In addn., AS2444697 showed beneficial effects on renal function as demonstrated by the decrease in levels of plasma creatinine and blood urea nitrogen and attenuation of decline in creatinine clearance. 5/6 Nx rats exhibited low-grade inflammation as evidenced by increased renal mRNA expression and plasma levels of proinflammatory cytokines (IL-1β, IL-6, TNF-α, and MCP-1) and C-reactive protein as a marker of systemic inflammation.  AS2444697 significantly reduced or showed a decreasing trend in expression and levels of these inflammatory parameters.  These results suggest that AS2444697 suppresses the progression of chronic renal failure via anti-inflammatory action and may therefore be potentially useful in treating CKD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfm1DDR5_qOLVg90H21EOLACvtfcHk0lji-QK4oH9LSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Sjsr%252FE&md5=50fe058ccb5247f50d93e3ccab85e169</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00210-014-1023-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-014-1023-z%26sid%3Dliteratum%253Aachs%26aulast%3DKondo%26aufirst%3DM.%26aulast%3DTahara%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DInami%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DTomura%26aufirst%3DY.%26atitle%3DRenoprotective%2520effects%2520of%2520novel%2520interleukin-1%2520receptor-associated%2520kinase%25204%2520inhibitor%2520AS2444697%2520through%2520anti-inflammatory%2520action%2520in%25205%252F6%2520nephrectomized%2520rats%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2014%26volume%3D387%26spage%3D909%26epage%3D919%26doi%3D10.1007%2Fs00210-014-1023-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibeau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinschek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leccese, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesburg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maclean, J. K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulrooney, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Presland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rakhilina, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinhuebel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span> </span><span class="NLM_article-title">Discovery of 5-amino-N-(1H-pyrazol-4-yl)pyrazolo1,5-a]pyrimidine-3-carboxamide inhibitors of IRAK4</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">688</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00107</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=683-688&author=J.+Limauthor=M.+D.+Altmanauthor=J.+Bakerauthor=J.+D.+Brubakerauthor=H.+Chenauthor=Y.+Chenauthor=T.+Fischmannauthor=C.+Gibeauauthor=M.+A.+Kleinschekauthor=E.+Lecceseauthor=C.+Lesburgauthor=J.+K.+F.+Macleanauthor=L.+Y.+Moyauthor=E.+F.+Mulrooneyauthor=J.+Preslandauthor=L.+Rakhilinaauthor=G.+F.+Smithauthor=D.+Steinhuebelauthor=R.+Yang&title=Discovery+of+5-amino-N-%281H-pyrazol-4-yl%29pyrazolo1%2C5-a%5Dpyrimidine-3-carboxamide+inhibitors+of+IRAK4&doi=10.1021%2Facsmedchemlett.5b00107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00107%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DBrubaker%26aufirst%3DJ.%2BD.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DGibeau%26aufirst%3DC.%26aulast%3DKleinschek%26aufirst%3DM.%2BA.%26aulast%3DLeccese%26aufirst%3DE.%26aulast%3DLesburg%26aufirst%3DC.%26aulast%3DMaclean%26aufirst%3DJ.%2BK.%2BF.%26aulast%3DMoy%26aufirst%3DL.%2BY.%26aulast%3DMulrooney%26aufirst%3DE.%2BF.%26aulast%3DPresland%26aufirst%3DJ.%26aulast%3DRakhilina%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DG.%2BF.%26aulast%3DSteinhuebel%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DR.%26atitle%3DDiscovery%2520of%25205-amino-N-%25281H-pyrazol-4-yl%2529pyrazolo1%252C5-a%255Dpyrimidine-3-carboxamide%2520inhibitors%2520of%2520IRAK4%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D683%26epage%3D688%26doi%3D10.1021%2Facsmedchemlett.5b00107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinschek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maclean, J. K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulrooney, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Presland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rakhilina, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span> </span><span class="NLM_article-title">Identification of N-(1H-pyrazol-4-yl)carboxamide inhibitors of interleukin-1 receptor associated kinase 4: Bicyclic core modifications</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">5384</span><span class="NLM_x">–</span> <span class="NLM_lpage">5388</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2015.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=26403930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFGlurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5384-5388&author=J.+Limauthor=M.+D.+Altmanauthor=J.+Bakerauthor=J.+D.+Brubakerauthor=H.+Chenauthor=Y.+Chenauthor=M.+A.+Kleinschekauthor=C.+Liauthor=D.+Liuauthor=J.+K.+F.+Macleanauthor=E.+F.+Mulrooneyauthor=J.+Preslandauthor=L.+Rakhilinaauthor=G.+F.+Smithauthor=R.+Yang&title=Identification+of+N-%281H-pyrazol-4-yl%29carboxamide+inhibitors+of+interleukin-1+receptor+associated+kinase+4%3A+Bicyclic+core+modifications&doi=10.1016%2Fj.bmcl.2015.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-(1H-pyrazol-4-yl)carboxamide inhibitors of interleukin-1 receptor associated kinase 4: Bicyclic core modifications</span></div><div class="casAuthors">Lim, Jongwon; Altman, Michael D.; Baker, James; Brubaker, Jason D.; Chen, Hongmin; Chen, Yiping; Kleinschek, Melanie A.; Li, Chaomin; Liu, Duan; MacLean, John K. F.; Mulrooney, Erin F.; Presland, Jeremy; Rakhilina, Larissa; Smith, Graham F.; Yang, Ruojing</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5384-5388</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">IRAK4 plays a crit. role in the IL-1R and TLR signaling, and selective inhibition of the kinase activity of the protein represents an attractive target for the treatment of inflammatory diseases.  A series of permeable N-(1H-pyrazol-4-yl)carboxamides was developed by introducing lipophilic bicyclic cores in place of the polar pyrazolopyrimidine core of 5-amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamides.  Replacement of the pyrazolo[1,5-a]pyrimidine core with the pyrrolo[2,1-f][1,2,4]triazine, the pyrrolo[1,2-b]pyridazine, and thieno[2,3-b]pyrazine cores guided by c Log D led to the identification of highly permeable IRAK4 inhibitors with excellent potency and kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWIvvaS6F5F7Vg90H21EOLACvtfcHk0lgjkLF_Cowxww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFGlurvJ&md5=f01d0d52d296c911016b3a53a5ef4957</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DBrubaker%26aufirst%3DJ.%2BD.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKleinschek%26aufirst%3DM.%2BA.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMaclean%26aufirst%3DJ.%2BK.%2BF.%26aulast%3DMulrooney%26aufirst%3DE.%2BF.%26aulast%3DPresland%26aufirst%3DJ.%26aulast%3DRakhilina%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DG.%2BF.%26aulast%3DYang%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%25281H-pyrazol-4-yl%2529carboxamide%2520inhibitors%2520of%2520interleukin-1%2520receptor%2520associated%2520kinase%25204%253A%2520Bicyclic%2520core%2520modifications%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5384%26epage%3D5388%26doi%3D10.1016%2Fj.bmcl.2015.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">McElroy, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michael Seganish, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jason Herr, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komanduri, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakash, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulshian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenlee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, X.</span><span> </span><span class="NLM_article-title">Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1836</span><span class="NLM_x">–</span> <span class="NLM_lpage">1841</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.03.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2015.03.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=25870132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVOru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1836-1841&author=W.+T.+McElroyauthor=W.+Michael+Seganishauthor=R.+Jason+Herrauthor=J.+Hardingauthor=J.+Yangauthor=L.+Yetauthor=V.+Komanduriauthor=K.+C.+Prakashauthor=B.+Laveyauthor=D.+Tulshianauthor=W.+J.+Greenleeauthor=C.+Sondeyauthor=T.+O.+Fischmannauthor=X.+Niu&title=Discovery+and+hit-to-lead+optimization+of+2%2C6-diaminopyrimidine+inhibitors+of+interleukin-1+receptor-associated+kinase+4&doi=10.1016%2Fj.bmcl.2015.03.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20cR"><div class="casContent"><span class="casTitleNuber">20c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4</span></div><div class="casAuthors">McElroy, William T.; Michael Seganish, W.; Jason Herr, R.; Harding, James; Yang, Jinhai; Yet, Larry; Komanduri, Venukrishnan; Prakash, Koraboina Chandra; Lavey, Brian; Tulshian, Deen; Greenlee, William J.; Sondey, Christopher; Fischmann, Thierry O.; Niu, Xiaoda</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1836-1841</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Interleukin receptor-assocd. kinase 4 (IRAK4) is a crit. element of the Toll-like/interleukin-1 receptor inflammation signaling pathway.  A screening campaign identified a novel diaminopyrimidine hit that exhibits weak IRAK4 inhibitory activity and a ligand efficiency of 0.25.  Hit-to-lead activities were conducted through independent SAR studies of each of the four pyrimidine substituents.  Optimal activity was obsd. upon removal of the pyrimidine C-4 chloro substituent.  The intact C-6 carboribose is required for IRAK4 inhibition.  Numerous heteroaryls were tolerated at the C-5 position, with azabenzothiazoles conferring the best activities.  Aminoheteroaryls were preferred at the C-2 position.  These studies led to the discovery of inhibitors 35, 36, and 38 that exhibit nanomolar inhibition of IRAK4, improved ligand efficiencies, and modest kinase selectivities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM21dnxkylY7Vg90H21EOLACvtfcHk0lgjkLF_Cowxww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVOru70%253D&md5=a17679e9d71889b01a2ad27d1f2bb653</span></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.03.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.03.043%26sid%3Dliteratum%253Aachs%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26aulast%3DMichael%2BSeganish%26aufirst%3DW.%26aulast%3DJason%2BHerr%26aufirst%3DR.%26aulast%3DHarding%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYet%26aufirst%3DL.%26aulast%3DKomanduri%26aufirst%3DV.%26aulast%3DPrakash%26aufirst%3DK.%2BC.%26aulast%3DLavey%26aufirst%3DB.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DSondey%26aufirst%3DC.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DNiu%26aufirst%3DX.%26atitle%3DDiscovery%2520and%2520hit-to-lead%2520optimization%2520of%25202%252C6-diaminopyrimidine%2520inhibitors%2520of%2520interleukin-1%2520receptor-associated%2520kinase%25204%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1836%26epage%3D1841%26doi%3D10.1016%2Fj.bmcl.2015.03.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">McElroy, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paliwal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seganish, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulshian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bober, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlisi, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, X.</span><span> </span><span class="NLM_article-title">Potent and selective amidopyrazole inhibitors of IRAK4 that are efficacious in a rodent model of inflammation</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">677</span><span class="NLM_x">–</span> <span class="NLM_lpage">682</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2MXot1Sqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=677-682&author=W.+T.+McElroyauthor=Z.+Tanauthor=G.+Hoauthor=S.+Paliwalauthor=G.+Liauthor=W.+M.+Seganishauthor=D.+Tulshianauthor=J.+Tataauthor=T.+O.+Fischmannauthor=C.+Sondeyauthor=H.+Bianauthor=L.+Boberauthor=J.+Jacksonauthor=C.+G.+Garlisiauthor=K.+Devitoauthor=J.+Fossettaauthor=D.+Lundellauthor=X.+Niu&title=Potent+and+selective+amidopyrazole+inhibitors+of+IRAK4+that+are+efficacious+in+a+rodent+model+of+inflammation&doi=10.1021%2Facsmedchemlett.5b00106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20dR"><div class="casContent"><span class="casTitleNuber">20d</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation</span></div><div class="casAuthors">McElroy, William T.; Tan, Zheng; Ho, Ginny; Paliwal, Sunil; Li, Guoqing; Seganish, W. Michael; Tulshian, Deen; Tata, James; Fischmann, Thierry O.; Sondey, Christopher; Bian, Hong; Bober, Loretta; Jackson, James; Garlisi, Charles G.; Devito, Kristine; Fossetta, James; Lundell, Daniel; Niu, Xiaoda</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">677-682</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">IRAK4 is a crit. upstream kinase in the IL-1R/TLR signaling pathway.  Inhibition of IRAK4 is hypothesized to be beneficial in the treatment of autoimmune related disorders.  A screening campaign identified a pyrazole class of IRAK4 inhibitors that were detd. by X-ray crystallog. to exhibit an unusual binding mode.  SAR efforts focused on the identification of a potent and selective inhibitor with good aq. soly. and rodent pharmacokinetics.  Pyrazole C-3 piperidines were well tolerated, with N-sulfonyl analogs generally having good rodent oral exposure but poor soly.  N-Alkyl piperidines exhibited excellent soly. and reduced exposure.  Pyrazoles possessing N-1 pyridine and fluorophenyl substituents were among the most active.  Piperazine 32 was a potent enzyme inhibitor with good cellular activity.  Compd. 32 reduced the in vivo prodn. of proinflammatory cytokines and was orally efficacious in a mouse antibody induced arthritis disease model of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNSA2VYtAf07Vg90H21EOLACvtfcHk0lgjkLF_Cowxww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXot1Sqtrk%253D&md5=2203ad720b478a6e415d7d9df3e82106</span></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00106%26sid%3Dliteratum%253Aachs%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DHo%26aufirst%3DG.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DSeganish%26aufirst%3DW.%2BM.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DTata%26aufirst%3DJ.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DSondey%26aufirst%3DC.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DBober%26aufirst%3DL.%26aulast%3DJackson%26aufirst%3DJ.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DDevito%26aufirst%3DK.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DX.%26atitle%3DPotent%2520and%2520selective%2520amidopyrazole%2520inhibitors%2520of%2520IRAK4%2520that%2520are%2520efficacious%2520in%2520a%2520rodent%2520model%2520of%2520inflammation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D677%26epage%3D682%26doi%3D10.1021%2Facsmedchemlett.5b00106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Seganish, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherborne, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matasi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulshian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlisi, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, X.</span><span> </span><span class="NLM_article-title">Discovery and structure enabled synthesis of 2,6-diaminopyrimidin-4-one IRAK4 inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">–</span> <span class="NLM_lpage">947</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00279</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFGitb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=942-947&author=W.+M.+Seganishauthor=T.+O.+Fischmannauthor=B.+Sherborneauthor=J.+Matasiauthor=B.+Laveyauthor=W.+T.+McElroyauthor=D.+Tulshianauthor=J.+Tataauthor=C.+Sondeyauthor=C.+G.+Garlisiauthor=K.+Devitoauthor=J.+Fossettaauthor=D.+Lundellauthor=X.+Niu&title=Discovery+and+structure+enabled+synthesis+of+2%2C6-diaminopyrimidin-4-one+IRAK4+inhibitors&doi=10.1021%2Facsmedchemlett.5b00279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20eR"><div class="casContent"><span class="casTitleNuber">20e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Structure Enabled Synthesis of 2,6-Diaminopyrimidin-4-one IRAK4 Inhibitors</span></div><div class="casAuthors">Seganish, W. Michael; Fischmann, Thierry O.; Sherborne, Brad; Matasi, Julius; Lavey, Brian; McElroy, William T.; Tulshian, Deen; Tata, James; Sondey, Christopher; Garlisi, Charles G.; Devito, Kristine; Fossetta, James; Lundell, Daniel; Niu, Xiaoda</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">942-947</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the identification and synthesis of a series of aminopyrimidin-4-one IRAK4 inhibitors.  Through high throughput screening, an aminopyrimidine hit was identified and modified via structure enabled design to generate a new, potent, and kinase selective pyrimidin-4-one chemotype.  This chemotype is exemplified by compd. 16 (XVI), which has potent IRAK4 inhibition activity (IC50 = 27 nM) and excellent kinase selectivity (>100-fold against 99% of 111 tested kinases), and compd. 31 (XXXI), which displays potent IRAK4 activity (IC50 = 93 nM) and good rat bioavailability (F = 42%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYA9sdnPVJ0bVg90H21EOLACvtfcHk0lj55B6g5ruaqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFGitb7F&md5=2ab5a89c059a1d3164e72ecc557daf56</span></div><a href="/servlet/linkout?suffix=cit20e&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00279%26sid%3Dliteratum%253Aachs%26aulast%3DSeganish%26aufirst%3DW.%2BM.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DSherborne%26aufirst%3DB.%26aulast%3DMatasi%26aufirst%3DJ.%26aulast%3DLavey%26aufirst%3DB.%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DTata%26aufirst%3DJ.%26aulast%3DSondey%26aufirst%3DC.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DDevito%26aufirst%3DK.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DX.%26atitle%3DDiscovery%2520and%2520structure%2520enabled%2520synthesis%2520of%25202%252C6-diaminopyrimidin-4-one%2520IRAK4%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D942%26epage%3D947%26doi%3D10.1021%2Facsmedchemlett.5b00279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Seganish, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herr, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brumfield, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenlee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komanduri, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matasi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakash, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulshian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlisi, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondey, C.</span><span> </span><span class="NLM_article-title">Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3203</span><span class="NLM_x">–</span> <span class="NLM_lpage">3207</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.05.097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2015.05.097" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3203-3207&author=W.+M.+Seganishauthor=W.+T.+McElroyauthor=R.+J.+Herrauthor=S.+Brumfieldauthor=W.+J.+Greenleeauthor=J.+Hardingauthor=V.+Komanduriauthor=J.+Matasiauthor=K.+C.+Prakashauthor=D.+Tulshianauthor=J.+Yangauthor=L.+Yetauthor=K.+Devitoauthor=J.+Fossettaauthor=C.+G.+Garlisiauthor=D.+Lundellauthor=X.+Niuauthor=C.+Sondey&title=Initial+optimization+and+series+evolution+of+diaminopyrimidine+inhibitors+of+interleukin-1+receptor+associated+kinase+4&doi=10.1016%2Fj.bmcl.2015.05.097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20f&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.05.097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.05.097%26sid%3Dliteratum%253Aachs%26aulast%3DSeganish%26aufirst%3DW.%2BM.%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26aulast%3DHerr%26aufirst%3DR.%2BJ.%26aulast%3DBrumfield%26aufirst%3DS.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DHarding%26aufirst%3DJ.%26aulast%3DKomanduri%26aufirst%3DV.%26aulast%3DMatasi%26aufirst%3DJ.%26aulast%3DPrakash%26aufirst%3DK.%2BC.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYet%26aufirst%3DL.%26aulast%3DDevito%26aufirst%3DK.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DSondey%26aufirst%3DC.%26atitle%3DInitial%2520optimization%2520and%2520series%2520evolution%2520of%2520diaminopyrimidine%2520inhibitors%2520of%2520interleukin-1%2520receptor%2520associated%2520kinase%25204%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3203%26epage%3D3207%26doi%3D10.1016%2Fj.bmcl.2015.05.097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Hanisak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seganish, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, H.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulshian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlisi, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, X.</span><span> </span><span class="NLM_article-title">Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">4250</span><span class="NLM_x">–</span> <span class="NLM_lpage">4255</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.07.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2016.07.048" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=4250-4255&author=J.+Hanisakauthor=W.+M.+Seganishauthor=W.+T.+McElroyauthor=H.+Tangauthor=R.+Zhangauthor=H.-C.+Tsuiauthor=T.+Fischmannauthor=D.+Tulshianauthor=J.+Tataauthor=C.+Sondeyauthor=K.+Devitoauthor=J.+Fossettaauthor=C.+G.+Garlisiauthor=D.+Lundellauthor=X.+Niu&title=Efforts+towards+the+optimization+of+a+bi-aryl+class+of+potent+IRAK4+inhibitors&doi=10.1016%2Fj.bmcl.2016.07.048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20g&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.07.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.07.048%26sid%3Dliteratum%253Aachs%26aulast%3DHanisak%26aufirst%3DJ.%26aulast%3DSeganish%26aufirst%3DW.%2BM.%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DTsui%26aufirst%3DH.-C.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DTata%26aufirst%3DJ.%26aulast%3DSondey%26aufirst%3DC.%26aulast%3DDevito%26aufirst%3DK.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DX.%26atitle%3DEfforts%2520towards%2520the%2520optimization%2520of%2520a%2520bi-aryl%2520class%2520of%2520potent%2520IRAK4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D26%26spage%3D4250%26epage%3D4255%26doi%3D10.1016%2Fj.bmcl.2016.07.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tumey, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagirath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Press, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frisbie, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, V. R.</span><span> </span><span class="NLM_article-title">Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2066</span><span class="NLM_x">–</span> <span class="NLM_lpage">2072</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.03.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2014.03.056" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2066-2072&author=L.+N.+Tumeyauthor=D.+H.+Boschelliauthor=N.+Bhagirathauthor=J.+Shimauthor=E.+A.+Murphyauthor=D.+Goodwinauthor=E.+M.+Bennettauthor=M.+Wangauthor=L.+Linauthor=B.+Pressauthor=M.+Shenauthor=R.+K.+Frisbieauthor=P.+Morganauthor=S.+Mohanauthor=J.+Shinauthor=V.+R.+Rao&title=Identification+and+optimization+of+indolo%5B2%2C3-c%5Dquinoline+inhibitors+of+IRAK4&doi=10.1016%2Fj.bmcl.2014.03.056"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.03.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.03.056%26sid%3Dliteratum%253Aachs%26aulast%3DTumey%26aufirst%3DL.%2BN.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DBhagirath%26aufirst%3DN.%26aulast%3DShim%26aufirst%3DJ.%26aulast%3DMurphy%26aufirst%3DE.%2BA.%26aulast%3DGoodwin%26aufirst%3DD.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DPress%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DFrisbie%26aufirst%3DR.%2BK.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DV.%2BR.%26atitle%3DIdentification%2520and%2520optimization%2520of%2520indolo%255B2%252C3-c%255Dquinoline%2520inhibitors%2520of%2520IRAK4%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2066%26epage%3D2072%26doi%3D10.1016%2Fj.bmcl.2014.03.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lee, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambler, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boscoe, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bree, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehnhardt, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dower, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drozda, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frisbie, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavrin, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hepworth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hope, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamtekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilty, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovering, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathias, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papaioannou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patny, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saiah, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samardjiev, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samas, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, M. W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soutter, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strohbach, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symanowicz, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomason, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trzupek, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zapf, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, S. W.</span><span> </span><span class="NLM_article-title">Discovery of clinical candidate 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a potent, selective inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), by fragment-based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">5521</span><span class="NLM_x">–</span> <span class="NLM_lpage">5542</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00231</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00231" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5521-5542&author=K.+L.+Leeauthor=C.+M.+Amblerauthor=D.+R.+Andersonauthor=B.+P.+Boscoeauthor=A.+G.+Breeauthor=J.+I.+Brodfuehrerauthor=J.+S.+Changauthor=C.+Choiauthor=S.+Chungauthor=K.+J.+Curranauthor=J.+E.+Dayauthor=C.+M.+Dehnhardtauthor=K.+Dowerauthor=S.+E.+Drozdaauthor=R.+K.+Frisbieauthor=L.+K.+Gavrinauthor=J.+A.+Goldbergauthor=S.+Hanauthor=M.+Hegenauthor=D.+Hepworthauthor=H.+R.+Hopeauthor=S.+Kamtekarauthor=I.+C.+Kiltyauthor=A.+Leeauthor=L.-L.+Linauthor=F.+E.+Loveringauthor=M.+D.+Loweauthor=J.+P.+Mathiasauthor=H.+M.+Morganauthor=E.+A.+Murphyauthor=N.+Papaioannouauthor=A.+Patnyauthor=B.+S.+Pierceauthor=V.+R.+Raoauthor=E.+Saiahauthor=I.+J.+Samardjievauthor=B.+M.+Samasauthor=M.+W.+H.+Shenauthor=J.+H.+Shinauthor=H.+H.+Soutterauthor=J.+W.+Strohbachauthor=P.+T.+Symanowiczauthor=J.+R.+Thomasonauthor=J.+D.+Trzupekauthor=R.+Vargasauthor=F.+Vincentauthor=J.+Yanauthor=C.+W.+Zapfauthor=S.+W.+Wright&title=Discovery+of+clinical+candidate+1-%7B%5B%282S%2C3S%2C4S%29-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%5Dmethoxy%7D-7-methoxyisoquinoline-6-carboxamide+%28PF-06650833%29%2C+a+potent%2C+selective+inhibitor+of+interleukin-1+receptor+associated+kinase+4+%28IRAK4%29%2C+by+fragment-based+drug+design&doi=10.1021%2Facs.jmedchem.7b00231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design</span></div><div class="casAuthors">Lee, Katherine L.; Ambler, Catherine M.; Anderson, David R.; Boscoe, Brian P.; Bree, Andrea G.; Brodfuehrer, Joanne I.; Chang, Jeanne S.; Choi, Chulho; Chung, Seungwon; Curran, Kevin J.; Day, Jacqueline E.; Dehnhardt, Christoph M.; Dower, Ken; Drozda, Susan E.; Frisbie, Richard K.; Gavrin, Lori K.; Goldberg, Joel A.; Han, Seungil; Hegen, Martin; Hepworth, David; Hope, Heidi R.; Kamtekar, Satwik; Kilty, Iain C.; Lee, Arthur; Lin, Lih-Ling; Lovering, Frank E.; Lowe, Michael D.; Mathias, John P.; Morgan, Heidi M.; Murphy, Elizabeth A.; Papaioannou, Nikolaos; Patny, Akshay; Pierce, Betsy S.; Rao, Vikram R.; Saiah, Eddine; Samardjiev, Ivan J.; Samas, Brian M.; Shen, Marina W. H.; Shin, Julia H.; Soutter, Holly H.; Strohbach, Joseph W.; Symanowicz, Peter T.; Thomason, Jennifer R.; Trzupek, John D.; Vargas, Richard; Vincent, Fabien; Yan, Jiangli; Zapf, Christoph W.; Wright, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5521-5542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topol. in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 inhibitors with nanomolar potency in cellular assays.  The medicinal chem. effort featured the judicious placement of lipophilicity, informed by cocrystal structures with IRAK4 and optimization of ADME properties to deliver clin. candidate I.  This compd. benefitted from a 5-unit increase in lipophilic efficiency from the fragment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYrCep64bhMbVg90H21EOLACvtfcHk0lgteWWxkL8UuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D&md5=9771ad2d33089f6ef3dba3556536ff1a</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00231%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BL.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DBoscoe%26aufirst%3DB.%2BP.%26aulast%3DBree%26aufirst%3DA.%2BG.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%2BI.%26aulast%3DChang%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DDower%26aufirst%3DK.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DFrisbie%26aufirst%3DR.%2BK.%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DGoldberg%26aufirst%3DJ.%2BA.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHope%26aufirst%3DH.%2BR.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DL.-L.%26aulast%3DLovering%26aufirst%3DF.%2BE.%26aulast%3DLowe%26aufirst%3DM.%2BD.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DMorgan%26aufirst%3DH.%2BM.%26aulast%3DMurphy%26aufirst%3DE.%2BA.%26aulast%3DPapaioannou%26aufirst%3DN.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DRao%26aufirst%3DV.%2BR.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSamardjiev%26aufirst%3DI.%2BJ.%26aulast%3DSamas%26aufirst%3DB.%2BM.%26aulast%3DShen%26aufirst%3DM.%2BW.%2BH.%26aulast%3DShin%26aufirst%3DJ.%2BH.%26aulast%3DSoutter%26aufirst%3DH.%2BH.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DThomason%26aufirst%3DJ.%2BR.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DVargas%26aufirst%3DR.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DWright%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%25201-%257B%255B%25282S%252C3S%252C4S%2529-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%255Dmethoxy%257D-7-methoxyisoquinoline-6-carboxamide%2520%2528PF-06650833%2529%252C%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520interleukin-1%2520receptor%2520associated%2520kinase%25204%2520%2528IRAK4%2529%252C%2520by%2520fragment-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5521%26epage%3D5542%26doi%3D10.1021%2Facs.jmedchem.7b00231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kelly, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhary, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rui, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapeller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">212</span><span class="NLM_x">, </span> <span class="NLM_fpage">2189</span><span class="NLM_x">–</span> <span class="NLM_lpage">2201</span><span class="refDoi"> DOI: 10.1084/jem.20151074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1084%2Fjem.20151074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=26621451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtlSgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2015&pages=2189-2201&author=P.+N.+Kellyauthor=D.+L.+Romeroauthor=Y.+Yangauthor=A.+L.+Shafferauthor=D.+Chaudharyauthor=S.+Robinsonauthor=W.+Miaoauthor=L.+Ruiauthor=W.+F.+Westlinauthor=R.+Kapellerauthor=L.+M.+Staudt&title=Selective+interleukin-1+receptor%E2%80%93associated+kinase+4+inhibitors+for+the+treatment+of+autoimmune+disorders+and+lymphoid+malignancy&doi=10.1084%2Fjem.20151074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy</span></div><div class="casAuthors">Kelly, Priscilla N.; Romero, Donna L.; Yang, Yibin; Shaffer, Arthur L., III; Chaudhary, Divya; Robinson, Shaughnessy; Miao, Wenyan; Rui, Lixin; Westlin, William F.; Kapeller, Rosana; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2189-2201</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Pathol. activation of the Toll-like receptor signaling adaptor protein MYD88 underlies many autoimmune and inflammatory disease states.  In the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLB CL), the oncogenic MYD88 L265P mutation occurs in 29% of cases, making it the most prevalent activating mutation in this malignancy.  IRAK4 kinase accounts for almost all of the biol. functions of MYD88, highlighting IRAK4 as a therapeutic target for diseases driven by aberrant MYD88 signaling.  Using innovative structure-based drug design methodologies, we report the development of highly selective and bioavailable small mol. IRAK4 inhibitors, ND-2158 and ND-2110.  These small mols. suppressed LPS-induced TNF prodn., alleviated collagen-induced arthritis, and blocked gout formation in mouse models.  IRAK4 inhibition promoted killing of ABC DLB CL lines harboring MYD88 L265P, by down-modulating survival signals, including NF-κB and autocrine IL-6/IL-10 engagement of the JAK-STAT3 pathway.  In ABC DLB CL xenograft models, IRAK4 inhibition suppressed tumor growth as a single agent, and in combination with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib or the Bcl-2 inhibitor ABT-199.  Our findings support pharmacol. inhibition of IRAK4 as a therapeutic strategy in autoimmune disorders, in a genetically defined population of ABC DLB CL, and possibly other malignancies dependent on aberrant MYD88 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJuS2v8AyXXrVg90H21EOLACvtfcHk0lgteWWxkL8UuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtlSgu7s%253D&md5=cf477aff5f649644017cbe5330995a70</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1084%2Fjem.20151074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20151074%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DP.%2BN.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DW.%26aulast%3DRui%26aufirst%3DL.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26aulast%3DKapeller%26aufirst%3DR.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DSelective%2520interleukin-1%2520receptor%25E2%2580%2593associated%2520kinase%25204%2520inhibitors%2520for%2520the%2520treatment%2520of%2520autoimmune%2520disorders%2520and%2520lymphoid%2520malignancy%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2015%26volume%3D212%26spage%3D2189%26epage%3D2201%26doi%3D10.1084%2Fjem.20151074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chaudhary, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapeller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span> </span><span class="NLM_article-title">Synergistic blockade of activated B cell-like DLBCL proliferation with a selective inhibitor of IRAK4 in combination with inhibition of the B-cell receptor signaling network</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">3833</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=3833&author=D.+Chaudharyauthor=N.+Woodauthor=D.+L.+Romeroauthor=S.+D.+Robinsonauthor=J.+R.+Greenwoodauthor=M.+Shelleyauthor=M.+Morinauthor=R.+Kapellerauthor=W.+F.+Westlin&title=Synergistic+blockade+of+activated+B+cell-like+DLBCL+proliferation+with+a+selective+inhibitor+of+IRAK4+in+combination+with+inhibition+of+the+B-cell+receptor+signaling+network"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DRobinson%26aufirst%3DS.%2BD.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DShelley%26aufirst%3DM.%26aulast%3DMorin%26aufirst%3DM.%26aulast%3DKapeller%26aufirst%3DR.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DSynergistic%2520blockade%2520of%2520activated%2520B%2520cell-like%2520DLBCL%2520proliferation%2520with%2520a%2520selective%2520inhibitor%2520of%2520IRAK4%2520in%2520combination%2520with%2520inhibition%2520of%2520the%2520B-cell%2520receptor%2520signaling%2520network%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D3833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kelly, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhary, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapeller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Highly potent and selective interleukin-1 receptor-associated kinase 4 inhibitors for the therapy of lymphoid malignancies</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">LB-112</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2014-LB-112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1158%2F1538-7445.AM2014-LB-112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=LB-112&author=P.+N.+Kellyauthor=D.+Chaudharyauthor=R.+M.+Youngauthor=A.+Shafferauthor=S.+Robinsonauthor=D.+L.+Romeroauthor=R.+Kapellerauthor=L.+M.+Staudt&title=Highly+potent+and+selective+interleukin-1+receptor-associated+kinase+4+inhibitors+for+the+therapy+of+lymphoid+malignancies&doi=10.1158%2F1538-7445.AM2014-LB-112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2014-LB-112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2014-LB-112%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DP.%2BN.%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DShaffer%26aufirst%3DA.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DKapeller%26aufirst%3DR.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DHighly%2520potent%2520and%2520selective%2520interleukin-1%2520receptor-associated%2520kinase%25204%2520inhibitors%2520for%2520the%2520therapy%2520of%2520lymphoid%2520malignancies%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3DLB-112%26doi%3D10.1158%2F1538-7445.AM2014-LB-112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span>Compound <b>1</b> is Example 49 (<b>I-12</b>) from; <span class="NLM_contrib-group">Corin, A. F.; Frye, L. L.; Greenwood, J. R.; Harriman, G. C.; Masse, C.; Robinson, S.; Romero, D. L.; Watts, K. S.; Wessel, M. D.</span><span> </span><span class="NLM_article-title">Irak inhibitors and uses thereof</span>. Patent application WO2012097013, July 19,<span class="NLM_x"> </span><span class="NLM_year">2012</span>. We profiled <b>1</b> in a panel (Millipore kinase selectivity panel) of 126 kinases at a concentration of 1 mM and found the profile to be highly selective (IRAK4 + 1/127 > 75%inh).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=A.+F.+Corin&author=L.+L.+Frye&author=J.+R.+Greenwood&author=G.+C.+Harriman&author=C.+Masse&author=S.+Robinson&author=D.+L.+Romero&author=K.+S.+Watts&author=M.+D.+Wessel&title=Irak+inhibitors+and+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCorin%26aufirst%3DA.%2BF.%26atitle%3DIrak%2520inhibitors%2520and%2520uses%2520thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Destro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soave, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barzaghi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo Presti, L.</span><span> </span><span class="NLM_article-title">Progress in the understanding of drug–receptor interactions, part 1: Experimental charge-density study of an angiotensin II receptor antagonist (C<sub>30</sub>H<sub>30</sub>N<sub>6</sub>O<sub>3</sub>S) at <i>T</i> = 17 K</span> <span class="citation_source-journal">Chem. - Eur. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">4621</span><span class="NLM_x">–</span> <span class="NLM_lpage">4634</span><span class="refDoi"> DOI: 10.1002/chem.200400964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1002%2Fchem.200400964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=15915518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD2MXoslGls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4621-4634&author=R.+Destroauthor=R.+Soaveauthor=M.+Barzaghiauthor=L.+Lo+Presti&title=Progress+in+the+understanding+of+drug%E2%80%93receptor+interactions%2C+part+1%3A+Experimental+charge-density+study+of+an+angiotensin+II+receptor+antagonist+%28C30H30N6O3S%29+at+T+%3D+17+K&doi=10.1002%2Fchem.200400964"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the understanding of drug-receptor interactions, part 1: Experimental charge-density study of an angiotensin II receptor antagonist (C30H30N6O3S) at T = 17 K</span></div><div class="casAuthors">Destro, Riccardo; Soave, Raffaella; Barzaghi, Mario; Lo Presti, Leonardo</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4621-4634</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An exptl. study of the electron-d. distribution ρ(r) in an angiotensin II receptor antagonist 1 has been made on the basis of single-crystal X-ray diffraction data collected at a low temp.  The crystal structure of 1 consists of infinite ribbons in which mols. are connected by an N-H···N hydrogen bond and several interactions of the C-H···O, C-H···N, and C-H···S type.  The mol. conformation, characterized by the syn orientation of a tetrazole and a pyrimidinone ring with respect to a Ph spacer group, is stabilized by two short S···O and S···N intramol. contacts between a substituted thiophene fragment and the other two heterocycles of 1.  The electrostatic nature of these interactions is documented.  Furthermore, the Laplacian of ρ(r) in the plane defined by the sulfur, oxygen, and nitrogen atoms involved in these interactions shows their strongly directional character as the regions of charge concn. on the valence shell of the nitrogen and oxygen atoms directly face the regions of charge depletion on the valence shell of the sulfur atom.  All the chem. bonds and the relevant intra- and intermol. interactions of 1 have been quant. described by the topol. anal. of ρ(r).  Simple relationships between the bond path lengths (Rb) and the values of ρ at the bond crit. points (ρbcp) have been obtained for the 28 C-C bonds, the seven N-C bonds, and the four O-C bonds.  For the first two classes of bonds the relationship is in the form of a straight line, whose parameters, for the C-C bonds, agree, within exptl. uncertainty, with those previously derived in our lab. from a 19 K X-ray diffraction study of crystals of a different compd.  Maps of the mol. electrostatic potential .vphi.(r) derived from the exptl. charge d. display features that are important for the drug-receptor recognition of 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYY79gcPwxjbVg90H21EOLACvtfcHk0liLYSnnXn68vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXoslGls70%253D&md5=a587827d1db49f53cfe6d4a464423f5d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fchem.200400964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.200400964%26sid%3Dliteratum%253Aachs%26aulast%3DDestro%26aufirst%3DR.%26aulast%3DSoave%26aufirst%3DR.%26aulast%3DBarzaghi%26aufirst%3DM.%26aulast%3DLo%2BPresti%26aufirst%3DL.%26atitle%3DProgress%2520in%2520the%2520understanding%2520of%2520drug%25E2%2580%2593receptor%2520interactions%252C%2520part%25201%253A%2520Experimental%2520charge-density%2520study%2520of%2520an%2520angiotensin%2520II%2520receptor%2520antagonist%2520%2528C30H30N6O3S%2529%2520at%2520T%2520%253D%252017%2520K%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2005%26volume%3D11%26spage%3D4621%26epage%3D4634%26doi%3D10.1002%2Fchem.200400964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="note"><p class="first last">Under acidic conditions, treatment with TFA/DCM afforded partial deprotection of the SEM group, with LC-MS showing the desired product mass in addition to variable amounts of an M + 30 impurity, corresponding to product with the CH<sub>2</sub>OH group remaining. Full conversion to the desired product was achieved by allowing the crude product following SCX purification to stand in NH<sub>3</sub>/MeOH solution for 1–24 h.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, J.</span><span> </span><span class="NLM_article-title">Copper-mediated trifluoromethylation of heteroaromatic compounds by trifluoromethyl sulfonium salts</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1896</span><span class="NLM_x">–</span> <span class="NLM_lpage">1900</span><span class="refDoi"> DOI: 10.1002/anie.201006823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1002%2Fanie.201006823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitVOhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=1896-1900&author=C.+Zhangauthor=Z.+Wangauthor=Q.+Chenauthor=C.+Zhangauthor=Y.+Guauthor=J.+Xiao&title=Copper-mediated+trifluoromethylation+of+heteroaromatic+compounds+by+trifluoromethyl+sulfonium+salts&doi=10.1002%2Fanie.201006823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Copper-Mediated Trifluoromethylation of Heteroaromatic Compounds by Trifluoromethyl Sulfonium Salts</span></div><div class="casAuthors">Zhang, Cheng-Pan; Wang, Zong-Ling; Chen, Qing-Yun; Zhang, Chun-Tao; Gu, Yu-Cheng; Xiao, Ji-Chang</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1896-1900, S1896/1-S1896/40</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A convenient method for the synthesis of trifluoromethylated heteroarom. compds. from heteroarom. systems contg. nitrogen, oxygen, and/or sulfur and substituted with iodine under mild conditions is reported.  It is based on the observation that (S)-(trifluoromethyl)diphenylsulfonium triflate can be reduced by certain metals.  Trifluoromethylated products were obtained in high yields.  That the (S)-(trifluoromethyl) diphenylsulfonium salt is reduced by copper via a SET mechanism, and that CuCF3 is the most probable intermediate in this reaction are proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp5n08Txx4QrVg90H21EOLACvtfcHk0liLYSnnXn68vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitVOhsLs%253D&md5=0635637cfc7aeb66f7a8c41a71c20f9c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fanie.201006823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201006823%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DJ.%26atitle%3DCopper-mediated%2520trifluoromethylation%2520of%2520heteroaromatic%2520compounds%2520by%2520trifluoromethyl%2520sulfonium%2520salts%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D1896%26epage%3D1900%26doi%3D10.1002%2Fanie.201006823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Bruno, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudge, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Design and preparation of new palladium precatalysts for C-C and C-N cross-coupling reactions</span> <span class="citation_source-journal">Chem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">916</span><span class="NLM_x">–</span> <span class="NLM_lpage">920</span><span class="refDoi"> DOI: 10.1039/C2SC20903A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1039%2FC2SC20903A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=23667737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFKjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=916-920&author=N.+C.+Brunoauthor=M.+T.+Tudgeauthor=S.+L.+Buchwald&title=Design+and+preparation+of+new+palladium+precatalysts+for+C-C+and+C-N+cross-coupling+reactions&doi=10.1039%2FC2SC20903A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design and preparation of new palladium precatalysts for C-C and C-N cross-coupling reactions</span></div><div class="casAuthors">Bruno, Nicholas C.; Tudge, Matthew T.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">916-920</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of easily prepd., phosphine-ligated palladium precatalysts based on the 2-aminobiphenyl scaffold have been prepd.  The role of the precatalyst-assocd. labile halide (or pseudohalide) in the formation and stability of the palladacycle has been examd.  It was found that replacing the chloride in the previous version of the precatalyst with a mesylate leads to a new class of precatalysts with improved soln. stability and that are readily prepd. from a wider range of phosphine ligands.  The differences between the previous version of precatalyst and that reported here are explored.  In addn., the reactivity of the latter is examd. in a range of C-C and C-N bond forming reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfHp6oyg4k_bVg90H21EOLACvtfcHk0lhkEOKuXcVW-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFKjtr0%253D&md5=5b50ac18cb67251e5439199c6746dba8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1039%2FC2SC20903A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2SC20903A%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DN.%2BC.%26aulast%3DTudge%26aufirst%3DM.%2BT.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DDesign%2520and%2520preparation%2520of%2520new%2520palladium%2520precatalysts%2520for%2520C-C%2520and%2520C-N%2520cross-coupling%2520reactions%26jtitle%3DChem.%2520Sci.%26date%3D2013%26volume%3D4%26spage%3D916%26epage%3D920%26doi%3D10.1039%2FC2SC20903A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span>During the evaluation of this series, a patent application (<span class="NLM_contrib-group">Harriman, G. C.; Romero, D. L.; Masse, C. E.; Robinson, S.; Wessel, M. D.; Greenwood, J. R.</span><span> </span><span class="NLM_article-title">Irak inhibitors and uses thereof</span>. Patent application WO2014011911, January 16,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">) </span><div class="note"><p class="first last">on IRAK inhibitors was published containing nine examples of pyrrolopyrimidines. Two of the most potent examples described had substitution at the 5-position with cyano (<b>I-1</b>) and fluoro (<b>I-3</b>). These were made and profiled in our assays and IRAK4 potency was found to be consistent with the binned data reported in the patent (0.1 < IC<sub>50</sub> < 1 mM) and less potent than many examples reported in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. <span class="NLM_inline-graphic"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0027.tif.gif" alt="" /></img></span>Compound <b>8</b> (<b>I-9</b>) was also included in the application and was reported to have IC<sub>50</sub> > 10 mM in an IRAK4 enzyme assay, also consistent with the results obtained in our assay (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). This patent application was subsequently abandoned</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=G.+C.+Harriman&author=D.+L.+Romero&author=C.+E.+Masse&author=S.+Robinson&author=M.+D.+Wessel&author=J.+R.+Greenwood&title=Irak+inhibitors+and+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHarriman%26aufirst%3DG.%2BC.%26atitle%3DIrak%2520inhibitors%2520and%2520uses%2520thereof%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="note"><p class="first last">For compounds <b>18</b>–<b>20</b> with chiral groups in the 4-position, we observed a doubling up of some signals in the <sup>13</sup>C spectra of the cyclohexyl ring, which we attributed to the chiral centre imparting diastereotopicity to the cyclohexyl carbons. This phenomenon was not observed with achiral 4-substituents.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><i>K</i><sub>d</sub> values were determined using the DiscoverX <i>Kd</i>ELECT platform. Data was generated in duplicate using an 11-point dose response curve with experimental details described on the company website (<a href="https://www.discoverx.com/home" class="extLink">https://www.discoverx.com/home</a>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kd+values+were+determined+using+the+DiscoverX+KdELECT+platform.+Data+was+generated+in+duplicate+using+an+11-point+dose+response+curve+with+experimental+details+described+on+the+company+website+%28https%3A%2F%2Fwww.discoverx.com%2Fhome%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesser, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlhammer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenwald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Hermelink, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimsza, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffe, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delabie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeland, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braziel, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubbs, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisenburger, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">463</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span><span class="refDoi"> DOI: 10.1038/nature08638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1038%2Fnature08638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=20054396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFCitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=88-92&author=R.+E.+Davisauthor=V.+N.+Ngoauthor=G.+Lenzauthor=P.+Tolarauthor=R.+M.+Youngauthor=P.+B.+Romesserauthor=H.+Kohlhammerauthor=L.+Lamyauthor=H.+Zhaoauthor=Y.+Yangauthor=W.+Xuauthor=A.+L.+Shafferauthor=G.+Wrightauthor=W.+Xiaoauthor=J.+Powellauthor=J.+K.+Jiangauthor=C.+J.+Thomasauthor=A.+Rosenwaldauthor=G.+Ottauthor=H.+K.+Muller-Hermelinkauthor=R.+D.+Gascoyneauthor=J.+M.+Connorsauthor=N.+A.+Johnsonauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=W.+H.+Wilsonauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+I.+Fisherauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=S.+K.+Pierceauthor=L.+M.+Staudt&title=Chronic+active+B-cell-receptor+signalling+in+diffuse+large+B-cell+lymphoma&doi=10.1038%2Fnature08638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma</span></div><div class="casAuthors">Davis, R. Eric; Ngo, Vu N.; Lenz, Georg; Tolar, Pavel; Young, Ryan M.; Romesser, Paul B.; Kohlhammer, Holger; Lamy, Laurence; Zhao, Hong; Yang, Yandan; Xu, Weihong; Shaffer, Arthur L.; Wright, George; Xiao, Wenming; Powell, John; Jiang, Jian-kang; Thomas, Craig J.; Rosenwald, Andreas; Ott, German; Muller-Hermelink, Hans Konrad; Gascoyne, Randy D.; Connors, Joseph M.; Johnson, Nathalie A.; Rimsza, Lisa M.; Campo, Elias; Jaffe, Elaine S.; Wilson, Wyndham H.; Delabie, Jan; Smeland, Erlend B.; Fisher, Richard I.; Braziel, Rita M.; Tubbs, Raymond R.; Cook, J. R.; Weisenburger, Dennis D.; Chan, Wing C.; Pierce, Susan K.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7277</span>),
    <span class="NLM_cas:pages">88-92</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A role for B-cell-receptor (BCR) signaling in lymphomagenesis has been inferred by studying Ig genes in human lymphomas and by engineering mouse models, but genetic and functional evidence for its oncogenic role in human lymphomas is needed.  Here the authors describe a form of chronic active' BCR signaling that is required for cell survival in the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).  The signaling adaptor CARD11 is required for constitutive NF-κB pathway activity and survival in ABC DLBCL.  Roughly 10% of ABC DLBCLs have mutant CARD11 isoforms that activate NF-κB, but the mechanism that engages wild-type CARD11 in other ABC DLBCLs was unknown.  An RNA interference genetic screen revealed that a BCR signaling component, Bruton's tyrosine kinase, is essential for the survival of ABC DLBCLs with wild-type CARD11.  In addn., knockdown of proximal BCR subunits (IgM, Ig-κ, CD79A and CD79B) killed ABC DLBCLs with wild-type CARD11 but not other lymphomas.  The BCRs in these ABC DLBCLs formed prominent clusters in the plasma membrane with low diffusion, similarly to BCRs in antigen-stimulated normal B cells.  Somatic mutations affecting the immunoreceptor tyrosine-based activation motif (ITAM) signaling modules of CD79B and CD79A were detected frequently in ABC DLBCL biopsy samples but rarely in other DLBCLs and never in Burkitt's lymphoma or mucosa-assocd. lymphoid tissue lymphoma.  In 18% of ABC DLBCLs, one functionally crit. residue of CD79B, the first ITAM tyrosine, was mutated.  These mutations increased surface BCR expression and attenuated Lyn kinase, a feedback inhibitor of BCR signaling.  These findings establish chronic active BCR signaling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzlT4q2Ie4lrVg90H21EOLACvtfcHk0lhkEOKuXcVW-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFCitw%253D%253D&md5=86d4bdf7f9af3fbe120d5b9175389e5a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnature08638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08638%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DNgo%26aufirst%3DV.%2BN.%26aulast%3DLenz%26aufirst%3DG.%26aulast%3DTolar%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DRomesser%26aufirst%3DP.%2BB.%26aulast%3DKohlhammer%26aufirst%3DH.%26aulast%3DLamy%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DR.%2BI.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DPierce%26aufirst%3DS.%2BK.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DChronic%2520active%2520B-cell-receptor%2520signalling%2520in%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D88%26epage%3D92%26doi%3D10.1038%2Fnature08638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Wilson, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pittaluga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lih, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerecitano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenkre, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shustov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fowler, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vose, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elstrom, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habermann, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrientos, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreivy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clow, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munneke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussa, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaupre, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">922</span><span class="NLM_x">–</span> <span class="NLM_lpage">926</span><span class="refDoi"> DOI: 10.1038/nm.3884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1038%2Fnm.3884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=26193343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WltLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=922-926&author=W.+H.+Wilsonauthor=R.+M.+Youngauthor=R.+Schmitzauthor=Y.+Yangauthor=S.+Pittalugaauthor=G.+Wrightauthor=C.+J.+Lihauthor=P.+M.+Williamsauthor=A.+L.+Shafferauthor=J.+Gerecitanoauthor=S.+de+Vosauthor=A.+Goyauthor=V.+P.+Kenkreauthor=P.+M.+Barrauthor=K.+A.+Blumauthor=A.+Shustovauthor=R.+Advaniauthor=N.+H.+Fowlerauthor=J.+M.+Voseauthor=R.+L.+Elstromauthor=T.+M.+Habermannauthor=J.+C.+Barrientosauthor=J.+McGreivyauthor=M.+Fardisauthor=B.+Y.+Changauthor=F.+Clowauthor=B.+Munnekeauthor=D.+Moussaauthor=D.+M.+Beaupreauthor=L.+M.+Staudt&title=Targeting+B+cell+receptor+signaling+with+ibrutinib+in+diffuse+large+B+cell+lymphoma&doi=10.1038%2Fnm.3884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma</span></div><div class="casAuthors">Wilson, Wyndham H.; Young, Ryan M.; Schmitz, Roland; Yang, Yandan; Pittaluga, Stefania; Wright, George; Lih, Chih-Jian; Williams, P. Mickey; Shaffer, Arthur L.; Gerecitano, John; de Vos, Sven; Goy, Andre; Kenkre, Vaishalee P.; Barr, Paul M.; Blum, Kristie A.; Shustov, Andrei; Advani, Ranjana; Fowler, Nathan H.; Vose, Julie M.; Elstrom, Rebecca L.; Habermann, Thomas M.; Barrientos, Jacqueline C.; McGreivy, Jesse; Fardis, Maria; Chang, Betty Y.; Clow, Fong; Munneke, Brian; Moussa, Davina; Beaupre, Darrin M.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">922-926</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The two major subtypes of diffuse large B cell lymphoma (DLBCL)-activated B cell-like (ABC) and germinal center B cell-like (GCB)-arise by distinct mechanisms, with ABC selectively acquiring mutations that target the B cell receptor (BCR), fostering chronic active BCR signaling.  The ABC subtype has a ∼40% cure rate with currently available therapies, which is worse than the rate for GCB DLBCL, and highlights the need for ABC subtype-specific treatment strategies.  We hypothesized that ABC, but not GCB, DLBCL tumors would respond to ibrutinib, an inhibitor of BCR signaling.  In a phase 1/2 clin. trial that involved 80 subjects with relapsed or refractory DLBCL, ibrutinib produced complete or partial responses in 37% (14/38) of those with ABC DLBCL, but in only 5% (1/20) of subjects with GCB DLBCL (P = 0.0106).  ABC tumors with BCR mutations responded to ibrutinib frequently (5/9; 55.5%), esp. those with concomitant myeloid differentiation primary response 88 (MYD88) mutations (4/5; 80%), a result that is consistent with in vitro cooperation between the BCR and MYD88 pathways.  However, the highest no. of responses occurred in ABC tumors that lacked BCR mutations (9/29; 31%), suggesting that oncogenic BCR signaling in ABC does not require BCR mutations and might be initiated by non-genetic mechanisms.  These results support the selective development of ibrutinib for the treatment of ABC DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpryc32RWzm77Vg90H21EOLACvtfcHk0lisRHtid3IVDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WltLjK&md5=d3342e8baa16eb379eed112c21d0b4ba</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnm.3884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3884%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DSchmitz%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DPittaluga%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DLih%26aufirst%3DC.%2BJ.%26aulast%3DWilliams%26aufirst%3DP.%2BM.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DGerecitano%26aufirst%3DJ.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DKenkre%26aufirst%3DV.%2BP.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DShustov%26aufirst%3DA.%26aulast%3DAdvani%26aufirst%3DR.%26aulast%3DFowler%26aufirst%3DN.%2BH.%26aulast%3DVose%26aufirst%3DJ.%2BM.%26aulast%3DElstrom%26aufirst%3DR.%2BL.%26aulast%3DHabermann%26aufirst%3DT.%2BM.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DMunneke%26aufirst%3DB.%26aulast%3DMoussa%26aufirst%3DD.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DTargeting%2520B%2520cell%2520receptor%2520signaling%2520with%2520ibrutinib%2520in%2520diffuse%2520large%2520B%2520cell%2520lymphoma%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D922%26epage%3D926%26doi%3D10.1038%2Fnm.3884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Davids, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. R.</span><span> </span><span class="NLM_article-title">Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">957</span><span class="NLM_x">–</span> <span class="NLM_lpage">967</span><span class="refDoi"> DOI: 10.2217/fon.14.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.2217%2Ffon.14.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=24941982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=957-967&author=M.+S.+Davidsauthor=J.+R.+Brown&title=Ibrutinib%3A+a+first+in+class+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.2217%2Ffon.14.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase</span></div><div class="casAuthors">Davids, Matthew S.; Brown, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">957-967</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Ibrutinib (formerly PCI-32765) is a potent, covalent inhibitor of Bruton's tyrosine kinase, a kinase downstream of the B-cell receptor that is crit. for B-cell survival and proliferation.  In preclin. studies, ibrutinib bound to Bruton's tyrosine kinase with high affinity, leading to inhibition of B-cell receptor signaling, decreased B-cell activation and induction of apoptosis.  In clin. studies, ibrutinib has been well-tolerated and has demonstrated profound anti-tumor activity in a variety of hematol. malignancies, most notably chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), leading to US FDA approval for relapsed CLL and MCL.  Ongoing studies are evaluating ibrutinib in other types of non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and Waldenstroem's macrogobulinemia, in larger Phase III studies in CLL and MCL, and in combination studies with monoclonal antibodies and chemotherapy.  Future studies will combine ibrutinib with other promising novel agents currently in development in hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3o_pMnFVskLVg90H21EOLACvtfcHk0lisRHtid3IVDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D&md5=345b4e839a830be822d474f62755a022</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.51%26sid%3Dliteratum%253Aachs%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DIbrutinib%253A%2520a%2520first%2520in%2520class%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DFuture%2520Oncol.%26date%3D2014%26volume%3D10%26spage%3D957%26epage%3D967%26doi%3D10.2217%2Ffon.14.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34a"><span><div class="note"><p class="first last">The roles of haspin and CLK in oncology are the subject on ongoing research. For recent work on haspin inhibition see</p></div><span class="NLM_contrib-group">Cuny, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulyanova, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auerbach, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glicksman, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J. M. G.</span><span> </span><span class="NLM_article-title">Structure–activity relationship study of beta-carboline derivatives as haspin kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2015</span><span class="NLM_x">–</span> <span class="NLM_lpage">2019</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2012.01.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2015-2019&author=G.+D.+Cunyauthor=N.+P.+Ulyanovaauthor=D.+Patnaikauthor=J.-F.+Liuauthor=X.+Linauthor=K.+Auerbachauthor=S.+S.+Rayauthor=J.+Xianauthor=M.+A.+Glicksmanauthor=R.+L.+Steinauthor=J.+M.+G.+Higgins&title=Structure%E2%80%93activity+relationship+study+of+beta-carboline+derivatives+as+haspin+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2012.01.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.028%26sid%3Dliteratum%253Aachs%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DUlyanova%26aufirst%3DN.%2BP.%26aulast%3DPatnaik%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.-F.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DAuerbach%26aufirst%3DK.%26aulast%3DRay%26aufirst%3DS.%2BS.%26aulast%3DXian%26aufirst%3DJ.%26aulast%3DGlicksman%26aufirst%3DM.%2BA.%26aulast%3DStein%26aufirst%3DR.%2BL.%26aulast%3DHiggins%26aufirst%3DJ.%2BM.%2BG.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520study%2520of%2520beta-carboline%2520derivatives%2520as%2520haspin%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2015%26epage%3D2019%26doi%3D10.1016%2Fj.bmcl.2012.01.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit34b"><span><div class="note"><p class="first last">For recent work on CLK inhibitors see</p></div><span class="NLM_contrib-group">Araki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dairiki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashita, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwatani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, O.</span><span> </span><span class="NLM_article-title">Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0116929</span><span class="refDoi"> DOI: 10.1371/journal.pone.0116929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1371%2Fjournal.pone.0116929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=25581376" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0116929&author=S.+Arakiauthor=R.+Dairikiauthor=Y.+Nakayamaauthor=A.+Muraiauthor=R.+Miyashitaauthor=M.+Iwataniauthor=T.+Nomuraauthor=O.+Nakanishi&title=Inhibitors+of+CLK+protein+kinases+suppress+cell+growth+and+induce+apoptosis+by+modulating+pre-mRNA+splicing&doi=10.1371%2Fjournal.pone.0116929"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0116929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0116929%26sid%3Dliteratum%253Aachs%26aulast%3DAraki%26aufirst%3DS.%26aulast%3DDairiki%26aufirst%3DR.%26aulast%3DNakayama%26aufirst%3DY.%26aulast%3DMurai%26aufirst%3DA.%26aulast%3DMiyashita%26aufirst%3DR.%26aulast%3DIwatani%26aufirst%3DM.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DNakanishi%26aufirst%3DO.%26atitle%3DInhibitors%2520of%2520CLK%2520protein%2520kinases%2520suppress%2520cell%2520growth%2520and%2520induce%2520apoptosis%2520by%2520modulating%2520pre-mRNA%2520splicing%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0116929%26doi%3D10.1371%2Fjournal.pone.0116929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Goedken, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devanarayan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowding, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakway, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talanian, R. V.</span><span> </span><span class="NLM_article-title">Minimum significant ratio of selectivity ratios (MSRSR) and confidence in ratio of selectivity ratios (CRSR): quantitative measures for selectivity ratios obtained by screening assays</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span><span class="refDoi"> DOI: 10.1177/1087057112447108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1177%2F1087057112447108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A280%3ADC%252BC38njtVKhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=857-867&author=E.+R.+Goedkenauthor=V.+Devanarayanauthor=C.+M.+Harrisauthor=L.+A.+Dowdingauthor=J.+P.+Jakwayauthor=J.+W.+Vossauthor=N.+Wishartauthor=D.+C.+Jordanauthor=R.+V.+Talanian&title=Minimum+significant+ratio+of+selectivity+ratios+%28MSRSR%29+and+confidence+in+ratio+of+selectivity+ratios+%28CRSR%29%3A+quantitative+measures+for+selectivity+ratios+obtained+by+screening+assays&doi=10.1177%2F1087057112447108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Minimum significant ratio of selectivity ratios (MSRSR) and confidence in ratio of selectivity ratios (CRSR): quantitative measures for selectivity ratios obtained by screening assays</span></div><div class="casAuthors">Goedken Eric R; Devanarayan Viswanath; Harris Christopher M; Dowding Lori A; Jakway James P; Voss Jeffrey W; Wishart Neil; Jordan David C; Talanian Robert V</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomolecular screening</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">857-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Development of inhibitor compounds selective against undesirable targets is critical in drug discovery.  Selectivity ratios for candidate compounds are evaluated by dividing potencies from two assays assessing the off-target and target.  Because all potency measurements have underlying uncertainty, understanding error propagation is essential to interpreting selectivity data.  Assay noise introduces ambiguity in the statistical significance of selectivity ratios, particularly at low replicate numbers when compounds are often prioritized for subsequent testing.  The ability to differentiate potency results for any pair of compounds in one assay is evaluated using a metric called minimum significant ratio (MSR).  Potency results of one compound tested in a pair of assays can be differentiated by the minimum significant selectivity ratio (MSSR).  To differentiate selectivity ratios for any pair of compounds, we extend this concept by proposing two new parameters called the minimum significant ratio of selectivity ratios (MSRSR) and confidence in ratio of selectivity ratios (CRSR).  Importantly, these tools can be used after a single selectivity measurement.  We describe these methods and illustrate their usefulness using structure-activity relationship data from a Janus kinase inhibitor project, in which these tools informed a cogent retesting strategy and enabled rapid and objective decision making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQODfWMvzjMgMNIRw0GKUoEfW6udTcc2ebCuqzgY_QvJbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38njtVKhsw%253D%253D&md5=e9f11323477b881401edcf72b77cddd7</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1177%2F1087057112447108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057112447108%26sid%3Dliteratum%253Aachs%26aulast%3DGoedken%26aufirst%3DE.%2BR.%26aulast%3DDevanarayan%26aufirst%3DV.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DDowding%26aufirst%3DL.%2BA.%26aulast%3DJakway%26aufirst%3DJ.%2BP.%26aulast%3DVoss%26aufirst%3DJ.%2BW.%26aulast%3DWishart%26aufirst%3DN.%26aulast%3DJordan%26aufirst%3DD.%2BC.%26aulast%3DTalanian%26aufirst%3DR.%2BV.%26atitle%3DMinimum%2520significant%2520ratio%2520of%2520selectivity%2520ratios%2520%2528MSRSR%2529%2520and%2520confidence%2520in%2520ratio%2520of%2520selectivity%2520ratios%2520%2528CRSR%2529%253A%2520quantitative%2520measures%2520for%2520selectivity%2520ratios%2520obtained%2520by%2520screening%2520assays%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2012%26volume%3D17%26spage%3D857%26epage%3D867%26doi%3D10.1177%2F1087057112447108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b'],'ref3':['cit3a','cit3b'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18a','cit18b','cit18c'],'ref19':['cit19'],'ref20':['cit20a','cit20b','cit20c','cit20d','cit20e','cit20f','cit20g'],'ref21':['cit21a','cit21b'],'ref22':['cit22a','cit22b','cit22c'],'ref23':['cit23'],'ref24':['cit24'],'ref25':[],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28a'],'ref29':[],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34a','cit34b'],'ref35':['cit35']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 28 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yun Chen, Yi Ning, Gang Bai, Linjiang Tong, Tao Zhang, Jinpei Zhou, Huibin Zhang, Hua Xie, Jian Ding, <span class="NLM_string-name hlFld-ContribAuthor">Wenhu Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     , 82-87. <a href="https://doi.org/10.1021/acsmedchemlett.0c00474" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00474</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00474%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BIRAK4-Targeting%252BPROTACs%26aulast%3DChen%26aufirst%3DYun%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28082020%26date%3D08122020%26date%3D10122020%26volume%3D12%26issue%3D1%26spage%3D82%26epage%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Venkateshwar Rao Gummadi, Anima Boruah, Bharathi Raja Ainan, Brahma Reddy Vare, Srinivas Manda, Hari Prakash Gondle, Shiva Nagendra Kumar, Subhendu Mukherjee, Suraj T. Gore, Narasimha Rao Krishnamurthy, Sivapriya Marappan, Shilpa S. Nayak, Kavitha Nellore, Wesley Roy Balasubramanian, Archana Bhumireddy, Sanjeev Giri, Sreevalsam Gopinath, Dodheri S. Samiulla, Girish Daginakatte, Aravind Basavaraju, Shekar Chelur, Rajesh Eswarappa, Charamanna Belliappa, Hosahalli S. Subramanya, Robert N. Booher, Murali Ramachandra, <span class="NLM_string-name hlFld-ContribAuthor">Susanta Samajdar</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (12)
                                     , 2374-2381. <a href="https://doi.org/10.1021/acsmedchemlett.0c00255" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00255</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00255%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BCA-4948%25252C%252Ban%252BOrally%252BBioavailable%252BIRAK4%252BInhibitor%252Bfor%252BTreatment%252Bof%252BHematologic%252BMalignancies%26aulast%3DGummadi%26aufirst%3DVenkateshwar%2BRao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D13052020%26date%3D06102020%26date%3D14102020%26volume%3D11%26issue%3D12%26spage%3D2374%26epage%3D2381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">John M. Hatcher, Guang Yang, Li Wang, Scott B. Ficarro, Sara Buhrlage, Hao Wu, Jarrod A. Marto, Steven P. Treon, <span class="NLM_string-name hlFld-ContribAuthor">Nathanael S. Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2238-2243. <a href="https://doi.org/10.1021/acsmedchemlett.0c00378" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00378</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00378%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BSelective%25252C%252BCovalent%252BIRAK1%252BInhibitor%252Bwith%252BAntiproliferative%252BActivity%252Bin%252BMYD88%252BMutated%252BB-Cell%252BLymphoma%26aulast%3DHatcher%26aufirst%3DJohn%2BM.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D08072020%26date%3D06102020%26date%3D09102020%26volume%3D11%26issue%3D11%26spage%3D2238%26epage%3D2243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sébastien L. Degorce, Omid Tavana, Erica Banks, Claire Crafter, Lakshmaiah Gingipalli, David Kouvchinov, Yumeng Mao, Fiona Pachl, Anisha Solanki, Viia Valge-Archer, Bin Yang, <span class="NLM_string-name hlFld-ContribAuthor">Scott D. Edmondson</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (18)
                                     , 10460-10473. <a href="https://doi.org/10.1021/acs.jmedchem.0c01125" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01125%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BProteolysis-Targeting%252BChimera%252BMolecules%252Bthat%252BSelectively%252BDegrade%252Bthe%252BIRAK3%252BPseudokinase%26aulast%3DDegorce%26aufirst%3DS%25C3%25A9bastien%2BL.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D30062020%26date%3D14092020%26date%3D17082020%26volume%3D63%26issue%3D18%26spage%3D10460%26epage%3D10473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Vakhid A. Mamedov, Elena A. Khafizova, Nataliya E. Algaeva, Shamil K. Latypov, <span class="NLM_string-name hlFld-ContribAuthor">Oleg G. Sinyashin</span>. </span><span class="cited-content_cbyCitation_article-title">Acid-Catalyzed Multicomponent Rearrangements via 2-((Quinoxalin-3(4H)-on-2-yl)(aryl)methylene)malononitriles, Generated In Situ, for Divergent Synthesis of Pyrroles with Different Substitution Patterns. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (15)
                                     , 9887-9904. <a href="https://doi.org/10.1021/acs.joc.0c01180" title="DOI URL">https://doi.org/10.1021/acs.joc.0c01180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c01180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c01180%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAcid-Catalyzed%252BMulticomponent%252BRearrangements%252Bvia%252B2-%252528%252528Quinoxalin-3%2525284H%252529-on-2-yl%252529%252528aryl%252529methylene%252529malononitriles%25252C%252BGenerated%252BIn%252BSitu%25252C%252Bfor%252BDivergent%252BSynthesis%252Bof%252BPyrroles%252Bwith%252BDifferent%252BSubstitution%252BPatterns%26aulast%3DMamedov%26aufirst%3DVakhid%2BA.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15052020%26date%3D16072020%26date%3D26062020%26volume%3D85%26issue%3D15%26spage%3D9887%26epage%3D9904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rino Ragno, Valeria Esposito, Martina Di Mario, Stefano Masiello, Marco Viscovo, <span class="NLM_string-name hlFld-ContribAuthor">Richard D. Cramer</span>. </span><span class="cited-content_cbyCitation_article-title">Teaching and Learning Computational Drug Design: Student Investigations of 3D Quantitative Structure–Activity Relationships through Web Applications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Education</span><span> <strong>2020,</strong> <em>97 </em>
                                    (7)
                                     , 1922-1930. <a href="https://doi.org/10.1021/acs.jchemed.0c00117" title="DOI URL">https://doi.org/10.1021/acs.jchemed.0c00117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jchemed.0c00117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jchemed.0c00117%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Education%26atitle%3DTeaching%252Band%252BLearning%252BComputational%252BDrug%252BDesign%25253A%252BStudent%252BInvestigations%252Bof%252B3D%252BQuantitative%252BStructure%2525E2%252580%252593Activity%252BRelationships%252Bthrough%252BWeb%252BApplications%26aulast%3DRagno%26aufirst%3DRino%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29022020%26date%3D06062020%26date%3D23062020%26volume%3D97%26issue%3D7%26spage%3D1922%26epage%3D1930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sébastien L. Degorce, Rana Anjum, Andrew Bloecher, Rodrigo J. Carbajo, Keith S. Dillman, Lisa Drew, Christopher T. Halsall, Eva M. Lenz, Nicola A. Lindsay, Michele F. Mayo, Jennifer H. Pink, Graeme R. Robb, Alan Rosen, James S. Scott, <span class="NLM_string-name hlFld-ContribAuthor">Yafeng Xue</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88L265P Mutant Diffuse Large B Cell Lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (21)
                                     , 9918-9930. <a href="https://doi.org/10.1021/acs.jmedchem.9b01346" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01346%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BSeries%252Bof%252B5-Azaquinazolines%252Bas%252BOrally%252BEfficacious%252BIRAK4%252BInhibitors%252BTargeting%252BMyD88L265P%252BMutant%252BDiffuse%252BLarge%252BB%252BCell%252BLymphoma%26aulast%3DDegorce%26aufirst%3DS%25C3%25A9bastien%2BL.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15082019%26date%3D01112019%26date%3D17102019%26volume%3D62%26issue%3D21%26spage%3D9918%26epage%3D9930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sébastien L. Degorce, Michael S. Bodnarchuk, <span class="NLM_string-name hlFld-ContribAuthor">James S. Scott</span>. </span><span class="cited-content_cbyCitation_article-title">Lowering Lipophilicity by Adding Carbon: AzaSpiroHeptanes, a logD Lowering Twist. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (8)
                                     , 1198-1204. <a href="https://doi.org/10.1021/acsmedchemlett.9b00248" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00248</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00248%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DLowering%252BLipophilicity%252Bby%252BAdding%252BCarbon%25253A%252BAzaSpiroHeptanes%25252C%252Ba%252BlogD%252BLowering%252BTwist%26aulast%3DDegorce%26aufirst%3DS%25C3%25A9bastien%2BL.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D06062019%26date%3D18072019%26date%3D25072019%26date%3D18072019%26volume%3D10%26issue%3D8%26spage%3D1198%26epage%3D1204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sébastien L. Degorce, Michael S. Bodnarchuk, Iain A. Cumming, <span class="NLM_string-name hlFld-ContribAuthor">James S. Scott</span>. </span><span class="cited-content_cbyCitation_article-title">Lowering Lipophilicity by Adding Carbon: One-Carbon Bridges of Morpholines and Piperazines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (19)
                                     , 8934-8943. <a href="https://doi.org/10.1021/acs.jmedchem.8b01148" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01148%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLowering%252BLipophilicity%252Bby%252BAdding%252BCarbon%25253A%252BOne-Carbon%252BBridges%252Bof%252BMorpholines%252Band%252BPiperazines%26aulast%3DDegorce%26aufirst%3DS%25C3%25A9bastien%2BL.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D23072018%26date%3D20092018%26date%3D06092018%26volume%3D61%26issue%3D19%26spage%3D8934%26epage%3D8943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nazarii Sabat, Lenka Poštová Slavětínská, Blanka Klepetářová, <span class="NLM_string-name hlFld-ContribAuthor">Michal Hocek</span>. </span><span class="cited-content_cbyCitation_article-title">C–H Imidation of 7-Deazapurines. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (4)
                                     , 4674-4678. <a href="https://doi.org/10.1021/acsomega.8b00520" title="DOI URL">https://doi.org/10.1021/acsomega.8b00520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b00520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b00520%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DC%2525E2%252580%252593H%252BImidation%252Bof%252B7-Deazapurines%26aulast%3DSabat%26aufirst%3DNazarii%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19032018%26date%3D20042018%26volume%3D3%26issue%3D4%26spage%3D4674%26epage%3D4678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Geetha  Nalairndran</span>, <span class="hlFld-ContribAuthor ">Ivy  Chung</span>, <span class="hlFld-ContribAuthor ">Azad Hassan  Abdul Razack</span>, <span class="hlFld-ContribAuthor ">Felicia Fei‐Lei  Chung</span>, <span class="hlFld-ContribAuthor ">Ling‐Wei  Hii</span>, <span class="hlFld-ContribAuthor ">Wei‐Meng  Lim</span>, <span class="hlFld-ContribAuthor ">Chin King  Looi</span>, <span class="hlFld-ContribAuthor ">Chun‐Wai  Mai</span>, <span class="hlFld-ContribAuthor ">Chee‐Onn  Leong</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular and Molecular Medicine</span><span> <strong>2021,</strong> <em>5 </em><a href="https://doi.org/10.1111/jcmm.16684" title="DOI URL">https://doi.org/10.1111/jcmm.16684</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jcmm.16684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjcmm.16684%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520and%2520Molecular%2520Medicine%26atitle%3DInhibition%252Bof%252BJanus%252BKinase%252B1%252Bsynergizes%252Bdocetaxel%252Bsensitivity%252Bin%252Bprostate%252Bcancer%252Bcells%26aulast%3DNalairndran%26aufirst%3DGeetha%26date%3D2021%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Tomas-Roca</span>, <span class="hlFld-ContribAuthor ">Marta  Rodriguez</span>, <span class="hlFld-ContribAuthor ">Ruth  Alonso-Alonso</span>, <span class="hlFld-ContribAuthor ">Socorro M.  Rodriguez-Pinilla</span>, <span class="hlFld-ContribAuthor ">Miguel Angel  Piris</span>. </span><span class="cited-content_cbyCitation_article-title">Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy. </span><span class="cited-content_cbyCitation_journal-name">Hemato</span><span> <strong>2021,</strong> <em>2 </em>
                                    (2)
                                     , 281-304. <a href="https://doi.org/10.3390/hemato2020017" title="DOI URL">https://doi.org/10.3390/hemato2020017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/hemato2020017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fhemato2020017%26sid%3Dliteratum%253Aachs%26jtitle%3DHemato%26atitle%3DDiffuse%252BLarge%252BB-Cell%252BLymphoma%25253A%252BRecognition%252Bof%252BMarkers%252Bfor%252BTargeted%252BTherapy%26aulast%3DTomas-Roca%26aufirst%3DLaura%26date%3D2021%26date%3D2021%26volume%3D2%26issue%3D2%26spage%3D281%26epage%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenyujing  Zhou</span>, <span class="hlFld-ContribAuthor ">Weihong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Development of molecular intervention strategies for B-cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Hematology</span><span> <strong>2021,</strong> <em>14 </em>
                                    (2)
                                     , 241-252. <a href="https://doi.org/10.1080/17474086.2021.1856652" title="DOI URL">https://doi.org/10.1080/17474086.2021.1856652</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17474086.2021.1856652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17474086.2021.1856652%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Hematology%26atitle%3DDevelopment%252Bof%252Bmolecular%252Bintervention%252Bstrategies%252Bfor%252BB-cell%252Blymphoma%26aulast%3DZhou%26aufirst%3DWenyujing%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D2%26spage%3D241%26epage%3D252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenqiang  Zhai</span>, <span class="hlFld-ContribAuthor ">Yongping  Lu</span>, <span class="hlFld-ContribAuthor ">Yabo  Zhu</span>, <span class="hlFld-ContribAuthor ">Mengguang  Zhou</span>, <span class="hlFld-ContribAuthor ">Cheng  Ye</span>, <span class="hlFld-ContribAuthor ">Zheng-Zheng  Shi</span>, <span class="hlFld-ContribAuthor ">Wenjian  Qian</span>, <span class="hlFld-ContribAuthor ">Taishan  Hu</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>31 </em>, 127686. <a href="https://doi.org/10.1016/j.bmcl.2020.127686" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127686</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127686%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Band%252Boptimization%252Bof%252Ba%252Bpotent%252Band%252Bselective%252Bindazolamine%252Bseries%252Bof%252BIRAK4%252Binhibitors%26aulast%3DZhai%26aufirst%3DWenqiang%26date%3D2021%26volume%3D31%26spage%3D127686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sébastien L.  Degorce</span>, <span class="hlFld-ContribAuthor ">Anna  Aagaard</span>, <span class="hlFld-ContribAuthor ">Rana  Anjum</span>, <span class="hlFld-ContribAuthor ">Iain A.  Cumming</span>, <span class="hlFld-ContribAuthor ">Coura R.  Diène</span>, <span class="hlFld-ContribAuthor ">Charlene  Fallan</span>, <span class="hlFld-ContribAuthor ">Tony  Johnson</span>, <span class="hlFld-ContribAuthor ">Karl-Johan  Leuchowius</span>, <span class="hlFld-ContribAuthor ">Alexandra L.  Orton</span>, <span class="hlFld-ContribAuthor ">Stuart  Pearson</span>, <span class="hlFld-ContribAuthor ">Graeme R.  Robb</span>, <span class="hlFld-ContribAuthor ">Alan  Rosen</span>, <span class="hlFld-ContribAuthor ">Graeme B.  Scarfe</span>, <span class="hlFld-ContribAuthor ">James S.  Scott</span>, <span class="hlFld-ContribAuthor ">James M.  Smith</span>, <span class="hlFld-ContribAuthor ">Oliver R.  Steward</span>, <span class="hlFld-ContribAuthor ">Ina  Terstiege</span>, <span class="hlFld-ContribAuthor ">Michael J.  Tucker</span>, <span class="hlFld-ContribAuthor ">Paul  Turner</span>, <span class="hlFld-ContribAuthor ">Stephen D.  Wilkinson</span>, <span class="hlFld-ContribAuthor ">Gail L.  Wrigley</span>, <span class="hlFld-ContribAuthor ">Yafeng  Xue</span>. </span><span class="cited-content_cbyCitation_article-title">Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (23)
                                     , 115815. <a href="https://doi.org/10.1016/j.bmc.2020.115815" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115815</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115815%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DImproving%252Bmetabolic%252Bstability%252Band%252Bremoving%252Baldehyde%252Boxidase%252Bliability%252Bin%252Ba%252B5-azaquinazoline%252Bseries%252Bof%252BIRAK4%252Binhibitors%26aulast%3DDegorce%26aufirst%3DS%25C3%25A9bastien%2BL.%26date%3D2020%26volume%3D28%26issue%3D23%26spage%3D115815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Liqiang  Fu</span>, <span class="hlFld-ContribAuthor ">Bin  Shen</span>, <span class="hlFld-ContribAuthor ">Yingtao  Liu</span>, <span class="hlFld-ContribAuthor ">Wenqian  Wang</span>, <span class="hlFld-ContribAuthor ">Xin  Cai</span>, <span class="hlFld-ContribAuthor ">Linglong  Kong</span>, <span class="hlFld-ContribAuthor ">Yilin  Yan</span>, <span class="hlFld-ContribAuthor ">Ryan  Meng</span>, <span class="hlFld-ContribAuthor ">Zhuming  Zhang</span>, <span class="hlFld-ContribAuthor ">Ying-Nan P.  Chen</span>, <span class="hlFld-ContribAuthor ">Qian  Liu</span>, <span class="hlFld-ContribAuthor ">Zhao-Kui  Wan</span>, <span class="hlFld-ContribAuthor ">Tianyuan  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaotao  Wang</span>, <span class="hlFld-ContribAuthor ">Paul  Gavine</span>, <span class="hlFld-ContribAuthor ">Amanda  Del Rosario</span>, <span class="hlFld-ContribAuthor ">Kay  Ahn</span>, <span class="hlFld-ContribAuthor ">Ulrike  Philippar</span>, <span class="hlFld-ContribAuthor ">Ricardo  Attar</span>, <span class="hlFld-ContribAuthor ">Jennifer  Yang</span>, <span class="hlFld-ContribAuthor ">Yanping  Xu</span>, <span class="hlFld-ContribAuthor ">James P.  Edwards</span>, <span class="hlFld-ContribAuthor ">Xuedong  Dai</span>. </span><span class="cited-content_cbyCitation_article-title">Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2020,</strong> <em>27 </em>
                                    (12)
                                     , 1500-1509.e13. <a href="https://doi.org/10.1016/j.chembiol.2020.08.010" title="DOI URL">https://doi.org/10.1016/j.chembiol.2020.08.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2020.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2020.08.010%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DAssessing%252BIRAK4%252BFunctions%252Bin%252BABC%252BDLBCL%252Bby%252BIRAK4%252BKinase%252BInhibition%252Band%252BProtein%252BDegradation%26aulast%3DZhang%26aufirst%3DJing%26date%3D2020%26volume%3D27%26issue%3D12%26spage%3D1500%26epage%3D1509.e13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yun-Ti  Chen</span>, <span class="hlFld-ContribAuthor ">Cheng-Hsuan  Wu</span>, <span class="hlFld-ContribAuthor ">Yi-Cyun  Chen</span>, <span class="hlFld-ContribAuthor ">Yen-Chao  Hsu</span>, <span class="hlFld-ContribAuthor ">Yu-Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Jinn-Moon  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Configurational Differences and Binding Mechanisms of Interleukin-1 Receptor-Associated Kinase 1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 160-167. <a href="https://doi.org/10.1109/BIBE50027.2020.00034" title="DOI URL">https://doi.org/10.1109/BIBE50027.2020.00034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1109/BIBE50027.2020.00034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1109%2FBIBE50027.2020.00034%26sid%3Dliteratum%253Aachs%26atitle%3DConfigurational%252BDifferences%252Band%252BBinding%252BMechanisms%252Bof%252BInterleukin-1%252BReceptor-Associated%252BKinase%252B1%26aulast%3DChen%26aufirst%3DYun-Ti%26date%3D2020%26spage%3D160%26epage%3D167%26pub%3DIEEE%26atitle%3D2020%252BIEEE%252B20th%252BInternational%252BConference%252Bon%252BBioinformatics%252Band%252BBioengineering%252B%252528BIBE%252529%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dana  Němečková</span>, <span class="hlFld-ContribAuthor ">Eva  Havránková</span>, <span class="hlFld-ContribAuthor ">Jan  Šimbera</span>, <span class="hlFld-ContribAuthor ">Richard  Ševčík</span>, <span class="hlFld-ContribAuthor ">Pavel  Pazdera</span>. </span><span class="cited-content_cbyCitation_article-title">Simplified Procedure for General Synthesis of Monosubstituted Piperazines—From a Batch Reaction Vessel to a Flow (Microwave) Reactor. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (9)
                                     , 2168. <a href="https://doi.org/10.3390/molecules25092168" title="DOI URL">https://doi.org/10.3390/molecules25092168</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25092168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25092168%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSimplified%252BProcedure%252Bfor%252BGeneral%252BSynthesis%252Bof%252BMonosubstituted%252BPiperazines%2525E2%252580%252594From%252Ba%252BBatch%252BReaction%252BVessel%252Bto%252Ba%252BFlow%252B%252528Microwave%252529%252BReactor%26aulast%3DN%25C4%259Bme%25C4%258Dkov%25C3%25A1%26aufirst%3DDana%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D9%26spage%3D2168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yun  Chen</span>, <span class="hlFld-ContribAuthor ">Gang  Bai</span>, <span class="hlFld-ContribAuthor ">Yi  Ning</span>, <span class="hlFld-ContribAuthor ">Shi  Cai</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Peiran  Song</span>, <span class="hlFld-ContribAuthor ">Jinpei  Zhou</span>, <span class="hlFld-ContribAuthor ">Wenhu  Duan</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Huibin  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>190 </em>, 112092. <a href="https://doi.org/10.1016/j.ejmech.2020.112092" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112092%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252BImidazo%25255B1%25252C2-b%25255Dpyridazine%252BIRAK4%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bmutant%252BMYD88%252BL265P%252Bdiffuse%252Blarge%252BB-cell%252Blymphoma%26aulast%3DChen%26aufirst%3DYun%26date%3D2020%26volume%3D190%26spage%3D112092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seyed Sajad  Sajadikhah</span>, <span class="hlFld-ContribAuthor ">Abdolkarim  Zare</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of pyrrolo[2,3-d]pyrimidines (microreview). </span><span class="cited-content_cbyCitation_journal-name">Chemistry of Heterocyclic Compounds</span><span> <strong>2019,</strong> <em>55 </em>
                                    (12)
                                     , 1168-1170. <a href="https://doi.org/10.1007/s10593-019-02595-2" title="DOI URL">https://doi.org/10.1007/s10593-019-02595-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10593-019-02595-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10593-019-02595-2%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520of%2520Heterocyclic%2520Compounds%26atitle%3DSynthesis%252Bof%252Bpyrrolo%25255B2%25252C3-d%25255Dpyrimidines%252B%252528microreview%252529%26aulast%3DSajadikhah%26aufirst%3DSeyed%2BSajad%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D12%26spage%3D1168%26epage%3D1170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joanna A  Korecka</span>, <span class="hlFld-ContribAuthor ">Ria  Thomas</span>, <span class="hlFld-ContribAuthor ">Dan P  Christensen</span>, <span class="hlFld-ContribAuthor ">Anthony J  Hinrich</span>, <span class="hlFld-ContribAuthor ">Eliza J  Ferrari</span>, <span class="hlFld-ContribAuthor ">Simon A  Levy</span>, <span class="hlFld-ContribAuthor ">Michelle L  Hastings</span>, <span class="hlFld-ContribAuthor ">Penelope J  Hallett</span>, <span class="hlFld-ContribAuthor ">Ole  Isacson</span>. </span><span class="cited-content_cbyCitation_article-title">Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson’s disease patient fibroblasts. </span><span class="cited-content_cbyCitation_journal-name">Human Molecular Genetics</span><span> <strong>2019,</strong> <em>28 </em>
                                    (19)
                                     , 3232-3243. <a href="https://doi.org/10.1093/hmg/ddz126" title="DOI URL">https://doi.org/10.1093/hmg/ddz126</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/hmg/ddz126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fhmg%2Fddz126%26sid%3Dliteratum%253Aachs%26jtitle%3DHuman%2520Molecular%2520Genetics%26atitle%3DMitochondrial%252Bclearance%252Band%252Bmaturation%252Bof%252Bautophagosomes%252Bare%252Bcompromised%252Bin%252BLRRK2%252BG2019S%252Bfamilial%252BParkinson%2525E2%252580%252599s%252Bdisease%252Bpatient%252Bfibroblasts%26aulast%3DKorecka%26aufirst%3DJoanna%2BA%26date%3D2019%26date%3D2019%26volume%3D28%26issue%3D19%26spage%3D3232%26epage%3D3243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katherine R.  Balka</span>, <span class="hlFld-ContribAuthor ">Dominic  Nardo</span>. </span><span class="cited-content_cbyCitation_article-title">Understanding early TLR signaling through the Myddosome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Leukocyte Biology</span><span> <strong>2019,</strong> <em>105 </em>
                                    (2)
                                     , 339-351. <a href="https://doi.org/10.1002/JLB.MR0318-096R" title="DOI URL">https://doi.org/10.1002/JLB.MR0318-096R</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/JLB.MR0318-096R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2FJLB.MR0318-096R%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Leukocyte%2520Biology%26atitle%3DUnderstanding%252Bearly%252BTLR%252Bsignaling%252Bthrough%252Bthe%252BMyddosome%26aulast%3DBalka%26aufirst%3DKatherine%2BR.%26date%3D2019%26date%3D2018%26volume%3D105%26issue%3D2%26spage%3D339%26epage%3D351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinrui  Yuan</span>, <span class="hlFld-ContribAuthor ">Hanshu  Wu</span>, <span class="hlFld-ContribAuthor ">Hong  Bu</span>, <span class="hlFld-ContribAuthor ">Jinpei  Zhou</span>, <span class="hlFld-ContribAuthor ">Huibin  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the immunity protein kinases for immuno-oncology. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>163 </em>, 413-427. <a href="https://doi.org/10.1016/j.ejmech.2018.11.072" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.11.072</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.11.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.11.072%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252Bthe%252Bimmunity%252Bprotein%252Bkinases%252Bfor%252Bimmuno-oncology%26aulast%3DYuan%26aufirst%3DXinrui%26date%3D2019%26volume%3D163%26spage%3D413%26epage%3D427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elisabetta  Chiarparin</span>, <span class="hlFld-ContribAuthor ">Martin J  Packer</span>, <span class="hlFld-ContribAuthor ">David M  Wilson</span>. </span><span class="cited-content_cbyCitation_article-title">Experimental free ligand conformations: a missing link in structure-based drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2019,</strong> <em>11 </em>
                                    (2)
                                     , 79-82. <a href="https://doi.org/10.4155/fmc-2018-0339" title="DOI URL">https://doi.org/10.4155/fmc-2018-0339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0339%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DExperimental%252Bfree%252Bligand%252Bconformations%25253A%252Ba%252Bmissing%252Blink%252Bin%252Bstructure-based%252Bdrug%252Bdiscovery%26aulast%3DChiarparin%26aufirst%3DElisabetta%26date%3D2019%26volume%3D11%26issue%3D2%26spage%3D79%26epage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander N. R.  Weber</span>, <span class="hlFld-ContribAuthor ">Yamel  Cardona Gloria</span>, <span class="hlFld-ContribAuthor ">Özcan  Çınar</span>, <span class="hlFld-ContribAuthor ">H. Christian  Reinhardt</span>, <span class="hlFld-ContribAuthor ">Antonio  Pezzutto</span>, <span class="hlFld-ContribAuthor ">Olaf-Oliver  Wolz</span>. </span><span class="cited-content_cbyCitation_article-title">Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities. </span><span class="cited-content_cbyCitation_journal-name">Cancer Immunology, Immunotherapy</span><span> <strong>2018,</strong> <em>67 </em>
                                    (11)
                                     , 1797-1807. <a href="https://doi.org/10.1007/s00262-018-2242-9" title="DOI URL">https://doi.org/10.1007/s00262-018-2242-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00262-018-2242-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00262-018-2242-9%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Immunology%252C%2520Immunotherapy%26atitle%3DOncogenic%252BMYD88%252Bmutations%252Bin%252Blymphoma%25253A%252Bnovel%252Binsights%252Band%252Btherapeutic%252Bpossibilities%26aulast%3DWeber%26aufirst%3DAlexander%2BN.%2BR.%26date%3D2018%26date%3D2018%26volume%3D67%26issue%3D11%26spage%3D1797%26epage%3D1807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jack W.  Singer</span>, <span class="hlFld-ContribAuthor ">Angela  Fleischman</span>, <span class="hlFld-ContribAuthor ">Suliman  Al-Fayoumi</span>, <span class="hlFld-ContribAuthor ">John O.  Mascarenhas</span>, <span class="hlFld-ContribAuthor ">Qiang  Yu</span>, <span class="hlFld-ContribAuthor ">Anupriya  Agarwal</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (70)
                                     , 33416-33439. <a href="https://doi.org/10.18632/oncotarget.26058" title="DOI URL">https://doi.org/10.18632/oncotarget.26058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.26058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.26058%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DInhibition%252Bof%252Binterleukin-1%252Breceptor-associated%252Bkinase%252B1%252B%252528IRAK1%252529%252Bas%252Ba%252Btherapeutic%252Bstrategy%26aulast%3DSinger%26aufirst%3DJack%2BW.%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D70%26spage%3D33416%26epage%3D33439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sébastien L.  Degorce</span>, <span class="hlFld-ContribAuthor ">Rana  Anjum</span>, <span class="hlFld-ContribAuthor ">Keith S.  Dillman</span>, <span class="hlFld-ContribAuthor ">Lisa  Drew</span>, <span class="hlFld-ContribAuthor ">Sam D.  Groombridge</span>, <span class="hlFld-ContribAuthor ">Christopher T.  Halsall</span>, <span class="hlFld-ContribAuthor ">Eva M.  Lenz</span>, <span class="hlFld-ContribAuthor ">Nicola A.  Lindsay</span>, <span class="hlFld-ContribAuthor ">Michele F.  Mayo</span>, <span class="hlFld-ContribAuthor ">Jennifer H.  Pink</span>, <span class="hlFld-ContribAuthor ">Graeme R.  Robb</span>, <span class="hlFld-ContribAuthor ">James S.  Scott</span>, <span class="hlFld-ContribAuthor ">Stephen  Stokes</span>, <span class="hlFld-ContribAuthor ">Yafeng  Xue</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (4)
                                     , 913-924. <a href="https://doi.org/10.1016/j.bmc.2018.01.008" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.01.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.01.008%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DOptimization%252Bof%252Bpermeability%252Bin%252Ba%252Bseries%252Bof%252Bpyrrolotriazine%252Binhibitors%252Bof%252BIRAK4%26aulast%3DDegorce%26aufirst%3DS%25C3%25A9bastien%2BL.%26date%3D2018%26volume%3D26%26issue%3D4%26spage%3D913%26epage%3D924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0024.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0001.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. X-ray crystal structure of tricylic inhibitor <b>1</b> in complex with IRAK4 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K75">5K75</a>). Green dotted lines indicate intermolecular interactions involved in binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0012.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Core Variation with S<sub>N</sub>Ar Displacement<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>trans</i>-H<sub>2</sub>NCyNMe<sub>2</sub>, DIPEA, iPrOH, MW, 85–150 °C, 4–14 h, 17–61%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Core Variation through Heterocycle Construction<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) cyclopentanone, EtOH, 80 °C, 4 h, 89%; (b) Ph<sub>2</sub>O, 250 °C, 6 h, 89%; (c) POCl<sub>3,</sub> 100 °C, 45 min, 85%; (d) <i>trans</i>-H<sub>2</sub>NCyNMe<sub>2</sub>, DIPEA, iPrOH, MW, 160 °C, 9 h, 39%; (e) HCl, PhMe, Δ, 24 h, 36%; (f) HCOOH, Δ, 7 h, 90%; (g) POCl<sub>3,</sub> PhNMe<sub>2</sub>, Δ, 3.5 h, 100%; (h) <i>trans</i>-H<sub>2</sub>NCyNMe<sub>2</sub>, DIPEA, iPrOH, MW, 150 °C, 10 h, 52%; (i) AlCl<sub>3</sub>, PhMe, Δ, 135 min, 32%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0014.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Variation of the 5-Position of the Pyrrolopyrimidine<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>trans</i>-H<sub>2</sub>NCyNMe<sub>2</sub>, DIPEA, iPrOH, MW, 130 °C, 5 h, 70%; (b) R<sub>2</sub>Zn or RZnBr, Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, THF, 80 °C, 3–16 h, 55–100%; (c) TBAF, THF, 80 °C, 16–72 h, 9–35% or TFA, CH<sub>2</sub>Cl<sub>2,</sub> 20 °C, 3–24 h then NH<sub>3</sub>/MeOH, 1–24 h, 44–81%; (d) RBpin, Pd(PPh<sub>3</sub>)<sub>4</sub> or Pd(dtbpf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub> or K<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 85–90 °C, 5–16 h, 41–67%; (e) Pd/C, H<sub>2</sub>, EtOH/THF or MeOH, rt, 3–16 h, 28–100% (alkenes) or Pd/C, NH<sub>4</sub>HCO<sub>2</sub>, MeOH, Δ, 4–8 h, 57–82% (furyls); (f) Cu, Ph<sub>2</sub>SCF<sub>3</sub>·CF<sub>3</sub>SO<sub>2</sub>, DMF, 80 °C, 16 h, 44%; (g) <i>trans</i>-H<sub>2</sub>NCyNMe<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, MeCN, 80 °C, 4 h, 51%; (h) NaOAc, H<sub>2</sub>O, 20 °C, 3 d, 72%; (i) POCl<sub>3</sub>, DIPEA, Δ, 16 h, 100%; (j) <i>trans</i>-H<sub>2</sub>NCyNMe<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, MeCN, MW, 140 °C, 16 h, 84%; (k) Pd/C, H<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, MeOH, 20 °C, 16 h, 16%.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0015.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Variation of the 4-Linkage of the Pyrrolopyrimidine (NMe<sub>2</sub>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>trans</i>-HXCyNMe<sub>2</sub>, (DIPEA, iPrOH, 90 °C, 12 h, 75% for <b>22</b> or NaH, DMF, 20 °C, 24 h, 63% for <b>23</b>); (b) dihydropyranylBpin, Pd(PPh<sub>3</sub>)<sub>4</sub> or Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane or DME, H<sub>2</sub>O, 85–100 °C, 1–6 h, 60–85%; (c) Pd/C, H<sub>2</sub>, MeOH or EtOH/THF, rt, 3–16 h, 86–93%; (d) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1–3 h then NH<sub>3</sub>/MeOH, 1–24 h, 32–67%.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0016.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Variation of the 4-Substituent of the Pyrrolopyrimidine<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) H<sub>2</sub>NCyY or H<sub>2</sub>NCyX, where X = N[(CH<sub>2</sub>)<sub>2</sub>]<sub>2</sub>NBz for <b>25</b>/<b>26</b> and N[(CH<sub>2</sub>)<sub>2</sub>]<sub>2</sub>CHCO<sub>2</sub>Me for <b>29</b>, DIPEA, <sup>i</sup>PrOH or <sup>n</sup>BuOH, MW, 80–150 °C, 3–18 h, 53–100%; (b) dihydropyranylBpin, Pd(PPh<sub>3</sub>)<sub>4</sub> or Pd(dtbpf)Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub> or K<sub>2</sub>CO<sub>3</sub>, THF or 1,4-dioxane or DME, H<sub>2</sub>O, 80–100 °C, 3–16 h, 52–100%; (c) Pd/C, H<sub>2</sub>, MeOH or EtOAc or EtOH/THF, rt, 11–18 h, 29–100%; (d) for <b>29</b> (i) LiOH, H<sub>2</sub>O, THF, rt, 2 h, 86%, (ii) Me<sub>2</sub>NH, HATU, DIPEA, DMF, rt, 2 h, 24%; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1–3 h then NH<sub>3</sub>/MeOH, 1–24 h, or Me<sub>2</sub>NCOCl for <b>25</b>/MeSO<sub>2</sub>Cl for <b>26</b>, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1 h then TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1 h, NH<sub>3</sub>/MeOH, 1–24 h, 39–74%; (f) 4-H<sub>2</sub>N-cyclohexanone, DIPEA, <sup>i</sup>PrOH, MW, 120 °C, 36 h, 34%; (g) HY, NaBH(OAc)<sub>3</sub>, AcOH, CH<sub>2</sub>Cl<sub>2</sub> or MeCN, 15–25 °C, 16–18 h, 52–100%.</p></p></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0017.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Variation of the 4-Linkage of the Pyrrolopyrimidine (Morpholine)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>trans</i>-4-morpholinocyclohexanol, NaH, DMF, 20 °C, 24 h, 61%; (b) dihydropyranylBpin, Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DME or 1,4-dioxane, H<sub>2</sub>O, 80–85 °C, 2–6 h, 73–100%; (c) Pd/C, H<sub>2</sub>, EtOH/THF, rt, 3 h, 97%; (d) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1–3 h then NH<sub>3</sub>/MeOH, 1–24 h, 25–56%; (e) Na<sub>2</sub>S, DMSO, rt, 2 h, 78%; (f) <i>cis</i>-4-morpholinocyclohexanol mesylate, K<sub>2</sub>CO<sub>3</sub>, MeCN, 80 °C, 16 h, 92%; (g) Rh(PPh<sub>3</sub>)<sub>3</sub>Cl, H<sub>2</sub>, THF, 50 °C, 7 d, 30%.</p></p></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0018.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Variation of the Six-Membered Ring<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) dihydropyranylBpin, Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 80 °C, 1–2 h, 76% for <b>35a</b>, 100% for <b>36a</b>; (b) SEMCl, NaH, THF, rt, 4–16 h, 48% for <b>35b</b>, 63% for <b>36b</b>; (c) LHMDS, <i>trans</i>-H<sub>2</sub>NCyMorph, BrettPhos Pd G3, THF, 80 °C, 16 h, 56%; (d) Pd/C, H<sub>2</sub> (2 atm), MeOH, rt, 2–3 h, 84% for <b>35</b>, 100% for <b>36</b>; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 3–4 h then NH<sub>3</sub>/MeOH, 3–4 h, 61% for <b>35</b>, 70% for <b>36</b>; (f) NBS, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 100% (g) <i>trans</i>-H<sub>2</sub>NCyMorph, DIPEA, iBuOH, MW, 180 °C, 5 h, 81%.</p></p></figure><figure data-id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0002.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Plot of IRAK4 enzyme pIC<sub>50</sub> (A), cell pIC<sub>50</sub> (B), cell LLE (C) against scaffolds with A = S or N showing divergent SAR between the cores. X = out of range value.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0003.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of pyrrolopyrimidine inhibitor <b>21</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K72">5K72</a>) in complex with IRAK4 and overlaid with tricyclic inhibitor <b>1</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K75">5K75</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0004.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of inhibitor <b>28</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K76">5K76</a>) in complex with IRAK4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0005.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Single crystal X-ray structure of <b>28</b>. (B) Crystal packing in the unit cell showing a centrosymmetric dimeric structure linked by intermolecular hydrogen bonding between the pyrrolopyrimidine units and flanked by two additional units bound through the THP moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0006.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Overlay between small molecule X-ray structure (gray carbons), major solution conformation as determined by NMR (orange carbons), and observed conformation of <b>28</b> bound to IRAK4 protein (purple carbons). Overlay based on pyrrolopyrimidine unit only.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0007.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Millipore kinome selectivity for <b>28</b> (%inhibition @ 0.1 μM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0008.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>28</b> inhibits NF-κB signaling and growth of ABC-DLBCL cell line. (A) Dose-dependent inhibition of IκBα phosphorylation in OCI-LY10 cells upon treatment of cells with compound <b>28</b> for 14 h. (B) OCI-LY10 and SUDHL2 were monitored for growth in the presence of various concentrations of compound <b>28</b> in a 3-day growth assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0009.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>28</b> combines synergistically with ibrutinib to inhibit growth and NF-κB signaling in vitro in OCI-LY10 cells. (A) Effects of compound <b>28</b> upon combination with ibrutinib (3 nM) on IκBα phosphorylation in OCI-LY10 cells. (B) Percent growth inhibition of compound <b>28</b> on proliferation of OCI-LY10 or SUDHL2 cells upon combination with ibrutinib in a 5 × 5 dose matrix in a 3-day growth assay. (C) Schematic to show the typical scale in a combination growth assay where % growth inhibition is measured from 0 to 200, and 100 is regarded as zero growth or stasis. Increasing numbers from 100 to 200 exemplifies increase in cell death. (D) Western blots showing induction of apoptosis, as measured by cleavage of caspase 3 upon treatment of OCI-LY10 cells with a combination of 10 nM ibrutinib and either 0.3 or 3 μM of compound <b>28</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0010.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Antitumor activity of compound <b>28</b> in combination with ibrutinib in OCI-LY10, an ABC-subtype DLBCL xenograft. (A) Daily oral dosing of Vehicle (×), ibrutinib 12 mg/kg (■), compound <b>28</b> 12.5 mg/kg (●), and combination (▲) in female SCID mice (<i>n</i> = 10 per data point) with blue coloring representing duration of dosing. (B) Body weight data for the four dose groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0011.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Steady-state plasma concentration with time in mice bearing OCI-LY10 xenografts. Female SCID mice were administered seven daily oral doses and plasma taken post-seventh dose of compound <b>28</b> 12.5 mpk alone (●) and in combination with ibrutinib (▲) (<i>n</i> = 3 per data point).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/large/jm-2017-01290b_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01290&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i69">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10140" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10140" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 35 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naishadham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Cancer statistics</span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.3322/caac.21166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.3322%2Fcaac.21166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=23335087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A280%3ADC%252BC3szgvFSqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2013&pages=11-30&author=R.+Siegelauthor=D.+Naishadhamauthor=A.+Jemal&title=Cancer+statistics&doi=10.3322%2Fcaac.21166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2013</span></div><div class="casAuthors">Siegel Rebecca; Naishadham Deepa; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics.  A total of 1,660,290 new cancer cases and 580,350 cancer deaths are projected to occur in the United States in 2013.  During the most recent 5 years for which there are data (2005-2009), delay-adjusted cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.5% per year in women.  Overall, cancer death rates have declined 20% from their peak in 1991 (215.1 per 100,000 population) to 2009 (173.1 per 100,000 population).  Death rates continue to decline for all 4 major cancer sites (lung, colorectum, breast, and prostate).  Over the past 10 years of data (2000-2009), the largest annual declines in death rates were for chronic myeloid leukemia (8.4%), cancers of the stomach (3.1%) and colorectum (3.0%), and non-Hodgkin lymphoma (3.0%).  The reduction in overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of approximately 1.18 million deaths from cancer, with 152,900 of these deaths averted in 2009 alone.  Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket and other underserved populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQA4Ff_lauq0IkFb3mqPUYDfW6udTcc2eZzbvklYi1wwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szgvFSqsw%253D%253D&md5=1b89010b6bcfc5472f32879085ab4ccc</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21166%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DNaishadham%26aufirst%3DD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2013%26volume%3D63%26spage%3D11%26epage%3D30%26doi%3D10.3322%2Fcaac.21166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sehn, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donaldson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chhanabhai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgerald, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klasa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacPherson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinelli, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, J. M.</span><span> </span><span class="NLM_article-title">Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5027</span><span class="NLM_x">–</span> <span class="NLM_lpage">5033</span><span class="refDoi"> DOI: 10.1200/JCO.2005.09.137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1200%2FJCO.2005.09.137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=15955905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFWmtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5027-5033&author=L.+H.+Sehnauthor=J.+Donaldsonauthor=M.+Chhanabhaiauthor=C.+Fitzgeraldauthor=K.+Gillauthor=R.+Klasaauthor=N.+MacPhersonauthor=S.+O%E2%80%99Reillyauthor=J.+J.+Spinelliauthor=J.+Sutherlandauthor=K.+S.+Wilsonauthor=R.+D.+Gascoyneauthor=J.+M.+Connors&title=Introduction+of+combined+CHOP+plus+rituximab+therapy+dramatically+improved+outcome+of+diffuse+large+B-cell+lymphoma+in+British+Columbia&doi=10.1200%2FJCO.2005.09.137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia</span></div><div class="casAuthors">Sehn, Laurie H.; Donaldson, Jane; Chhanabhai, Mukesh; Fitzgerald, Catherine; Gill, Karamjit; Klasa, Richard; MacPherson, Nicol; O'Reilly, Susan; Spinelli, John J.; Sutherland, Judy; Wilson, Kenneth S.; Gascoyne, Randy D.; Connors, Joseph M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5027-5033</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">For more than two decades, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been the std. therapy for diffuse large B-cell lymphoma (DLBCL).  The addn. of rituximab to CHOP has been shown to improve outcome in elderly patients with DLBCL.  We conducted a population-based anal. to assess the impact of this combination therapy on adult patients with DLBCL in the province of British Columbia (BC).  We compared outcomes during a 3-yr period; 18 mo before (prerituximab) and 18 mo after (postrituximab) institution of a policy recommending the combination of CHOP and rituximab for all patients with newly diagnosed advanced-stage (stage III or IV or stage I or II with "B" symptoms or bulky [> 10 cm] disease) DLBCL.  A total of 292 patients were evaluated; 140 in the prerituximab group (median follow-up, 42 mo) and 152 in the postrituximab group (median follow-up, 24 mo).  Both progression-free survival (risk ratio, 0.56; 95% CI, 0.39 to 0.81; P = .002) and overall survival (risk ratio, 0.40; 95% CI, 0.27 to 0.61, P < .0001) were significantly improved in the postrituximab group.  After controlling for age and International Prognostic Index score, era of treatment remained a strong independent predictor of progression-free survival (risk ratio, 0.59; 95% CI, 0.41 to 0.85; P = .005) and overall survival (risk ratio, 0.43; 95% CI, 0.29 to 0.66; P < .001).  The benefit of treatment in the postrituximab era was present regardless of age.  The addn. of rituximab to CHOP chemotherapy has resulted in a dramatic improvement in outcome for DLBCL patients of all ages in the province of BC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJyQAmyoPMTLVg90H21EOLACvtfcHk0lhlfh3I5OGelQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFWmtLs%253D&md5=b9d4a2e52564591eda23216437d6df52</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.09.137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.09.137%26sid%3Dliteratum%253Aachs%26aulast%3DSehn%26aufirst%3DL.%2BH.%26aulast%3DDonaldson%26aufirst%3DJ.%26aulast%3DChhanabhai%26aufirst%3DM.%26aulast%3DFitzgerald%26aufirst%3DC.%26aulast%3DGill%26aufirst%3DK.%26aulast%3DKlasa%26aufirst%3DR.%26aulast%3DMacPherson%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DS.%26aulast%3DSpinelli%26aufirst%3DJ.%2BJ.%26aulast%3DSutherland%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26atitle%3DIntroduction%2520of%2520combined%2520CHOP%2520plus%2520rituximab%2520therapy%2520dramatically%2520improved%2520outcome%2520of%2520diffuse%2520large%2520B-cell%2520lymphoma%2520in%2520British%2520Columbia%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5027%26epage%3D5033%26doi%3D10.1200%2FJCO.2005.09.137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Camicia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassa, P. O.</span><span> </span><span class="NLM_article-title">Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="refDoi"> DOI: 10.1186/s12943-015-0474-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1186%2Fs12943-015-0474-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=26654227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpt1Olurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=207&author=R.+Camiciaauthor=H.+C.+Winklerauthor=P.+O.+Hassa&title=Novel+drug+targets+for+personalized+precision+medicine+in+relapsed%2Frefractory+diffuse+large+B-cell+lymphoma%3A+a+comprehensive+review&doi=10.1186%2Fs12943-015-0474-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review</span></div><div class="casAuthors">Camicia, Rosalba; Winkler, Hans C.; Hassa, Paul O.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207/1-207/62</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Diffuse large B-cell lymphoma (DLBCL) is a clin. heterogeneous lymphoid malignancy and the most common subtype of non-Hodgkin's lymphoma in adults, with one of the highest mortality rates in most developed areas of the world.  More than half of DLBLC patients can be cured with std. R-CHOP regimens, however approx. 30 to 40 % of patients will develop relapsed/refractory disease that remains a major cause of morbidity and mortality due to the limited therapeutic options.  Recent advances in gene expression profiling have led to the identification of at least three distinct mol. subtypes of DLBCL: a germinal center B cell-like subtype, an activated B cell-like subtype, and a primary mediastinal B-cell lymphoma subtype.  Moreover, recent findings have not only increased our understanding of the mol. basis of chemotherapy resistance but have also helped identify mol. subsets of DLBCL and rational targets for drug interventions that may allow for subtype/subset-specific molecularly targeted precision medicine and personalized combinations to both prevent and treat relapsed/refractory DLBCL.  Novel agents such as lenalidomide, ibrutinib, bortezomib, CC-122, epratuzumab or pidilizumab used as single-agent or in combination with (rituximab-based) chemotherapy have already demonstrated promising activity in patients with relapsed/ refractory DLBCL.  Several novel potential drug targets have been recently identified such as the BET bromodomain protein (BRD)-4, phosphoribosyl-pyrophosphate synthetase (PRPS)-2, macrodomain-contg. mono-ADP-ribosyltransferase (ARTD)-9 (also known as PARP9), deltex-3-like E3 ubiquitin ligase (DTX3L) (also known as BBAP), NF-kappaB inducing kinase (NIK) and transforming growth factor beta receptor (TGFssR).  This review highlights the new insights into the mol. basis of relapsed/refractory DLBCL and summarizes the most promising drug targets and exptl. treatments for relapsed/refractory DLBCL, including the use of novel agents such as lenalidomide, ibrutinib, bortezomib, pidilizumab, epratuzumab, brentuximab-vedotin or CAR T cells, dual inhibitors, as well as mechanism-based combinatorial exptl. therapies.  We also provide a comprehensive and updated list of current drugs, drug targets and preclin. and clin. exptl. studies in DLBCL.  A special focus is given on STAT1, ARTD9, DTX3L and ARTD8 (also known as PARP14) as novel potential drug targets in distinct mol. subsets of DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJp4JiT_yM07Vg90H21EOLACvtfcHk0lhlfh3I5OGelQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpt1Olurk%253D&md5=c4365573bf9b7d942ecdefadf08c7741</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1186%2Fs12943-015-0474-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-015-0474-2%26sid%3Dliteratum%253Aachs%26aulast%3DCamicia%26aufirst%3DR.%26aulast%3DWinkler%26aufirst%3DH.%2BC.%26aulast%3DHassa%26aufirst%3DP.%2BO.%26atitle%3DNovel%2520drug%2520targets%2520for%2520personalized%2520precision%2520medicine%2520in%2520relapsed%252Frefractory%2520diffuse%2520large%2520B-cell%2520lymphoma%253A%2520a%2520comprehensive%2520review%26jtitle%3DMol.%2520Cancer%26date%3D2015%26volume%3D14%26spage%3D207%26doi%3D10.1186%2Fs12943-015-0474-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sidorova, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvonkov, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarikov, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severina, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovrigina, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troitskaya, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savchenko, V. G.</span><span> </span><span class="NLM_article-title">MYD88 L265P Mutation is a possible unfavorable prognostic factor in patients with diffuse B-Cell lymphoma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">5051</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=5051&author=A.+A.+Sidorovaauthor=E.+E.+Zvonkovauthor=A.+B.+Sudarikovauthor=N.+A.+Severinaauthor=A.+M.+Kovriginaauthor=V.+V.+Troitskayaauthor=V.+G.+Savchenko&title=MYD88+L265P+Mutation+is+a+possible+unfavorable+prognostic+factor+in+patients+with+diffuse+B-Cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSidorova%26aufirst%3DA.%2BA.%26aulast%3DZvonkov%26aufirst%3DE.%2BE.%26aulast%3DSudarikov%26aufirst%3DA.%2BB.%26aulast%3DSeverina%26aufirst%3DN.%2BA.%26aulast%3DKovrigina%26aufirst%3DA.%2BM.%26aulast%3DTroitskaya%26aufirst%3DV.%2BV.%26aulast%3DSavchenko%26aufirst%3DV.%2BG.%26atitle%3DMYD88%2520L265P%2520Mutation%2520is%2520a%2520possible%2520unfavorable%2520prognostic%2520factor%2520in%2520patients%2520with%2520diffuse%2520B-Cell%2520lymphoma%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D5051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Alizadeh, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisen, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lossos, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenwald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldrick, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabet, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marti, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibshirani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherlock, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greiner, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisenburger, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armitage, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">403</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">511</span><span class="refDoi"> DOI: 10.1038/35000501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1038%2F35000501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10676951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1Shtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=403&publication_year=2000&pages=503-511&author=A.+A.+Alizadehauthor=M.+B.+Eisenauthor=R.+E.+Davisauthor=C.+Maauthor=I.+S.+Lossosauthor=A.+Rosenwaldauthor=J.+C.+Boldrickauthor=H.+Sabetauthor=T.+Tranauthor=X.+Yuauthor=J.+I.+Powellauthor=L.+Yangauthor=G.+E.+Martiauthor=T.+Mooreauthor=J.+Hudsonauthor=L.+Luauthor=D.+B.+Lewisauthor=R.+Tibshiraniauthor=G.+Sherlockauthor=W.+C.+Chanauthor=T.+C.+Greinerauthor=D.+D.+Weisenburgerauthor=J.+O.+Armitageauthor=R.+Warnkeauthor=R.+Levyauthor=W.+Wilsonauthor=M.+R.+Greverauthor=J.+C.+Byrdauthor=D.+Botsteinauthor=P.+O.+Brownauthor=L.+M.+Staudt&title=Distinct+types+of+diffuse+large+B-cell+lymphoma+identified+by+gene+expression+profiling&doi=10.1038%2F35000501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling</span></div><div class="casAuthors">Alizadeh, Ash A.; Eisen, Michael B.; Davis, R. Eric; Ma, Chi; Lossos, Izidore S.; Rosenwald, Andreas; Boldrick, Jennifer C.; Sabet, Hajeer; Tran, Truc; Yu, Xin; Powell, John I.; Yang, Liming; Marti, Gerald E.; Moore, Troy; Hudson, James, Jr.; Luo, Lisheng; Lewis, David B.; Tibshirani, T, Robert; Sherlock, Gavin; Chan, Wing C.; Greiner, Timothy C.; Weisenburger, Dennis D.; Armitage, James O.; Wamke, Roger; Levy, Ronald; Wilson, Wyndham; Grever, Michael R.; Byrd, John C.; Botstein, David; Brown, Patrick O.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">403</span>
        (<span class="NLM_cas:issue">6769</span>),
    <span class="NLM_cas:pages">503-511</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clin. heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease.  We proposed that this variability in natural history reflects unrecognized mol. heterogeneity in the tumors.  Using DNA microarrays, we have conducted a systematic characterization of gene expression in B-cell malignancies.  Here we show that there is diversity in gene expression among the tumors of DLBCL patients, apparently reflecting the variation in tumor proliferation rate, host response and differentiation state of the tumor.  We identified two molecularly distinct forms of DLBCL which had gene expression patterns indicative of different stages of B-cell differentiation.  One type expressed genes characteristic of germinal center B cells ('germinal center B-like DLBCL'); the second type expressed genes normally induced during in vitro activation of peripheral blood B cells ('activated B-like DLBCL').  Patients with germinal center B-like DLBCL had a significantly better overall survival than those with activated B-like DLBCL.  The mol. classification of tumors on the basis of gene expression can thus identify previously undetected and clin. significant subtypes of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof-ooPQqcS3rVg90H21EOLACvtfcHk0lhlfh3I5OGelQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1Shtrg%253D&md5=d56170148faf43b53abfd129a38b6c9e</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1038%2F35000501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35000501%26sid%3Dliteratum%253Aachs%26aulast%3DAlizadeh%26aufirst%3DA.%2BA.%26aulast%3DEisen%26aufirst%3DM.%2BB.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DLossos%26aufirst%3DI.%2BS.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DBoldrick%26aufirst%3DJ.%2BC.%26aulast%3DSabet%26aufirst%3DH.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DPowell%26aufirst%3DJ.%2BI.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DMarti%26aufirst%3DG.%2BE.%26aulast%3DMoore%26aufirst%3DT.%26aulast%3DHudson%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DD.%2BB.%26aulast%3DTibshirani%26aufirst%3DR.%26aulast%3DSherlock%26aufirst%3DG.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DGreiner%26aufirst%3DT.%2BC.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DArmitage%26aufirst%3DJ.%2BO.%26aulast%3DWarnke%26aufirst%3DR.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DWilson%26aufirst%3DW.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DBotstein%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DP.%2BO.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DDistinct%2520types%2520of%2520diffuse%2520large%2520B-cell%2520lymphoma%2520identified%2520by%2520gene%2520expression%2520profiling%26jtitle%3DNature%26date%3D2000%26volume%3D403%26spage%3D503%26epage%3D511%26doi%3D10.1038%2F35000501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Ngo, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jhavar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlhammer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesser, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenwald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Hermelink, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimsza, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffe, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delabie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeland, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braziel, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubbs, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisenburger, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Oncogenically active MYD88 mutations in human lymphoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">470</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span><span class="refDoi"> DOI: 10.1038/nature09671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1038%2Fnature09671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=21179087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVCksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=470&publication_year=2011&pages=115-119&author=V.+N.+Ngoauthor=R.+M.+Youngauthor=R.+Schmitzauthor=S.+Jhavarauthor=W.+Xiaoauthor=K.+H.+Limauthor=H.+Kohlhammerauthor=W.+Xuauthor=Y.+Yangauthor=H.+Zhaoauthor=A.+L.+Shafferauthor=P.+Romesserauthor=G.+Wrightauthor=J.+Powellauthor=A.+Rosenwaldauthor=H.+K.+Muller-Hermelinkauthor=G.+Ottauthor=R.+D.+Gascoyneauthor=J.+M.+Connorsauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+I.+Fisherauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=L.+M.+Staudt&title=Oncogenically+active+MYD88+mutations+in+human+lymphoma&doi=10.1038%2Fnature09671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenically active MYD88 mutations in human lymphoma</span></div><div class="casAuthors">Ngo, Vu N.; Young, Ryan M.; Schmitz, Roland; Jhavar, Sameer; Xiao, Wenming; Lim, Kian-Huat; Kohlhammer, Holger; Xu, Weihong; Yang, Yandan; Zhao, Hong; Shaffer, Arthur L.; Romesser, Paul; Wright, George; Powell, John; Rosenwald, Andreas; Muller-Hermelink, Hans Konrad; Ott, German; Gascoyne, Randy D.; Connors, Joseph M.; Rimsza, Lisa M.; Campo, Elias; Jaffe, Elaine S.; Delabie, Jan; Smeland, Erlend B.; Fisher, Richard I.; Braziel, Rita M.; Tubbs, Raymond R.; Cook, J. R.; Weisenburger, Denny D.; Chan, Wing C.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">470</span>
        (<span class="NLM_cas:issue">7332</span>),
    <span class="NLM_cas:pages">115-119</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) remains the least curable form of this malignancy despite recent advances in therapy.  Constitutive nuclear factor (NF)-κB and JAK kinase signaling promotes malignant cell survival in these lymphomas, but the genetic basis for this signaling is incompletely understood.  Here we describe the dependence of ABC DLBCLs on MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signaling, and the discovery of highly recurrent oncogenic mutations affecting MYD88 in ABC DLBCL tumors.  RNA interference screening revealed that MYD88 and the assocd. kinases IRAK1 and IRAK4 are essential for ABC DLBCL survival.  High-throughput RNA resequencing uncovered MYD88 mutations in ABC DLBCL lines.  Notably, 29% of ABC DLBCL tumors harbored the same amino acid substitution, L265P, in the MYD88 Toll/IL-1 receptor (TIR) domain at an evolutionarily invariant residue in its hydrophobic core.  This mutation was rare or absent in other DLBCL subtypes and Burkitt's lymphoma, but was obsd. in 9% of mucosa-assocd. lymphoid tissue lymphomas.  At a lower frequency, addnl. mutations were obsd. in the MYD88 TIR domain, occurring in both the ABC and germinal center B-cell-like (GCB) DLBCL subtypes.  Survival of ABC DLBCL cells bearing the L265P mutation was sustained by the mutant but not the wild-type MYD88 isoform, demonstrating that L265P is a gain-of-function driver mutation.  The L265P mutant promoted cell survival by spontaneously assembling a protein complex contg. IRAK1 and IRAK4, leading to IRAK4 kinase activity, IRAK1 phosphorylation, NF-κB signaling, JAK kinase activation of STAT3, and secretion of IL-6, IL-10 and interferon-β.  Hence, the MYD88 signaling pathway is integral to the pathogenesis of ABC DLBCL, supporting the development of inhibitors of IRAK4 kinase and other components of this pathway for the treatment of tumors bearing oncogenic MYD88 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5pEPxh1G6J7Vg90H21EOLACvtfcHk0livrw_gPFn2dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVCksQ%253D%253D&md5=3dff4d54af8f64bb9e57f04cf274fee8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature09671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09671%26sid%3Dliteratum%253Aachs%26aulast%3DNgo%26aufirst%3DV.%2BN.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DSchmitz%26aufirst%3DR.%26aulast%3DJhavar%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DLim%26aufirst%3DK.%2BH.%26aulast%3DKohlhammer%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DRomesser%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DR.%2BI.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DOncogenically%2520active%2520MYD88%2520mutations%2520in%2520human%2520lymphoma%26jtitle%3DNature%26date%3D2011%26volume%3D470%26spage%3D115%26epage%3D119%26doi%3D10.1038%2Fnature09671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Fernández-Rodríguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellosillo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-García, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez-González, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimeno, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vela, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besses, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salar, A.</span><span> </span><span class="NLM_article-title">MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">2104</span><span class="NLM_x">–</span> <span class="NLM_lpage">2106</span><span class="refDoi"> DOI: 10.1038/leu.2014.184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1038%2Fleu.2014.184" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=2104-2106&author=C.+Fern%C3%A1ndez-Rodr%C3%ADguezauthor=B.+Bellosilloauthor=M.+Garc%C3%ADa-Garc%C3%ADaauthor=B.+S%C3%A1nchez-Gonz%C3%A1lezauthor=E.+Gimenoauthor=M.+C.+Velaauthor=S.+Serranoauthor=C.+Bessesauthor=A.+Salar&title=MYD88+%28L265P%29+mutation+is+an+independent+prognostic+factor+for+outcome+in+patients+with+diffuse+large+B-cell+lymphoma&doi=10.1038%2Fleu.2014.184"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fleu.2014.184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2014.184%26sid%3Dliteratum%253Aachs%26aulast%3DFern%25C3%25A1ndez-Rodr%25C3%25ADguez%26aufirst%3DC.%26aulast%3DBellosillo%26aufirst%3DB.%26aulast%3DGarc%25C3%25ADa-Garc%25C3%25ADa%26aufirst%3DM.%26aulast%3DS%25C3%25A1nchez-Gonz%25C3%25A1lez%26aufirst%3DB.%26aulast%3DGimeno%26aufirst%3DE.%26aulast%3DVela%26aufirst%3DM.%2BC.%26aulast%3DSerrano%26aufirst%3DS.%26aulast%3DBesses%26aufirst%3DC.%26aulast%3DSalar%26aufirst%3DA.%26atitle%3DMYD88%2520%2528L265P%2529%2520mutation%2520is%2520an%2520independent%2520prognostic%2520factor%2520for%2520outcome%2520in%2520patients%2520with%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DLeukemia%26date%3D2014%26volume%3D28%26spage%3D2104%26epage%3D2106%26doi%3D10.1038%2Fleu.2014.184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Iwasaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medzhitov, R.</span><span> </span><span class="NLM_article-title">Regulation of adaptive immunity by the innate immune system</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">327</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.1126/science.1183021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1126%2Fscience.1183021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=20075244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktlWkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2010&pages=291-295&author=A.+Iwasakiauthor=R.+Medzhitov&title=Regulation+of+adaptive+immunity+by+the+innate+immune+system&doi=10.1126%2Fscience.1183021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of Adaptive Immunity by the Innate Immune System</span></div><div class="casAuthors">Iwasaki, Akiko; Medzhitov, Ruslan</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">5963</span>),
    <span class="NLM_cas:pages">291-295</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Twenty years after the proposal that pattern recognition receptors detect invasion by microbial pathogens, the field of immunol. has witnessed several discoveries that have elucidated receptors and signaling pathways of microbial recognition systems and how they control the generation of T and B lymphocyte-mediated immune responses.  However, there are still many fundamental questions that remain poorly understood, even though sometimes the answers are assumed to be known.  Here, the authors discuss some of these questions, including the mechanisms by which pathogen-specific innate immune recognition activates antigen-specific adaptive immune responses and the roles of different types of innate immune recognition in host defense from infection and injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9JwoyOJ_s1bVg90H21EOLACvtfcHk0livrw_gPFn2dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktlWkuw%253D%253D&md5=8af81826f9cee93a51dff10ffb8140de</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.1183021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1183021%26sid%3Dliteratum%253Aachs%26aulast%3DIwasaki%26aufirst%3DA.%26aulast%3DMedzhitov%26aufirst%3DR.%26atitle%3DRegulation%2520of%2520adaptive%2520immunity%2520by%2520the%2520innate%2520immune%2520system%26jtitle%3DScience%26date%3D2010%26volume%3D327%26spage%3D291%26epage%3D295%26doi%3D10.1126%2Fscience.1183021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">O’Neill, L. A.</span><span> </span><span class="NLM_article-title">The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">226</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00701.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1111%2Fj.1600-065X.2008.00701.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=19161412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGlsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=2008&pages=10-18&author=L.+A.+O%E2%80%99Neill&title=The+interleukin-1+receptor%2FToll-like+receptor+superfamily%3A+10+years+of+progress&doi=10.1111%2Fj.1600-065X.2008.00701.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The interleukin-1 receptor/toll-like receptor superfamily: 10 years of progress</span></div><div class="casAuthors">O'Neill, Luke A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-18</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The interleukin-1 receptor (IL-1R)/Toll-like receptor (TLR) superfamily was first defined in 1998 as a family of proteins that contain the Toll-IL-1 receptor domain.  At that time, there were a no. of orphan receptors in the IL-1R branch, and the TLRs had yet to be shown to be key innate immune receptors that sense microbial products.  We now know a great deal more about this superfamily, with the description of novel IL-1 family members such as IL-1F6 signaling via IL-1Rrp2 and IL33 signaling via ST2.  Remarkable progress has been made in our understanding of the functions of the TLRs, leading to a renaissance of interest in innate immunity.  The importance of IL-1 is also being rediscovered, with the observation that Nalp3 is a key regulator of caspase-1, the enzyme that processes pro-IL-1β into the mature cytokine.  This area has therefore proved very fruitful in terms of improving our knowledge of the mol. basis for innate immunity and inflammation, and we can anticipate further discoveries in the coming years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGGZYo1rHKc7Vg90H21EOLACvtfcHk0lg3OC-Dq1Z05A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGlsrfF&md5=5765db66cbf1fcff210c715dea71cdb2</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00701.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00701.x%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%2BA.%26atitle%3DThe%2520interleukin-1%2520receptor%252FToll-like%2520receptor%2520superfamily%253A%252010%2520years%2520of%2520progress%26jtitle%3DImmunol.%2520Rev.%26date%3D2008%26volume%3D226%26spage%3D10%26epage%3D18%26doi%3D10.1111%2Fj.1600-065X.2008.00701.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Wang, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeelall, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horikawa, K.</span><span> </span><span class="NLM_article-title">Toll-like receptors and cancer: MYD88 Mutation and Inflammation</span> <span class="citation_source-journal">Front. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="refDoi"> DOI: 10.3389/fimmu.2014.00367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.3389%2Ffimmu.2014.00367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=25132836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FivValtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=367&author=J.+Q.+Wangauthor=Y.+S.+Jeelallauthor=L.+L.+Fergusonauthor=K.+Horikawa&title=Toll-like+receptors+and+cancer%3A+MYD88+Mutation+and+Inflammation&doi=10.3389%2Ffimmu.2014.00367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation</span></div><div class="casAuthors">Wang James Q; Jeelall Yogesh S; Ferguson Laura L; Horikawa Keisuke</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">367</span>
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    </div><div class="casAbstract">Pattern recognition receptors (PRRs) expressed on immune cells are crucial for the early detection of invading pathogens, in initiating early innate immune response and in orchestrating the adaptive immune response.  PRRs are activated by specific pathogen-associated molecular patterns that are present in pathogenic microbes or nucleic acids of viruses or bacteria.  However, inappropriate activation of these PRRs, such as the Toll-like receptors (TLRs), due to genetic lesions or chronic inflammation has been demonstrated to be a major cause of many hematological malignancies.  Gain-of-function mutations in the TLR adaptor protein MYD88 found in 39% of the activated B cell type of diffuse large B cell lymphomas and almost 100% of Waldenstrom's macroglobulinemia further highlight the involvement of TLRs in these malignancies.  MYD88 mutations result in the chronic activation of TLR signaling pathways, thus the constitutive activation of the transcription factor NFκB to promote cell survival and proliferation.  These recent insights into TLR pathway driven malignancies warrant the need for a better understanding of TLRs in cancers and the development of novel anti-cancer therapies targeting TLRs.  This review focuses on TLR function and signaling in normal or inflammatory conditions, and how mutations can hijack the TLR signaling pathways to give rise to cancer.  Finally, we discuss how potential therapeutic agents could be used to restore normal responses to TLRs and have long lasting anti-tumor effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLaqWjAreWhjdblLE_E9PWfW6udTcc2eY493E_r2HaGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FivValtw%253D%253D&md5=22747c832ecae697e2aa767fddbeb43a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2014.00367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2014.00367%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BQ.%26aulast%3DJeelall%26aufirst%3DY.%2BS.%26aulast%3DFerguson%26aufirst%3DL.%2BL.%26aulast%3DHorikawa%26aufirst%3DK.%26atitle%3DToll-like%2520receptors%2520and%2520cancer%253A%2520MYD88%2520Mutation%2520and%2520Inflammation%26jtitle%3DFront.%2520Immunol.%26date%3D2014%26volume%3D5%26spage%3D367%26doi%3D10.3389%2Ffimmu.2014.00367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Varettoni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcaini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zibellini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boveri, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rattotti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riboni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlandi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonfichi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascutto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangiacavalli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croci, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiaccadori, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morello, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrera, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paulli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cazzola, M.</span><span> </span><span class="NLM_article-title">Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">2522</span><span class="NLM_x">–</span> <span class="NLM_lpage">2528</span><span class="refDoi"> DOI: 10.1182/blood-2012-09-457101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1182%2Fblood-2012-09-457101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2013&pages=2522-2528&author=M.+Varettoniauthor=L.+Arcainiauthor=S.+Zibelliniauthor=E.+Boveriauthor=S.+Rattottiauthor=R.+Riboniauthor=A.+Corsoauthor=E.+Orlandiauthor=M.+Bonfichiauthor=M.+Gottiauthor=C.+Pascuttoauthor=S.+Mangiacavalliauthor=G.+Crociauthor=V.+Fiaccadoriauthor=L.+Morelloauthor=M.+L.+Guerreraauthor=M.+Paulliauthor=M.+Cazzola&title=Prevalence+and+clinical+significance+of+the+MYD88+%28L265P%29+somatic+mutation+in+Waldenstrom%E2%80%99s+macroglobulinemia+and+related+lymphoid+neoplasms&doi=10.1182%2Fblood-2012-09-457101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-09-457101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-09-457101%26sid%3Dliteratum%253Aachs%26aulast%3DVarettoni%26aufirst%3DM.%26aulast%3DArcaini%26aufirst%3DL.%26aulast%3DZibellini%26aufirst%3DS.%26aulast%3DBoveri%26aufirst%3DE.%26aulast%3DRattotti%26aufirst%3DS.%26aulast%3DRiboni%26aufirst%3DR.%26aulast%3DCorso%26aufirst%3DA.%26aulast%3DOrlandi%26aufirst%3DE.%26aulast%3DBonfichi%26aufirst%3DM.%26aulast%3DGotti%26aufirst%3DM.%26aulast%3DPascutto%26aufirst%3DC.%26aulast%3DMangiacavalli%26aufirst%3DS.%26aulast%3DCroci%26aufirst%3DG.%26aulast%3DFiaccadori%26aufirst%3DV.%26aulast%3DMorello%26aufirst%3DL.%26aulast%3DGuerrera%26aufirst%3DM.%2BL.%26aulast%3DPaulli%26aufirst%3DM.%26aulast%3DCazzola%26aufirst%3DM.%26atitle%3DPrevalence%2520and%2520clinical%2520significance%2520of%2520the%2520MYD88%2520%2528L265P%2529%2520somatic%2520mutation%2520in%2520Waldenstrom%25E2%2580%2599s%2520macroglobulinemia%2520and%2520related%2520lymphoid%2520neoplasms%26jtitle%3DBlood%26date%3D2013%26volume%3D121%26spage%3D2522%26epage%3D2528%26doi%3D10.1182%2Fblood-2012-09-457101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Treon, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripsas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcaini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkus, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohani, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laramie, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skifter, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lincoln, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, Z. R.</span><span> </span><span class="NLM_article-title">MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">826</span><span class="NLM_x">–</span> <span class="NLM_lpage">833</span><span class="refDoi"> DOI: 10.1056/NEJMoa1200710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1056%2FNEJMoa1200710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=22931316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGktLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=826-833&author=S.+P.+Treonauthor=L.+Xuauthor=G.+Yangauthor=Y.+Zhouauthor=X.+Liuauthor=Y.+Caoauthor=P.+Sheehyauthor=R.+J.+Manningauthor=C.+J.+Pattersonauthor=C.+Tripsasauthor=L.+Arcainiauthor=G.+S.+Pinkusauthor=S.+J.+Rodigauthor=A.+R.+Sohaniauthor=N.+L.+Harrisauthor=J.+M.+Laramieauthor=D.+A.+Skifterauthor=S.+E.+Lincolnauthor=Z.+R.+Hunter&title=MYD88+L265P+somatic+mutation+in+Waldenstr%C3%B6m%E2%80%99s+macroglobulinemia&doi=10.1056%2FNEJMoa1200710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia</span></div><div class="casAuthors">Treon, Steven P.; Xu, Lian; Yang, Guang; Zhou, Yangsheng; Liu, Xia; Cao, Yang; Sheehy, Patricia; Manning, Robert J.; Patterson, Christopher J.; Tripsas, Christina; Arcaini, Luca; Pinkus, Geraldine S.; Rodig, Scott J.; Sohani, Aliyah R.; Harris, Nancy Lee; Laramie, Jason M.; Skifter, Donald A.; Lincoln, Stephen E.; Hunter, Zackary R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">826-833</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Waldenstrom's macroglobulinemia is an incurable, IgM-secreting lymphoplasmacytic lymphoma (LPL).  The underlying mutation in this disorder has not been delineated.  METHODS We performed whole-genome sequencing of bone marrow LPL cells in 30 patients with Waldenstrom's macroglobulinemia, with paired normal-tissue and tumor-tissue sequencing in 10 patients.  Sanger sequencing was used to validate the findings in samples from an expanded cohort of patients with LPL, those with other B-cell disorders that have some of the same features as LPL, and healthy donors.  RESULTS Among the patients with Waldenstrom's macroglobulinemia, a somatic variant (T→C) in LPL cells was identified at position 38182641 at 3p22.2 in the samples from all 10 patients with paired tissue samples and in 17 of 20 samples from patients with unpaired samples.  This variant predicted an amino acid change (L265P) in MYD88, a mutation that triggers IRAK-mediated NF-κB signaling.  Sanger sequencing identified MYD88 L265P in tumor samples from 49 of 54 patients with Waldenstrom's macroglobulinemia and in 3 of 3 patients with non-IgM-secreting LPL (91%0 of all patients with LPL).  MYD88 L265P was absent in paired normal tissue samples from patients with Waldenstrom's macroglobulinemia or non-IgM LPL and in B cells from healthy donors and was absent or rarely expressed in samples from patients with multiple myeloma, marginal-zone lymphoma, or IgM monoclonal gammopathy of unknown significance.  Inhibition of MYD88 signaling reduced IκBα and NF-κB p65 phosphorylation, as well as NF-κB nuclear staining, in Waldenstrom's macroglobulinemia cells expressing MYD88 L265P.  Somatic variants in ARID1A in 5 of 30 patients (17%), leading to a premature stop or frameshift, were also identified and were assocd. with an increased disease burden.  In addn., 2 of 3 patients with Waldenstrom's macroglobulinemia who had wild-type MYD88 had somatic variants in MLL2.  CONCLUSIONS MYD88 L265P is a commonly recurring mutation in patients with Waldenstrom's macroglobulinemia that can be useful in differentiating Waldenstrom's macroglobulinemia and non-IgM LPL from B-cell disorders that have some of the same features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8DO7wCi3bbrVg90H21EOLACvtfcHk0lj96e4rvLYROQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGktLrN&md5=fc9ac9b80297d49c8d5f2fa0965415de</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1200710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1200710%26sid%3Dliteratum%253Aachs%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DSheehy%26aufirst%3DP.%26aulast%3DManning%26aufirst%3DR.%2BJ.%26aulast%3DPatterson%26aufirst%3DC.%2BJ.%26aulast%3DTripsas%26aufirst%3DC.%26aulast%3DArcaini%26aufirst%3DL.%26aulast%3DPinkus%26aufirst%3DG.%2BS.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DSohani%26aufirst%3DA.%2BR.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DLaramie%26aufirst%3DJ.%2BM.%26aulast%3DSkifter%26aufirst%3DD.%2BA.%26aulast%3DLincoln%26aufirst%3DS.%2BE.%26aulast%3DHunter%26aufirst%3DZ.%2BR.%26atitle%3DMYD88%2520L265P%2520somatic%2520mutation%2520in%2520Waldenstr%25C3%25B6m%25E2%2580%2599s%2520macroglobulinemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D826%26epage%3D833%26doi%3D10.1056%2FNEJMoa1200710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Pham-Ledard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappellen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beylot-Barry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlio, J. P.</span><span> </span><span class="NLM_article-title">MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">2118</span><span class="NLM_x">–</span> <span class="NLM_lpage">2120</span><span class="refDoi"> DOI: 10.1038/jid.2012.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1038%2Fjid.2012.102" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2012&pages=2118-2120&author=A.+Pham-Ledardauthor=D.+Cappellenauthor=F.+Martinezauthor=B.+Vergierauthor=M.+Beylot-Barryauthor=J.+P.+Merlio&title=MYD88+somatic+mutation+is+a+genetic+feature+of+primary+cutaneous+diffuse+large+B-cell+lymphoma%2C+leg+type&doi=10.1038%2Fjid.2012.102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fjid.2012.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2012.102%26sid%3Dliteratum%253Aachs%26aulast%3DPham-Ledard%26aufirst%3DA.%26aulast%3DCappellen%26aufirst%3DD.%26aulast%3DMartinez%26aufirst%3DF.%26aulast%3DVergier%26aufirst%3DB.%26aulast%3DBeylot-Barry%26aufirst%3DM.%26aulast%3DMerlio%26aufirst%3DJ.%2BP.%26atitle%3DMYD88%2520somatic%2520mutation%2520is%2520a%2520genetic%2520feature%2520of%2520primary%2520cutaneous%2520diffuse%2520large%2520B-cell%2520lymphoma%252C%2520leg%2520type%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2012%26volume%3D132%26spage%3D2118%26epage%3D2120%26doi%3D10.1038%2Fjid.2012.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Montesinos-Rongen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godlewska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiestler, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siebert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deckert, M.</span><span> </span><span class="NLM_article-title">Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma</span> <span class="citation_source-journal">Acta Neuropathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">791</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1007/s00401-011-0891-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1007%2Fs00401-011-0891-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2011&pages=791-792&author=M.+Montesinos-Rongenauthor=E.+Godlewskaauthor=A.+Brunnauthor=O.+D.+Wiestlerauthor=R.+Siebertauthor=M.+Deckert&title=Activating+L265P+mutations+of+the+MYD88+gene+are+common+in+primary+central+nervous+system+lymphoma&doi=10.1007%2Fs00401-011-0891-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs00401-011-0891-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-011-0891-2%26sid%3Dliteratum%253Aachs%26aulast%3DMontesinos-Rongen%26aufirst%3DM.%26aulast%3DGodlewska%26aufirst%3DE.%26aulast%3DBrunn%26aufirst%3DA.%26aulast%3DWiestler%26aufirst%3DO.%2BD.%26aulast%3DSiebert%26aufirst%3DR.%26aulast%3DDeckert%26aufirst%3DM.%26atitle%3DActivating%2520L265P%2520mutations%2520of%2520the%2520MYD88%2520gene%2520are%2520common%2520in%2520primary%2520central%2520nervous%2520system%2520lymphoma%26jtitle%3DActa%2520Neuropathol.%26date%3D2011%26volume%3D122%26spage%3D791%26epage%3D792%26doi%3D10.1007%2Fs00401-011-0891-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Kraan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Keimpema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horlings, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schilder-Tol, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oud, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noorduyn, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluin, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersten, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spaargaren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pals, S. T.</span><span> </span><span class="NLM_article-title">High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">719</span><span class="NLM_x">–</span> <span class="NLM_lpage">720</span><span class="refDoi"> DOI: 10.1038/leu.2013.348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1038%2Fleu.2013.348" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=719-720&author=W.+Kraanauthor=M.+van+Keimpemaauthor=H.+M.+Horlingsauthor=E.+J.+Schilder-Tolauthor=M.+E.+Oudauthor=L.+A.+Noorduynauthor=P.+M.+Kluinauthor=M.+J.+Kerstenauthor=M.+Spaargarenauthor=S.+T.+Pals&title=High+prevalence+of+oncogenic+MYD88+and+CD79B+mutations+in+primary+testicular+diffuse+large+B-cell+lymphoma&doi=10.1038%2Fleu.2013.348"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.348%26sid%3Dliteratum%253Aachs%26aulast%3DKraan%26aufirst%3DW.%26aulast%3Dvan%2BKeimpema%26aufirst%3DM.%26aulast%3DHorlings%26aufirst%3DH.%2BM.%26aulast%3DSchilder-Tol%26aufirst%3DE.%2BJ.%26aulast%3DOud%26aufirst%3DM.%2BE.%26aulast%3DNoorduyn%26aufirst%3DL.%2BA.%26aulast%3DKluin%26aufirst%3DP.%2BM.%26aulast%3DKersten%26aufirst%3DM.%2BJ.%26aulast%3DSpaargaren%26aufirst%3DM.%26aulast%3DPals%26aufirst%3DS.%2BT.%26atitle%3DHigh%2520prevalence%2520of%2520oncogenic%2520MYD88%2520and%2520CD79B%2520mutations%2520in%2520primary%2520testicular%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DLeukemia%26date%3D2014%26volume%3D28%26spage%3D719%26epage%3D720%26doi%3D10.1038%2Fleu.2013.348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Picard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bustamante, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soudais, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupuis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fieschi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elbim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Ghonaium, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Rayes, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Jumaah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Hajjar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Mohsen, I. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frayha, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rucker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawn, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aderem, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tufenkeji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haraguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gougerot-Pocidalo, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozinsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casanova, J. L.</span><span> </span><span class="NLM_article-title">Pyogenic bacterial infections in humans with IRAK-4 deficiency</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">2076</span><span class="NLM_x">–</span> <span class="NLM_lpage">2079</span><span class="refDoi"> DOI: 10.1126/science.1081902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1126%2Fscience.1081902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=12637671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlCisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=2076-2079&author=C.+Picardauthor=A.+Puelauthor=M.+Bonnetauthor=C.+L.+Kuauthor=J.+Bustamanteauthor=K.+Yangauthor=C.+Soudaisauthor=S.+Dupuisauthor=J.+Feinbergauthor=C.+Fieschiauthor=C.+Elbimauthor=R.+Hitchcockauthor=D.+Lammasauthor=G.+Daviesauthor=A.+Al-Ghonaiumauthor=H.+Al-Rayesauthor=S.+Al-Jumaahauthor=S.+Al-Hajjarauthor=I.+Z.+Al-Mohsenauthor=H.+H.+Frayhaauthor=R.+Ruckerauthor=T.+R.+Hawnauthor=A.+Aderemauthor=H.+Tufenkejiauthor=S.+Haraguchiauthor=N.+K.+Dayauthor=R.+A.+Goodauthor=M.+A.+Gougerot-Pocidaloauthor=A.+Ozinskyauthor=J.+L.+Casanova&title=Pyogenic+bacterial+infections+in+humans+with+IRAK-4+deficiency&doi=10.1126%2Fscience.1081902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Pyogenic Bacterial Infections in Humans with IRAK-4 Deficiency</span></div><div class="casAuthors">Picard, Capucine; Puel, Anne; Bonnet, Marion; Ku, Cheng-Lung; Bustamante, Jacinta; Yang, Kun; Soudais, Claire; Dupuis, Stephanie; Feinberg, Jacqueline; Fieschi, Claire; Elbim, Carole; Hitchcock, Remi; Lammas, David; Davies, Graham; Al-Ghonaium, Abdulaziz; Al-Rayes, Hassan; Al-Jumaah, Sulaiman; Al-Hajjar, Sami; Al-Mohsen, Ibrahim Zaid; Frayha, Husn H.; Rucker, Rajivi; Hawn, Thomas R.; Aderem, Alan; Tufenkeji, Haysam; Haraguchi, Soichi; Day, Noorbibi K.; Good, Robert A.; Gougerot-Pocidalo, Marie-Anne; Ozinsky, Adrian; Casanova, Jean-Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">5615</span>),
    <span class="NLM_cas:pages">2076-2079</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Members of the Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) superfamily share an intracytoplasmic Toll-IL-1 receptor (TIR) domain, which mediates recruitment of the interleukin-1 receptor-assocd. kinase (IRAK) complex via TIR-contg. adapter mols.  The authors describe three unrelated children with inherited IRAK-4 deficiency.  Their blood and fibroblast cells did not activate nuclear factor κB and mitogen-activated protein kinase (MAPK) and failed to induce downstream cytokines in response to any of the known ligands of TIR-bearing receptors.  The otherwise healthy children developed infections caused by pyogenic bacteria.  These findings suggest that, in humans, the TIR-IRAK signaling pathway is crucial for protective immunity against specific bacteria but is redundant against most other microorganisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGone924bm7Fl7Vg90H21EOLACvtfcHk0lj96e4rvLYROQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlCisLo%253D&md5=4c70a72ac33d3e3ce8b194befd8a3211</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.1081902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1081902%26sid%3Dliteratum%253Aachs%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DPuel%26aufirst%3DA.%26aulast%3DBonnet%26aufirst%3DM.%26aulast%3DKu%26aufirst%3DC.%2BL.%26aulast%3DBustamante%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DSoudais%26aufirst%3DC.%26aulast%3DDupuis%26aufirst%3DS.%26aulast%3DFeinberg%26aufirst%3DJ.%26aulast%3DFieschi%26aufirst%3DC.%26aulast%3DElbim%26aufirst%3DC.%26aulast%3DHitchcock%26aufirst%3DR.%26aulast%3DLammas%26aufirst%3DD.%26aulast%3DDavies%26aufirst%3DG.%26aulast%3DAl-Ghonaium%26aufirst%3DA.%26aulast%3DAl-Rayes%26aufirst%3DH.%26aulast%3DAl-Jumaah%26aufirst%3DS.%26aulast%3DAl-Hajjar%26aufirst%3DS.%26aulast%3DAl-Mohsen%26aufirst%3DI.%2BZ.%26aulast%3DFrayha%26aufirst%3DH.%2BH.%26aulast%3DRucker%26aufirst%3DR.%26aulast%3DHawn%26aufirst%3DT.%2BR.%26aulast%3DAderem%26aufirst%3DA.%26aulast%3DTufenkeji%26aufirst%3DH.%26aulast%3DHaraguchi%26aufirst%3DS.%26aulast%3DDay%26aufirst%3DN.%2BK.%26aulast%3DGood%26aufirst%3DR.%2BA.%26aulast%3DGougerot-Pocidalo%26aufirst%3DM.%2BA.%26aulast%3DOzinsky%26aufirst%3DA.%26aulast%3DCasanova%26aufirst%3DJ.%2BL.%26atitle%3DPyogenic%2520bacterial%2520infections%2520in%2520humans%2520with%2520IRAK-4%2520deficiency%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D2076%26epage%3D2079%26doi%3D10.1126%2Fscience.1081902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">von Bernuth, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pankla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrabieh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustapha, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghandil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camcioglu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasconcelos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirvent, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitor, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrero-Mata, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aróstegui, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsina, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz-Ortiz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortuny, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yagüe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antón, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janniere, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garty, B. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issekutz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maródi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Gallego, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banchereau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaussabel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casanova, J. L.</span><span> </span><span class="NLM_article-title">Pyogenic bacterial infections in humans with MYD88 deficiency</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">321</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">696</span><span class="refDoi"> DOI: 10.1126/science.1158298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1126%2Fscience.1158298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=18669862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVKnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2008&pages=691-696&author=H.+von+Bernuthauthor=C.+Picardauthor=Z.+Jinauthor=R.+Panklaauthor=H.+Xiaoauthor=C.+L.+Kuauthor=M.+Chrabiehauthor=I.+B.+Mustaphaauthor=P.+Ghandilauthor=Y.+Camciogluauthor=J.+Vasconcelosauthor=N.+Sirventauthor=M.+Guedesauthor=A.+B.+Vitorauthor=M.+J.+Herrero-Mataauthor=J.+I.+Ar%C3%B3steguiauthor=C.+Rodrigoauthor=L.+Alsinaauthor=E.+Ruiz-Ortizauthor=M.+Juanauthor=C.+Fortunyauthor=J.+Yag%C3%BCeauthor=J.+Ant%C3%B3nauthor=M.+Pascalauthor=H.+H.+Changauthor=L.+Janniereauthor=Y.+Roseauthor=B.+Z.+Gartyauthor=H.+Chapelauthor=A.+Issekutzauthor=L.+Mar%C3%B3diauthor=C.+Rodriguez-Gallegoauthor=J.+Banchereauauthor=L.+Abelauthor=X.+Liauthor=D.+Chaussabelauthor=A.+Puelauthor=J.+L.+Casanova&title=Pyogenic+bacterial+infections+in+humans+with+MYD88+deficiency&doi=10.1126%2Fscience.1158298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Pyogenic Bacterial Infections in Humans with MyD88 Deficiency</span></div><div class="casAuthors">von Bernuth, Horst; Picard, Capucine; Jin, Zhongbo; Pankla, Rungnapa; Hui, Xiao; Ku, Cheng-Lung; Chrabieh, Maya; Ben Mustapha, Imen; Ghandil, Pegah; Camcioglu, Yildiz; Vasconcelos, Julia; Sirvent, Nicolas; Guedes, Margarida; Vitor, Artur Bonito; Herrero-Mata, Maria Jose; Arostegui, Juan Ignacio; Rodrigo, Carlos; Alsina, Laia; Ruiz-Ortiz, Estibaliz; Juan, Manel; Fortuny, Claudia; Yaguee, Jordi; Anton, Jordi; Pascal, Mariona; Chang, Huey-Hsuan; Janniere, Lucile; Rose, Yoann; Garty, Ben-Zion; Chapel, Helen; Issekutz, Andrew; Marodi, Laszlo; Rodriguez-Gallego, Carlos; Banchereau, Jacques; Abel, Laurent; Li, Xiaoxia; Chaussabel, Damien; Puel, Anne; Casanova, Jean-Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">5889</span>),
    <span class="NLM_cas:pages">691-696</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">MyD88 is a key downstream adapter for most Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs).  MyD88 deficiency in mice leads to susceptibility to a broad range of pathogens in exptl. settings of infection.  We describe a distinct situation in a natural setting of human infection.  Nine children with autosomal recessive MyD88 deficiency suffered from life-threatening, often recurrent pyogenic bacterial infections, including invasive pneumococcal disease.  However, these patients were otherwise healthy, with normal resistance to other microbes.  Their clin. status improved with age, but not due to any cellular leakiness in MyD88 deficiency.  The MyD88-dependent TLRs and IL-1Rs are therefore essential for protective immunity to a small no. of pyogenic bacteria, but redundant for host defense to most natural infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo9Ly_7pHPp7Vg90H21EOLACvtfcHk0ljTLlmkC-IlXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVKnurc%253D&md5=c81dbb50564824a9a49bebf826d1c2c2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscience.1158298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1158298%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BBernuth%26aufirst%3DH.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DPankla%26aufirst%3DR.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DKu%26aufirst%3DC.%2BL.%26aulast%3DChrabieh%26aufirst%3DM.%26aulast%3DMustapha%26aufirst%3DI.%2BB.%26aulast%3DGhandil%26aufirst%3DP.%26aulast%3DCamcioglu%26aufirst%3DY.%26aulast%3DVasconcelos%26aufirst%3DJ.%26aulast%3DSirvent%26aufirst%3DN.%26aulast%3DGuedes%26aufirst%3DM.%26aulast%3DVitor%26aufirst%3DA.%2BB.%26aulast%3DHerrero-Mata%26aufirst%3DM.%2BJ.%26aulast%3DAr%25C3%25B3stegui%26aufirst%3DJ.%2BI.%26aulast%3DRodrigo%26aufirst%3DC.%26aulast%3DAlsina%26aufirst%3DL.%26aulast%3DRuiz-Ortiz%26aufirst%3DE.%26aulast%3DJuan%26aufirst%3DM.%26aulast%3DFortuny%26aufirst%3DC.%26aulast%3DYag%25C3%25BCe%26aufirst%3DJ.%26aulast%3DAnt%25C3%25B3n%26aufirst%3DJ.%26aulast%3DPascal%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DH.%2BH.%26aulast%3DJanniere%26aufirst%3DL.%26aulast%3DRose%26aufirst%3DY.%26aulast%3DGarty%26aufirst%3DB.%2BZ.%26aulast%3DChapel%26aufirst%3DH.%26aulast%3DIssekutz%26aufirst%3DA.%26aulast%3DMar%25C3%25B3di%26aufirst%3DL.%26aulast%3DRodriguez-Gallego%26aufirst%3DC.%26aulast%3DBanchereau%26aufirst%3DJ.%26aulast%3DAbel%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChaussabel%26aufirst%3DD.%26aulast%3DPuel%26aufirst%3DA.%26aulast%3DCasanova%26aufirst%3DJ.%2BL.%26atitle%3DPyogenic%2520bacterial%2520infections%2520in%2520humans%2520with%2520MYD88%2520deficiency%26jtitle%3DScience%26date%3D2008%26volume%3D321%26spage%3D691%26epage%3D696%26doi%3D10.1126%2Fscience.1158298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Genung, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guckian, K. M.</span><span> </span><span class="NLM_article-title">Small molecule inhibition of interleukin-1 receptor-associated kinase 4 (IRAK4)</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">163</span><span class="refDoi"> DOI: 10.1016/bs.pmch.2016.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fbs.pmch.2016.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=28314411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A280%3ADC%252BC1czot12hsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=117-163&author=N.+E.+Genungauthor=K.+M.+Guckian&title=Small+molecule+inhibition+of+interleukin-1+receptor-associated+kinase+4+%28IRAK4%29&doi=10.1016%2Fbs.pmch.2016.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4)</span></div><div class="casAuthors">Genung N E; Guckian K M</div><div class="citationInfo"><span class="NLM_cas:title">Progress in medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">117-163</span>
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    </div><div class="casAbstract">In recent years, interleukin-1 receptor-associated kinase 4, IRAK4, has become an attractive target for many medicinal chemistry programmes.  Target inhibition is of potential therapeutic value in areas including autoimmune disorders, cancer, inflammatory diseases, and possibly neurodegenerative diseases.  Results from high-throughput screening efforts have led, in conjunction with structure-based drug design, to the identification of highly potent and selective small molecule IRAK4 inhibitors from many diverse chemical series.  In vitro and in vivo studies with entities from distinct structural classes have helped elucidate the downstream pharmacological responses associated with IRAK4 inhibition as a proof of concept in disease models, leading to the recent initiation of human clinical trials.  Within this review, we will highlight the considerable effort by numerous groups dedicated to the development of small molecule IRAK4 inhibitors for the treatment of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZNiMykZj_Wv6xYuD7tu2XfW6udTcc2eaStDa9k6auxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czot12hsg%253D%253D&md5=30805b2fb55ac3e6be120a7557c0f24c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmch.2016.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmch.2016.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DGenung%26aufirst%3DN.%2BE.%26aulast%3DGuckian%26aufirst%3DK.%2BM.%26atitle%3DSmall%2520molecule%2520inhibition%2520of%2520interleukin-1%2520receptor-associated%2520kinase%25204%2520%2528IRAK4%2529%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D56%26spage%3D117%26epage%3D163%26doi%3D10.1016%2Fbs.pmch.2016.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Powers, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesche, H.</span><span> </span><span class="NLM_article-title">Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2842</span><span class="NLM_x">–</span> <span class="NLM_lpage">2845</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.03.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2006.03.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=16563752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFygsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=2842-2845&author=J.+P.+Powersauthor=S.+Liauthor=J.+C.+Jaenauthor=J.+Liuauthor=N.+P.+C.+Walkerauthor=Z.+Wangauthor=H.+Wesche&title=Discovery+and+initial+SAR+of+inhibitors+of+interleukin-1+receptor-associated+kinase-4&doi=10.1016%2Fj.bmcl.2006.03.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4</span></div><div class="casAuthors">Powers, Jay P.; Li, Shyun; Jaen, Juan C.; Liu, Jinqian; Walker, Nigel P. C.; Wang, Zhulun; Wesche, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2842-2845</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">High-throughput screening of a small-mol. compd. library resulted in the identification of a novel series of N-acyl 2-aminobenzimidazoles that are potent inhibitors of interleukin-1 receptor-assocd. kinase-4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgZ37zw75f-7Vg90H21EOLACvtfcHk0lhYU1njob5dTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFygsb8%253D&md5=7a8a2ebe4c155ac8999ff4a63e3ed139</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.03.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.03.020%26sid%3Dliteratum%253Aachs%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DN.%2BP.%2BC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWesche%26aufirst%3DH.%26atitle%3DDiscovery%2520and%2520initial%2520SAR%2520of%2520inhibitors%2520of%2520interleukin-1%2520receptor-associated%2520kinase-4%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D2842%26epage%3D2845%26doi%3D10.1016%2Fj.bmcl.2006.03.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lively, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomooka, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, J. P.</span><span> </span><span class="NLM_article-title">Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">5546</span><span class="NLM_x">–</span> <span class="NLM_lpage">5550</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.10.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2015.10.060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5546-5550&author=Z.+Wangauthor=D.+Sunauthor=S.+Johnstoneauthor=Z.+Caoauthor=X.+Gaoauthor=J.+C.+Jaenauthor=J.+Liuauthor=S.+Livelyauthor=S.+Miaoauthor=A.+Sudomauthor=C.+Tomookaauthor=N.+P.+C.+Walkerauthor=M.+Wrightauthor=X.+Yanauthor=Q.+Yeauthor=J.+P.+Powers&title=Discovery+of+potent%2C+selective%2C+and+orally+bioavailable+inhibitors+of+interleukin-1+receptor-associate+kinase-4&doi=10.1016%2Fj.bmcl.2015.10.060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.10.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.10.060%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DJohnstone%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLively%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DTomooka%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DN.%2BP.%2BC.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitors%2520of%2520interleukin-1%2520receptor-associate%2520kinase-4%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5546%26epage%3D5550%26doi%3D10.1016%2Fj.bmcl.2015.10.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Buckley, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gowers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higueruelo, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rausch, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, J. L.</span><span> </span><span class="NLM_article-title">IRAK-4 inhibitors. Part 1: A series of amides</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3211</span><span class="NLM_x">–</span> <span class="NLM_lpage">3214</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2008.04.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=18474425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD1cXms1yiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3211-3214&author=G.+M.+Buckleyauthor=L.+Gowersauthor=A.+P.+Higuerueloauthor=K.+Jenkinsauthor=S.+R.+Mackauthor=T.+Morganauthor=D.+M.+Parryauthor=W.+R.+Pittauthor=O.+Rauschauthor=M.+D.+Richardauthor=V.+Sabinauthor=J.+L.+Fraser&title=IRAK-4+inhibitors.+Part+1%3A+A+series+of+amides&doi=10.1016%2Fj.bmcl.2008.04.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">IRAK-4 inhibitors. Part 1: A series of amides</span></div><div class="casAuthors">Buckley, George M.; Gowers, Lewis; Higueruelo, Alicia Perez; Jenkins, Kerry; Mack, Stephen R.; Morgan, Trevor; Parry, David M.; Pitt, William R.; Rausch, Oliver; Richard, Marianna D.; Sabin, Verity; Fraser, Joanne L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3211-3214</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The synthesis and profile of a series of amides, e.g., I, are described.  Some of these compds. were potent IRAK-4 inhibitors and two examples were evaluated in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2WnghW2pEwbVg90H21EOLACvtfcHk0lhYU1njob5dTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXms1yiu78%253D&md5=75fb794d58ae52827a58b8ff59394111</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.058%26sid%3Dliteratum%253Aachs%26aulast%3DBuckley%26aufirst%3DG.%2BM.%26aulast%3DGowers%26aufirst%3DL.%26aulast%3DHigueruelo%26aufirst%3DA.%2BP.%26aulast%3DJenkins%26aufirst%3DK.%26aulast%3DMack%26aufirst%3DS.%2BR.%26aulast%3DMorgan%26aufirst%3DT.%26aulast%3DParry%26aufirst%3DD.%2BM.%26aulast%3DPitt%26aufirst%3DW.%2BR.%26aulast%3DRausch%26aufirst%3DO.%26aulast%3DRichard%26aufirst%3DM.%2BD.%26aulast%3DSabin%26aufirst%3DV.%26aulast%3DFraser%26aufirst%3DJ.%2BL.%26atitle%3DIRAK-4%2520inhibitors.%2520Part%25201%253A%2520A%2520series%2520of%2520amides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3211%26epage%3D3214%26doi%3D10.1016%2Fj.bmcl.2008.04.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Buckley, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceska, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gowers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groom, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higueruelo, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rausch, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabin, V.</span><span> </span><span class="NLM_article-title">IRAK-4 inhibitors. Part II: A structure-based assessment of imidazo1,2-a]pyridine binding</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3291</span><span class="NLM_x">–</span> <span class="NLM_lpage">3295</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2008.04.039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3291-3295&author=G.+M.+Buckleyauthor=T.+A.+Ceskaauthor=J.+L.+Fraserauthor=L.+Gowersauthor=C.+R.+Groomauthor=A.+P.+Higuerueloauthor=K.+Jenkinsauthor=S.+R.+Mackauthor=T.+Morganauthor=D.+M.+Parryauthor=W.+R.+Pittauthor=O.+Rauschauthor=M.+D.+Richardauthor=V.+Sabin&title=IRAK-4+inhibitors.+Part+II%3A+A+structure-based+assessment+of+imidazo1%2C2-a%5Dpyridine+binding&doi=10.1016%2Fj.bmcl.2008.04.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.039%26sid%3Dliteratum%253Aachs%26aulast%3DBuckley%26aufirst%3DG.%2BM.%26aulast%3DCeska%26aufirst%3DT.%2BA.%26aulast%3DFraser%26aufirst%3DJ.%2BL.%26aulast%3DGowers%26aufirst%3DL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DHigueruelo%26aufirst%3DA.%2BP.%26aulast%3DJenkins%26aufirst%3DK.%26aulast%3DMack%26aufirst%3DS.%2BR.%26aulast%3DMorgan%26aufirst%3DT.%26aulast%3DParry%26aufirst%3DD.%2BM.%26aulast%3DPitt%26aufirst%3DW.%2BR.%26aulast%3DRausch%26aufirst%3DO.%26aulast%3DRichard%26aufirst%3DM.%2BD.%26aulast%3DSabin%26aufirst%3DV.%26atitle%3DIRAK-4%2520inhibitors.%2520Part%2520II%253A%2520A%2520structure-based%2520assessment%2520of%2520imidazo1%252C2-a%255Dpyridine%2520binding%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3291%26epage%3D3295%26doi%3D10.1016%2Fj.bmcl.2008.04.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Buckley, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fosbeary, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gowers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higueruelo, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rausch, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabin, V.</span><span> </span><span class="NLM_article-title">IRAK-4 inhibitors. Part III: A series of imidazo1,2-a]pyridines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3656</span><span class="NLM_x">–</span> <span class="NLM_lpage">3660</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2008.04.042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3656-3660&author=G.+M.+Buckleyauthor=R.+Fosbearyauthor=J.+L.+Fraserauthor=L.+Gowersauthor=A.+P.+Higuerueloauthor=L.+A.+Jamesauthor=K.+Jenkinsauthor=S.+R.+Mackauthor=T.+Morganauthor=D.+M.+Parryauthor=W.+R.+Pittauthor=O.+Rauschauthor=M.+D.+Richardauthor=V.+Sabin&title=IRAK-4+inhibitors.+Part+III%3A+A+series+of+imidazo1%2C2-a%5Dpyridines&doi=10.1016%2Fj.bmcl.2008.04.042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.042%26sid%3Dliteratum%253Aachs%26aulast%3DBuckley%26aufirst%3DG.%2BM.%26aulast%3DFosbeary%26aufirst%3DR.%26aulast%3DFraser%26aufirst%3DJ.%2BL.%26aulast%3DGowers%26aufirst%3DL.%26aulast%3DHigueruelo%26aufirst%3DA.%2BP.%26aulast%3DJames%26aufirst%3DL.%2BA.%26aulast%3DJenkins%26aufirst%3DK.%26aulast%3DMack%26aufirst%3DS.%2BR.%26aulast%3DMorgan%26aufirst%3DT.%26aulast%3DParry%26aufirst%3DD.%2BM.%26aulast%3DPitt%26aufirst%3DW.%2BR.%26aulast%3DRausch%26aufirst%3DO.%26aulast%3DRichard%26aufirst%3DM.%2BD.%26aulast%3DSabin%26aufirst%3DV.%26atitle%3DIRAK-4%2520inhibitors.%2520Part%2520III%253A%2520A%2520series%2520of%2520imidazo1%252C2-a%255Dpyridines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3656%26epage%3D3660%26doi%3D10.1016%2Fj.bmcl.2008.04.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Kondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomura, Y.</span><span> </span><span class="NLM_article-title">Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats</span> <span class="citation_source-journal">Naunyn-Schmiedeberg's Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span><span class="refDoi"> DOI: 10.1007/s00210-014-1023-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1007%2Fs00210-014-1023-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=25052043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Sjsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2014&pages=909-919&author=M.+Kondoauthor=A.+Taharaauthor=K.+Hayashiauthor=M.+Abeauthor=H.+Inamiauthor=T.+Ishikawaauthor=H.+Itoauthor=Y.+Tomura&title=Renoprotective+effects+of+novel+interleukin-1+receptor-associated+kinase+4+inhibitor+AS2444697+through+anti-inflammatory+action+in+5%2F6+nephrectomized+rats&doi=10.1007%2Fs00210-014-1023-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats</span></div><div class="casAuthors">Kondo, Mitsuhiro; Tahara, Atsuo; Hayashi, Kazumi; Abe, Masaki; Inami, Hiroshi; Ishikawa, Takeshi; Ito, Hiroyuki; Tomura, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">909-919</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Renal inflammation is a final common pathway of chronic kidney disease (CKD), and its progression can be used to effectively gauge the degree of renal dysfunction.  Interleukin-1 (IL-1) receptor-assocd. kinase 4 (IRAK-4) has been reported to be a pivotal mol. for IL-1 receptor- and Toll-like receptor-induced signaling and activation of proinflammatory mediators.  In this study, we hypothesized that if inflammation plays a key role in renal failure, then the anti-inflammatory effect of IRAK-4 inhibitor should be effective in improving CKD.  To det. its pharmacol. potency, we investigated the renoprotective properties of the novel IRAK-4 inhibitor AS2444697 (N-[3-carbamoyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide hydrochloride (1:1)) in 5/6 nephrectomized (Nx) rats, a model of CKD.  Six weeks' repeated administration of AS2444697 (0.3-3 mg/kg, twice daily) dose-dependently and significantly reduced urinary protein excretion and prevented the development of glomerulosclerosis and interstitial fibrosis without affecting the blood pressure.  In addn., AS2444697 showed beneficial effects on renal function as demonstrated by the decrease in levels of plasma creatinine and blood urea nitrogen and attenuation of decline in creatinine clearance. 5/6 Nx rats exhibited low-grade inflammation as evidenced by increased renal mRNA expression and plasma levels of proinflammatory cytokines (IL-1β, IL-6, TNF-α, and MCP-1) and C-reactive protein as a marker of systemic inflammation.  AS2444697 significantly reduced or showed a decreasing trend in expression and levels of these inflammatory parameters.  These results suggest that AS2444697 suppresses the progression of chronic renal failure via anti-inflammatory action and may therefore be potentially useful in treating CKD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfm1DDR5_qOLVg90H21EOLACvtfcHk0lhutbhtQ2jtIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Sjsr%252FE&md5=50fe058ccb5247f50d93e3ccab85e169</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00210-014-1023-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-014-1023-z%26sid%3Dliteratum%253Aachs%26aulast%3DKondo%26aufirst%3DM.%26aulast%3DTahara%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DInami%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DTomura%26aufirst%3DY.%26atitle%3DRenoprotective%2520effects%2520of%2520novel%2520interleukin-1%2520receptor-associated%2520kinase%25204%2520inhibitor%2520AS2444697%2520through%2520anti-inflammatory%2520action%2520in%25205%252F6%2520nephrectomized%2520rats%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2014%26volume%3D387%26spage%3D909%26epage%3D919%26doi%3D10.1007%2Fs00210-014-1023-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibeau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinschek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leccese, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesburg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maclean, J. K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulrooney, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Presland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rakhilina, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinhuebel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span> </span><span class="NLM_article-title">Discovery of 5-amino-N-(1H-pyrazol-4-yl)pyrazolo1,5-a]pyrimidine-3-carboxamide inhibitors of IRAK4</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">688</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00107</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=683-688&author=J.+Limauthor=M.+D.+Altmanauthor=J.+Bakerauthor=J.+D.+Brubakerauthor=H.+Chenauthor=Y.+Chenauthor=T.+Fischmannauthor=C.+Gibeauauthor=M.+A.+Kleinschekauthor=E.+Lecceseauthor=C.+Lesburgauthor=J.+K.+F.+Macleanauthor=L.+Y.+Moyauthor=E.+F.+Mulrooneyauthor=J.+Preslandauthor=L.+Rakhilinaauthor=G.+F.+Smithauthor=D.+Steinhuebelauthor=R.+Yang&title=Discovery+of+5-amino-N-%281H-pyrazol-4-yl%29pyrazolo1%2C5-a%5Dpyrimidine-3-carboxamide+inhibitors+of+IRAK4&doi=10.1021%2Facsmedchemlett.5b00107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00107%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DBrubaker%26aufirst%3DJ.%2BD.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DGibeau%26aufirst%3DC.%26aulast%3DKleinschek%26aufirst%3DM.%2BA.%26aulast%3DLeccese%26aufirst%3DE.%26aulast%3DLesburg%26aufirst%3DC.%26aulast%3DMaclean%26aufirst%3DJ.%2BK.%2BF.%26aulast%3DMoy%26aufirst%3DL.%2BY.%26aulast%3DMulrooney%26aufirst%3DE.%2BF.%26aulast%3DPresland%26aufirst%3DJ.%26aulast%3DRakhilina%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DG.%2BF.%26aulast%3DSteinhuebel%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DR.%26atitle%3DDiscovery%2520of%25205-amino-N-%25281H-pyrazol-4-yl%2529pyrazolo1%252C5-a%255Dpyrimidine-3-carboxamide%2520inhibitors%2520of%2520IRAK4%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D683%26epage%3D688%26doi%3D10.1021%2Facsmedchemlett.5b00107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinschek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maclean, J. K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulrooney, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Presland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rakhilina, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span> </span><span class="NLM_article-title">Identification of N-(1H-pyrazol-4-yl)carboxamide inhibitors of interleukin-1 receptor associated kinase 4: Bicyclic core modifications</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">5384</span><span class="NLM_x">–</span> <span class="NLM_lpage">5388</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2015.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=26403930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFGlurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5384-5388&author=J.+Limauthor=M.+D.+Altmanauthor=J.+Bakerauthor=J.+D.+Brubakerauthor=H.+Chenauthor=Y.+Chenauthor=M.+A.+Kleinschekauthor=C.+Liauthor=D.+Liuauthor=J.+K.+F.+Macleanauthor=E.+F.+Mulrooneyauthor=J.+Preslandauthor=L.+Rakhilinaauthor=G.+F.+Smithauthor=R.+Yang&title=Identification+of+N-%281H-pyrazol-4-yl%29carboxamide+inhibitors+of+interleukin-1+receptor+associated+kinase+4%3A+Bicyclic+core+modifications&doi=10.1016%2Fj.bmcl.2015.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-(1H-pyrazol-4-yl)carboxamide inhibitors of interleukin-1 receptor associated kinase 4: Bicyclic core modifications</span></div><div class="casAuthors">Lim, Jongwon; Altman, Michael D.; Baker, James; Brubaker, Jason D.; Chen, Hongmin; Chen, Yiping; Kleinschek, Melanie A.; Li, Chaomin; Liu, Duan; MacLean, John K. F.; Mulrooney, Erin F.; Presland, Jeremy; Rakhilina, Larissa; Smith, Graham F.; Yang, Ruojing</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5384-5388</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">IRAK4 plays a crit. role in the IL-1R and TLR signaling, and selective inhibition of the kinase activity of the protein represents an attractive target for the treatment of inflammatory diseases.  A series of permeable N-(1H-pyrazol-4-yl)carboxamides was developed by introducing lipophilic bicyclic cores in place of the polar pyrazolopyrimidine core of 5-amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamides.  Replacement of the pyrazolo[1,5-a]pyrimidine core with the pyrrolo[2,1-f][1,2,4]triazine, the pyrrolo[1,2-b]pyridazine, and thieno[2,3-b]pyrazine cores guided by c Log D led to the identification of highly permeable IRAK4 inhibitors with excellent potency and kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWIvvaS6F5F7Vg90H21EOLACvtfcHk0lhutbhtQ2jtIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFGlurvJ&md5=f01d0d52d296c911016b3a53a5ef4957</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DBrubaker%26aufirst%3DJ.%2BD.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKleinschek%26aufirst%3DM.%2BA.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMaclean%26aufirst%3DJ.%2BK.%2BF.%26aulast%3DMulrooney%26aufirst%3DE.%2BF.%26aulast%3DPresland%26aufirst%3DJ.%26aulast%3DRakhilina%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DG.%2BF.%26aulast%3DYang%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%25281H-pyrazol-4-yl%2529carboxamide%2520inhibitors%2520of%2520interleukin-1%2520receptor%2520associated%2520kinase%25204%253A%2520Bicyclic%2520core%2520modifications%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5384%26epage%3D5388%26doi%3D10.1016%2Fj.bmcl.2015.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">McElroy, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michael Seganish, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jason Herr, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komanduri, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakash, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulshian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenlee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, X.</span><span> </span><span class="NLM_article-title">Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1836</span><span class="NLM_x">–</span> <span class="NLM_lpage">1841</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.03.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2015.03.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=25870132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVOru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1836-1841&author=W.+T.+McElroyauthor=W.+Michael+Seganishauthor=R.+Jason+Herrauthor=J.+Hardingauthor=J.+Yangauthor=L.+Yetauthor=V.+Komanduriauthor=K.+C.+Prakashauthor=B.+Laveyauthor=D.+Tulshianauthor=W.+J.+Greenleeauthor=C.+Sondeyauthor=T.+O.+Fischmannauthor=X.+Niu&title=Discovery+and+hit-to-lead+optimization+of+2%2C6-diaminopyrimidine+inhibitors+of+interleukin-1+receptor-associated+kinase+4&doi=10.1016%2Fj.bmcl.2015.03.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20cR"><div class="casContent"><span class="casTitleNuber">20c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4</span></div><div class="casAuthors">McElroy, William T.; Michael Seganish, W.; Jason Herr, R.; Harding, James; Yang, Jinhai; Yet, Larry; Komanduri, Venukrishnan; Prakash, Koraboina Chandra; Lavey, Brian; Tulshian, Deen; Greenlee, William J.; Sondey, Christopher; Fischmann, Thierry O.; Niu, Xiaoda</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1836-1841</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Interleukin receptor-assocd. kinase 4 (IRAK4) is a crit. element of the Toll-like/interleukin-1 receptor inflammation signaling pathway.  A screening campaign identified a novel diaminopyrimidine hit that exhibits weak IRAK4 inhibitory activity and a ligand efficiency of 0.25.  Hit-to-lead activities were conducted through independent SAR studies of each of the four pyrimidine substituents.  Optimal activity was obsd. upon removal of the pyrimidine C-4 chloro substituent.  The intact C-6 carboribose is required for IRAK4 inhibition.  Numerous heteroaryls were tolerated at the C-5 position, with azabenzothiazoles conferring the best activities.  Aminoheteroaryls were preferred at the C-2 position.  These studies led to the discovery of inhibitors 35, 36, and 38 that exhibit nanomolar inhibition of IRAK4, improved ligand efficiencies, and modest kinase selectivities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM21dnxkylY7Vg90H21EOLACvtfcHk0ljiVc6SEE5WQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVOru70%253D&md5=a17679e9d71889b01a2ad27d1f2bb653</span></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.03.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.03.043%26sid%3Dliteratum%253Aachs%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26aulast%3DMichael%2BSeganish%26aufirst%3DW.%26aulast%3DJason%2BHerr%26aufirst%3DR.%26aulast%3DHarding%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYet%26aufirst%3DL.%26aulast%3DKomanduri%26aufirst%3DV.%26aulast%3DPrakash%26aufirst%3DK.%2BC.%26aulast%3DLavey%26aufirst%3DB.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DSondey%26aufirst%3DC.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DNiu%26aufirst%3DX.%26atitle%3DDiscovery%2520and%2520hit-to-lead%2520optimization%2520of%25202%252C6-diaminopyrimidine%2520inhibitors%2520of%2520interleukin-1%2520receptor-associated%2520kinase%25204%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1836%26epage%3D1841%26doi%3D10.1016%2Fj.bmcl.2015.03.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">McElroy, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paliwal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seganish, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulshian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bober, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlisi, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, X.</span><span> </span><span class="NLM_article-title">Potent and selective amidopyrazole inhibitors of IRAK4 that are efficacious in a rodent model of inflammation</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">677</span><span class="NLM_x">–</span> <span class="NLM_lpage">682</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2MXot1Sqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=677-682&author=W.+T.+McElroyauthor=Z.+Tanauthor=G.+Hoauthor=S.+Paliwalauthor=G.+Liauthor=W.+M.+Seganishauthor=D.+Tulshianauthor=J.+Tataauthor=T.+O.+Fischmannauthor=C.+Sondeyauthor=H.+Bianauthor=L.+Boberauthor=J.+Jacksonauthor=C.+G.+Garlisiauthor=K.+Devitoauthor=J.+Fossettaauthor=D.+Lundellauthor=X.+Niu&title=Potent+and+selective+amidopyrazole+inhibitors+of+IRAK4+that+are+efficacious+in+a+rodent+model+of+inflammation&doi=10.1021%2Facsmedchemlett.5b00106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20dR"><div class="casContent"><span class="casTitleNuber">20d</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation</span></div><div class="casAuthors">McElroy, William T.; Tan, Zheng; Ho, Ginny; Paliwal, Sunil; Li, Guoqing; Seganish, W. Michael; Tulshian, Deen; Tata, James; Fischmann, Thierry O.; Sondey, Christopher; Bian, Hong; Bober, Loretta; Jackson, James; Garlisi, Charles G.; Devito, Kristine; Fossetta, James; Lundell, Daniel; Niu, Xiaoda</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">677-682</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">IRAK4 is a crit. upstream kinase in the IL-1R/TLR signaling pathway.  Inhibition of IRAK4 is hypothesized to be beneficial in the treatment of autoimmune related disorders.  A screening campaign identified a pyrazole class of IRAK4 inhibitors that were detd. by X-ray crystallog. to exhibit an unusual binding mode.  SAR efforts focused on the identification of a potent and selective inhibitor with good aq. soly. and rodent pharmacokinetics.  Pyrazole C-3 piperidines were well tolerated, with N-sulfonyl analogs generally having good rodent oral exposure but poor soly.  N-Alkyl piperidines exhibited excellent soly. and reduced exposure.  Pyrazoles possessing N-1 pyridine and fluorophenyl substituents were among the most active.  Piperazine 32 was a potent enzyme inhibitor with good cellular activity.  Compd. 32 reduced the in vivo prodn. of proinflammatory cytokines and was orally efficacious in a mouse antibody induced arthritis disease model of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNSA2VYtAf07Vg90H21EOLACvtfcHk0ljiVc6SEE5WQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXot1Sqtrk%253D&md5=2203ad720b478a6e415d7d9df3e82106</span></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00106%26sid%3Dliteratum%253Aachs%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DHo%26aufirst%3DG.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DSeganish%26aufirst%3DW.%2BM.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DTata%26aufirst%3DJ.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DSondey%26aufirst%3DC.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DBober%26aufirst%3DL.%26aulast%3DJackson%26aufirst%3DJ.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DDevito%26aufirst%3DK.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DX.%26atitle%3DPotent%2520and%2520selective%2520amidopyrazole%2520inhibitors%2520of%2520IRAK4%2520that%2520are%2520efficacious%2520in%2520a%2520rodent%2520model%2520of%2520inflammation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D677%26epage%3D682%26doi%3D10.1021%2Facsmedchemlett.5b00106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Seganish, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherborne, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matasi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulshian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlisi, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, X.</span><span> </span><span class="NLM_article-title">Discovery and structure enabled synthesis of 2,6-diaminopyrimidin-4-one IRAK4 inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">–</span> <span class="NLM_lpage">947</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00279</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFGitb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=942-947&author=W.+M.+Seganishauthor=T.+O.+Fischmannauthor=B.+Sherborneauthor=J.+Matasiauthor=B.+Laveyauthor=W.+T.+McElroyauthor=D.+Tulshianauthor=J.+Tataauthor=C.+Sondeyauthor=C.+G.+Garlisiauthor=K.+Devitoauthor=J.+Fossettaauthor=D.+Lundellauthor=X.+Niu&title=Discovery+and+structure+enabled+synthesis+of+2%2C6-diaminopyrimidin-4-one+IRAK4+inhibitors&doi=10.1021%2Facsmedchemlett.5b00279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20eR"><div class="casContent"><span class="casTitleNuber">20e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Structure Enabled Synthesis of 2,6-Diaminopyrimidin-4-one IRAK4 Inhibitors</span></div><div class="casAuthors">Seganish, W. Michael; Fischmann, Thierry O.; Sherborne, Brad; Matasi, Julius; Lavey, Brian; McElroy, William T.; Tulshian, Deen; Tata, James; Sondey, Christopher; Garlisi, Charles G.; Devito, Kristine; Fossetta, James; Lundell, Daniel; Niu, Xiaoda</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">942-947</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the identification and synthesis of a series of aminopyrimidin-4-one IRAK4 inhibitors.  Through high throughput screening, an aminopyrimidine hit was identified and modified via structure enabled design to generate a new, potent, and kinase selective pyrimidin-4-one chemotype.  This chemotype is exemplified by compd. 16 (XVI), which has potent IRAK4 inhibition activity (IC50 = 27 nM) and excellent kinase selectivity (>100-fold against 99% of 111 tested kinases), and compd. 31 (XXXI), which displays potent IRAK4 activity (IC50 = 93 nM) and good rat bioavailability (F = 42%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYA9sdnPVJ0bVg90H21EOLACvtfcHk0ljiVc6SEE5WQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFGitb7F&md5=2ab5a89c059a1d3164e72ecc557daf56</span></div><a href="/servlet/linkout?suffix=cit20e&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00279%26sid%3Dliteratum%253Aachs%26aulast%3DSeganish%26aufirst%3DW.%2BM.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DSherborne%26aufirst%3DB.%26aulast%3DMatasi%26aufirst%3DJ.%26aulast%3DLavey%26aufirst%3DB.%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DTata%26aufirst%3DJ.%26aulast%3DSondey%26aufirst%3DC.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DDevito%26aufirst%3DK.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DX.%26atitle%3DDiscovery%2520and%2520structure%2520enabled%2520synthesis%2520of%25202%252C6-diaminopyrimidin-4-one%2520IRAK4%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D942%26epage%3D947%26doi%3D10.1021%2Facsmedchemlett.5b00279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Seganish, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herr, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brumfield, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenlee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komanduri, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matasi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakash, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulshian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlisi, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondey, C.</span><span> </span><span class="NLM_article-title">Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3203</span><span class="NLM_x">–</span> <span class="NLM_lpage">3207</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.05.097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2015.05.097" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3203-3207&author=W.+M.+Seganishauthor=W.+T.+McElroyauthor=R.+J.+Herrauthor=S.+Brumfieldauthor=W.+J.+Greenleeauthor=J.+Hardingauthor=V.+Komanduriauthor=J.+Matasiauthor=K.+C.+Prakashauthor=D.+Tulshianauthor=J.+Yangauthor=L.+Yetauthor=K.+Devitoauthor=J.+Fossettaauthor=C.+G.+Garlisiauthor=D.+Lundellauthor=X.+Niuauthor=C.+Sondey&title=Initial+optimization+and+series+evolution+of+diaminopyrimidine+inhibitors+of+interleukin-1+receptor+associated+kinase+4&doi=10.1016%2Fj.bmcl.2015.05.097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20f&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.05.097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.05.097%26sid%3Dliteratum%253Aachs%26aulast%3DSeganish%26aufirst%3DW.%2BM.%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26aulast%3DHerr%26aufirst%3DR.%2BJ.%26aulast%3DBrumfield%26aufirst%3DS.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DHarding%26aufirst%3DJ.%26aulast%3DKomanduri%26aufirst%3DV.%26aulast%3DMatasi%26aufirst%3DJ.%26aulast%3DPrakash%26aufirst%3DK.%2BC.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYet%26aufirst%3DL.%26aulast%3DDevito%26aufirst%3DK.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DSondey%26aufirst%3DC.%26atitle%3DInitial%2520optimization%2520and%2520series%2520evolution%2520of%2520diaminopyrimidine%2520inhibitors%2520of%2520interleukin-1%2520receptor%2520associated%2520kinase%25204%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3203%26epage%3D3207%26doi%3D10.1016%2Fj.bmcl.2015.05.097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Hanisak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seganish, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, H.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulshian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlisi, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, X.</span><span> </span><span class="NLM_article-title">Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">4250</span><span class="NLM_x">–</span> <span class="NLM_lpage">4255</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.07.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2016.07.048" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=4250-4255&author=J.+Hanisakauthor=W.+M.+Seganishauthor=W.+T.+McElroyauthor=H.+Tangauthor=R.+Zhangauthor=H.-C.+Tsuiauthor=T.+Fischmannauthor=D.+Tulshianauthor=J.+Tataauthor=C.+Sondeyauthor=K.+Devitoauthor=J.+Fossettaauthor=C.+G.+Garlisiauthor=D.+Lundellauthor=X.+Niu&title=Efforts+towards+the+optimization+of+a+bi-aryl+class+of+potent+IRAK4+inhibitors&doi=10.1016%2Fj.bmcl.2016.07.048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20g&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.07.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.07.048%26sid%3Dliteratum%253Aachs%26aulast%3DHanisak%26aufirst%3DJ.%26aulast%3DSeganish%26aufirst%3DW.%2BM.%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DTsui%26aufirst%3DH.-C.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DTata%26aufirst%3DJ.%26aulast%3DSondey%26aufirst%3DC.%26aulast%3DDevito%26aufirst%3DK.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DX.%26atitle%3DEfforts%2520towards%2520the%2520optimization%2520of%2520a%2520bi-aryl%2520class%2520of%2520potent%2520IRAK4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D26%26spage%3D4250%26epage%3D4255%26doi%3D10.1016%2Fj.bmcl.2016.07.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tumey, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagirath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Press, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frisbie, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, V. R.</span><span> </span><span class="NLM_article-title">Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2066</span><span class="NLM_x">–</span> <span class="NLM_lpage">2072</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.03.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2014.03.056" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2066-2072&author=L.+N.+Tumeyauthor=D.+H.+Boschelliauthor=N.+Bhagirathauthor=J.+Shimauthor=E.+A.+Murphyauthor=D.+Goodwinauthor=E.+M.+Bennettauthor=M.+Wangauthor=L.+Linauthor=B.+Pressauthor=M.+Shenauthor=R.+K.+Frisbieauthor=P.+Morganauthor=S.+Mohanauthor=J.+Shinauthor=V.+R.+Rao&title=Identification+and+optimization+of+indolo%5B2%2C3-c%5Dquinoline+inhibitors+of+IRAK4&doi=10.1016%2Fj.bmcl.2014.03.056"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.03.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.03.056%26sid%3Dliteratum%253Aachs%26aulast%3DTumey%26aufirst%3DL.%2BN.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DBhagirath%26aufirst%3DN.%26aulast%3DShim%26aufirst%3DJ.%26aulast%3DMurphy%26aufirst%3DE.%2BA.%26aulast%3DGoodwin%26aufirst%3DD.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DPress%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DFrisbie%26aufirst%3DR.%2BK.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DV.%2BR.%26atitle%3DIdentification%2520and%2520optimization%2520of%2520indolo%255B2%252C3-c%255Dquinoline%2520inhibitors%2520of%2520IRAK4%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2066%26epage%3D2072%26doi%3D10.1016%2Fj.bmcl.2014.03.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lee, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambler, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boscoe, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bree, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehnhardt, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dower, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drozda, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frisbie, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavrin, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hepworth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hope, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamtekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilty, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovering, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathias, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papaioannou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patny, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saiah, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samardjiev, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samas, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, M. W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soutter, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strohbach, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symanowicz, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomason, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trzupek, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zapf, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, S. W.</span><span> </span><span class="NLM_article-title">Discovery of clinical candidate 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a potent, selective inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), by fragment-based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">5521</span><span class="NLM_x">–</span> <span class="NLM_lpage">5542</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00231</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00231" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5521-5542&author=K.+L.+Leeauthor=C.+M.+Amblerauthor=D.+R.+Andersonauthor=B.+P.+Boscoeauthor=A.+G.+Breeauthor=J.+I.+Brodfuehrerauthor=J.+S.+Changauthor=C.+Choiauthor=S.+Chungauthor=K.+J.+Curranauthor=J.+E.+Dayauthor=C.+M.+Dehnhardtauthor=K.+Dowerauthor=S.+E.+Drozdaauthor=R.+K.+Frisbieauthor=L.+K.+Gavrinauthor=J.+A.+Goldbergauthor=S.+Hanauthor=M.+Hegenauthor=D.+Hepworthauthor=H.+R.+Hopeauthor=S.+Kamtekarauthor=I.+C.+Kiltyauthor=A.+Leeauthor=L.-L.+Linauthor=F.+E.+Loveringauthor=M.+D.+Loweauthor=J.+P.+Mathiasauthor=H.+M.+Morganauthor=E.+A.+Murphyauthor=N.+Papaioannouauthor=A.+Patnyauthor=B.+S.+Pierceauthor=V.+R.+Raoauthor=E.+Saiahauthor=I.+J.+Samardjievauthor=B.+M.+Samasauthor=M.+W.+H.+Shenauthor=J.+H.+Shinauthor=H.+H.+Soutterauthor=J.+W.+Strohbachauthor=P.+T.+Symanowiczauthor=J.+R.+Thomasonauthor=J.+D.+Trzupekauthor=R.+Vargasauthor=F.+Vincentauthor=J.+Yanauthor=C.+W.+Zapfauthor=S.+W.+Wright&title=Discovery+of+clinical+candidate+1-%7B%5B%282S%2C3S%2C4S%29-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%5Dmethoxy%7D-7-methoxyisoquinoline-6-carboxamide+%28PF-06650833%29%2C+a+potent%2C+selective+inhibitor+of+interleukin-1+receptor+associated+kinase+4+%28IRAK4%29%2C+by+fragment-based+drug+design&doi=10.1021%2Facs.jmedchem.7b00231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design</span></div><div class="casAuthors">Lee, Katherine L.; Ambler, Catherine M.; Anderson, David R.; Boscoe, Brian P.; Bree, Andrea G.; Brodfuehrer, Joanne I.; Chang, Jeanne S.; Choi, Chulho; Chung, Seungwon; Curran, Kevin J.; Day, Jacqueline E.; Dehnhardt, Christoph M.; Dower, Ken; Drozda, Susan E.; Frisbie, Richard K.; Gavrin, Lori K.; Goldberg, Joel A.; Han, Seungil; Hegen, Martin; Hepworth, David; Hope, Heidi R.; Kamtekar, Satwik; Kilty, Iain C.; Lee, Arthur; Lin, Lih-Ling; Lovering, Frank E.; Lowe, Michael D.; Mathias, John P.; Morgan, Heidi M.; Murphy, Elizabeth A.; Papaioannou, Nikolaos; Patny, Akshay; Pierce, Betsy S.; Rao, Vikram R.; Saiah, Eddine; Samardjiev, Ivan J.; Samas, Brian M.; Shen, Marina W. H.; Shin, Julia H.; Soutter, Holly H.; Strohbach, Joseph W.; Symanowicz, Peter T.; Thomason, Jennifer R.; Trzupek, John D.; Vargas, Richard; Vincent, Fabien; Yan, Jiangli; Zapf, Christoph W.; Wright, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5521-5542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topol. in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 inhibitors with nanomolar potency in cellular assays.  The medicinal chem. effort featured the judicious placement of lipophilicity, informed by cocrystal structures with IRAK4 and optimization of ADME properties to deliver clin. candidate I.  This compd. benefitted from a 5-unit increase in lipophilic efficiency from the fragment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYrCep64bhMbVg90H21EOLACvtfcHk0lh7M_-PgHrC9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D&md5=9771ad2d33089f6ef3dba3556536ff1a</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00231%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BL.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DBoscoe%26aufirst%3DB.%2BP.%26aulast%3DBree%26aufirst%3DA.%2BG.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%2BI.%26aulast%3DChang%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DDower%26aufirst%3DK.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DFrisbie%26aufirst%3DR.%2BK.%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DGoldberg%26aufirst%3DJ.%2BA.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHope%26aufirst%3DH.%2BR.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DL.-L.%26aulast%3DLovering%26aufirst%3DF.%2BE.%26aulast%3DLowe%26aufirst%3DM.%2BD.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DMorgan%26aufirst%3DH.%2BM.%26aulast%3DMurphy%26aufirst%3DE.%2BA.%26aulast%3DPapaioannou%26aufirst%3DN.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DRao%26aufirst%3DV.%2BR.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSamardjiev%26aufirst%3DI.%2BJ.%26aulast%3DSamas%26aufirst%3DB.%2BM.%26aulast%3DShen%26aufirst%3DM.%2BW.%2BH.%26aulast%3DShin%26aufirst%3DJ.%2BH.%26aulast%3DSoutter%26aufirst%3DH.%2BH.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DThomason%26aufirst%3DJ.%2BR.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DVargas%26aufirst%3DR.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DWright%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%25201-%257B%255B%25282S%252C3S%252C4S%2529-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%255Dmethoxy%257D-7-methoxyisoquinoline-6-carboxamide%2520%2528PF-06650833%2529%252C%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520interleukin-1%2520receptor%2520associated%2520kinase%25204%2520%2528IRAK4%2529%252C%2520by%2520fragment-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5521%26epage%3D5542%26doi%3D10.1021%2Facs.jmedchem.7b00231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kelly, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhary, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rui, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapeller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">212</span><span class="NLM_x">, </span> <span class="NLM_fpage">2189</span><span class="NLM_x">–</span> <span class="NLM_lpage">2201</span><span class="refDoi"> DOI: 10.1084/jem.20151074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1084%2Fjem.20151074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=26621451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtlSgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2015&pages=2189-2201&author=P.+N.+Kellyauthor=D.+L.+Romeroauthor=Y.+Yangauthor=A.+L.+Shafferauthor=D.+Chaudharyauthor=S.+Robinsonauthor=W.+Miaoauthor=L.+Ruiauthor=W.+F.+Westlinauthor=R.+Kapellerauthor=L.+M.+Staudt&title=Selective+interleukin-1+receptor%E2%80%93associated+kinase+4+inhibitors+for+the+treatment+of+autoimmune+disorders+and+lymphoid+malignancy&doi=10.1084%2Fjem.20151074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy</span></div><div class="casAuthors">Kelly, Priscilla N.; Romero, Donna L.; Yang, Yibin; Shaffer, Arthur L., III; Chaudhary, Divya; Robinson, Shaughnessy; Miao, Wenyan; Rui, Lixin; Westlin, William F.; Kapeller, Rosana; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2189-2201</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Pathol. activation of the Toll-like receptor signaling adaptor protein MYD88 underlies many autoimmune and inflammatory disease states.  In the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLB CL), the oncogenic MYD88 L265P mutation occurs in 29% of cases, making it the most prevalent activating mutation in this malignancy.  IRAK4 kinase accounts for almost all of the biol. functions of MYD88, highlighting IRAK4 as a therapeutic target for diseases driven by aberrant MYD88 signaling.  Using innovative structure-based drug design methodologies, we report the development of highly selective and bioavailable small mol. IRAK4 inhibitors, ND-2158 and ND-2110.  These small mols. suppressed LPS-induced TNF prodn., alleviated collagen-induced arthritis, and blocked gout formation in mouse models.  IRAK4 inhibition promoted killing of ABC DLB CL lines harboring MYD88 L265P, by down-modulating survival signals, including NF-κB and autocrine IL-6/IL-10 engagement of the JAK-STAT3 pathway.  In ABC DLB CL xenograft models, IRAK4 inhibition suppressed tumor growth as a single agent, and in combination with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib or the Bcl-2 inhibitor ABT-199.  Our findings support pharmacol. inhibition of IRAK4 as a therapeutic strategy in autoimmune disorders, in a genetically defined population of ABC DLB CL, and possibly other malignancies dependent on aberrant MYD88 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJuS2v8AyXXrVg90H21EOLACvtfcHk0lh7M_-PgHrC9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtlSgu7s%253D&md5=cf477aff5f649644017cbe5330995a70</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1084%2Fjem.20151074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20151074%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DP.%2BN.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DW.%26aulast%3DRui%26aufirst%3DL.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26aulast%3DKapeller%26aufirst%3DR.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DSelective%2520interleukin-1%2520receptor%25E2%2580%2593associated%2520kinase%25204%2520inhibitors%2520for%2520the%2520treatment%2520of%2520autoimmune%2520disorders%2520and%2520lymphoid%2520malignancy%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2015%26volume%3D212%26spage%3D2189%26epage%3D2201%26doi%3D10.1084%2Fjem.20151074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chaudhary, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapeller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span> </span><span class="NLM_article-title">Synergistic blockade of activated B cell-like DLBCL proliferation with a selective inhibitor of IRAK4 in combination with inhibition of the B-cell receptor signaling network</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">3833</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=3833&author=D.+Chaudharyauthor=N.+Woodauthor=D.+L.+Romeroauthor=S.+D.+Robinsonauthor=J.+R.+Greenwoodauthor=M.+Shelleyauthor=M.+Morinauthor=R.+Kapellerauthor=W.+F.+Westlin&title=Synergistic+blockade+of+activated+B+cell-like+DLBCL+proliferation+with+a+selective+inhibitor+of+IRAK4+in+combination+with+inhibition+of+the+B-cell+receptor+signaling+network"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DRobinson%26aufirst%3DS.%2BD.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DShelley%26aufirst%3DM.%26aulast%3DMorin%26aufirst%3DM.%26aulast%3DKapeller%26aufirst%3DR.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DSynergistic%2520blockade%2520of%2520activated%2520B%2520cell-like%2520DLBCL%2520proliferation%2520with%2520a%2520selective%2520inhibitor%2520of%2520IRAK4%2520in%2520combination%2520with%2520inhibition%2520of%2520the%2520B-cell%2520receptor%2520signaling%2520network%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D3833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kelly, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhary, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapeller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Highly potent and selective interleukin-1 receptor-associated kinase 4 inhibitors for the therapy of lymphoid malignancies</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">LB-112</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2014-LB-112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1158%2F1538-7445.AM2014-LB-112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=LB-112&author=P.+N.+Kellyauthor=D.+Chaudharyauthor=R.+M.+Youngauthor=A.+Shafferauthor=S.+Robinsonauthor=D.+L.+Romeroauthor=R.+Kapellerauthor=L.+M.+Staudt&title=Highly+potent+and+selective+interleukin-1+receptor-associated+kinase+4+inhibitors+for+the+therapy+of+lymphoid+malignancies&doi=10.1158%2F1538-7445.AM2014-LB-112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2014-LB-112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2014-LB-112%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DP.%2BN.%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DShaffer%26aufirst%3DA.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DKapeller%26aufirst%3DR.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DHighly%2520potent%2520and%2520selective%2520interleukin-1%2520receptor-associated%2520kinase%25204%2520inhibitors%2520for%2520the%2520therapy%2520of%2520lymphoid%2520malignancies%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3DLB-112%26doi%3D10.1158%2F1538-7445.AM2014-LB-112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span>Compound <b>1</b> is Example 49 (<b>I-12</b>) from; <span class="NLM_contrib-group">Corin, A. F.; Frye, L. L.; Greenwood, J. R.; Harriman, G. C.; Masse, C.; Robinson, S.; Romero, D. L.; Watts, K. S.; Wessel, M. D.</span><span> </span><span class="NLM_article-title">Irak inhibitors and uses thereof</span>. Patent application WO2012097013, July 19,<span class="NLM_x"> </span><span class="NLM_year">2012</span>. We profiled <b>1</b> in a panel (Millipore kinase selectivity panel) of 126 kinases at a concentration of 1 mM and found the profile to be highly selective (IRAK4 + 1/127 > 75%inh).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=A.+F.+Corin&author=L.+L.+Frye&author=J.+R.+Greenwood&author=G.+C.+Harriman&author=C.+Masse&author=S.+Robinson&author=D.+L.+Romero&author=K.+S.+Watts&author=M.+D.+Wessel&title=Irak+inhibitors+and+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCorin%26aufirst%3DA.%2BF.%26atitle%3DIrak%2520inhibitors%2520and%2520uses%2520thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Destro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soave, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barzaghi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo Presti, L.</span><span> </span><span class="NLM_article-title">Progress in the understanding of drug–receptor interactions, part 1: Experimental charge-density study of an angiotensin II receptor antagonist (C<sub>30</sub>H<sub>30</sub>N<sub>6</sub>O<sub>3</sub>S) at <i>T</i> = 17 K</span> <span class="citation_source-journal">Chem. - Eur. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">4621</span><span class="NLM_x">–</span> <span class="NLM_lpage">4634</span><span class="refDoi"> DOI: 10.1002/chem.200400964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1002%2Fchem.200400964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=15915518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BD2MXoslGls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4621-4634&author=R.+Destroauthor=R.+Soaveauthor=M.+Barzaghiauthor=L.+Lo+Presti&title=Progress+in+the+understanding+of+drug%E2%80%93receptor+interactions%2C+part+1%3A+Experimental+charge-density+study+of+an+angiotensin+II+receptor+antagonist+%28C30H30N6O3S%29+at+T+%3D+17+K&doi=10.1002%2Fchem.200400964"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the understanding of drug-receptor interactions, part 1: Experimental charge-density study of an angiotensin II receptor antagonist (C30H30N6O3S) at T = 17 K</span></div><div class="casAuthors">Destro, Riccardo; Soave, Raffaella; Barzaghi, Mario; Lo Presti, Leonardo</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4621-4634</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An exptl. study of the electron-d. distribution ρ(r) in an angiotensin II receptor antagonist 1 has been made on the basis of single-crystal X-ray diffraction data collected at a low temp.  The crystal structure of 1 consists of infinite ribbons in which mols. are connected by an N-H···N hydrogen bond and several interactions of the C-H···O, C-H···N, and C-H···S type.  The mol. conformation, characterized by the syn orientation of a tetrazole and a pyrimidinone ring with respect to a Ph spacer group, is stabilized by two short S···O and S···N intramol. contacts between a substituted thiophene fragment and the other two heterocycles of 1.  The electrostatic nature of these interactions is documented.  Furthermore, the Laplacian of ρ(r) in the plane defined by the sulfur, oxygen, and nitrogen atoms involved in these interactions shows their strongly directional character as the regions of charge concn. on the valence shell of the nitrogen and oxygen atoms directly face the regions of charge depletion on the valence shell of the sulfur atom.  All the chem. bonds and the relevant intra- and intermol. interactions of 1 have been quant. described by the topol. anal. of ρ(r).  Simple relationships between the bond path lengths (Rb) and the values of ρ at the bond crit. points (ρbcp) have been obtained for the 28 C-C bonds, the seven N-C bonds, and the four O-C bonds.  For the first two classes of bonds the relationship is in the form of a straight line, whose parameters, for the C-C bonds, agree, within exptl. uncertainty, with those previously derived in our lab. from a 19 K X-ray diffraction study of crystals of a different compd.  Maps of the mol. electrostatic potential .vphi.(r) derived from the exptl. charge d. display features that are important for the drug-receptor recognition of 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYY79gcPwxjbVg90H21EOLACvtfcHk0liR4Ku0Jz6y_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXoslGls70%253D&md5=a587827d1db49f53cfe6d4a464423f5d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fchem.200400964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.200400964%26sid%3Dliteratum%253Aachs%26aulast%3DDestro%26aufirst%3DR.%26aulast%3DSoave%26aufirst%3DR.%26aulast%3DBarzaghi%26aufirst%3DM.%26aulast%3DLo%2BPresti%26aufirst%3DL.%26atitle%3DProgress%2520in%2520the%2520understanding%2520of%2520drug%25E2%2580%2593receptor%2520interactions%252C%2520part%25201%253A%2520Experimental%2520charge-density%2520study%2520of%2520an%2520angiotensin%2520II%2520receptor%2520antagonist%2520%2528C30H30N6O3S%2529%2520at%2520T%2520%253D%252017%2520K%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2005%26volume%3D11%26spage%3D4621%26epage%3D4634%26doi%3D10.1002%2Fchem.200400964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="note"><p class="first last">Under acidic conditions, treatment with TFA/DCM afforded partial deprotection of the SEM group, with LC-MS showing the desired product mass in addition to variable amounts of an M + 30 impurity, corresponding to product with the CH<sub>2</sub>OH group remaining. Full conversion to the desired product was achieved by allowing the crude product following SCX purification to stand in NH<sub>3</sub>/MeOH solution for 1–24 h.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, J.</span><span> </span><span class="NLM_article-title">Copper-mediated trifluoromethylation of heteroaromatic compounds by trifluoromethyl sulfonium salts</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1896</span><span class="NLM_x">–</span> <span class="NLM_lpage">1900</span><span class="refDoi"> DOI: 10.1002/anie.201006823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1002%2Fanie.201006823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitVOhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=1896-1900&author=C.+Zhangauthor=Z.+Wangauthor=Q.+Chenauthor=C.+Zhangauthor=Y.+Guauthor=J.+Xiao&title=Copper-mediated+trifluoromethylation+of+heteroaromatic+compounds+by+trifluoromethyl+sulfonium+salts&doi=10.1002%2Fanie.201006823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Copper-Mediated Trifluoromethylation of Heteroaromatic Compounds by Trifluoromethyl Sulfonium Salts</span></div><div class="casAuthors">Zhang, Cheng-Pan; Wang, Zong-Ling; Chen, Qing-Yun; Zhang, Chun-Tao; Gu, Yu-Cheng; Xiao, Ji-Chang</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1896-1900, S1896/1-S1896/40</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A convenient method for the synthesis of trifluoromethylated heteroarom. compds. from heteroarom. systems contg. nitrogen, oxygen, and/or sulfur and substituted with iodine under mild conditions is reported.  It is based on the observation that (S)-(trifluoromethyl)diphenylsulfonium triflate can be reduced by certain metals.  Trifluoromethylated products were obtained in high yields.  That the (S)-(trifluoromethyl) diphenylsulfonium salt is reduced by copper via a SET mechanism, and that CuCF3 is the most probable intermediate in this reaction are proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp5n08Txx4QrVg90H21EOLACvtfcHk0liR4Ku0Jz6y_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitVOhsLs%253D&md5=0635637cfc7aeb66f7a8c41a71c20f9c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fanie.201006823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201006823%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DJ.%26atitle%3DCopper-mediated%2520trifluoromethylation%2520of%2520heteroaromatic%2520compounds%2520by%2520trifluoromethyl%2520sulfonium%2520salts%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D1896%26epage%3D1900%26doi%3D10.1002%2Fanie.201006823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Bruno, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudge, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Design and preparation of new palladium precatalysts for C-C and C-N cross-coupling reactions</span> <span class="citation_source-journal">Chem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">916</span><span class="NLM_x">–</span> <span class="NLM_lpage">920</span><span class="refDoi"> DOI: 10.1039/C2SC20903A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1039%2FC2SC20903A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=23667737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFKjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=916-920&author=N.+C.+Brunoauthor=M.+T.+Tudgeauthor=S.+L.+Buchwald&title=Design+and+preparation+of+new+palladium+precatalysts+for+C-C+and+C-N+cross-coupling+reactions&doi=10.1039%2FC2SC20903A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design and preparation of new palladium precatalysts for C-C and C-N cross-coupling reactions</span></div><div class="casAuthors">Bruno, Nicholas C.; Tudge, Matthew T.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">916-920</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of easily prepd., phosphine-ligated palladium precatalysts based on the 2-aminobiphenyl scaffold have been prepd.  The role of the precatalyst-assocd. labile halide (or pseudohalide) in the formation and stability of the palladacycle has been examd.  It was found that replacing the chloride in the previous version of the precatalyst with a mesylate leads to a new class of precatalysts with improved soln. stability and that are readily prepd. from a wider range of phosphine ligands.  The differences between the previous version of precatalyst and that reported here are explored.  In addn., the reactivity of the latter is examd. in a range of C-C and C-N bond forming reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfHp6oyg4k_bVg90H21EOLACvtfcHk0liR4Ku0Jz6y_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFKjtr0%253D&md5=5b50ac18cb67251e5439199c6746dba8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1039%2FC2SC20903A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2SC20903A%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DN.%2BC.%26aulast%3DTudge%26aufirst%3DM.%2BT.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DDesign%2520and%2520preparation%2520of%2520new%2520palladium%2520precatalysts%2520for%2520C-C%2520and%2520C-N%2520cross-coupling%2520reactions%26jtitle%3DChem.%2520Sci.%26date%3D2013%26volume%3D4%26spage%3D916%26epage%3D920%26doi%3D10.1039%2FC2SC20903A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span>During the evaluation of this series, a patent application (<span class="NLM_contrib-group">Harriman, G. C.; Romero, D. L.; Masse, C. E.; Robinson, S.; Wessel, M. D.; Greenwood, J. R.</span><span> </span><span class="NLM_article-title">Irak inhibitors and uses thereof</span>. Patent application WO2014011911, January 16,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">) </span><div class="note"><p class="first last">on IRAK inhibitors was published containing nine examples of pyrrolopyrimidines. Two of the most potent examples described had substitution at the 5-position with cyano (<b>I-1</b>) and fluoro (<b>I-3</b>). These were made and profiled in our assays and IRAK4 potency was found to be consistent with the binned data reported in the patent (0.1 < IC<sub>50</sub> < 1 mM) and less potent than many examples reported in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. <span class="NLM_inline-graphic"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01290/20171221/images/medium/jm-2017-01290b_0027.tif.gif" alt="" /></img></span>Compound <b>8</b> (<b>I-9</b>) was also included in the application and was reported to have IC<sub>50</sub> > 10 mM in an IRAK4 enzyme assay, also consistent with the results obtained in our assay (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). This patent application was subsequently abandoned</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=G.+C.+Harriman&author=D.+L.+Romero&author=C.+E.+Masse&author=S.+Robinson&author=M.+D.+Wessel&author=J.+R.+Greenwood&title=Irak+inhibitors+and+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHarriman%26aufirst%3DG.%2BC.%26atitle%3DIrak%2520inhibitors%2520and%2520uses%2520thereof%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="note"><p class="first last">For compounds <b>18</b>–<b>20</b> with chiral groups in the 4-position, we observed a doubling up of some signals in the <sup>13</sup>C spectra of the cyclohexyl ring, which we attributed to the chiral centre imparting diastereotopicity to the cyclohexyl carbons. This phenomenon was not observed with achiral 4-substituents.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><i>K</i><sub>d</sub> values were determined using the DiscoverX <i>Kd</i>ELECT platform. Data was generated in duplicate using an 11-point dose response curve with experimental details described on the company website (<a href="https://www.discoverx.com/home" class="extLink">https://www.discoverx.com/home</a>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kd+values+were+determined+using+the+DiscoverX+KdELECT+platform.+Data+was+generated+in+duplicate+using+an+11-point+dose+response+curve+with+experimental+details+described+on+the+company+website+%28https%3A%2F%2Fwww.discoverx.com%2Fhome%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesser, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlhammer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenwald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Hermelink, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimsza, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffe, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delabie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeland, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braziel, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubbs, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisenburger, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">463</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span><span class="refDoi"> DOI: 10.1038/nature08638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1038%2Fnature08638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=20054396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFCitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=88-92&author=R.+E.+Davisauthor=V.+N.+Ngoauthor=G.+Lenzauthor=P.+Tolarauthor=R.+M.+Youngauthor=P.+B.+Romesserauthor=H.+Kohlhammerauthor=L.+Lamyauthor=H.+Zhaoauthor=Y.+Yangauthor=W.+Xuauthor=A.+L.+Shafferauthor=G.+Wrightauthor=W.+Xiaoauthor=J.+Powellauthor=J.+K.+Jiangauthor=C.+J.+Thomasauthor=A.+Rosenwaldauthor=G.+Ottauthor=H.+K.+Muller-Hermelinkauthor=R.+D.+Gascoyneauthor=J.+M.+Connorsauthor=N.+A.+Johnsonauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=W.+H.+Wilsonauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+I.+Fisherauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=S.+K.+Pierceauthor=L.+M.+Staudt&title=Chronic+active+B-cell-receptor+signalling+in+diffuse+large+B-cell+lymphoma&doi=10.1038%2Fnature08638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma</span></div><div class="casAuthors">Davis, R. Eric; Ngo, Vu N.; Lenz, Georg; Tolar, Pavel; Young, Ryan M.; Romesser, Paul B.; Kohlhammer, Holger; Lamy, Laurence; Zhao, Hong; Yang, Yandan; Xu, Weihong; Shaffer, Arthur L.; Wright, George; Xiao, Wenming; Powell, John; Jiang, Jian-kang; Thomas, Craig J.; Rosenwald, Andreas; Ott, German; Muller-Hermelink, Hans Konrad; Gascoyne, Randy D.; Connors, Joseph M.; Johnson, Nathalie A.; Rimsza, Lisa M.; Campo, Elias; Jaffe, Elaine S.; Wilson, Wyndham H.; Delabie, Jan; Smeland, Erlend B.; Fisher, Richard I.; Braziel, Rita M.; Tubbs, Raymond R.; Cook, J. R.; Weisenburger, Dennis D.; Chan, Wing C.; Pierce, Susan K.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7277</span>),
    <span class="NLM_cas:pages">88-92</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A role for B-cell-receptor (BCR) signaling in lymphomagenesis has been inferred by studying Ig genes in human lymphomas and by engineering mouse models, but genetic and functional evidence for its oncogenic role in human lymphomas is needed.  Here the authors describe a form of chronic active' BCR signaling that is required for cell survival in the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).  The signaling adaptor CARD11 is required for constitutive NF-κB pathway activity and survival in ABC DLBCL.  Roughly 10% of ABC DLBCLs have mutant CARD11 isoforms that activate NF-κB, but the mechanism that engages wild-type CARD11 in other ABC DLBCLs was unknown.  An RNA interference genetic screen revealed that a BCR signaling component, Bruton's tyrosine kinase, is essential for the survival of ABC DLBCLs with wild-type CARD11.  In addn., knockdown of proximal BCR subunits (IgM, Ig-κ, CD79A and CD79B) killed ABC DLBCLs with wild-type CARD11 but not other lymphomas.  The BCRs in these ABC DLBCLs formed prominent clusters in the plasma membrane with low diffusion, similarly to BCRs in antigen-stimulated normal B cells.  Somatic mutations affecting the immunoreceptor tyrosine-based activation motif (ITAM) signaling modules of CD79B and CD79A were detected frequently in ABC DLBCL biopsy samples but rarely in other DLBCLs and never in Burkitt's lymphoma or mucosa-assocd. lymphoid tissue lymphoma.  In 18% of ABC DLBCLs, one functionally crit. residue of CD79B, the first ITAM tyrosine, was mutated.  These mutations increased surface BCR expression and attenuated Lyn kinase, a feedback inhibitor of BCR signaling.  These findings establish chronic active BCR signaling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzlT4q2Ie4lrVg90H21EOLACvtfcHk0lilmHk43s43dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFCitw%253D%253D&md5=86d4bdf7f9af3fbe120d5b9175389e5a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnature08638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08638%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DNgo%26aufirst%3DV.%2BN.%26aulast%3DLenz%26aufirst%3DG.%26aulast%3DTolar%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DRomesser%26aufirst%3DP.%2BB.%26aulast%3DKohlhammer%26aufirst%3DH.%26aulast%3DLamy%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DR.%2BI.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DPierce%26aufirst%3DS.%2BK.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DChronic%2520active%2520B-cell-receptor%2520signalling%2520in%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D88%26epage%3D92%26doi%3D10.1038%2Fnature08638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Wilson, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pittaluga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lih, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerecitano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenkre, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shustov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fowler, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vose, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elstrom, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habermann, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrientos, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreivy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clow, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munneke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussa, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaupre, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">922</span><span class="NLM_x">–</span> <span class="NLM_lpage">926</span><span class="refDoi"> DOI: 10.1038/nm.3884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1038%2Fnm.3884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=26193343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WltLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=922-926&author=W.+H.+Wilsonauthor=R.+M.+Youngauthor=R.+Schmitzauthor=Y.+Yangauthor=S.+Pittalugaauthor=G.+Wrightauthor=C.+J.+Lihauthor=P.+M.+Williamsauthor=A.+L.+Shafferauthor=J.+Gerecitanoauthor=S.+de+Vosauthor=A.+Goyauthor=V.+P.+Kenkreauthor=P.+M.+Barrauthor=K.+A.+Blumauthor=A.+Shustovauthor=R.+Advaniauthor=N.+H.+Fowlerauthor=J.+M.+Voseauthor=R.+L.+Elstromauthor=T.+M.+Habermannauthor=J.+C.+Barrientosauthor=J.+McGreivyauthor=M.+Fardisauthor=B.+Y.+Changauthor=F.+Clowauthor=B.+Munnekeauthor=D.+Moussaauthor=D.+M.+Beaupreauthor=L.+M.+Staudt&title=Targeting+B+cell+receptor+signaling+with+ibrutinib+in+diffuse+large+B+cell+lymphoma&doi=10.1038%2Fnm.3884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma</span></div><div class="casAuthors">Wilson, Wyndham H.; Young, Ryan M.; Schmitz, Roland; Yang, Yandan; Pittaluga, Stefania; Wright, George; Lih, Chih-Jian; Williams, P. Mickey; Shaffer, Arthur L.; Gerecitano, John; de Vos, Sven; Goy, Andre; Kenkre, Vaishalee P.; Barr, Paul M.; Blum, Kristie A.; Shustov, Andrei; Advani, Ranjana; Fowler, Nathan H.; Vose, Julie M.; Elstrom, Rebecca L.; Habermann, Thomas M.; Barrientos, Jacqueline C.; McGreivy, Jesse; Fardis, Maria; Chang, Betty Y.; Clow, Fong; Munneke, Brian; Moussa, Davina; Beaupre, Darrin M.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">922-926</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The two major subtypes of diffuse large B cell lymphoma (DLBCL)-activated B cell-like (ABC) and germinal center B cell-like (GCB)-arise by distinct mechanisms, with ABC selectively acquiring mutations that target the B cell receptor (BCR), fostering chronic active BCR signaling.  The ABC subtype has a ∼40% cure rate with currently available therapies, which is worse than the rate for GCB DLBCL, and highlights the need for ABC subtype-specific treatment strategies.  We hypothesized that ABC, but not GCB, DLBCL tumors would respond to ibrutinib, an inhibitor of BCR signaling.  In a phase 1/2 clin. trial that involved 80 subjects with relapsed or refractory DLBCL, ibrutinib produced complete or partial responses in 37% (14/38) of those with ABC DLBCL, but in only 5% (1/20) of subjects with GCB DLBCL (P = 0.0106).  ABC tumors with BCR mutations responded to ibrutinib frequently (5/9; 55.5%), esp. those with concomitant myeloid differentiation primary response 88 (MYD88) mutations (4/5; 80%), a result that is consistent with in vitro cooperation between the BCR and MYD88 pathways.  However, the highest no. of responses occurred in ABC tumors that lacked BCR mutations (9/29; 31%), suggesting that oncogenic BCR signaling in ABC does not require BCR mutations and might be initiated by non-genetic mechanisms.  These results support the selective development of ibrutinib for the treatment of ABC DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpryc32RWzm77Vg90H21EOLACvtfcHk0lilmHk43s43dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WltLjK&md5=d3342e8baa16eb379eed112c21d0b4ba</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnm.3884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3884%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DSchmitz%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DPittaluga%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DLih%26aufirst%3DC.%2BJ.%26aulast%3DWilliams%26aufirst%3DP.%2BM.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DGerecitano%26aufirst%3DJ.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DKenkre%26aufirst%3DV.%2BP.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DShustov%26aufirst%3DA.%26aulast%3DAdvani%26aufirst%3DR.%26aulast%3DFowler%26aufirst%3DN.%2BH.%26aulast%3DVose%26aufirst%3DJ.%2BM.%26aulast%3DElstrom%26aufirst%3DR.%2BL.%26aulast%3DHabermann%26aufirst%3DT.%2BM.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DMunneke%26aufirst%3DB.%26aulast%3DMoussa%26aufirst%3DD.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DTargeting%2520B%2520cell%2520receptor%2520signaling%2520with%2520ibrutinib%2520in%2520diffuse%2520large%2520B%2520cell%2520lymphoma%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D922%26epage%3D926%26doi%3D10.1038%2Fnm.3884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Davids, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. R.</span><span> </span><span class="NLM_article-title">Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">957</span><span class="NLM_x">–</span> <span class="NLM_lpage">967</span><span class="refDoi"> DOI: 10.2217/fon.14.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.2217%2Ffon.14.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=24941982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=957-967&author=M.+S.+Davidsauthor=J.+R.+Brown&title=Ibrutinib%3A+a+first+in+class+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.2217%2Ffon.14.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase</span></div><div class="casAuthors">Davids, Matthew S.; Brown, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">957-967</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Ibrutinib (formerly PCI-32765) is a potent, covalent inhibitor of Bruton's tyrosine kinase, a kinase downstream of the B-cell receptor that is crit. for B-cell survival and proliferation.  In preclin. studies, ibrutinib bound to Bruton's tyrosine kinase with high affinity, leading to inhibition of B-cell receptor signaling, decreased B-cell activation and induction of apoptosis.  In clin. studies, ibrutinib has been well-tolerated and has demonstrated profound anti-tumor activity in a variety of hematol. malignancies, most notably chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), leading to US FDA approval for relapsed CLL and MCL.  Ongoing studies are evaluating ibrutinib in other types of non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and Waldenstroem's macrogobulinemia, in larger Phase III studies in CLL and MCL, and in combination studies with monoclonal antibodies and chemotherapy.  Future studies will combine ibrutinib with other promising novel agents currently in development in hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3o_pMnFVskLVg90H21EOLACvtfcHk0lg45N22Lcaxrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D&md5=345b4e839a830be822d474f62755a022</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.51%26sid%3Dliteratum%253Aachs%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DIbrutinib%253A%2520a%2520first%2520in%2520class%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DFuture%2520Oncol.%26date%3D2014%26volume%3D10%26spage%3D957%26epage%3D967%26doi%3D10.2217%2Ffon.14.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34a"><span><div class="note"><p class="first last">The roles of haspin and CLK in oncology are the subject on ongoing research. For recent work on haspin inhibition see</p></div><span class="NLM_contrib-group">Cuny, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulyanova, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auerbach, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glicksman, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J. M. G.</span><span> </span><span class="NLM_article-title">Structure–activity relationship study of beta-carboline derivatives as haspin kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2015</span><span class="NLM_x">–</span> <span class="NLM_lpage">2019</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1016%2Fj.bmcl.2012.01.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2015-2019&author=G.+D.+Cunyauthor=N.+P.+Ulyanovaauthor=D.+Patnaikauthor=J.-F.+Liuauthor=X.+Linauthor=K.+Auerbachauthor=S.+S.+Rayauthor=J.+Xianauthor=M.+A.+Glicksmanauthor=R.+L.+Steinauthor=J.+M.+G.+Higgins&title=Structure%E2%80%93activity+relationship+study+of+beta-carboline+derivatives+as+haspin+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2012.01.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.028%26sid%3Dliteratum%253Aachs%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DUlyanova%26aufirst%3DN.%2BP.%26aulast%3DPatnaik%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.-F.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DAuerbach%26aufirst%3DK.%26aulast%3DRay%26aufirst%3DS.%2BS.%26aulast%3DXian%26aufirst%3DJ.%26aulast%3DGlicksman%26aufirst%3DM.%2BA.%26aulast%3DStein%26aufirst%3DR.%2BL.%26aulast%3DHiggins%26aufirst%3DJ.%2BM.%2BG.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520study%2520of%2520beta-carboline%2520derivatives%2520as%2520haspin%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2015%26epage%3D2019%26doi%3D10.1016%2Fj.bmcl.2012.01.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit34b"><span><div class="note"><p class="first last">For recent work on CLK inhibitors see</p></div><span class="NLM_contrib-group">Araki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dairiki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashita, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwatani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, O.</span><span> </span><span class="NLM_article-title">Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0116929</span><span class="refDoi"> DOI: 10.1371/journal.pone.0116929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1371%2Fjournal.pone.0116929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=25581376" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0116929&author=S.+Arakiauthor=R.+Dairikiauthor=Y.+Nakayamaauthor=A.+Muraiauthor=R.+Miyashitaauthor=M.+Iwataniauthor=T.+Nomuraauthor=O.+Nakanishi&title=Inhibitors+of+CLK+protein+kinases+suppress+cell+growth+and+induce+apoptosis+by+modulating+pre-mRNA+splicing&doi=10.1371%2Fjournal.pone.0116929"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0116929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0116929%26sid%3Dliteratum%253Aachs%26aulast%3DAraki%26aufirst%3DS.%26aulast%3DDairiki%26aufirst%3DR.%26aulast%3DNakayama%26aufirst%3DY.%26aulast%3DMurai%26aufirst%3DA.%26aulast%3DMiyashita%26aufirst%3DR.%26aulast%3DIwatani%26aufirst%3DM.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DNakanishi%26aufirst%3DO.%26atitle%3DInhibitors%2520of%2520CLK%2520protein%2520kinases%2520suppress%2520cell%2520growth%2520and%2520induce%2520apoptosis%2520by%2520modulating%2520pre-mRNA%2520splicing%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0116929%26doi%3D10.1371%2Fjournal.pone.0116929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Goedken, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devanarayan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowding, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakway, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talanian, R. V.</span><span> </span><span class="NLM_article-title">Minimum significant ratio of selectivity ratios (MSRSR) and confidence in ratio of selectivity ratios (CRSR): quantitative measures for selectivity ratios obtained by screening assays</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span><span class="refDoi"> DOI: 10.1177/1087057112447108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=10.1177%2F1087057112447108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;key=1%3ACAS%3A280%3ADC%252BC38njtVKhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=857-867&author=E.+R.+Goedkenauthor=V.+Devanarayanauthor=C.+M.+Harrisauthor=L.+A.+Dowdingauthor=J.+P.+Jakwayauthor=J.+W.+Vossauthor=N.+Wishartauthor=D.+C.+Jordanauthor=R.+V.+Talanian&title=Minimum+significant+ratio+of+selectivity+ratios+%28MSRSR%29+and+confidence+in+ratio+of+selectivity+ratios+%28CRSR%29%3A+quantitative+measures+for+selectivity+ratios+obtained+by+screening+assays&doi=10.1177%2F1087057112447108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Minimum significant ratio of selectivity ratios (MSRSR) and confidence in ratio of selectivity ratios (CRSR): quantitative measures for selectivity ratios obtained by screening assays</span></div><div class="casAuthors">Goedken Eric R; Devanarayan Viswanath; Harris Christopher M; Dowding Lori A; Jakway James P; Voss Jeffrey W; Wishart Neil; Jordan David C; Talanian Robert V</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomolecular screening</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">857-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Development of inhibitor compounds selective against undesirable targets is critical in drug discovery.  Selectivity ratios for candidate compounds are evaluated by dividing potencies from two assays assessing the off-target and target.  Because all potency measurements have underlying uncertainty, understanding error propagation is essential to interpreting selectivity data.  Assay noise introduces ambiguity in the statistical significance of selectivity ratios, particularly at low replicate numbers when compounds are often prioritized for subsequent testing.  The ability to differentiate potency results for any pair of compounds in one assay is evaluated using a metric called minimum significant ratio (MSR).  Potency results of one compound tested in a pair of assays can be differentiated by the minimum significant selectivity ratio (MSSR).  To differentiate selectivity ratios for any pair of compounds, we extend this concept by proposing two new parameters called the minimum significant ratio of selectivity ratios (MSRSR) and confidence in ratio of selectivity ratios (CRSR).  Importantly, these tools can be used after a single selectivity measurement.  We describe these methods and illustrate their usefulness using structure-activity relationship data from a Janus kinase inhibitor project, in which these tools informed a cogent retesting strategy and enabled rapid and objective decision making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQODfWMvzjMgMNIRw0GKUoEfW6udTcc2eYaIUSXO-WkALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38njtVKhsw%253D%253D&md5=e9f11323477b881401edcf72b77cddd7</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1177%2F1087057112447108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057112447108%26sid%3Dliteratum%253Aachs%26aulast%3DGoedken%26aufirst%3DE.%2BR.%26aulast%3DDevanarayan%26aufirst%3DV.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DDowding%26aufirst%3DL.%2BA.%26aulast%3DJakway%26aufirst%3DJ.%2BP.%26aulast%3DVoss%26aufirst%3DJ.%2BW.%26aulast%3DWishart%26aufirst%3DN.%26aulast%3DJordan%26aufirst%3DD.%2BC.%26aulast%3DTalanian%26aufirst%3DR.%2BV.%26atitle%3DMinimum%2520significant%2520ratio%2520of%2520selectivity%2520ratios%2520%2528MSRSR%2529%2520and%2520confidence%2520in%2520ratio%2520of%2520selectivity%2520ratios%2520%2528CRSR%2529%253A%2520quantitative%2520measures%2520for%2520selectivity%2520ratios%2520obtained%2520by%2520screening%2520assays%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2012%26volume%3D17%26spage%3D857%26epage%3D867%26doi%3D10.1177%2F1087057112447108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K75" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K75','PDB','5K75'); return false;">PDB: 5K75</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K72" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K72','PDB','5K72'); return false;">PDB: 5K72</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K76" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K76','PDB','5K76'); return false;">PDB: 5K76</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i63"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01290">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_84878"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01290">10.1021/acs.jmedchem.7b01290</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental procedures for the synthesis of intermediates together with biological data and associated errors, kinase selectivity data, NMR conformation, crystallography, and molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01290/suppl_file/jm7b01290_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01290/suppl_file/jm7b01290_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01290/suppl_file/jm7b01290_si_001.pdf">jm7b01290_si_001.pdf (1.34 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01290/suppl_file/jm7b01290_si_002.csv">jm7b01290_si_002.csv (2.13 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Crystal structures of IRAK4 in complex with compounds <b>1</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K75">5K75</a>), <b>21</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K72">5K72</a>), <b>28</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K76">5K76</a>), and crystal structure of <b>28</b> (1572736). Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-24%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01290" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01290" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679915b968e93d54","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
